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ABSTRACT
Using radioimmunoassay, radiolabelling and subcellular 
fractionation techniques, further information as to the 
role of metallothionein in the disposition of cadmium 
in the rat and man, following exposure to this metal, 
was obtained.
A radioimmunoassay for the specific measurement of 
mammalian metallothionein I and II was developed, using 
a sheep anti-(rat metallothionein) antibody. The assay 
had a large linear working range (6.6ng - l.Omg/ tube) 
and was capable of metallothionein measurement in the 
mammalian tissues and body fluids without the need for 
high dilutions.
Chronic dietary administration of 75, 150 and 3 00ppm 
cadmium to rats lead to a dose- and time-related 
accumulation of this metal in the liver, kidney and 
small intestine.The highest cadmium concentrations were 
located in the kidney. This was accompanied by 
disturbances in zinc and copper concentrations in these 
tissues. Using the radioimmunoassay, metallothionein 
induction was seen to parallel cadmium accumulation in 
these tissues.
Chromatographic separation of the cytosolic fractions 
of some of these tissue samples revealed that only 42% 
of the cadmium was associated with metallothionein in 
the small intestine, whereas about 90% of the cadmium 
was associated with this protein in the other tissues. 
Urinary excretion of cadmium was about 10 fold 
higher(3-4ug/day) in the 3 00ppm dose group than the 
lower dose groups. Copper and not cadmium was 
associated with metallothionein in the urine; cadmium 
was located in the lower molecular weight fraction. 
Urinary metallothionein appeared to be a good index of 
cadmium body burden and also a good indicator of recent
exposure - being detected in the urine after 3 days 
cadmium exposure.
Studies using the isolated perfused liver system, 
revealed the paralleled release of cadmium and 
metallothionein from the liver of rats exposed to 
cadmium. The profile of this release suggests an active 
mechanism. Using 109Cd,3H-labelled metallothionein, an 
exponential uptake of 10^Cd by the liver of rats not 
previously exposed to cadmium, was observed. Tritium 
uptake was less rapid. Subcellular fractionation, 
revealed that most of the tritium was located in the 
membranous fraction of the liver, whereas 109Cd was 
found mainly in the cytosol (associated with endogenous 
metallothionein).
Intravenously injected 109Cd,3H-labelled metallo­
thionein into rats,showed that 30-40% of this protein 
was taken up by the renal cortex within 10 minutes. 
Subcellular fractionation studies indicated the 
lysosomal degradation of this protein. 109Cd was 
retained in the cortex- associated with endogenous 
metallothionein of the cytosol fraction. Tritium was 
lost from the cortex by 24 hours after. injection. The 
biological half-life of the exogenous metallothionein 
was calculated to be between 10 and 3 0 minutes.
A group of human volunteers repeatedly consumed "brown 
crabmeat" containing cadmium for up to 12 weeks. Plasma 
and urine cadmium concentrations showed a paralleled 
increase after 2 and 6 weeks suggesting a "cyclic" 
release of cadmium possibly from the liver to the 
kidney, bound to metallothionein. This is discussed in 
the light of the data obtained from the in vitro organ 
perfusion studies and animal studies in vivo.descibed 
previously.
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CHAPTER I
General Introduction
1Pref ace
In 1957 Margoshes and Vallee (1957) reported the 
isolation of an unusual low molecular weight cadmium 
binding protein from horse renal cortex.
Subsequently Kagi and Vallee (1960, 1961) purified a
meta11oprotein with a molecular size of about 10,000 
dal tons which they named metallothionein because of 
its high content of metals (cadmium and zinc) and 
sulphur. In the past 10 years, there has been an 
increasing interest in metallothioneins among 
scientists in the field of toxicology, environmental 
hygiene, medicine pathology, biochemistry and 
nutrition. However, to date the exact functional 
role(s) of this protein remains a matter of 
contention.
An increasing awareness of the potential hazard to 
human health and the environment caused by excess 
levels of cadmium has occurred in recent years. This 
has been highlighted by the outbreak of Itai-Itai in 
Japan and the discovery of high levels of 
environmental cadmium in the English village of 
Shipham. There appears to be a marked correlation 
between tissue concentrations of cadmium and 
metallothionein in animals and man exposed to this 
metal. Thus a functional role in the disposition, 
metabolism and toxicity of cadmium has been proposed 
for metallothionein. However, whether such a role 
exists, or whether cadmium interferes in other 
functional role(s) of this protein remains to be 
resolved.
21. 1 History of discovery and Identification of 
metallothioneins
As the horse seemed to accumulate a higher renal 
burden of Cd2"*" from its food than did other domestic 
animals eg. the cow, sheep or pig (Margoshes and 
Vallee, 1957), biochemical studies were performed by 
these workers to determine the location of cadmium in 
equine renal cortex. This led to the isolation of a 
soluble, apparently monodisperse metalloprotein of 
low molecular weight, that contained 2. 0-2. 5% Cd2^  
together with appreciable amounts of zinc (0.5-0.6%' 
Subsequent studies by Kagi and Vallee (1960) on a 
further preparation of this metalloprotein (2.9%
Cd’2^ ; 0.6% Zn2^ ) , in which minor impurities were 
detectable by analytical electrophoresis, showed that 
it also contained a high content (4%) of sulphur, 
mainly as cysteine residues. Kagi and Vallee (1960) 
termed this metalloprotein, which was also deficient 
in aromatic amino-acids, metallothionein; ie a 
metallo-derivative of the sulphur— rich protein.
With improved methods of isolation and purification, 
an electrophoretically and ultracentrifugally 
homogenous preparation of the horse-kidney 
metallothionein was obtained by Kagi and Vallee 
(1961). This contained 5.9% Cd2-*", 2.2% Zn2-*” and 8.5% 
Sulphur (95% of which was present as sulphydryl 
groups of cysteine residues).
The characterisation of the cadmium-binding protein 
from equine renal cortex was followed by the 
isolation of a similar metallothionein from human 
kidney (Pullido et a1. 1966). In addition to Cd2"4"
(4.2%) Zn2^ (.2.6%) and copper (0.3%), this 
metal loprotein also contained Hg2-+' (0.5%), the 
presence of which was attributed to previously 
therapeutic treatment with mercurial diuretics.
3Piscator (1964) showed that repeated dosing of 
rabbits with cadmium led to a progressive 
accumulation in the liver and kidney of not only the 
metal but also metallothionein. This led to the 
suggestion that the synthesis of thionein is 
inducible and provides a detoxification mechanism 
against this cation. Further developments in the 
areas of identification and characterisation of this 
metalloprotein and the possible biological roles with 
which it may be involved, are the subject of the 
following sections in this chapter.
1.2 Tissue distribution and occurrence of 
metallothionein In mnmmnlc;
1.2.1 Liver and Kidney
Since the isolation and identification of 
metallothionein from equine renal cortex (Margoshes 
and Vallee, 1957; Kagi and Vallee 1960, 1961). The
protein has been identified in the liver and kidneys 
of various species. These include an hepatic 
cadmium, zinc protein in rabbit (Piscator, 1964; 
Nordberg et al. 1972), rat (Weser et a 1. 1973a; Winge
and Ragagopalan, 1972), mouse (Nordberg et a1. 1971),
chicken (Weser et al. 1973b) and sheep (Bremner et_
al. 1977); a renal cadmium, zinc binding protein in
rat (Kimura et al. 1974) rabbit (Suda et al. 1974)
and human (Pul lido et al. 1966). These proteins were
found in the cytosolic fraction of tissue homogenate 
following either deliberate or accidental cadmium 
exposure to animals. An hepatic zinc-metallothionein 
has also been identified, albeit at low 
concentrations, without prior induction of the 
protein. Examples include the horse (Kagi, 1970;
Kagi et al. 1974), rat (Webb, 1972; Bremner and
Davies, 1975), and human (Buhler and Kagi, 1974).
4The livers of certain embryonic and newborn mammals 
seem to contain high concentrations of this protein, 
eg. foetal and newborn rats, human and lamb foetuses 
(Bakka and Webb, 1981). A similar copper, zinc 
metalloprotein has also been identified in the pig 
(Bremner and Young 1976), foetal calf (Hartman and 
Weser, 1977) and sheep and calf (Bremner and Marshall 
1974a, 1974b).
Mercury exposure to experimental animals by means of 
enteral or parenteral administration have given rise 
to the identification of a renal mercury 
metallothionein (Bryan and Hayes, 1972; Shaikh and 
Smith, 1975a and Piotrowski et al. 1973, 1974).
Certain metals appear to bind metallothionein, for 
example gold (Mogilnicka and Webb, 1982), silver 
(Winge et a 1. 1975) and platinum (Zelazowski et a1.
1984), but the induction of this protein may occur by 
a secondary metal such as zinc or copper (Sharma and 
McQueen 1982). The identity of a rat renal bismuth 
metalloprotein (Piotrowski et a1. 1979) is however
unclear, although immunological studies suggest that 
these proteins may be related to metallothionein 
(Zelazowski et al. 1980a).
1.2.2 Intest ine
Similar metalloproteins of low molecular weight 
(10,000 daltons) with copper as the main metal 
constituent have been isolated from the intestinal 
cytosol of the chick (Starcher, 1969), neonatal rat 
(Johnson and Evans, 1980) and from bovine duodenum 
(Evans et al. 1970).
Although the rat intestinal protein appears to be 
similar to hepatic metallothionein, the identity of 
the other proteins has not equivocally been 
established and as yet are only tentatively
5classified as metallothioneins. However, enteral or 
perenteral exposure to zinc have led to the 
induction of zinc-binding protein in the intestinal 
cytosol, classified as metallothionein (Olafson,
1983; Richards and Cousins, 1977). Intestinal 
metallothionein has been reported to be induced by 
oral administration of cadmium (Squibb et a1. 1976;
Taguchi and Nakamura, 1982) . These proteins also had 
similar physical and chemical properties to hepatic 
and renal metallothionein and thus were classified as 
metallothioneins.
The existence of a zinc, copper— metallothionein in 
the cytosol of the gastrointestinal tract of newborn 
rats was revealed by gel-fi1tration chromatography 
and occluded in the profile by a polydisperse copper- 
binding fraction (Mason et al. 1981). It is apparent
that the copper complex rather than metallothionein 
is more evident in the intestinal binding of cadmium 
in the neonatal rat following an acute intragastric 
dose of the metal. However, after an intraperitoneal 
injection the converse was true.
1.2.3 Pancreas
The occurence of cadmium-metallothionein has been 
reported in the pancreas following chronic oral 
administration (Sabbioni et al. 1978) and acute
intraperitoneal injection (Yau and Mennear, 1977). 
However, the physico-chemical properties of these 
proteins have not been investigated in detail, 
probably due to the low accumulation of the metal and 
small size of the tissues.
A cadmium metalloprotein containing zinc and not 
copper as its secondary metal was also located in 
this tissue by Suzuki et al. (1983). The
metallothionein was found to be heat stable and a
6similar molecular weight to hepatic metallothionein, 
but was susceptible to oxidation reactions. Using 
gel filtration, Sato and Takizawa (1982) have 
indicated the presence of cadmium-binding proteins in 
various human organs from a cadaver (who had eaten 
considerable amounts of rice contaminated with 
cadmium). The pancreatic metallothionein was of 
approximately similar molecular weight to hepatic 
metallothionein and tentatively suggested to be 
pancreatic metallothionein.
1.2.4 Testes
The existence of a metallothionein-1ike zinc binding 
protein capable of binding cadmium, has been located 
in the testes of 25-50 day old rats (Brady and Webb, 
1981). Using a radioimmunoassay with a specific 
metallothionein I antibody, a similar protein has 
also been detected in the testes of growing rats 
(Bremner, 1983). However, recent reports have 
indicated that these testicular metalloproteins may 
differ from hepatic metallothionein with respect to 
certain physico-chemical properties (Waalkes et al. 
1984; Klaassen, 1985). These cadmium-binding 
proteins are briefly reviewed in Appendix I.
1.2.5 Blood
A protein of similar molecular weight to hepatic and 
renal metallothioneins was reported to bind about 40% 
of the total cadmium in haemolysed erythocytes, at 48 
and 96 hours post injection of a single dose of 
cadmium (1.0 mg/kg body weight) to mice (Nordberg, 
1972). Also, after repeated injections of cadmium, 
at least 60% of the metal in the blood has been 
reported to be bound to metallothionein in the rat 
erythrocytes (Nordberg et a 1. 1971a,b).
7The cadmium binding protein in red blood cells in 
mice and rats has been demonstrated to be similar to 
hepatic metallothionein in its gel filtration 
(Nordberg et al. 1978; Suzuki, 1980; Garty et a 1.
1981) and ion exchange characteristics (Suzuki et a 1. 
1983a).
Two erythrocyte metallothioneins with similar ion- 
exchange properties as hepatic metallothionein I and 
II have also been shown in mice (Tanaka et al. 1985).
It is known that mature erythrocytes are unable to 
synthesise the. protein. However, the erythrocytic 
metallothionein may originate from the erythrocytes 
in erythropoietic tissues in mice (Tanaka et al.
1985) Using experiments to induce haemolytic 
anaemia; followed by a blood transfusion and doses of 
erythropoietin to stimulate erythropoieses, increases 
in metallothionein concentration in erythrocytes was 
shown. These workers (Tanaka et al. 1986) also
provided evidence that erythrocyte metallothionein 
degrades upon degradation of the erythrocytes. 
Erythrocytic metallothionein was induced in mice 
pretreated with los*CdClS: and then the erythrocytes 
were transfused to the normal mice. The cadmium from 
this metallothionein was deposited in the spleen and 
liver where blood cells are catabolised.
1.2.6 Other tissues
The induction of metallothionein by cadmium 
administration in spleen has also been reported 
(Amacher and Ewing, 1975; Suzuki et al. 1980, 1983b),
revealing the existence of two isoproteins similar to 
hepatic metallothionein I and II. Using the 203Hg- 
displacement of zinc technique (Holt et a1. 1980),
Brady (1982) demonstrated the presence of 
metallothionein in neonatal rat brain, heart, lung, 
spleen and thymus. The metallothionein concentration
8in these tissues were all higher than adult rat liver 
but lower than neonatal rat liver, kidney and 
maturing testes.
1.3 Properties of mammalian metallothioneins
1.3.1 Chemical structure
A) Primary structure - amino acid composition
Mammalian metallothioneins are proteins containing 61 
or 62 amino acids of which between 18-20 are cysteine 
(Kojima et al. 1976). They have no aromatic amino
acids or histidine (Kagi and Nordberg, 1979; Kagi et_ 
al 1984). The protein contains methionine, serine 
and a number of basic amino acids. In vivo, the 
thiol moiety of the cysteine residues are not in the 
reduced form but are dimerised or binding metals, 
such as cadmium, copper, zinc or mercury. Acetyl 
methionine and alanine are the respective amino- and 
carboxy-terminal amino acids of the protein. The 
predominating amino acid sequence is cys-x-cys, where 
x is a variable amino acid residue (Kagi et al.
1984). Ten cysteine residues are found as 5 cys-x- 
cys units, a further 7 cysteine residues are present 
in two groups-cys-cys-x-cys-cys (position 33-37) and 
cys-x-cys-cys (position 57-60). All the cysteine 
residues are known to be involved in the co­
ordination of 6-7 gram atoms of metal per mole of 
metallothionein and the repetitive locations of these 
patterns suggest a common metal co-ordination mode 
for all mammalian metallothioneins (a concept further 
developed in section 1.3.1 C). The basic amino acids 
and serine also tend not be located in ’.juxta­
position' to cysteinyl residues, the latter of which
9appear to be invariant between all mammalian 
metallothionein species (Huang et al. 1981).
Metallothionein is also noted for its high content of 
lysine (6-8 residues) and serine (7-10 residues). 
(Boulanger et a 1. 1983), and it has been suggested
these residues may play an important role in charge 
neutralization at the metal thiolate centre (Kojima 
et al. 1976).
The amino acid sequence has been determined for 
metallothioneins obtained from various animal species 
eg. horse kidney (Kojima et a 1. 1976) mouse(Huang et
al. 1977, 1979, 1981), rats (Winge et a1. 1984)
rabbits (Kimura et a 1. 1979a), human (Kissling and
Kagi, 1979) and human foetal and adult liver (Ryden 
and Deutch, 1978, Karin and Richards, 1982); and non­
mammalian species e.g. Plaice (partial sequence) 
(Overnall et al♦ 1981), hepato-pancreas of the crab
(Lerch et a1. 1982) the fruit f1v-Drosoph11 a
Melanogaster (Lastowski-Perry et al. 1985) and the
mould-Neurospora crassa (Lerch, 1979). Certain of 
these amino-acid sequences are shown in Figure 1.1 
for comparative purposes. There appears to be strong 
conservation of the 20 positions occupied by 
cysteinyl residues of metallothionein from the 
various species. (The structural and physicochemical 
properties of these non-mammalian metallothioneins 
are described elsewhere in this chapter - section 
1.6 .1).
Multiple forms of metallothionein, separable by 
charge properties, have been isolated (see Kagi and 
Nordberg, 1979; Webb, 1979; Foulkes, 1982).
Generally mammalian metallothionein consists of two 
iso-proteins although 3-4 have been detected in the 
livers of pigs and rats injected with copper (Bremner 
and Young, 1976a, 1976b). Three forms of mercury
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metallothionein have also been detected in the kidney 
of rats exposed to the metal (Zelazowski et al. 1980)
and 3-5 forms in monkey tissues following cadmium 
exposure (Kimura et al. 1979b). Because these
isometallothioneins differ in their hydrophobic 
properties, they can be separated by reverse-phase 
HPLC (which has a superior resolving power to ion- 
exchange) . Using this technique, Klausser et a 1. 
(1983) have been able to detect 4-6 isoproteins from 
horse kidney and rabbit liver and kidney.
Metallothionein isolated from the livers of rats 
exposed to cadmium can be resolved into two 
polymorphic forms (refered to as I and II). The 
primary structure of form I of the hepatic cadmium, 
zinc metallothionein differs from form II in that the 
former contains more glutamate, valine and leucine, 
but less cysteine (26% as opposed to 28%), aspartate 
and alanine than the latter, (Buhler and Kagi, 1974; 
Winge and Rajagopalan, 1972; Kagi et a 1. 1974a).
The primary structure of human metallothionein II has 
been found to be homogenous, whereas metallothionein 
I is a mixture of at least 2 different proteins - 
heterogeneity occuring in 6 different amino acid 
positions (Karin and Richards, 1982). Recently five 
subforms of human metallothionein I have been 
isolated (Hunziker and Kagi, 1985), and slight 
variations in the numbers of 10 amino-acids including 
cysteine have been reported. As the number of 
cysteines are reduced by 5-10% in 3 of the isoforms, 
the metal binding characteristics of these isoforms 
may differ from the other isoforms containing 20 
cysteines. Evidence to support this view is provided 
by the existence of an additional two multiples in 
the '13Cd NMR spectrum of meta11othionein I in 
contrast to metallothionein II - attributed to a
12
mixture of isoproteins in the former (Otvos and 
Armitage, 1980).
B) Secondary structure
These metallothioneins are single but tightly folded 
polypeptide chains. The general shape of the 
protein, calculated from its hydrodynamic properties 
during gel filtration, has been represented as a 
prolate ellipsoid with a axial ratio (a/b) of 6 (Kagi 
et al. 1974). Using dark-field electron microscopy,
the shape of the metalloprotein also appears to have 
an elongated shape with dimensions of 36 x 25 x 16 A 
(Fiskin et al. 1977). The difference in absolute
dimensions observed in these two studies could 
possibly be explained either by alterations in shape 
of metallothionein due to the different media used, 
or to methodological artifacts. A diagramatic 
representation of the metallothionein structure is 
shown in figure 1.2.
Circular dichroism (CD) and ultraviolet spectra have 
been recorded for the Cd2'*',Zn2+ and Cu2+ forms of the 
protein (Buhler and Kagi, 1979; Weser and Rupp, 1979; 
Rupp and Weser, 1978; Vasak et al. 1981). The CD
spectra showed that little or no secondary structure 
such as ot-helix or p-pleated sheet was present in the 
polypeptide chain whether or not it contained metals 
and a random coil arrangement has been suggested.
Using the Chou-Fasman method (Fasman, 1980), short 
regions of oc-helix and (3-pleated sheet have been 
predicted in human metallothionein II. The dominant 
secondary structure of this protein is the predicted 
II {3-bends (each containing 1-2 cysteine residues) - 
a secondary structure ideally poised for the multiple 
binding of metal ions.
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Figure 1.2 A dlagramatlc representation of the 
structure of metollothionein
Amino acid sequence - O— —— O 
Cadmium ion - ☆
Sulphydryl groups - •— •
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C> Tertiary structure - metal binding character1stlcs
In different preparations of metallothionein, 
relative proportions of cadmium and zinc cations were 
variable but the total ion content was similar (6-7 
gramations/mole of metallothionein - Nordberg et al. 
1972; Buhler and Kagi, 1974). In order to bind 7 
metal ions, trithiolate complexes CM2-*' (Cys)_3)'~
(Kagi, 1970) or polynuclear metal clusters involving 
3 co-ordinated cysteine-sulphur bridges (Weser and 
Rupp, 1979) were thought to exist. However, 
spectroscopic and complexomatic titration data (Kagi, 
1970), and dark field electronmicroscopy (Brady et_ 
al. 1979) support a model of well separated domains.
Broad ultra violet and circular dichroism absorption 
bands characteristic of metal thiolate charge 
transfer transitions have been observed with 
metallothionein (Buhler and Kagi, 1979; Weser and 
Rupp, 1979; Vasak et al. 1981). However, no detailed
structural characterisation of the individual metal 
binding sites, other than that of a tetrahedral 
metal-thiolate co-ordination, can be made due to the 
overlapping metal-thiolate charge transfer 
transitions. Although, the structure of individual 
metal co-ordination sites has been obtained from 
113Cd-NMR studies of the isotopically labelled 113Cd- 
metallothionein I and II, isolated from rabbit, calf 
and human liver, this showed that 7 cadmium atoms are 
arranged in two separate clusters - one containing 
three and the other four cadmium ions. (Otvos and 
Armitage, 1980). The 3 metal cluster forms a 
"cyclohexane-1ike" six membered ring requiring nine 
cysteine thiolate ligands; whereas the 4 metal 
cluster forms a bicyclo [3:1:31 structure requiring 
11 cysteine thiolate ligands. In total 5 metal ions 
are linked to 2 bridging and 2 non-bridging 
cysteines; and the other 2 metal ions are
15
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linked to three bridging and one non-bridging 
cysteine. A schematic representation of these 
structures is presented in figure 1.3.
Winge and Miklossy (1982) also revealed the presence 
of these domains by proteolysis with prior treatment 
with EDTA (to remove zinc ions and destabilize the 3 
metal cluster).
The 3 metal cysteine cluster was found in the amino 
terminal half of the molecule ('B' domain) and the 4 
metal cysteine cluster in the carboxy-terminal half 
CA' domain) of the molecule.
Crystals of cadmium, zinc metallothionein II have now 
been isolated (Melis et al. 1983) and, using a 2.3 A
resolution electron density map, the molecule appears 
to fold into two domains of equal size (Furey et al.
1986). Each domain is globular with a diameter of 
15-20 A and there is limited contact between the ot- 
and p-domains Both domains consist of an 'anti­
parallel (3-sandwich' incorporating homologeous folds 
such that of the 4 strands, 1 and 3, and 2 and 4 run 
in parallel (see figure 1.4). The 3 metal cluster 
was observed to adopt a 'chair conformation', with 
the metal ions co-ordinated to form an equilateral 
triangle and interionic distance of 4. 1 +_ 0. 1 A.
Thus the three axial ligands of the cluster 
(cysteines 15, 21 and 29) are exposed by this folding 
of the (3-domain, but are protected to some extent by 
the oc-domain. The metal cluster of the a-domain 
consists of 5 bridging thiolate ligands, with the 
metal ions being tetrahedrally co-ordinated with a 
cadmium-cadmiurn distance of between 3.9 and 4.4 A.
The sixth cadmium-cadmiurn distance (CdT-Cd^) is 
significantly longer at 5.2 A and is not bridged by 
cysteinyl sulphur. The 4 cadmium ions of the a-
17
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cluster form a distorted tetrahedron which has been 
described as a "butterfly" by these authors.
Using two-dimensional correlated (2D COSY) spectra, 
the resonances: in the spectra from a solution of
reconsituted rabbit 113Cd-metallothionein II were 
composite in nature (Frey et al. 1985). This
provided evidence that metallothionein does not 
possess a unique rigid structure but that a great 
deal of structural variability and flexibility is 
present in the metal-thiolate clusters of the protein 
(resulting from temporary breaking and reforming of 
these bonds and undergoing facile exchange between 
molecules see Nettesheim et al. 1985). Thus the
protein exists in various conformational and/or 
configurational substates. However, these 
conformational and/or configurational substates may 
also be perturbed by changes in solvents of high 
ionic strengths and by temperature, as indicated by a 
change in Stokes radius of the protein (Vasak et al. 
1984). The absence of resonances assigned to the 3 
metal cluster in the 113Cd spectrum of calf liver 
113Cd,Cu metallothionein I (Briggs and Armitage,
1982), reflects preference of the copper ion for the 
3-metal cluster. These workers also observed that 
85% of the zinc in a 113Cd,Zn-metallothionein hybrid 
was bound to the 3-metal cluster. The differences in 
affinity of the two metal clusters for these metals 
was Cu’O Z n ^ ^ C d 3'*" for the 3 metal clusters and the 
reverse order for the 4 metal clusters.
Using either mild proteolysis (Nielson and Winge,
1983, 1984) or ion exchange chromatography (Byrd and
Nielson, 1986) to "trap" 2 intermediates of the 
metal-reconstituted metallothionein from the apo- 
metallothionein (metallothionein "stripped" of all 
metal ions), an ordered binding of Cd3"*" and Cu-* to 
the 4 and 3 metal cluster respectively, was observed.
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These workers further report that the results suggest 
a co-operative binding of the metal to the respective 
cluster.
The structure of metallothionein appears to be 
similar to other proteins in that hydrophilic side 
chains are excluded from the interior of the molecule 
but unusual in that it is essentially a monolayer of 
polypeptide wrapping around the thiolate clusters.
The clusters take the place of the hydrophobic core 
and hydrogen bonded secondary structure found in the 
larger proteins. Ten of the twenty cysteine residues 
in metallothionein occur in the central region of the 
molecule (cys 19 to cys 41) and thus the two clusters 
are into close proximity at the a-p domain interface. 
There is also a definite tendency for the peptide 
planes near the cluster to have the carbonyl groups 
of the amino acid residues directed outwards toward 
the solvent, directing the amido groups toward the 
cluster.
This stereochemistry has been observed with other 
metalloproteins - rubredoxin and ferredoxin (Adman et_ 
al. 1975) and the amido group may act to stabilize
the metal-thiolate cluster by charge neutralization 
particularly by lysine residues. Evidence for this 
has been given by Vasak et a 1. (1985) using H-NMR and
Kagi et al. (1986) by assessing the chemical
reactivity of the cadmium thiolate cluster following 
derivitization of the lysine Y“amino group.
The random structure of metallothionein will have a 
major impact on the antigenicity of this protein. 
Predictions from the structure have correlated well 
with the assessment of immunoreactivity of peptide 
sections from metallothionein towards anti­
metal 1 othi onein antiserum (Winge and Garvey 1983).
For example the residues 22-23 are exposed to the
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solvent and ore relatively hydrophilic (both 
parameters are usually required for the formation of 
an antigenic determinant), and from studies by Winge 
and Garvey, (1983), immunoreact1vity is found in the 
region of residues 20-25. However residues 27-32 
which are also hydrophilic residues are not found to 
participate significantly in immunoreactivity, 
probably because it is an inaccessible hinge linking 
the 'A' and ' B' domains of metallothionein.
1.3.2 Ionic optical and metal binding properties
The metallothioneins characterised thus far are 
negatively charged at neutral pH (Buhler and Kagi
1974), their iso-electric points being close to 4 
(Nordberg et al. 1974; Cherian, 1974). The apo­
protein is stable and is formed at low pH, but 
polymerises rapidly by disulphide formation when 
adjusted to neutral pH. A 50% dissociation of metal 
from the protein occurs at pH 3.5-4.5 for zinc, 2.5-
3.5 for cadmium and <1.0 for copper (Kagi and Vallee 
1960, Weser and Rupp, 1979) observed at 190 nm, 
attributed to primary and secondary amide transitions 
and cysteine side chains (Buhler and Kagi, 1979). 
There is also minimal absorption at 280 nm due to the 
distinct lack of aromatic amino acids (Kagi, 1970). 
The molar absorption coefficient of apo-thionein 
(metallothionein 'stripped* of all metal ions in 
vl tro by decreasing the pH) at 250 nm (pH 6. 6) was 
found to be 1.32 x 10A 1. mol."'1 cm.-1 and the 
cadmium, zinc metallothionein from rat liver had a 
molar absorption coefficient of 8.06 x 10A1. mol. ~~1 
cm.-1 (Weser et al. 1973a). However, the molar
absorption coefficients of native cadmium, zinc- 
metallothionein will vary with the cadmium:zinc ratio 
of the molecule. Zinc has the lowest binding 
affinity constant (1011 M_1) for meta11othionein, and 
cadmium binds 3000 times more strongly with an
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affinity constant of 10iei M-1 at pH 7.0. Thus 
cadmium will displace zinc from metallothionein 
(Kagi, 1970). Copper is much more firmly bound than 
cadmium or zinc (Weser and Rupp, 1979),
The metallothionein molecule reveals broad absorption 
bands, typical of the metal thiolate complexes with 
absorption maximium at 250 nm for cadmium, 220 nm for 
zinc and 270 nm for copper (Nordberg et al. 1972,
Buhler and Kagi, 1979; Weser and Rupp, 1979). These 
'maxima' are characteristically seen as "shoulders" 
obscurred by the absorption maxima.
1.4 Induction and synthesis of mammalian 
metallothionein
1.4.1 Regulation by metals
A) L 1ver
After the parenteral administration of a single dose 
of cadmium chloride in rats (Webb, 1972) and mice 
(Nordberg et al. 1971a,b), the cation is taken up by
the liver (about 40% of the dose) and is bound 
intracellularly, particularly by the high molecular 
weight proteins of the cytosol (Cempel and Webb,
1976). The cadmium content of the high molecular 
weight fraction decreases by 80-90% after 8 hours 
whilst that in the low molecular weight region of 
elution profiles (obtained by gel filtration of liver 
homogenates*) increased by 80-90% in the same time 
period (Cempel and Webb, 1976). This appearance of 
thionein also marks a decrease in cation 
concentration in nuclear, mitochrondria1 and 
microsomal fractions (Yoshikawa and Suzuki, 1976).
The cytosol fraction revealed a 50% increase in 
cadmium content between 4 and 24 hours after the
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parenteral administration of the cation. The presence 
of hepatic metallothionein in response to the 
administration of the cadmium has been shown by 
increased incorporation of [ 3<*S] cysteine and 1 °‘*Cd 
into this cytosolic protein (Skaikh and Lucis, 1970; 
Shaikh and Smith 1976, 1977). Evidence that
metallothionein was an inducible protein was presented 
by Squibb and Cousins (1974). Cyc1oheximide (an 
inhibitor of protein synthesis) was shown to inhibit 
the increased incorporation of 3H-cysteine into the 
metal 1othionein that in control animals, followed the 
administration.of cadmium. More precise studies by 
Cempel and Webb (1976) have established that in the 
male rat, there is a lag phase of 3-4 hours between 
the administration of the cation and onset of hepatic 
metallothionein synthesis. The synthesis being 
complete within a further 4-5 hours. In the female 
rat, about 5% of the cadmium in the cytosolic fraction 
of the liver has been observed bound to 
metallothionein 1 hour after administration of 
cadmium. This seems to be due to the replacement of 
Zn3-1" by Cd3"1" in zinc- metal lothionein, which is 
present at low concentrations in the liver of the 
female animal. The concentration of the cadmium- 
metallothionein increases during the next 2-3 hours, 
reaching a maximum level at the same time as the male. 
Thionein synthesis seems to be limited by the hepatic 
concentration of cadmium as there is an almost linear 
relationship between the content of thionein-bound 
cadmium and total cadmium (Sabbioni and Marfante 
1975). However, incorporation of C3eSlcysteine into 
thionein is only proportional to cadmium dose up to a 
maximum of 277 ug Cd3+/rat. The thionein-bound 
cadmium was found to remain at 20 ug/g wet weight 
tissue, at and above these dose levels (Sabbioni and 
Marfante, 1975). This suggests that the cadmium 
induction of thionein synthesis is a saturable 
process.
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The site of synthesis of hepatic metallothionein was 
found to be on "free" rather than membrane-bound 
polysomes from the results of in vitro studies by 
Cherian et a 1. (1981). This is in agreement with the
observation that most soluble cytoplasmic proteins 
are synthesised on free polysomes (Redman, 1969). In 
vitro studies have led to the conclusion that 
increased synthesis of metallothionein is thought to 
be due to an increased level of metallothionein 
messenger RNA. (Andersen and Weser, 1978, Shapiro et 
al. 1978). Cher ian et al. (1981) however, found no
difference in induced metallothionein synthesis 
between liver from control and cadmium treated rats 
using an in vitro preparation of polysomes. However 
the animals in this experiment were starved 24 hours 
before being killed to increase the concentration of 
free polysomes in the liver cytosol. Starvation is 
known to increase hepatic metallothionein concentrat­
ions (Bremner and Davies, 1975), explaining the lack 
of difference in induced metallothionein synthesis 
between test and control animals observed by Cherian 
et al. (1981 ).
The synthesis of metallothionein is thought to be 
controlled at the transcriptional level. Maximal 
rates of transcription from the metallothionein I and 
II genes occurring 1 hour after Cd3-*" administration 
(Durnam and Palmiter, 1980; Palmiter 1981). Using 
cDNA hybridization and [3eS3cysteiny1 incorporation 
(as a measure of rate of synthesis of metallo­
thionein) , these authors were able to detect maximal 
levels of metallothionein four hours after cadmium 
administration in vi tro. Squibb and Cousins (1974) 
also came to the same conclusion, using actinomycin D 
(which inhibits RNA synthesis). This antibiotic only 
inhibits meta11othionein synthesis up to but not 
after 3 hours post cadmium administration. It has 
also been found that in both normal and
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odrenalectomized (to prevent changes in levels of 
corticoid hormones) rats, preinjection of Cd2^ (10 ug 
ions/kg) 10 hours before administration of a 10 min 
pulse of [6-1AC]orotic acid stimulates nuclear RNA 
synthesis by 116% (Weser et a 1. 1970). Squibb et a 1.
(1977) demonstrated that metallothionein synthesis as 
judged by pulse labelling with C3SS]cysteine, reached 
the maximum rate 5-7 hours after parenteral 
administration of zinc (containing E,E1Zn) . Subsequent 
to this increased in biosynthetic rate there was an 
increase incorporation of *-E1Zn from the administered 
dose into the newly synthesized protein. These data 
established that the induction of metallothionein by 
zinc involved increased transcription of the metallo- 
thionein gene. Chen et al. (1975) proposed a similar
estimate of the rate of metallothionein synthesis 
after cadmium administration.
The use of cell free translation systems to measure 
metallothionein mRNA levels in nucleic acid extracts 
of various tissues has led to a deeper understanding 
of metal 1othionein synthesis. Poly (A)* RNA used to 
program the translation system was isolated from rat 
liver polyribosomes. Metallothionein mRNA levels 
after administration of zinc were found to closely 
parallel the rate of metallothionein synthesis, 
using covalent chromatography with activated thiol- 
sepharose chromatography, (Shapiro et al. 1978) and
employing SDS-PAGE (Andersen and Weser, 1978). 
Antibodies directed against purified metallothionein 
have been used to immunoprecipitate meta11othionein 
produced in these systems (Cherian et a1. 1981).
Cell-free translation systems have provided evidence 
which suggests that metallothionein mRNA levels in 
animals are increased during foetal and neonatal 
development.
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Winge et al. (1975) suggested that copper induced a
distinct copper binding protein, named copper 
chelatin. The properties of the protein were similar 
to metallothionein. The cysteine content was low and 
no dimorphism were the major differences observed. 
Actinomycin D administration appears to block 
induction of this copper protein. Bremner and Young, 
<1976) investigated this copper protein and found it 
to be metallothionein when isolated under low 
temperature and anaerobic conditions - precluding 
oxidative changes due to the high copper content. 
Numerous other studies have verified the influence of 
copper on metallothionein induction by the liver 
(Bremner and Davis, 1976; Kagi and Nordberg, 1979).
In support of this work, it was demonstrated that 
antisera to the copper induced protein would 
precipitate either the copper induced protein or the 
cadmium induced metallothionein suggesting 
essentially identical antigenic sites for both 
proteins (Mandapal1imatam and Riordan, 1977). Using 
cDNA hybridization techniques, copper also appeared 
to induce hepatic metallothionein I gene 
transcription and mRNA accumulation. However, there 
are quantitative and kinetic differences in the 
induction of metallothionein I mRNA between this 
metal and that of cadmium or zinc (Durham and 
Palmiter, 1981). These data collectively provide 
strong support for the contention that copper induces 
metallothionein. However, it is conceivable that 
copper replaces zinc from existing metallothionein, 
and then the newly released zinc activates the 
metallothionein gene promoter.
Piotrowski et a 1. (1973) detected the presence of a
mercury metallothionein in the liver of rats 
following acute exposure to the metal, and Winge et_ 
al. (1975) suggested that acute exposure to silver
induced a silver metallothionein when given in
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addition to cadmium, zinc and mercury. Although 
induction of metallothionein took place, whether 
silver or mercury induced metallothionein is a matter 
of contention as in induction of metallothionein may 
be due to cadmium or zinc that is displaced from the 
protein by mercury or silver.
Preliminary studies (Banerjee et al. 1982) on the
localization of metallothionein in liver and kidney 
sections, by the immunohistochemical technique of 
peroxidase/antiperoxidase, provided evidence that 
metallothionein may be present in cell nuclei and not 
just the cytoplasm. The presence of metallothionein 
exclusively in the cytoplasm in control rat liver, 
and its localisation in the cell nuclei and cytoplasm 
following injection of metals to adult rats and also 
in foetal and newborn tissues, were indications of a 
unique cellular regulation where the apoprotein 
(thionein) in the cytoplasm could exert post- 
transcriptional control on the inactivation of 
thionein mRNA. This metallothionein cytoplasmic/ 
nuclear interaction is not yet clearly understood. 
Bannerjee et al. (1982) postulated that the small
amount of thionein present in the cytoplasm of cells 
in control animals can inhibit the translation of 
metallothionein mRNA by an unknown new mechanism.
The binding of metallothionein to its mRNA may be one 
possible mechanism of inhibition. The presence of 
small amounts of metallothionein mRNA has been 
reported in control animals using recombinant DNA 
techniques (Ohi et al. 1981) which gives support for
this postulation.
A current hypothesis for the mechanism of induction 
involves repression of transcription by apo- 
metallothionein (Karin et al. 1984). Absorbed metal
binds to the apoprotein (providing it exists for any 
significant time) altering the conformation and
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thereby relieving repression. Transcription would 
persist until an excess of apometallothionein was 
synthesised, whereupon the apoprotein would rebind to 
the gene promoter region and terminate expression of 
mRNA. In such a scheme, metal ions and 
apometallothionein would need to be translocated to 
the nuclei for induction or repression. The 
differential effect of copper and zinc could then 
result from differences in (i) the rate of nuclear 
uptake or (ii) the binding of the apoprotein to 
chromatin. However, there is no evidence for a 
direct binding, of metallothionein itself to 
chromatin; but increased binding of cadmium to 
nuclear components soon after exposure to Cd'^"*" has 
been reported (Hidalgo et a1. 1976).
B> Kidney
Although it was considered that the kidney 
accumulated metallothionein-bound cadmium by 
glomerular filtration and tubular absorption after 
its hepatic synthesis and export (Piscator 1964), it 
is now known that synthesis of metallothionein occurs 
in the kidney (Webb and Daniel 1975; Wisnewska-Kngpl,
1975). Synthesis of metallothionein occurs in the 
kidney once the cadmium concentration exceeds the 
necessary renal threshold and is independent of that 
of the liver (Probst et a 1. 1977a,b).
Biosynthesis of the renal protein commenced 1 hour 
after cadmium administration in rats and reached a 
maximum after a further 3 hours, (Shaikh and Smith 
1975, 1977). This time course for renal induction is
totally different from the induction of hepatic 
metallothionein synthesis. Actinomycin D prevented 
the synthesis of this protein only in the liver, 
suggesting different control mechanisms in these two 
organs.
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Experimental evidence suggests that renal thionein 
synthesis is regulated at the translation level after 
Cd2+ exposure. Results of experiments using 
polysomal poly(A)"*" RNA provide evidence that control 
rat kidneys contain metallothionein messenger RNA. 
Furthermore, an increase in the rate of translation 
can be detected 24 hours after Cds‘f' administration 
(Kuliszewski and McEwen Nicolls, 1982). This 
suggests that the kidneys may contain more 
metallothionein than the liver of control animals and 
supports the observation of relatively higher 
concentrations of specific metallothionein messenger 
RNA’s in the kidney (Shaikh and Smith, 1977).
However, there is also evidence to suggest that 
cadmium increases the rate of transcription from the 
metallothionein I gene in mouse kidney as in the 
liver (Durnam and Palmiter, 1981). Thus it seems 
that cadmium is bound within 1 hour to nascent 
metallothionein or to metallothionein already 
present. This metal also appears to act at the 
transcriptional level to induce synthesis of specific 
messenger RNA*s for the synthesis of the thionein 
moiety.
The difference in metallothionein concentrations in 
liver and kidney of control animals could be due to 
the retention of essential metal cations (eg. copper 
and zinc) and prevent their eventual excretion. It 
may also exist to bind toxic cations, such as 
cadmium, preventing damage to the kidney particularly 
the nephron whose function is essential for the 
retention of many essential elements and compounds.
C) Other tissues
Sabbioni at al, (197S) reported the accumulation of 
cadmium metallothionein in the pancreas of rats 
following continuous ingestion of cadmium (2.1 ug/
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day) for 2 years. It seems however that the kinetics 
of metallothionein induction in this organ are very 
different from those in the liver. In the mouse, the 
metal lothionein content of the pancreas increases 
immediately after an intraperitoneal injection 
<2.0 mg/kg bodyweight), reaching a maximum at 6 hours 
and then falling by 60% and plateauing at 24 hours 
(You and Mennear, 1977). This apparently lag-free 
synthesis implies that mechanisms already exist in 
the pancreas for the formation of metallothionein 
possibly, as Bremner and Davies (1974) suggest, 
because this organ acts as a buffer to prevent the 
rapid uptake of Zn2"*- by the liver. These authors 
established that administration of Zn^ "*" (300 ug) to 
the rat caused the appearance in the soluble fraction 
of the pancreas of an additional Zn2-1" binding 
component, the properties of which were similar to 
hepatic zinc-thionein. The concentration of this 
protein increased rapidly to a maximum at 6 hour and 
then decreased. The ability of the pancreas to 
synthesize this zinc-protein without an induction lag 
was demonstrated by incubation of slices of 
pancreatic tissue with Zn^-*- (20 ug/ml). The 
incorporation of Zn2"*- into the metal loprotein that 
was observed within a 3 hour period under these 
conditions was dependant on protein synthesis.
Metallothionein has also been reported in a variety 
of other tissues (Onosaka and Cherian 1981; Kagi and 
Nordberg, 1979), although the concentrations are 
generally lower in these tissues than in the liver 
and kidney. Using the hybridization assay to monitor 
changes in metallothionein I MRNA levels following 
cadmium administration, Durham and Palmiter (1981) 
found a general correlation between tissue cadmium 
content (which increased proportionally with dose) 
and metallothionein I mRNA induction in the mouse 
spleen, heart, brain, muscle and intestine. However,
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with the testes, increased cadmium content did not 
induce metallothionein I mRNA, despite a relatively 
high constitutive level of this mRNA. It is well 
established that testes of certain strains of mice 
are unusually sensitive to cadmiurn-induced necrosis, 
an observation that may be related to the lack of 
metallothionein induction in this tissue (Gunn et al. 
1968). Durham and Palmiter, (1981) also observed 
that tissues differed quantitatively and kinetically 
in metallothionein I mRNA induction following cadmium 
absorption and concluded that tissue-specific factors 
are involved in the induction of metallothionein I 
mRNA. The tissue specific induction may be due to 1) 
absorbed cadmium not being equally accessible to the 
regulatory proteins involved in metallothionein I 
gene transcription possibly due to the presence of 
other cadmium binding proteins, ii) the rate of 
transcription of this gene varying in different cell 
types or iii) the stability of the messenger RNA 
specific for this protein varying in different 
t issues.
1.4.2 Regulation bv dietary control
Food restriction in rats has been shown to increase 
liver metallothionein-bound zinc (Bremner and Davies, 
1976; Richards and Cousins, 1975). In the latter 
study, there was a 10 fold increase in these levels 
in rats fed either zinc adequate or zinc deficient 
diets immediately prior to fast. In zinc-depleted 
rats, fasting increased the serum zinc concentration 
suggesting a mobilization of zinc stores.
Actinomycin D administration blocked the induction of 
liver metallothionein in response to food restriction 
suggesting that increased metallothionein gene 
expression accounted for the induction, and implying 
that zinc was acting as a primary inducer. This 
response to fasting was broadly viewed as an
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indication of the sensitivity of this system to mild 
metabolic changes (Cousins, 1985). Competition 
between the intestinal absorption of cadmium and iron 
(Hamilton and Valberg, 1974; Valberg et al. 1976) or
cadmium and calcium (Hamilton and Smith, 1978; Yuhas 
et al. 1978; Flanagen et al. 1978, 1980) has been
found in experimental animals. Under conditions of 
iron or calcium deficiency, intestinal cadmium 
absorption appears to increase and increased 
metallothionein concentrations follow to compensate 
the increased absorption of this metal (acting as a 
control mechanism in cases of cadmium poisoning in 
iron or calcium deficient animals). However if this 
were a form of control, it is very inefficient, as 
cases of Itai-itai disease in Japan have shown us 
(see section 1.9.9).
1.4.3 Regulation bv hormonal control
Glucocorticoids have been shown to enhance cellular 
zinc uptake and induce metallothionein in isolated 
rat liver parenchymal cells (Failla and Cousins., 
1978), Hela cells (Karin and Hershman, 1979) and 
in vivo (Etzel et al. 1979) demonstrating hormonal
control of the metallothionein induction process.
Cox (1969) demonstrated the effect of glucocorticoids 
on protein synthesis-dependent zinc uptake in Hela 
cells and Cousins (1985) has suggested from this that 
metallothionein induction in response to 
physiological stimuli, involves in part altered 
regulation of metallothionein gene expression in the 
presence of glucocorticoids.
Further experimentation led to the suggestion that 
the hormonal induction of metallothionein is not 
solely under glucocorticoid control (Etzel and 
Cousins, 1981). Current knowledge of both steroid 
and peptide hormone action on cellular processes, eg.
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in carbohydrate metabolism (Kletzien et al. 1981)
suggests a multifunctional control. Specifically, 
glucagon administration was shown to increase hepatic 
metallothionein (Etzel and Cousins, 1981). 
Administration of glucagon and dexamethasone together 
significantly augmented the response observed with 
either hormone alone, in a rat liver perenchymal 
primary cell culture (Kiupers and Cousins, 1984). 
However, the induction of hepatic metallothionein by 
glucagon was blocked by eyeloheximide but not with 
Actinomycin D (DiSilvestro and Cousins, 1984; Etzel 
and Cousins, 1981). Hepatic mRNA derived from free 
polysomes showed increased metallothionein mRNA 
levels in glucagon-treated rats, especially when 
given with dexamethasone. Metallothionein mRNA 
levels in the total RNA extract did not show 
increases of the same magnitude. Therefore glucagon 
may act through translational regulation to promote 
translation of pre-existing metallothionein mRNA.
Experiments with isolated hepatocytes suggest that 
both glucagon and adrenaline with glucocorticoids 
have additive effects on zinc uptake and 
metallothionein induction. However, in these 
experiments, the effects of epinephrine and glucagon 
are blocked by Actinomycin D; suggesting 
transcriptional control (Cousins, 1985). This has 
been made more tenable with the identification of a 
cAMP-sensitive sequence of the promoter of the 
phospho-enol pyruvate carboxykinase (Hod et a 1.
1984). A similar coding sequence may impart cAMP 
sensitivity to the meta11othionein genes.
Brady and Helvig (1984) have provided data suggesting 
that both adrenaline and noradrenaline administration 
increase metallothionein-bound zinc. However only 
the adrenaline treatment was additive with that of 
dexamethasone. Collectively the evidence that
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glucagon and adrenaline have an independant effect as 
well as an additive effect with glucocorticoids 
suggest that they have an extremely important role in 
altering zinc metabolism as they do in the regulation 
of glucose metabolism. However to date, whether 
metallothionein is induced directly by 
glucocorticoids or secondary to the effect of 
increased tissue concentrations of zinc is not known.
1.4.4 Regulation bv stress factors and mediators
Acute physical, and chemical stresses were reported to 
increase zinc-metallothionein in rat liver COh et a 1.
1978). These stresses causing metallothionein 
induction included, cold environment (322% increase) 
hot environment (56%), heat burn (17%), strenuous 
exercise (218%) and CC1A intoxification (580%). 
Sobocinski et al. (1978) presented evidence to show
that the increase in hepatic zinc metallothionein is 
involved in the zinc redistribution, which occurs 
during acute bacterial infections. Sham operations 
for adrenalectomy produced the largest stress-related 
increase in zinc metallothionein (30 fold) when 
followed over a 2 day period (Brady, 1981).
Inflammation induced by the administration of 
turpentine (Sobocinski and Canterbury, 1982) and 
isopropanol (Swerdel and Cousins, 1984), also induces 
hypozincaemia and hepatic metallothionein synthesis. 
DiSilvestro and Cousins, (1984) and Karin et a 1
(1985) demonstrated with rats that inter 1eukin-1 
administration significantly increases mRNA levels, 
accompanied by an increase in liver metallothionein 
concentrations and hypozincaemia. Cyc1oheximide 
totally blocked these interleukin-1 effects; however 
they were not totally inhibited by Actinomycin D.
The induction of metallothionein in response to 
interleukin-1 suggests a role of metallothionein in
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the interleukin-1 linked host defence mechanisms (see 
sect ion 1.6).
1•5 Degradation of hepatic and renal mammalian 
metallothionein
The apparent half life of cadmium induced metallo­
thionein is reported to be between 2.8 and 6.8 days 
(Shaikh and Smith, 1975, 1976; Feldman et al. 1978a; 
Chen et al. 1975 and Brady et al. 1979). The wide 
range in half life values may be due to either 
experimental error or to the different methods used 
in assessing the half life. The use of the different 
radioisotopes 3H, 1*C or 3SS incorporated into L-
cysteine molecules of metallothionein to estimate the 
degradation of this protein (as described by the 
above workers) would be expected to give variable 
values as the metabolism of sulphur differs from that 
of carbon or hydrogen. It is also possible that the 
half life varies with metal content (ie. Cd:Zn or 
Cd:Cu ratio). Shaikh and Smith (1975, 1976)
calculated that after cadmium administration the half 
life of renal Cd,Cu metallothionein (5 days) was 
almost double that of the hepatic Cd,Zn protein (2-5 
days). However, Cain and Holt (1979) found that the 
rate of degradation and hence turnover of the protein 
varied with metal ratio (Cain and Holt, 1979) - as 
all metallothioneins used had the same total metal 
content. In zinc deficient animals, where the zinc 
content of metallothionein is reduced, the rate of 
turnover for metallothionein was also found to be 
reduced (Bremner et a1. 1978; Cain and Holt 1979).
Zinc and copper metallothioneins are reported to be 
degraded faster than Cd,Zn or Cd,Cu metallothioneins 
- the former having half lives of 19-30 and 10-19
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hours respectively (Feldman and Cousins, 1976;
Bremner et al. 1978; Cain and Griffiths, 1984;
Andersen et a 1. 1978). Thus as zinc and copper
metallothioneins are apparently degraded much faster 
than the cadmium metallothioneins, it may be that the 
secondary cation of the cadmium metallothioneins 
determines the degradation time. It is also possible 
that the presence of a third cation also affects the 
turnover time - particularly as hepatic metallo­
thionein I contains more copper than hepatic metallo­
thionein II and the former also has a shorter 
degradation time (2.2 days) compared with 3. 1 days for 
the latter (Cain and Holt, 1979). The rate of 
degradation of metallothionein in vitro has been 
reported to be in the order apo-metallothionein 
greater than zinc-thionein greater than cadmium/zinc- 
thionein. As the rates of degradation of copper and 
zinc metallothioneins are similar, it seems feasible 
that cadmium is the major factor affecting the 
degradation of mixed metallothioneins. (Bremner,
1979; Whanger and Oh, 1979). The exact mechanisms by 
which the metal composition of the metallothionein 
affects the turnover of this protein are not known. 
There has been speculation that the turnover involves 
lysosomal uptake of the protein and its hydolysis by 
enzymes located therein at a rate which depends on 
the ease of metal removal from the protein (Feldman 
et a1. 1978b; Mehra and Bremner, 1985). In accord
with this view, zinc metallothionein is degraded more 
extensively than cadmium met a 11 oth i one i n (Feldman et_ 
al. 1978b), and zinc metallothionein I more
extensively than zinc meta11othionein II with 
lysosomal enzymes in vitro (Mehra and Bremner, 1985). 
Moreover copper metallothionein is resistant to 
degradation by lysosomal enzymes in vi tro (Mehra and 
Bremner, 1985) which is consistent with the strength 
of the Cu-S bonds, and the accumulation of aggregated 
forms of copper metallothionein in the particulate
36
fractions (possibly lysosomes) (Riorden and Richards, 
1980; Johnson et a 1. 1981). However, it is at odds
with the rapid turnover of copper metallothionein in 
vi tro (Mehra and Bremner, 1985).
However, the metal composition of metallothionein may 
radically alter its conformational state and thereby 
change the proteins suseptabi1ity to proteolytic 
attack. Although there is strong evidence that rat 
liver cadmium, zinc metallothioneins have the same 
solution structure, copper metal 1othionein has a 
different solution structure, thus replacement of 
cadmium or zinc with copper may change the 
conformational structure of metallothionein and, 
therefore, its degradation.
1.6 Occurrence and physico-chemical properties of
non—mamma1ian metallothioneins (comparison with 
mammalian metallothioneins)
Many low molecular weight metal 1oproteins have been 
identified in several phylla of the animal (Kagi and 
Nordberg, 1979) and plant (Rausser and Curvetto,
1980) kingdoms. The parallelism between high storage 
capacity for cadmium by the excretory organs of not 
just mammalian but also non-mammalian organisms has 
led to the identification of metallothionein in the 
latter as well the former group of organisms.
However, because of the varying degrees of 
similarities in physico chemical properties with the 
metallothionein isolated and identified by Kagi and 
Vallee (1960, 1961), not all these proteins are
classed as metallothioneins. The definition of 
metallothionein relates to its structural rather than 
functional character1stics, and as such must include 
structural homology with equine metallothionein, even 
though one or more characteristics of metal 1othionein
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are different. Those cadmium-binding proteins, which 
because of their physico-chemical properties are not 
classed as metallothioneins but are "metallothionein 
like", are briefly reviewed in Appendix I.
1.6.1 Aquatic Vertebrates
Metallothioneins have been isolated from the liver 
and kidney of fish including eel liver (Noel-Lambot 
et al. 1978), plaice liver (Overnall and Coombs,
1979), the hepatopancreas and the kidney of the carp 
(Kito et al. 1986) and liver of the rainbow trout
(Ley et al. 1983; Thomas et a1. 1983). These
metal 1oproteins have similar amino-acid compositions 
to mammalian metallothioneins (high cysteine content 
and’an almost total absence of aromatic amino acids); 
and also have similar molecular weights (9-15 
Kilodaltons), high metal content (5.2%), heat 
stability and U.V. absorbtion spectra characteristics 
to mammalian metallothioneins. With the exception of 
rainbow trout liver metal 1othionein (Ley et al. 1983)
these proteins exist as two isoforms.
Metallothionein has also been located in the acinar 
cells of the hepatopancreas and renal convoluted 
tubules of the carp, using immunological staining 
techniques (Kito et al. 1986). However, further work
to determine the specificity of the anti-carp 
metallothionein antibody used in this method will 
have to be undertaken before the significance of 
these results can be ascertained. Using a double 
immunodiffusion technique these workers were not only 
able to demonstrate possible structural similarities 
between metallothioneins of the hepatopancreas and 
kidney of the carp but also between carp 
hepatopancreas and porcine kidney metallothioneins. 
This exemplifies the structurally similar antigenic
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determinants of metallothionein between certain 
species of fish and mammals.
1.6.2 Arthropods
Metallothionein has be isolated from the 
hepatopancreas of the crab, Scvlla serrata (Olafson 
et a1. 1979). As with the metallothioneins isolated
from aquatic vertebrates, these proteins have similar 
properties to mammalian metallothioneins with little 
difference in amino acid composition. Lerch et a1. 
(1982) demonstrated that the sequence homology in the 
principal metal-binding ligands of the metallo­
thionein from the crab and mammal had been preserved. 
These workers also noted that the amino acid 
sequence homology between metallothioneins from crab 
and mammal is more pronounced in the middle region 
and carboxy-terminal part of the molecule than in the 
amino-terminal part. There is a rigid sequence 
conservation suggesting a fundamental structure- 
related function to this section of the molecule. 
Evidence for the existence of several isoforms of 
metallothionein has been provided by NMR studies 
(Higham et a1. 1986), but further work is required
before these results are deemed as conclusive.
A cadmium-binding protein with a molecular weight of 
3000 daltons had been detected in adult Drosophi1 a 
melanogaster. (Jacobsen et a 1. 1981). Maroni et a 1.
(1986) also isolated a cadmium-binding protein in the 
midgut epitheliam of Drosophila melanogaster larvae 
fed sublethal concentrations of cadmium. This 
protein was induced by cadmium but not zinc (even at 
500 times the level of induction by cadmium). From 
the analysis of a Drosphila complementary DNA (CDNA) 
fragments for this protein, these workers predicted 
the amino acid composition of the protein and noted 
the strong resemblence to mammalian metallothioneins.
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The CDNA fragment was particularly similar to the N- 
terminal portion of metallothionein II CDNA (Karin et 
al. 1982). The arrangement of all 10 cysteine
residues was in a sequence cys-X-cys resembling the 
sequence of 14 of the 20 cysteine residues in 
mammalian metallothioneins.
The cys-X-cys groups occur in similar positions in 
insects as well as crab, and 4 of the first 5 
cysteine groups of the mammalian metallothionein are 
also in comparable positions. This suggests a 
combination of homology and convergent evolution 
possibly brought about by functionaJ constraints.
1.6.3 Molluscs
Cadmium and other heavy metals are concentrated to a 
greater extent in molluscs than in other phylla - a 
fact which lead to recent research into cadmium 
binding proteins (CdBP) of the mollusc.
Of the 3 classes of cadmium binding protein found in 
the Scallop (Pecten maximus), one class has a 
molecular weight of about 10,000 daltons, and 
produced a single peak following DEAE ion-exchange 
chromatography (Stone et al. 1986). The metals in
this protein consisted of cadmium, zinc and copper 
(with molar ratios of 1.0:8.1:0.18 and a 
metal:sulphuryl ratio of 2.0). The molecular weight 
as assessed by SDS gel electrophoresis, was similar 
to mammalian metallothionein (about 8 kiloda1 tons) .
The scallop metallothionein was heat stable and had a 
similar amino acid composition to horse renal 
metallothionein, however, the lower cysteine content 
(16.9%) and the presence of tyrosine and 
phenylalanine were distinguishing features of scallop 
metallothionein compared to horse meta11othionein.
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A 10,000 dalton cadmium binding protein from the 
mussel, Mvt i1 us edulis was isolated and purified by 
ion-exchange chromatography into 4 peaks (Frazier , 
1986). However, only two of these proteins 
(classified as CdBP10 I and III) had a high cysteine 
content (23.9-26.6%). The other two proteins had 
lower cysteine content (11.6-18.2%) but either high 
serine (CdBP10 IV) or low serine (CdBPno I D  
contents. Frazier et al. (1986) also isolated 4 
proteins of a molecular weight of 20,000 dal tons from 
this mollusc; two of which (CdBPso I and IV) 
contained high.cysteine content (23.9-26.6%). All 
eight proteins were also found to have low 
phenylalanine and isoleucine contents, and the CdBP3;0 
proteins were believed to be dimers of the CdBP10 
proteins.
1.6.4 Moulds
A 61 amino-acid polypeptide resembling mammalian 
metallothionein has been isolated from the yeast 
Sacchromvces cerevisiae which has developed 
resistance to toxic concentrations of exogenous 
copper (Karin et a1. 1984b, Fogel and Welch, 1982).
The yeast metallothionein has a high cysteine content 
but also contains two phenylalanine residues. The 
purified protein binds 8g atoms of copper/mole, 
compared to 12g atoms of copper/mole in rat copper 
metallothionein. Cadmium and zinc also bind to the 
yeast protein exhibiting two distinct metal-binding 
configurations-another factor analogous to mammalian 
metallothioneins. Also unlike mammalian 
metallothioneins, transcription of the yeast gene is 
only induced by copper and not other metals such as 
cadmium and zinc.
The amino acid composition of Neurospora crassa 
copper metallothionein (molecular weight = 2000
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dal tons) is again similar to mammalian 
metallothioneins, high cysteine content, no aromatic 
amino acids nor histidine. The protein also has a 
high serine and glycine content (Beltramim and Lerch, 
1986). No free sulphydryl or disulphide groups are 
present in this metalloprotein, which indicates that 
all cysteine residues (7) are involved in metal 
binding (6g atoms of copper/mole). A very low pH 
(<1.0) is also required to displace the metal from 
the protein. Neurospora crassa metallothionein has a 
similar amino-acid composition to mammalian 
metallothionein residues 1-30. The 7 cysteine of 
Neurospora crassa are located in the same position as 
the first seven cysteine residues from the amino 
terminals of mammalian metallothioneins.
The primary structure of Neurospora crassa 
metallothionein has also recently been confirmed by 
gene sequence analysis (Munger et a 1. 1985). It
appears to be a distinct protein and not a product of 
a proteolytic cleavage of a larger molecule. Ultra 
violet absorbtion, circular dichroism, and EPR 
spectroscopy indicate that the copper of Neurospora 
crassa metallothionein is bound to the cysteinyl 
residues as a Copper I thiolate complex and forms a 
polymeric 'U* thiolate structure CCu(l) 6(Cys-S)l.
The Neurospora crassa apo-metallothionein is capable 
of binding Cd(II), Hg(II) and Co(II) with a 
metal/protein stoichometry of 3. However, the EPR 
signals following metal titration of the apo-protein 
show that the 3rd metal is probably differently co­
ordinated to the other two - a factor which may be 
explained by the presence of only seven cysteine 
residues compared to nine in the 3-metal cluster of 
mammalian metallothioneins.
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1.7 Proposed functions of metallothioneins
1.7.1 Detoxification of metals
The role of metallothionein in this area is rather 
obscure, although there is evidence to suggest a 
protective role against low level exposure to 
cadmium, by sequestering this cation and rendering it 
unavailable for interaction with cellular components. 
The detoxification mechanism provided by this protein 
could possibly include the protection of the Na'4', K-4 
ATPase mitochrondrial oxiditative phosphorylation 
system of the rat kidney in vivo (Webb, 1977) as well 
as other mitrochrondrial enzymes of the liver, kidney 
and lung (Prasad et al. 1983), from cadmium or high
concentrations of zinc and copper.
Metal induction of this protein also demonstrates its 
protective role in metal toxicity. Animals which 
have been pretreated with small amounts of cadmium or 
relatively large amounts of zinc, are generally less 
susceptible to a toxic dose of cadmium (as measured 
by an increase in the LD50 value) (Webb and 
Verschoyle, 1976; Webb, 1979). Although 
metallothionein synthesis increased during restricted 
food intake, the LD50 for cadmium had not changed and 
this metallothionein does not appear to protect 
against cadmium toxicity. However, these two systems 
are difficult to compare as the LD50 for cadmium may 
have been affected by other effects brought about by 
the starvation of animals. High concentrations of 
metal 1othionein exist in the tissues of newborn rats, 
but no protective effect against the toxicity of 
injected cadmium salts has been observed (Klaassen 
and Wong, 19S2). This also casts doubt on the 
validity of the "pretreatment protective" mechanism, 
although Ferm and Carpenter (1968) provided evidence
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that zinc pretreatment protected against the 
teralogenic effects brought about by cadmium in 
hamsters.
By far the strongest evidence for the role of 
metallothionein as a detoxifying agent comes from 1n 
vi tro studies, where the increased resistance of a 
CHO cell line was found to be due to the induction of 
metallothionein and not decreased uptake (Hildebrand 
et al. 1982). Resistance to cadmium by cell lines
has also been found to correlate with intracellular 
concentrations of metallothionein, eg. human 
epithelial cells (Rugstad and Norseth, 1975; Haffner 
and Rugstad, 1976).
Following the observation that severe nephrotoxicity 
was caused by the renal uptake of cadmium- 
metallothionein (Cherian et a 1. 1976), and that
circulating cadmium-metallothionein was more 
nephrotoxic than circulating cadmium (Webb and 
Etienne, 1977) it seemed highly unlikely that the 
function of this protein would represent a 
detoxification process. To support this proposal 
Cherian (1982) showed that naive kidney epithelial 
cells did not show any resistance to cadmium toxicity 
when added as metallothionein to the medium.
Gold has been shown to bind and induce 
metallothionein-1ike proteins in the kidney 
(Mogilnicka and Piotrowski, 1979; Thompson et a 1. 
1978). However these proteins bind only a small 
fraction of the total cellular gold (Lawson et a 1.
1977); and thus are not apparently important in the 
detoxification of gold. Although metallothionein has 
been shown to be induced by the metals, bismuth 
(Zelazowski et a 1. 1980a), platinum (Zelazowski et_
al. 1984), and preadministration of bismuth, copper,
zinc, mercury, nickel, cobalt or cadmium protects
14-
mice against a normally lethal dose of cisplatin 
(Nagamura et al. 1985), there is no significant
correlation between protection and metallothionein 
concentration in either the liver or kidney.
1.7.2 Copper and zinc metabolism
The existence of low levels of endogenous (non­
induced) zinc or copper metallothioneins in the 
liver, kidney (Kagi and Nordberg, 1979) and intestine 
(Clarkson et al. 1985) and the induction of this
protein by zinc and copper have led to the suggestion 
that metallothionein has a singular purpose in 
maintaining zinc and copper homeostasis (Webb and 
Cain, 1982; Pattison and Cousins, 1984).
A homeostatic role for metal 1othionein in intestinal 
zinc and copper absorption has been proposed by 
Cousins (1985) and Evans (1979). Although an inverse 
relationship is reported to exist between zinc 
absorption and intestinal metallothionein 
concentrations in rats (Evans and Hahn, 1974;
Richards and Cousins, 1976; Smith and Cousins, 1980); 
in other studies in rats and sheep no such 
relationship has been found, (Hall et al. 1979;
Saylor et al. 1980). Also evidence that copper
induces intestinal metallothionein is far from 
conclusive (Saylor et al. 1980; Bremner, 1980). The
examples where an inverse correlation between the 
efficiency of copper absorption and the binding of 
copper to intestinal meta11othionein may be partly 
explained by the sequestration of copper by 
intestinal mucosal meta11othionein (Hall et a 1. 1979;
Fischer et al. 1983) or disruption of the normal
copper metabolism by genetic or metabolic 
abnormalities (Cohen et a 1. 1979; Leone et ai. 1985;.
As it appears that the genetic abnormalities are 
associated with failure of an unidentified transport
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system for copper, probably In the efflux of copper 
into cells (Leone et a 1. 1985); it follows therefore,
that increased metallothionein concentrations are not 
responsible for impaired copper absorption but are a 
consequence of the defect. From this it is likely 
that in the genetically normal animal, metallo- 
thionein is not part of the homeostatic control 
mechanism for zinc or copper but is more likely to be 
a reflection of a breakdown of regulatory control 
mechanisms under conditions of excessive metal supply 
and increase in intracellular zinc or copper 
concentrat i ons.
A role for metallothionein in the hepatic metabolism 
of zinc and copper has been suggested following the 
induction of this protein by zinc, in vivo and in 
vi tro (McCormick et al. 1981; Fail la and Cousins,
1978; Karin et al. 1980) or by copper (prior to zinc
uptake) in vivo (Wake, 1985). Since the uptake of 
zinc and synthesis of metallothionein occurs in the 
liver of zinc-injected rats, it has been further 
suggested that metallothionein may play an important 
role in the hepatic uptake of the metal, perhaps 
designed to accomodate an influx of zinc into an 
intracellular pool (Cousins 1985) or as a storage 
form of zinc in the liver. However the rapid 
reduction in zinc metal 1othionein concentration after 
zinc-loading (Bremner and Davies, 1975; McCormick et_ 
al. 1981) and the short half life of zinc-
metallothionein (Feldman and Cousins, 1978) indicate 
that this protein probably does not act as a long 
term storage depot for this metal.
There is strong evidence that binding of copper by 
metallothionein in both the cytosolic and particulate 
fractions of the liver results in a reduction in the 
cytotoxicity of the metal (see section 1.6.1) and 
evidence to suggest a role for metallothionein in the
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hepatic uptake of copper (Weiner and Cousins, 1980). 
Isotopic exchange experiments showing the transfer of 
copper from metallothioneins to other proteins and 
enzymes in vitro (Marceau and Aspin, 1973; Terao and 
Owen, 1973) support the view that metallothionein 
plays a intermediary role in copper distribution. 
However the absence of any major disturbance in 
copper metabolism in zinc-deficient animals, in which 
no significant amounts of hepatic copper 
metallothionein are present, is not consistent with 
the obligatory role of metallothionein in the uptake 
and transfer of copper in the liver. Many tissues 
and cell types have the ability to synthesise 
metallothionein in response to copper and zinc 
administration (Olafson, 1981; Onosaka and Cherian, 
1982; Searle et a1. 1984; Durnam and Palmiter, 1981)
There are thus strong grounds for suspecting that the 
function of metallothionein is diverse and possibly 
identical in all tissues, rather than just in 
specific regulatory roles in the control of 
absorption, hepatic uptake or renal tubular 
absorption of these metals.
1.7.3 Host defence mechanisms
The complex system for the regulation of
metallothionein synthesis in animals is subjected to
a wide variety of stresses (see section 1.4.4).
This, together with the correlation between acute 
physical and chemical stress and tissue zinc- 
metallothionein (Oh et al. 1978: Sobocinski et a 1.
1978), suggest that this meta11othionein forms part 
of the host-defence mechanism and has some functional 
significance in cellular metabolism. However, this 
is still a matter of conjecture as this function is 
likely to be related to zinc-dependent processes eg. 
the in vitro induction of meta11othionein by 
glucocorticoids (Karin et al. 1980; Failla and
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Cousins, 1978; Karin and Herschman, 1981); reduction 
in inflammation CSwerdel and Cousins, 1984).
Many treatments which result in metallothionein 
synthesis, such as administration of interleukin-I 
(Disilvestro and Cousins, 1984; Karin et al. 1985),
interferon (Friedman and Stark 1985, Friedman et al. 
1984), and exposure to x-irradiation and increased 
oxygen tension (Camakaris et al. 1983) can cause
increased production of oxygen radicals. This has 
led to a suggestion of a possible role for 
metal 1othionein as a scavenger of free radicals.
The reactivity of metallothionein towards superoxide 
and hydroxyl radicals in an in vitro system has also 
been established (Thornally and Vasak, 1985). The 
bimolecular rate constant for metallothionein 
(Ko h -1012m_1s~1 at 298K) is far greater than the 
corresponding rate constant for proteins 10-50 times 
the molecular weight of metallothionein eg. 
ferricytochrome c (Kos^lO^m-1 s_1 ) . These workers 
have suggested that the primary structure of this 
protein may be a crucial feature in the expression of 
the reactivity with hydroxy radicals, as the target 
of free radical attack believed to be the metal- 
thiolate clusters. Indeed pretreatment of rats with 
high doses of zinc (which induces metallothionein) 
appears to provide some protection against x-ray 
irradiation (Matsubara et a1. 1982; Bakka et a 1.
1982) and other stresses (Hildebrand et a 1. 1980; Oh
et a1. 1978) which cause free radical production.
The 'quenching' by metallothionein is believed to 
occur by loss of metal (ie. reduction), followed by 
oxidation of metallothionein (regaining its former 
metal thiolate status) by a glutathione based pair 
mechanism (Flohe and Gunzler, 1976). Whether such an 
occurance happens in vivo remains to be established.
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1.7.4. Growth and Development
Metallothioneins are found in high concentrations in 
the livers of newborn pigs, foetal and newborn rats 
and both human and lamb foetuses CBakka and Webb, 
1981). Zinc metallothionein which is present in 
tissues undergoing rapid growth and development, may 
serve as a reserve for the supply of zinc and copper 
for nucleic acid metabolism, protein synthesis and 
other metabolic processes (Mason et a 1. 1981; Brady
and Webb, 1981). These authors found that the total 
concentration of zinc and zinc metallothionein 
declines from day 16 after birth to adult in the rat 
liver, after a dramatic rise in total copper and zinc 
just prior to birth. However the testes of the male 
rat have more zinc-metal1othionein (if this protein 
is metallothionein in the testes) than the liver and 
kidneys combined by day 50 after birth. As this 
tissue is possibly the most rapidly developing tissue 
at this stage of development, this provides more 
evidence that metallothionein also has a role in zinc 
(and copper) mobilization to developing tissue. In 
the foetal rat, before closure of the intestine, 
metallothionein is at high concentrations in the 
testes and has been proposed to function regulating 
copper absorption (Mason et al. 1981).
Only one isometallothionein appears to be present in 
both the kidney and testes of the male rat up to 35 
days (Brady and Webb, 1981). Whether this is an 
indication of differing function with different 
isoprotein or as a result of methodolgical problems 
is not known - particularly as problems have been 
found in the isolation of these proteins (see section 
1.3).
Brady and Webb (1981) did observe a decrease in 
hepatic zinc metallothionein when growth patterns
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changed from an increase in cell number to increase 
in cell size in Wistar newborn rats. Ohtake and Koga 
<1979) also presented evidence for the association 
between metallothionein concentration and DNA 
synthesis. However this does not occur in most 
organs of the newborn rat which grow by cell 
proliferation (from days 16-20) eg. kidney and 
testis.
As physiologically, metallothionein appears most 
prominantly in the animal tissues during gestation 
and early postnatal 'life, Webb and Cain (1982) 
proposed that zinc-meta11othionein is a normal foetal 
protein which functions in zinc and possibly copper 
homeostasis. However the capacity to synthesise this 
protein is retained in the adult and can form a 
control mechanism when serious disturbances occur in 
the metabolism of these cations (see section 1.7.2).
1. 8 Sources of exposure to cadmium 
1.8. 1 Occurence and use of cadmium
Cadmium belongs to group IIB of the periodic table, 
with atomic number 48, and an atomic weight of 
112.40. The metal occurs naturally in the 
lithosphere, not in a pure state but always in the 
presence of zinc, and is principally concentrated in 
sulphide deposits. The natural concentration of 
cadmium in rocks is approximately 0.15 - 0.20 pg/g 
but the content in zinc ores may be considerably 
higher, varying from 0.1 to 5%. The production of 
cadmium as a by-product of zinc refining began 
towards the end of the nineteenth :century, but 
increased industrial demand for the metal has rapidly 
promoted its production to the extent that about 70% 
of the total world production has occurred within the
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last 20 years. Between 1960 and 1969, an estimated 
124,207 metric tons of cadmium were produced 
worldwide. This represents more that a twelvefold 
increase since the period 1910 - 1919. The 
properties of cadmium made it suitable for a range of 
uses including pigments, batteries, electro-plating, 
plastics stabilisers, solders and alloys. The 
statistics of the production and usage of cadmium 
have been thorougly reviewed (Friberg et al. 1974;
C.E.C., 1978).
1.8.2 Levels of cadmium in the environment
The contamination of the environment with cadmium by 
natural processes is insignificant compared to the 
dissipation of the element brought about by the 
advancement in industrialisation. However, analysis 
of the cadmium concentration of air samples shows 
that the levels of the metal are generally low, even 
in industrialised areas, but increase significantly 
in the vicinity of cadmium-emitting sources. Table
1.1 summarises the concentration of cadmium found in 
various environmental compartments.
Similarly in areas not known to be polluted by 
cadmium, the concentration of the metal in water is 
low, values of less than 1.0 pg/1 being commonly 
found. In polluted areas levels are higher, though a 
large proportion of the cadmium may be located as 
particulate matter in sediments.
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Table 1.1 The concentration of cadmium In the 
environment
Environmental
Compartment
Concentration of 
Cadmi urn
AIR rural 
urban 
industr ial
u g / n f *
0.0001 - 0.043
0.002 - 0.7
0.01 - 5.0
WATER - mar ine 
f resh 
drink ing
0. 05
1. 0 
<5.0
ug/1
9.0 
10. 0
EARTH - earths crust 
igneous rock 
soi 1
0. 15 
0 . 001 
< 1.0
ug/g
0 . 20 
0 . 6
Data from Friberg et a1. 1974 and C.E.C., 1978
The concentration of cadmium in soils is influenced 
by water supply and air deposition. Many plants 
including foodstuffs are capable of absorbing and 
accumulating considerable quantities of cadmium from 
the soil. Transfer and concentration of the metal 
along food chains may thus be important. A wide 
range of cadmium concentrations have been reported in 
various foods (table 1.2) and has been thoroughly 
reviewed (Friberg et a 1. 1985).
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Table 1.2 The concentration of cadmium In food
Foodstuff Concentration of Cadmium
ug/g wet weight
vegetables 0.001 - 0. 04
cereals 0.005 - 0. 03
fruit 0.001 - 0. 02
milk 0.001 - 0.01
meat 0. 02 - 0. 10
kidney 0.04 - 40. 0
1 i ver 0. 05 - 1. 13
f ish (f1esh) 0.001 - 0.01
oyster 0. 01 - 34. 5
mussels 0. 07 - 0. 6
Data from Friberg et al. 1974; C.E.C., 1978; FA0/WH0,
1981.
There appears to be a tendency towards increasing 
contamination of the environment by cadmium. This 
trend is reflected in a study by Kjellstrom et al.
(1975), who reported a significant increase in the 
cadmium content of cereals harvested between the 
years 1916 and 1972 in Sweden.
1.8.3 Routes of exposure to cadmium
Exposure to cadmium occurs mainly through the lungs 
or the gastro-intestina1 tract. For individuals in 
the general environment, not exposed to cadmium 
occupationally, intake of the metal by inhalation is 
not very significant. For persons living close to a 
cadmium-emitting industry, however, uptake by 
inhalation may become an important source of 
exposure. Tobacco has also been shown to contain
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significant amounts of cadmium and concentrations of 
1-2 jig per cigarette have been reported (Nandi et a 1. 
1969), of which about 10% may be inhaled. Cadmium 
present in the soil may enter the body, either 
directly from soil to crops to human beings, or 
indirectly, from soil to crops to animals to human 
beings, via meat or animal products (Sherlock, 1984). 
Cadmium intake via animals is minimal, but intake 
from crops grown in soil high in cadmium may be cause 
for concern. Leafy crops such as lettuce and 
brassicas, take up more cadmium from the soil than do 
fruit or root crops. In normal soils, the cadmium 
content is around 0.05-1 mg/kg. In abnormal 
conditions, levels of 20-40 mg/kg are possible (Page, 
1981).
Recent research has also considered sewage sludge as 
a source of cadmium applied to the soil. Sludge can 
contain anything between 2 and 1500 mg/kg (Sommers, 
1977). In Europe, a large proportion of sludge is 
disposed of by applying it to agricultural land. It 
is regarded as a valuable soil improver.
Table 1.3 provides an estimate of the contribution of 
various sources to the daily intake of cadmium for an 
individual in the general population. The daily 
intake reflects geographical variations in the 
natural level of cadmium, and the extent of 
environmental contamination, and is influenced by 
culture, dietary habits, etc., but it is estimated 
that the average daily intake of cadmium is around 50 
fjig, with some countries higher (eg. Canada - 80 pg) 
and others lower (eg. UK - 15-30 pig) . This daily 
intake produces an estimated body burden of about 30 
mg of cadmium by the age of 50 years.
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Table 1.3 Contribution of dailv cadmium intake from
various sources
Source Contr i but i on 
MS
AIR - rural 0.0005 - 0. 215
urban 0 . 1 3.5
industrial 0. 05 25. 0
WATER 2 - 4
FOOD 10 - 80
SMOKING (20 cigs/day) 2 - 4
Average daily intake 50
Data from Friberg et al, 1974 and C.E.C., 1978
1.9 Toxicity and metabolism of cadmium In
experimental animals and man
1.9.1 Site of exposure
The development of systemic toxicity to cadmium is 
dependent to an extent upon the route of exposure and 
subsequent uptake into organs, but toxic changes may 
also occur at the sites of exposure, particularly 
after acute exposure.
Morphological and biochemical changes are apparent in 
the lungs of rats exposed to a single treatment of 
cadmium aerosol. Palmer et a 1 , (1975) and Hayes et
al. (1976) observed cellular proliferation and an
55
associated increased content of lipid and DNA.
Various enzymes such as lactate dehydrogenase showed 
elevated activities. Histological changes included 
alveolar swelling and distension of mitochondria. 
Similar results were reported by Bus et al. (1978)
who described decreased lung function, pulmonary 
oedema and interstitial pneumonitis. After repeated 
inhalative exposure in rats, Snider et a 1. (1973)
observed emphysema-1 ike changes and acute vascular 
congestion. Prigge (1978) also reported hyperplasia 
and impaired lung function (decreased gas exchange).
After repeated oral administration of cadmium to rats 
(100 p.p.m for 30 days), Sugawara and Sugawara (1977) 
reported a significant increase in the mucosal weight 
of the duodenum and also observed cadmium zinc- 
metallothionein in this tissue. There was a cadmium- 
induced alteration of various enzymes in the 
duodenum. The ingestion of cadmium has also been 
associated with morphological changes of the 
intestine in rats, indicative of an increased cell 
turnover (Sugawara and Sugawara, 1974). Pathological 
changes in the intestine have also been described in 
Japanese Quail (Richardson et a1. 1974) and damage to
mouse intestine was induced by the metal in vitro 
(Valberg et al. 1977).
1.9.2 Liver
The liver accumulates large amounts of cadmium after 
both acute and long term exposure to the metal. 
Hepatic cellular degeneration, and dilation and 
degranulation of smooth endoplasmic reticulum have 
been observed after the repeated parenteral 
administration of various doses of cadmium to rats 
(Colucci et a1. 1975; Feeder et al, 1977). Similar
findings have been reported after continuous oral 
administration of the metal to rabbits (160 ppm for
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200 days) (Stowe et al. 1972). Faeder et al. (1977) 
demonstrated that these morphological changes were 
accompanied by the elevation of certain plasma 
enzymes which are normally indicative of liver 
damage. An enhancement of gluconeogenesis in rats 
repeatedly injected with cadmium (1 mg/kg for 45 
days) has also been shown, since there were 
significant increases in the enzyme activities 
associated with the process, and depletion of hepatic 
glycogen (Singhal et a 1. 1974).
Potentiation of drug response due to an inhibition of 
hepatic drug metabolising activity by the acute 
administration of cadmium has been reported in mice 
and rats. A decreased microsomal content of 
cytochromes PA3o and bs, together with significantly 
decreased activities of amino-pyrine demethylase, 
aniline hydroxylase, nitroreductase and 0-demethylase 
have been observed (Unger and Clausen, 1973; Hadley 
et a 1. 1974; Johnston et a 1. 1975; Krasny and
Holbrook, 1977; Teare et a1. 1977). A sex-related
difference seems to exist in the ability of cadmium 
to alter drug action in the rat since females are 
less susceptible to the effect (Schnell et al. 1976;
Pence et al. 1977).
Animals exposed to 0.25 mg/kg Cd'2"*", 5 days a week for
24 weeks revealed an increase in SGOT activity. 
However, following a further period of 30 weeks, no 
elvation of the SGOT levels and a decrease in liver 
cadmium concentration was observed (Piscator and 
Axelsson, 1970). These findings suggest that the 
liver damage is reversible with cessastion of 
exposure, and cadmium is lost from the liver in a 
time dependent manner during this period after 
exposure.
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A variety of mechanisms have been proposed to explain 
cadmium-induced liver injury including increased 
lipid peroxidation (Stacey et a 1. 1980), altered
calcium flux across the hepatocyte plasma membrane 
(Farber, 1979) and direct processes (Fowler, 1978). 
However, increased lipid peroxidation or changes in 
calcium flux probably do not play an important role 
in acute Cd hepatoxicity from in vitro studies 
(Stacey et al. 1980; Stacey and Klaassen, 1982). As
cadmium preferentially binds to sulphydryl groups 
(Vallee and Ullmer, 1972), it seems likely that the 
mechanisms of cadmium hepatotoxicity are probably by 
direct action on cellular organelles and 
macromolecules as well as the perturbation of zinc 
and copper availability following their displacement 
from proteins by cadmium, occuring prior to 
metallothionein induction of states of 
metallothionein or glutathione depletion (Pool, 1981; 
Dudley and Klaassen, 1984). However, hepatoxicity 
following chronic cadmium exposure may be due to a 
result of all these mechanisms.
1.9.3 Kidney
The kidney is regarded as the critical organ after 
long term exposure to cadmium although considerable 
concentrations of the metal accumulate after acute 
treatment also. There is little evidence that the 
acute administration of cadmium salts causes 
significant renal damage. When the metal is 
complexed with thiol-compounds, however, retention in 
the kidney is promoted and toxicity may be induced.
A single dose of a mixture of cadmium chloride (10 
umol/kg) and mercaptoethanol caused inteference with 
both glomerular and proximal tubule function in 
rabbits (Giesk.e and Foulkes, 1974). Administration 
of a cadmium-thionein complex also produces
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morphological changes in the proximal tubules 
(Cherian et al. 1976).
After repeated parenteral administration of cadmium 
to rabbits (0.25 mg/kg/day for various time periods), 
histological and biochemical changes have been 
produced in the kidney (Axelsson and Piscator, 1966). 
Cadmium was deposited mainly in the renal cortex and 
degenerative changes were confined to the proximal 
tubules, but with increased exposure time, 
pathological changes were evident in other regions. 
Renal dysfunction was characterised by a proteinuria, 
predominantly of a. and P globulins, and was 
associated with an increased urinary excretion of 
cadmium, glucose and amino acids.
Stowe et al. (1972) have also investigated the renal
effects of cadmium in rabbits but after long term, 
oral treatment (160 ppm for 200 days). The kidneys 
of cadmium-exposed animals exhibited pathological 
alterations including interstitial fibrosis and 
necrosis, and there was also evidence of collagen 
deposition in the glomerulus. Cadmium-induced 
biochemical changes in the kidney have also been 
observed. In swine receiving dietary cadmium (0 - 
1350 ppm for 42 days), a decreased activity of renal 
leucine aminopeptidase was observed (Cousins et a 1. 
1973), and in rats, after parenteral treatment 
(1 mg/kg for 45 days), enhanced activities of the 
renal gluconeogenic enzymes have been reported. Such 
changes may persist even after exposure to cadmium 
has ceased and therefore supports the view that 
cadmiurn-induced changes in the kidney are 
irreversible.
Nomiyarns at a 1, (1973, 1975) have investigated renal
function after both parenteral (1.5 - 15 mg/kg daily 
for various times) and oral (300 ppm for 54 weeks)
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treatment with cadmium. In both cases, cadmium 
induced increases in urinary enzymes, amino acids, 
proteins and glucose, indicating cellular damage. 
Changes in renal function after cadmium injections 
(eg. decreased insulin clearance, and maximum tubular 
capacity for secreting p-aminohippurate) suggested 
disturbances of both glomerular and tubular function. 
Other studies have reported similar findings in rats 
after oral cadmium administration (Kotsonis and 
Klaassen, 1978) and after parenteral administration a 
mixed type proteinuria was confirmed. Proximal 
convoluted tubular degeneration, with swelling and 
vacuolation has been noted in Wistar rats given 300 
ppm Cd^-*- in their drinking water or diet for 24 weeks 
(Nishizumi, 1972). These changes may appear much 
earlier on exposure to lower levels of cadmium. Thus 
Stowe et al. (1972) produced similar renal changes in
rats at 24 weeks with 160 ppm cadmium in drinking 
water. It is possible therefore, that cadmium in 
high concentrations either inhibits its own 
intestinal transport or damages the intestinal 
mucosa, such that only part of the cadmium is 
absorbed. Such efforts may be inferred from the 
results of Itokawa et a 1. (1974) and Stonard and Webb
(1976). In the former study, 50 ppm cadmium in the 
diet produced moderate to severe degree of necrosis 
of the proximal tubule at 17 weeks, whereas the 
latter did not produce renal dysfunction before 37 
weeks at a dose of 100 ppm. Kawai and co-workers
(1976) described a series of studies of different 
animals using different cadmium doses. They divided 
the renal effects into "acute", "subacute", 
"subchronic" and "chronic". The more acute lesions 
had hydrophic swelling and acidophilic necrosis as 
the main feature; whereas the more chronic lesions 
were characterised by typical tubular atrophy.
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1.9.4 Test i s
The induction of testicular damage in rats and mice 
by the acute parenteral administration of cadmium was 
described by Parizek (1957). The effect is 
restricted mainly to those species possessing scrotal 
testes. This selective response is produced by 
cadmium at doses of approximately 0.012 mmol/kg (1.35 
mg/kg) (Gunn et a1. 1968), and consists of
haemorrhagic necrosis within 48 hours, followed by 
atrophy and permanent sterility.
Cadmium also disrupts the nuclei of spermatogenia, 
spermatocytes and spermatids. The interstitial cells 
become necrotic and spermatozoa disintegrate. 
Widespread calcification followed by
revascularization of the testis occurs. Regeneration 
occurs with a marked proliferation of the 
interstitual cells from which tumours develop 
(Samarawickrama, 1979). Maintenance doses of
testosterone completely prevent the degeneration of 
the distal epididymal tract and maintain normal 
reaction and fertility indicating that these changes 
are secondary due to androgen loss from testicular 
injury (Sacksena et al. 1977). Onset of the
testicular nerosis is marked by a loss of hormonal 
control over accessory glands leading to a reduction 
in their size (Maekawa et a 1. 1965). Biochemical
changes such as a decrease in the testicular content 
of DNA, RNA and zinc-containing enzymes such as 
carbonic anhydrase have been observed (Johnson and 
Walker, 1970; Webb, 1972). An action of cadmium on 
the utilisation of zinc by spermiogenic cells has 
also been indicated as a possible mechanism for the 
toxic effect (Lee and Dixon, 1973).
These testicular effects have also been related to 
the lack of macro-molecules with high cysteine
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content such as metallothionein and glutathione 
(Waalkes et al. 1984).
1.9.5 Bone
Cadmium does not accumulate to any considerable 
extent in osseous tissue so an effect of the metal on 
the bone is generally considered to be secondary to 
disturbances of calcium and phosphate metabolism 
caused by the cadmiurn-induced renal damage, and such 
effects probably, therefore, require a long time to 
develop.
An acute and subacute effect of cadmium on the bone 
has, however, been reported in rats. Furuta (1978) 
administered cadmium chloride by subcutaneous 
injection at a single dose of 11.2 mg/kg, or 
repeatedly at 1.7 mg/kg/day for 21 days, and observed 
thinning of the epiphyseal cartilage, the effect 
being more severe after repeated dosing. Increased 
numbers of osteoclasts, and osteoporotic changes were 
noted.
Itokawa et al. (1973) administered dietary cadmium to
rats (200 ppm) for relatively short periods (30 days) 
and observed some changes in the metal content of 
bone, such as a decreased concentration of zinc and 
magnesium. There are also reports of histological 
changes in the bone, especially thinning of the 
epiphyseal cartilage and cortical tissue, after the 
administration of dietary cadmium (Itokawa et a 1.
1974, 1978: Takashima et al. 1978). These changes
were accompanied by pathological changes in the 
kidneys. Yoshiki et a 1. (1975) have demonstrated the
presence of osteoporotic changes in the bones before 
the development- of renal damage, in rats fed dietary 
cadmium (10 - 300 ppm for 12 weeks).
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Other workers have shown an effect of cadmium upon 
various aspects of calcium metabolism, eg. Kawamura 
et al. (1978). Ando et al. (1977, 1978) using rats
dosed orally with cadmium (10 mg/kg daily for up to 
24 weeks) observed a decreased intestinal absorption 
and bone uptake of calcium, while the half-life of 
calcium decreased and its excretion was enhanced.
The decreased calcium absorption in rats has been 
related to a decreased binding activity of the 
calcium-binding protein in the duodenum and kidney 
(Sugawara, 1977). In vitro studies have provided 
similar evidence for cadmiurn-interference in the 
uptake and metabolism of calcium (Gruden, 1977; 
Hamilton and Smith, 1978; Yuhas et a1. 1978). It is
well documented that calcium-deficiency enhances the 
cadmiurn-induced changes in bone and calcium 
homeostasis (eg. Larsson and Piscator, 1971; Itokawa 
et al. 1978).
Feldman and Cousins (1973) have demonstrated an 
inhibition by cadmium of the renal hydroxylation of 
25-hydroxycholecalciferol in chicks, in vitro, and 
similar findings have been reported in vivo in rats 
exposed to cadmium in drinking water (Lorentzon and 
Larsson, 1977). A cadmium-induced disturbance in 
vitamin D metabolism may therefore be important.
1.9.6 Cardiovascular system
An acute effect of cadmium upon the cardiovascular 
system is dependent upon the dose, route of 
administration and species. Both increases and 
decreases in blood pressure have been observed (Perry 
and Yunice, 1965; Perry et al. 1970). The
development of hypertension has been studied after 
long term exposure to cadmium. Schroeder and Vinton 
(1962) induced hypertension in rats with chronic 
administration of low levels of dietary cadmium 0 5  
ppm), but at higher levels of cadmium (50 ppm), blood
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pressure may be reduced (Perry and Erlanger, 1974).
A biphaslc action of cadmium is therefore possible. 
Other workers have produced hypertension in rabbits 
after repeated parenteral administration of cadmium 
(2 mg/kg) and demonstrated decreased vascular 
reactivity to angiotensin in vitro (Fischer and 
Thind, 1971; Thind, 1972). Disturbances in the 
renin-aldosterone system have also been indicated 
(Perry and Erlanger, 1973), and inhibition of the 
enzymes responsible for the deactivation of 
catecholamines in the aorta has also been described 
(Revis, 1978)..
Using hypertension sensitive and resistant strains of 
rats, Ohanian and Dahl (1976), and Ohanian et al. 
(1978) have suggested that genetic factors may be a 
critical determinant in this cadmium induced 
hypertension. Such genetic differences observed are 
interesting in that they may account, in part, for 
the differences observed in individual laboratories.
1.9.7 Haematopoietic system
Anaemia is a common finding after cadmium-treatment 
but the exact mechanism is not known. Repeated 
parenteral administration of the metal to rabbits 
(1 mg/kg) produced an increased destruction of 
erythrocytes, pathological changes in the bone 
marrow, and lowered incorporation of iron, which 
caused a microcytic, hypochromic type of anaemia 
(Berlin and Friberg, 1960; Berlin et a 1. 1961).
Decreased haematocrit and haemoglobin levels have 
commonly been reported after both acute oral dosing 
(Kotsonis and Klaassen, 1977) and repeated dietary 
administration of cadmium (eg. Jacobs et a 1. 1969;
Doyle et a1. 1974; Prigge et a1. 1977).
Morphological changes in the spleen of rats have been 
reported after repeated parenteral dosing (Der et a 1. 
1977).
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Several authors (Fox et al. 1971; Hamilton and
Valberg, 1974; Prigge et al. 1977) believe that
cadmium alters the absorption of dietary iron which 
in turn produces an iron deficiency anaemia.
However, Washko and Cousins (1977) have shown the 
reduction in body iron and packed cell volume is 
directly related to cadmium ingestion and not 
secondary to reduced diet consumption.
1.9.8 Miscellaneous effects
Various other toxic manifestations of cadmium 
treatment have been reported in experimental animals. 
Appreciable amounts of cadmium also accumulate in the 
pancreas and parenteral administration of the metal 
to mice (2.0-6.0 mg/kg) has been shown to produce 
hyperglycaemia and glucose intolerance (Ghafghazi and 
Mennear, 1973), associated with a significant 
decrease in circulating serum insulin. Other studies 
in rats using lower doses of cadmium (0.25-0.5 mg/ 
kg) failed to show significant changes in blood 
glucose and insulin, though glucose metabolism was 
affected, eg. glycolysis and tricarboxylic acid cycle 
(Ithakissios et al. 1974).
Haemorrhagic lesions in the sensory ganglia of the 
nervous system have been reported after parenteral 
administration of high doses of cadmium to adult rats 
(2.5 - 28 mg/kg) (Gabbiani, 1966), but the brain was 
reported to be unaffected (Gabbiani et a 1. 1967; Wong
and Klaassen, 1982). Behavioural effects such as 
depressed spontaneous locomotor activity have been 
observed in rats following prenatal exposure to the 
metal (Hastings et a 1. 1978).
Other effects include disturbances in nucleic acid 
synthesis exemplified by a cadmium dependent 
inhibition of RNA polymerase activity in rats (Stoll
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et a1. 1976; Hidalgo et al. 1976); and inhibition of
protein synthesis has also been reported using 
isolated ribosomal preparations from the livers of 
mice following an acute parenteral administration of 
cadmium (Gramulin et al. 1977). The effect of
cadmium on the activity of many metallo-enzymes has 
been reported. Coleman and Vallee (I960) reported an 
altered specificity of the enzyme - carboxypeptidase; 
the peptidase activity is abolished whilst the 
esterase activity is retained. A decrease in renal 
alkaline phosphatase activity has also been reported 
(Axelsson and Piscator, 1966, Jenny et al. 1979) as
well as bone isoenzyme activity (Sufgawara et a 1.
1983). However an increase in alkaline phosphatase 
activities in liver and testes of rats was observed 
after an acute cadmium administration (5.0 mg/kg) 
(Junko et al. 1985). Increases in renal and
intestinal glutathione peroxidase were also reported 
in cadmium exposed rats, while no observable effect 
on this enzyme was recorded in the liver, heart and 
erythrocytes (Kaur, 1982).
Cadmium exposure may also influence antibody 
production and the humoral immune response (Kook et_ 
al. 1975; Koller et al. 1975, 1976; Koller, 1979).
However, Fuzimaki et al. (1982) found that low
cadmium concentrations (2-8 ug) significantly 
Increased the antibody production while high 
concentrations ie. 20-40 ug were inhibitory. There 
are controversial reports regarding the effects of 
cadmium on cell-mediated immune response with both 
inhibitory and stimulating effects reported (Gawonski 
and Sharma, 1978, Koller et a1. 1979; Muller et a 1.
1979; Bozelka and Berkaholder, 1982).
Several investigators have demonstrated the 
development of sarcomas at the injection site after 
doses of both cadmium metal (Heath et al. 1962) and
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metal salts (Roe et al. 1964). Takenka et a 1. (1983)
have also demonstrated a high incidence of lung 
cancer following long term inhalatory cadmium 
exposure.
Cadmium was found to cause chromosomal abnormalities 
in cultured human leucocytes (Shiraishi et al. 1972),
in human peripheral leucocytes from normal subjects 
(Shiraishi et a 1. 1972) and in human peripheral
leucocytes from Itai-Itai patients (Shiraishi and 
Yoshida, 1972).
Several studies have demonstrated the teratogenic 
action of cadmium on the developing CNS, resulting in 
brain abnormalities (Ferm, 1971; Barr, 1973; Gale and 
Layton 1980).
1.9.9 Health effects in humans
In human beings, the main targets of cadmiurn-toxicity 
after acute exposure to the metal are the gastro­
intestinal tract following ingestion, and the lungs 
following inhalation. After long term exposure, the 
lungs and the kidneys are primary target organs.
Acute oral toxicity has usually resulted from the 
accidental ingestion of contaminated -foodstuffs, and 
produces symptoms such as nausea and other 
disturbances of gastro-intestinal function. Liver 
and kidney damage may follow and in severe 
intoxification, death may result (C.E.C., 1978).
A) Occupational exposure
Cadmium inhaled in the form of fumes or dust can lead 
to lung damage* even after very short- periods of high 
exposure, but this is mainly confined to those 
occupationally exposed (Townsend, 1982; Lucas et a1.
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1980). Other symptoms Include nausea, headache, 
dizziness, etc. (C.E.C., 1978). The possibility of
long term effects developing after acute inhalative 
exposure has not been properly investigated.
The most common form of chronic poisoning in man 
results from the long term inhalation of cadmium dust 
or fumes. Pulmonary oedema, pneumonitis, emphysma 
and other changes in lung morphology have been 
reported, and produce an impaired respiratory 
function (Kazantzis et al. 1963; Gill, 1978; Lauwerys
et al. 1978; Lucas et al. 1980; Townsend, 1982).
Exposure to cadmium via inhalation inevitably leads 
to an accumulation of the metal in other tissues, 
especially liver and kidney.
Renal tubular malfunction, usually characterized by 
proteinuria has been commonly reported, usually in 
industrial workers (Kazantzis et al. 1963; Adams et.
al. 1969; Frlberg et al. 1974; C.E.C., 1978;
Kazantzis, 1978). Occasionally these effects have 
been associated with osteomalacia-like changes. 
Kjellstrtim et al. (1977) have demonstrated an
increased prevalence of oc^-microglobul in in the urine 
of workers exposed to cadmium industrially.
Other health effects of cadmium have not been 
recorded in detail, although the potential of the 
metal to be carcinogenic and to produce hypertension 
has been considered. Some researchers have 
investigated the incidence of malignancies in cadmium 
workers (eg. C.E.C., 1978, Kazantzis, 1985) and
correlated the extent of pollution by cadmium to 
mortality rates caused by cardiovascular diseases.
The development of high blood pressure has been 
related to blood and tissue cadmium levels, but
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health studies of occupationally exposed personnel 
have not shown a tendency towards hypertension.
B) Non-occupat1ona1 exposure
The occurance of cadmium poisoning in Japan due to 
environmental exposure - the so-called Itai-Itai 
disease is beyond the realms of this thesis. To 
review the literature and opinions of this subject 
readers should refer to, eg. Friberg et al. 1974:
Edited Proceedings First International Cadmium 
Conference, 1978; Friberg et al. 1985. However, some
of the important features will be indicated.
Various regions of Japan, particularly the Toyama 
region have been found to contain high concentrations 
of cadmim in the environment. A high incidence of 
the unusual disease (Itai-Itai), characterised by 
severe pain in the joints and bones, and other 
skeletal malformation was noted around 1948. 
Subsequent investigations have indicated a possible 
role for cadmium in the aetiology of the condition 
which occured mainly in post menopausal, multi-parous 
women. The skeletal condition was associated with 
renal damage and the symptoms of the disease were 
exacerbated by dietary factors such as deficiencies 
of calcium, protein and Vitamin D (see the review by 
Kjellstromm 1985). Some workers have doubted the 
importance of the role played by cadmium in the 
pathogenesis of the disease. Further investigations 
of the effects of cadmium on the kidney in the area 
where Itai-itai disease was epidemic and in other 
cadmium-polluted regions of Japan have been reported 
(Nogawa et al. 1975, 1978; Kjellstrom, 1977).
High levels of cadmium have been found in the soils 
of farm land and in the vegetables grown in and 
around the village of Shipham, Somerset, U.K. (29-
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880 ug/g soil), where high levels of pollution are 
associated with zinc mines (Dept. Environment/MAFF,
1979). However, despite claims that there could be a 
health risk for those eating large quantities of 
these vegetables (MARC 1982), the final report of the 
Department of the Environment (1982) found that there 
was no evidence of a health problem due to cadmium in 
the soil, and that cadmium intake per person was not 
much above the UK average. The residents were 
advised to give up smoking, and not to eat locally- 
grown leafy vegetables, which were found to contain 
high levels of.cadmium. Thomas (1982) suggests that 
the low intake is due to the low availability to 
plants of the form of cadmium present in the soil, 
dietary preferences, and population mobility.
1.10 The importance of studies on cadmium toxicity — 
the risk to human health
The occurance of cadmium in the environment has been 
reviewed in an earlier section. Similarly, the 
metabolism and toxicity of the metal after various 
routes of exposure has been discussed, mainly in 
relation to animal studies. The importance of these 
findings to possible health effects in humans is a 
complex question. In an attempt to relate exposure 
and accumulation of the metal, an elaborate eight- 
compartment kinetic model has been formulated by 
Kjellstrom and Nordberg (1978). Accepting the 
limitations of such a mathematical model, it appears 
to be able to calculate the cadmium accumulation in 
several tissues with reasonable accuracy (Elinder et_ 
al. 1978; Ellis et al. 1981, 1984; Roels et a 1.
1981).
The present view of risk is based on the assumption 
that a critical concentration of cadmium needs to be 
attained in a critical organ which is the kidney
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after long term exposure. This has been estimated to 
be about 200 ug/g in the renal cortex (Roels et al. 
1981, 1983). A daily intake limit of 60-70 ug/day of
cadmium from all sources is recommended by the WHO as 
the level at which accumulation likely to lead to 
dangerously high levels in the kidney will not occur 
(WHO, 1980).
The critical concentration is a fundamental variable 
in cadmium dose-response analysis. It varies between 
individuals and it is, therefore, not possible to 
find one single value for the critical concentration. 
However, using population critical concentrations 
(defined as the proportion of a population that has a 
critical concentration below a certain level, PPC), 
an attempt to estimate the exposure required to reach 
this critical concentration has been made 
(Kjellstromn, 1985) and thus some measure of a safety 
margin can be provided. However, the existance of a 
critical concentration of cadmium in the human renal 
cortex has been questioned (Nomiyama, 1977).
After making assumptions for the retention and 
excretion rates and factors such as the proportion of 
dose deposited in the kidney, it has been estimated 
from epidemiological studies that 10% of a population 
orally exposed to an average of 200 ug cadmium per 
day is likely to develop tubular proteinuria at an 
age of 45, and this is sufficient to reach the 
critical concentration in the renal cortex 
(Kjellstromn 1985). When we consider that the average 
daily intake of cadmium is around 50 ug and that 
smoking may significantly contribute to the body 
burden, then the safety margin for cadmium is low.
It should also be indicated that no effect levels for 
long term exposure to cadmium are not adequately 
def ined.
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The Increase In the body burden of cadmium form a 
negligible amount in a newborn human (< 1 ug) 
compared to about 30 mg in a 50 year old adult. This 
illustrates that exposure to and accumulation of the 
metal is unavoidable and progressive. The continuing 
demand for the metal would suggest that exposure will 
increase due to greater environmental contamination 
resulting in an increased health hazard to society. 
Thus a greater understanding of the toxicology and 
metabolism of cadmium would seem essential to the 
well being of society. The studies described in this 
thesis was designed to investigate the role of the 
cadmium binding protein - metallothionein in cadmium 
metabolism and toxicity; particularly in the areas of 
mechanisms of cadmium toxicity/metabolism and in the 
diagnosis of cadmium exposure/toxicity.
1.11 Alms of this thesis
The work presented in this thesis is a study of 
varous aspects of the metabolism and kinetics of 
cadmium and diagnosis of cadmium exposure and 
toxicity, particularly relevent to the role 
metallothionein plays in these events.
The study set out to investigate:-
1. Characterisation of the rat liver
metallothioneins and the sheep anti-(rat liver 
metallothionein) antiserum for use as 
experimental tools.
2. Role of metallothionein in the absorption, 
transport, distribution and excretion of 
cadmi urn.
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3. Significance of metallothionein in the toxicity 
of cadmium.
4. The value of urinary metallothionein in the 
detection of cadmium exposure in the rat and 
man, so as to establish a model for following 
the course of cadmium
toxici ty.
CHAPTER 2
Characterisation of rat liver Cd,Zn 
Metallothionein I and II and sheep 
anti-rat metallothionein antiserum for 
the further development of radioimmuno­
assay for metallothionein
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2.1 IntroductIon
The availability of a sensitive and reliable assay 
for the estimation of metallothionein is a 
prerequisite for a clear understanding of the 
functions of this protein. A method used in the 
determination of metallothionein must be valid for 
complex mixtures, and the effects of other biological 
molecules bearing multiple thiolate and/or other 
metal-binding functional group must be considered. 
Thus a method is restricted by its capability to 
characterise and quantify not only endogenous 
metallothionein but also internal or external 
standard metallothionein.
Certain current methods of metallothionein estimation 
in biological samples have relied on rather non­
specific parameters such as the metal content of the 
protein (Piotrowski et a1. 1973; Onosaka and Cherian,
1982b), thiol content of the heat-stable proteins in 
a tissue homogenate (Olafson and Sim, 1979, Menzel &t_ 
al. 1982), or by metal Cd®**, Hg2^  or Ag-* saturation
techniques (Kotsonis and Klaassen, 1977, 1979;
Patierno et al. 1983; and Waalkes et al. 1985,
Scheuhammer and Cherian, 1986). However, more 
specific procedures for the measurement of this 
protein have been developed in the last few years by 
the advent of radioimmunoassay.
One of the criteria in developing a radioimmunoassay 
to any protein is that the protein (or antigen) must 
be of a high purity. Metallothionein is commonly 
purified from the cytosol fraction of a liver 
homogenate by a combination of gel-fi1tration and 
ion-exchange chromatography (eg. Kagi et al. 1974 
Bremner and Davies, 1975). However isolectric 
focusing (Nordberg et a 1. 1972), preparative
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electrophoresis (Zelazowski et a1. 1980a), covalent
chromatography (Ryden and Deutsch, 1978, Bremner and 
Mehra, 1983), and hydroxy-apatite chromatography 
(Chen and Whanger, 1980) have also been used.
Although the purification method by a combination of 
gel filtration and ion-exchange chromotography did 
not give the highest degree of purity or recovery, it 
has been used more than other methods because of the 
larger scale of preparation obtainable. However 
specific measure of purification has been made using 
this method. Vandermallie and Garvey (1978) used 
cadmium and total protein as a measure of percentage 
recovery and purification of. Cd, Zn-metal lothionein 
from the rat liver homogenate. However, as 62% of 
the cadmium was lost during the preparation, this 
only gave an apparent 11-fold purification on a ug 
Cd^'/mg protein basis. Winge et a 1, (1981) used
copper and total protein as a measure of purification 
of copper metallothionein from rat liver homogenate. 
Again as copper was lost during the preparation 
(99%), an apparent 400-fold purification (ug Cu^'/mg 
protein) was observed. Thus a more specific 
measurement of purification/recovery may be made 
using a metallothionein radioimmunoassay whereby the 
content of metallothionein at each preparative stage 
is determined by its immunoreactivity.
For the development of a quantitative radio­
immunoassay, a specific antibody to the antigen has 
to be obtained. This has proved difficult as 
metallothionein is a small molecular weight protein, 
and the metallothioneins from different mammalian 
species show a marked degree of homology (see section 
3.4.1), thus this protein may not evoke an immune 
response following its injection into an animal of 
another species.
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As native metallothionein was found to be a poor 
immunogen, the pioneers of the work on the 
immunogenicity of metallothionein, VanderMallie and 
Garvey (1978), demonstrated that the immunogenicity 
of metallothionein could be greatly increased by the 
use of a polymerised form of this protein. When 
rabbits were immunized with both soluble and 
insoluble polymers of rat liver Cd,Zn- 
metallothionein I or Cd,Zn-metallothionein II, 
prepared using glutaraldehyde, between 10-20% of the 
animals produced high titre antisera (Garvey et al.
1982). Complete cross-reaction occurred between the 
apo-, or the Zn- and Cd- containing metallothioneins. 
The RIA subsequently developed by VanderMallie and 
Garvey (1979) had a detection limit of about 1.0 ng. 
The detection limit was later reduced to about 100 pg 
using a modified procedure (Chang et a 1. 1980a), and
again reduced to 1 pg using inverse variance weighted 
logit-log regression analysis (Garvey, 1984). Thus 
metallothionein in the serum of young healthy human 
non-smokers, could be detected.
Antiserum obtained by Tohyama and Shaikh (1978) by 
the immunization of rabbits with rat liver Cd,Zn- 
metal lothionein II, precipitated both rat liver 
Cd, Zn-metallothionein I and II in a double diffusion 
assay. When cadmium labelled metallothionein was 
used, as little as 0.1 ug metallothionein could be 
detected. There was complete cross reactivity with 
rat and rabbit liver and human kidney 
metallothionein, whereas metallothionein from the 
crab hepato-pancreas did not show any cross 
reactivity. The generation of rabbit antibodies to 
rat liver Zn-metallothionein II and their application 
in an RIAfor meta1 lothionein was also reported by 
Brady and Kafka (1979). The binding of 1osCd- 
meta11othione in II to the antibody was inhibited to 
an equal extent by Cd-meta11othionein I, Cd-
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metallothionein II, and Zn-metallothionein I and II, 
indicating that total metallothionein concentrations 
could be measured with this assay. However this 
assay had a linear working range of 10-500 ng 
metallothionein, - indicating a far lower sensitivity 
than the original RIA developed by VanderMallie and 
Garvey (1978).
A difference in the immunoreactivities of the 
different isoforms of rat meta11othionein was 
reported with a competitive binding assay using an 
anti-rat hepatic Cd-metallothionein II antiserum 
(Chen and Whanger, 1980). The various liver and 
kidney metallothionein II isoforms cross-reacted by 
72-103%, whereas equivalent forms of meta11othionein 
I showed only about 25% cross-reactivity.
Higher titre antibodies to rat liver metal lothionein 
I were obtained by Mehra and Bremner (i983), by 
immunizing two sheep with a rat liver Cd- 
metal lothionein I - immunoglobin G conjugate. There 
was equal cross reactivity between Zn,Cd- and Zn,Cu- 
metallothionein I with the antiserum. No significant 
cross-reaction was reported with the various 
metallothionein II isoforms of the rat liver. An RIA 
method was developed by Mehra and Bremner (1983), 
using this antiserum. Logit-log transformation 
described by Rodbard and Lewald, (1970) was also used 
giving a linear working range from 100 to 11,000 pg 
of protein. This assay has been used as a very 
successful research tool, but it is obviously limited 
to research on just the single isoform, and not as 
sensitive as the assay optimized by Garvey (1984) .
The preparation of a monoclonal antibody against 
liver metallothionein I and II by the immunization of 
mouse lymphocytes in vitro with a mixture of rabbit 
liver meta11othionein forms I and II, has been
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reported (Talbot et a 1. 1986). However even the most
specific antibodies (anti-rabbit metallothionein I 
and II) were not specific to the rabbit but cross­
reacted with hamster liver meta11othioneins.
Although they may prove useful in the development of 
RIA procedures, in order to investigate possible 
specific functions for each of these isoforms.
Both 1 oe*Cd- and 1 ^ ^I-label led metal lothionein have 
been used in RIA procedures, but specific activities 
of the 1°3Cd-label led protein have been only 1-2 x 
10*=- cpm/mg protein below that required for a 
sensitive RIA. Radioiodination of proteins is 
normally accomplished by incorporating iodine into 
their tyrosine residues (Greenwood et a 1. 1963). As
metallothionein does not contain tyrosine (Kagi and 
Nordberg, 1980), the 12SI-label1ing of this protein 
has been carried out by the conjugation procedure 
developed by Bolton and Hunter (1973). This involves 
the reaction of N-succinimidy1 3-(4-hydroxy 5- ['^1] 
iodophenyl) propionate with free amino groups in the 
protein. Chang et al. (1980a) used a modification of
this procedure which involved initial reaction of N- 
succimidyl 3-(4-hydroxypheny1) propionate with 
metallothionein, followed by radioiodination of the 
conjugate using the conventional chloramine-T 
reaction. The radio-labelled antigens prepared by 
this method had very high specific activities but 
quickly aged, having to be used within 2-3 weeks of 
preparation (Garvey et al. 1982).
Separation of free and bound radio-1abe11ed antigens 
has usually been achieved by double-antibody or 
ammonium sulphate precipitation procedures. The 
solid phase double-antibody method used by Maiti et_ 
a1, (1982), is a faster separation procedure than the
solution phase method by Garvey et a1. (1982), but as
the cost of solid phase is high its use has been
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limited. Brady and Kafka <1979) separated the 
immunoprecipitate produced by the second antibody by 
filtering the assay mixture through cellulose 
acetate, but this is not suitable for large numbers 
of samples. Tohyama and Shaikh (1981) used the 
ammonium sulphate precipitat ion method which is both 
cheap and quick. However, high non-specific binding 
<11%) can be a potential source of error, especially 
in an RIA which utilises low titre antibodies, such 
as those used by these workers.
Recently an enzyme linked immunoabsorbant assay 
<ELISA) has been developed for the detection and 
quantitation of metallothionein (Garvey, 1984; Thomas 
et a1. 1986). The assay is heterogenic. The
reference antigen is in the solid phase, coated to 
the walls of a microtitre plate; the competitor 
antigen is in the fluid phase, competing with a 
rabbit primary anti-rat-metallothionein antibody. An 
enzyme-conjugate (alkaline phosphatase coupled to 
goat anti-rabbit IgG) then subsequently binds to the 
immobilized antigen-antibody complex. Quantitation 
of metallothionein is made using a substrate (4- 
methy1-bel1ifery1 phosphate) which reacts with the 
enzyme-conjugate to form a fluorogenic product (4- 
methy1- bel1 iferone) . The linear working range 
(using inverse variance weighted logit-log 
regression) was found to be 100 pg-40 ng of competing 
antigen and the accuracy was reported to be 5-10%. 
This working range and accuracy is similar to the RIA 
used by Chang et al (1980). The main advantages of 
the ELISA system are the rapidity with which the 
assay may be performed and the absence of radioactive 
material in its execution.
A sheep antibody to rat liver metallothionein I 
conjugated to chick gamma globulin has been developed 
in our laboratory (Carter, unpublished observations).
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This antibody was used in the development of a 
radioimmunoassay for the measurement of 
metallothionein. The aim of the work presented in 
this chapter was to:-
a) further characterise the metallothionein 
isolated from rat liver and the sheep anti-rat 
metallothionein antiserum produced in our 
laboratory,
b) further develop the radioimmunoassay to give 
the highest sensitivity and largest linear 
working range for the routine measurement of 
metallothionein in different tissues and body 
fluids.
2.2 Exper1men t a1
2.2.1 Ma ter i a 1s
In general, all chemicals and biochemicals were of 
analytical (Analar) grade with the exception of 
nitric acid used in atomic absorbtion
spectrophotometry which was of high purity (Aristar) 
grade. Most chemicals were obtained from B.D.H.
Ltd.(Poole, Dorset, U.K.). Diamino benzidine was 
obtained from Sigma Chemical Co. Ltd. (Dorset U.K.). 
Sephadex G25, G75 and DEAE Sepharose CL6B were
supplied by Pharmacia (G.B.) Ltd. (Hounslow, Middx., 
U.K.). DEAE-cellulose was supplied by Whatman Ltd. 
(Maidstone, Kent U.K.). The YM5 and YM10 diaflo- 
ultrafiltration membranes were obtained from Amicon 
Corp. (Stonehouse, Gloucester, U.K.). The cellulose 
nitrate paper was of 0.45p. thickness and was supplied 
by Schleicher and Schuell (Keene, New Hampshire 
U.S.A.). Carrier free Na'1 I was obtained from
Amersham International Ltd. Donkey anti-sheep IgG
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antiserum, and horse serum were all obtained from 
Guildhay Antisera Ltd., (Dept, of Biochemistry, 
University of Surrey, Guildford, Surrey, U.K.). The 
sheep anti-rat metallothionein antiserum and anti-rat 
cytosol antiserum were produced in our laboratory.
2.2.2 Analytical methods
A) Protein determination
Protein was estimated by the method of Lowry et a1 
(1951) using bovine serum albumin as a standard. 
However, as the Lowry estimation has been reported to 
give 2.5 fold higher values than protein estimations 
by nitrogen content (Vander Mai lie and Garvey, 1978), 
all protein determinations were divided by this 
f actor.
B) Metal determination
Cadmium, zinc and copper were measured by atomic 
absorption spectrophotometry using an SP9 
Spectrophotometer (Philips, Cambridge, U.K.) with 
deuterium background correction. For the measurement 
of cadmium, a slotted tube trap accessory was 
incorported. This accessory is a double slotted 
quartz tube which is supported above the 
air/acetylene flame from a conventional burner. A
3.5 fold increase in sensitivity over conventional 
methods has been reported (Milner, 1983)
This method gave recoveries of >98% zinc and copper 
at concentrations of 0.4 pg/ml with a coefficient of 
variation of <+8% at a concentration of 0.1 pg/ml. 
Incorporation of a slotted tube atom trap accessory 
gave a recovery of >98% for cadmium at a 
concentration of 0.02 pg/ml with a coefficient of
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variation of < + 10% at a concentration of 0.01 jig. 
Further practical details are given in Appendix II.
2.2.3 Characterisation of Cd.Zn meta11oth1 onein.
A) Isolation of the Cd.Zn meta 11oth1 one 1ns
Cd,Zn-metallothioneins (I and II) were isolated from 
the livers of male Wistar albino rats by one of three 
methods, aiming to improve the purification, recovery 
and rapidity of the isolation method for hepatic 
metallothionein. The approach of each of the three 
methods is described below:
1. A modification of the-method described by 
Vander Mai lie and Garvey (1978), incorporating gel 
filtration and ion-exchange chromatography on the 
heat-treated supernatant fraction of a liver 
homogenate containing metallothionein,
2. Ultrafiltration of the heat-treated supernatant
fraction of a liver homogenate containing
metallothionein using ultrafiltration membranes, 
followed by ion-exchange chromatography,
3. The method of Winge et al (1981) with the
modification that only a DEAE Sepharose CL6B and not 
thiopropy1-Sepharose was utilized at the final stage 
of the purificat ion.
i) Reagents
a) 15 mM Ammonium formate buffer (pH8.0)
An ammonium formate stock solution was made by 
dissolving 63.06 cr in a final volume of 1 litre of 
distilled water. To 15 ml of this stock solution was 
added about 950 ml of distilled water. The pH of the
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solution was then adjusted to 8.0 by the addition of 
a 35% ammonium hydroxide solution. Sodium azide 
(0.01%) was then added and the solution was made up 
to a final volume of 1 litre with diluted water.
b) 10 mM Tris-HCl buffer (pH8.0)
A 0.2 M Tris stock solution was made by dissolving 
24.23 g of Tris in a final volume of 1 litre of 
distilled water. To 50 ml of the 0.2 M Tris stock 
solution was added 0.1 g of sodium azide followed by 
about 900 ml of distilled water. The pH was then 
adjusted to 8.0 with 1 M HC1 (about 5 ml), and the 
volume adjusted to 1 litre with distilled water.
c) 300 mM Tris-HCl buffer (pH8,0)
A 1.2 M Tris stock solution was made by dissolving
145.8 g in a final volume of 1 litre of distilled 
water. To 250 ml of the 1.2 M Tris stock solution 
was added 0.1 g of sodium azide and the resulting 
mixture was diluted with about 600 ml of distilled 
water. The pH was then adjusted to 8.0 with 1 M HC1 
(about 5 ml), and the volume made up to to 1 litre 
with distilled water.
i i ) Method
a) Male Wistar albino rats (University of Surrey 
strain) of about 250 g body weight were injected 
subcutaneous 1 y with 1.5 mg Cd^'/kg body weight, 5 
days/week for 10 doses. The livers' from these 
animals were exised following cervical dislocation. 
After weighing the liver was homogenized in a Potter—  
Elvejohn homogenizer with 5 vol (w/v) 15 mM ammonium
formate buffer CpHS.0). The homogenate was 
centrifuged at 10,000 g for 20min and the supernatant 
fraction was retained and the pellet discarded. The
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supernatant fraction was centrifuged at 106,000 g for 
1 hour. The resulting supernatant fractions were 
heated rapidly to SO^C for 2 min and then rapidly 
cooled to 4^0. Following this, the heat-treated 
fraction was centrifuged at 10,000 g for 20 min and 
the supernatant fraction retained at 4c:’C. The pellet 
from this treatment was washed with 15 mM ammonium 
formate buffer (pH8.0) and recentrifuged at 10,600 g 
for 20 min. The resulting supernatant fraction was 
added to the original liver heat-treated supernatant 
f rac t i on.
The heat-treated supernatant fraction was lyophilysed 
and approximately 1 g portions were reconstitued in 
10 ml of 15 mM ammonium formate buffer pH8.0. This 
solution was applied to a Sephadex G75 column (80 x
2.6 cm) equilibrated with 15 mM ammonium formate 
buffer (pH8.0) with and without 5 mM mercaptoethano1 
or 20 mM dithiothreitol. The eluate was monitored at 
254 nm and collected as fractions which were assessed 
for cadmium, zinc and copper content (see section
2.2.2), Fractions containing high concentrations of 
cadmium, high absorbance at 254 nm and a Ve/Vo 
(elution volume/void volume) of between 2.0-2.5 were 
pooled and again lyophilysed. The crude 
metallothionein was reconstituted in distilled water 
and desalted using a Sephadex PD 10 column, and again 
lyophilysed. The protein was then reconstituted in 
10 mM Tris-HCL (pH8.0) buffer and applied to a DEAE 
Sepharose CL6B ion exchange column (20 x 2 cm) 
equilibrated with 10 mM Tris-HCL (pH8.0). Two 
components of the metallothionein fraction were 
eluted using a concentration gradient of 10 mM to 
300 mM Tris-HCL (pH8.0) buffer. Fractions 
corresponding to each of these components were 
pooled. Each component designated metallothionein I 
and II was then desalted on Sephadex PD-10 columns 
equilibrated with distilled water. The desalted
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fractions corresponding to each of the metallo- 
thioneins were pooled and cadmium, zinc and copper 
determinations were made using flame atomic 
absorption methods (see section 2.2.2). The protein 
concentration of the pooled fractions were assessed 
by the method of Lowry et a 1 (1951). The solution
was lyophilysed and dried to constant weight.
b) The heat-treated supernatant fraction of a 
liver homogenate was prepared as described in the 
previous section (Method (a)). It was then filtered 
on a YM 10 diaflo-ultrafi1tration membrane under 
negative pressure. The filtrate was retained and 
kept at 4c,C. To the residue was added 20 mM
dithiothreitol in 15 mM ammonium formate buffer, 
(pH8.0), and the mixture was then refiltered on the 
YM10 membrane. Both filtrates collected were pooled 
and filtered on a YM5 diaflo-ultrafi1tration membrane 
under positive pressure. The residue from this 
filtration was retained and lyophilysed. This 
lyophilate (the crude metallothionein preparation) 
was desalted on a Sephadex PD10 column, re1yophi1ysed 
and then reconstitued in 10 ml of 0.01 m Tris-HCL 
buffer (pH8.0). The crude metallothionein was then 
applied to a DEAE Sepharose CL6B column equilibrated 
with 10 mM Tris-HCL buffer (pH8.0) and eluted as 
described previously (Method (a)).
c) The heat treated supernatant fration of the 
liver homogenate was prepared as described in Method 
(a). Metallothionein was then isolated from the 
heat-treated supernatant fraction by a method of 
aqueous/organic solvent extraction as described by 
Winge et a1 (1981). However, a DEAE Sepharose CL6B 
not a thiopropy1-Sepharose column was utilized as 
described in the final stage of purification in 
Method (a).
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B) Examination of the liver, kidnev. Intestine and
urine meta 11oth1 one1ns
i) Polvacrvlamide gel electrophoresis
Metallothionein was examined at each stage of 
purification (from the heated treatment of the 
hepatic cytosol to the metallothionein purified by 
ion-exchange chromatography - see section 2.2.3 A,
(ii> by slab gel electrophoresis using 10% (w/v) 
polyacrylamide with a stacking gel (30% w/v 
polyacrylamide).
Prior to application, the protein samples were 
solubilized in a solution containing:-
0.9% (w/v) saline
15% (v/v) glycerol
0.001% (w/v) bromophenol blue
a) Separation of the proteins
The separation of the various protein samples was 
performed using an LKB 2117 Multiphor apparatus with 
a Tris-glycine buffer system as described by 
Fehrnstrom and Moberg (1977). A 10% gel (in a pH8.9 
buffer) and a 3% stacking gel (in a pH6.8 buffer) 
were employed. The samples were applied to the wells 
in the stacking gel (15 pg protein/well) and 
electrophoresed at a current of 20 mA until the 
bromophenol blue had formed a sharp band in the 
running gel. The current was then increased to 40 mA 
and electrophoresis continued until the bromophenol 
blue band was about 5 mm from the bottom edge of the 
gel.
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b) Staining of gels to visualise the proteins
Gels were stained with Coomassie Brilliant Blue R250 
which was made up as follows:- 0.5 g of stain was 
dissolved in 11 of 2-propanol/glacial acetic 
acid/distilled water (1:1:8). The stain solution was 
filtered before use. The gels were stained for 18 
hours. Destaining was achieved by repeated changes 
of a solution containing 2-propanol/glacial acetic 
acid/distilled water (1:1:8) over a period of 3-4 
days.
i i) Sodium dodecvl sulphate (SDS) - polyacrylamide 
gel e1ectrophoresis
Purified hepatic meta11othionein I and 
metallothionein in the supernatant fractions of 
liver, kidney and intestinal homogenate and urine 
samples from rats exposed to cadmium (300 ppm) were 
examined by SDS polyacrylamide gel electrophoresis to 
ascertain the molecular weight of metallothionein and 
to show the presence of this protein in tissues and 
body fluids of the rat. Single concentration gels 
(either 10 or 20%) with a stacking gel (3%) and a 
discontinuous buffer system were used.
Prior to application, the protein samples taken were 
solubilized in a solution containing:-
62.5 mM Tris-HCL pH6.8
2.3% (w/v) SDS
15% (v/v) glycerol
8% (v/v) mercaptoethano1
0.001% (w/v) bromophenol blue
This SDS containing buffer was added to the samples 
in the appropriate amounts to adjust the protein 
concentration to an optimum of 3 ug/ul. It was,
87
however, important for the efficient solubilization 
of the sample that the proportion of buffer to sample 
was in all cases greater than 1. After addition of 
the SDS buffer, the samples were placed in a boiling 
water bath for 3 min.
a) Separation of proteins
The separation of the various protein samples was 
performed using a LKB 2117 Multiplor apparatus, 
incorporating an adaption of the method of Laemli 
(1970), employing a 10% or 20% gel (in a pH8.9 
buffer) and a 3% stacking gel (in a pH6.8 buffer).
The samples were applied to the wells in the stacking 
gel (15 ng protein/we11). A sample of standards of
molecular weight range 12,300-78,000 was applied to 
the 10% gel system and a sample of standards of 
molecular weight range 2,500-16,500 was applied to
i
the 20% gel system. The samples were then
electrophoresed as described in section 2.2.3 B (i) .
b) Staining of gels to visualise the proteins
The staining/destaining procedure has previously been 
described in section 2.2.3 B (i).
2.2.4 Characterisation of the sheep anti-rat 
meta 11othionein antiserum using 
Immunoelectrophoretic methods
i ) Crossed immunoelectrophoresis
The antiserum was examined by crossed Immuno­
electrophoresis and the method employed was 
essent. i s 11 y se deecr-1 bed by Axe 1 sen et el 11 y /d.>»
For this work a range of antigens were employed:-
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- Rat liver metallothionein I.
- Chicken gamma globulin (this protein was conjugated 
to rat liver metallothionein to produce the sheep 
anti-meta11othionein antiserum used in this thesis).
- Supernatant fraction of a 
rat exposed to 300 ppm Cd*-*" 
(see Chapter 3, section 3.2 
details of this sample).
- Supernatant fraction of a 
rat exposed to' 300 ppm Cd^'1" 
(see Chapter 3, section 3.2 
detaiIs).
liver homogenate from a 
in the diet for 16 weeks 
for further preparative
kidney homogenate from a 
in the diet for 16 weeks 
for further preparative
and two different antisera were also used
- sheep anti-rat meta11othionein
- rabbit anti-rat liver cytosol.
a) Reagents
1. Stock buffer: barbitone-acetate. For 10
litres, 65 g of sodium acetate (trihydrate),
88 g sodium barbitone and 11.3 g 
diethylbarbituric acid were dissolved in 
distilled water. The pH should be 8.6.
2. Tank buffer: 3 litres of stock buffer [reagent
11 was diluted with 2 litres of distilled 
water.
3. Agarose buffer: stock buffer [reagent 1] was
diluted with an equal volume of distilled 
water.
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4. Agarose (Indubiose)/Lubro1 W: 1% (w/v) solution
of agarose was made up in the agarose buffer 
treagent 31. To dissolve, this solution was 
heated and stirred. Sufficient Lubrol W to 
give a 0.5% (w/v) concentration in the agarose 
was melted in a conical flask and the hot, 
dissolved agarose was poured over it with 
continuous stirring.
b) Method
Ten ml of molten agarose (maintained at 57c:'C') were 
poured onto each of 4 glass plates (8.3 x 8.3 cm). 
After cooling for a few minutes two sample wells were 
cut in the gel. The plates were put in a standard 
electrophoresis tank (Chem Lab Ltd., Ilford) 
prefilled with tank buffer. Samples of each of the 
antigens described above (3-5 ul) were added to the 
left hand well of separate plates and a drop of 
concentrated bromophenol blue was added to the right- 
hand well of each plate. The plates were then 
electrophoresed (with the negative terminal at the 
sample end) at 200 V for about hours or until the 
bromophenol blue spot was within 5mm of the end of 
the plate. The layout of the plate is illustrated in 
figure 2.1.
For electrophoresis in the second dimension the gel 
was cut as shown by the dashed line in figure 2.1 and 
the agarose to the right of each sample track was 
scraped off. Antiserum was pipetted into a prewarmed 
test tube which contained the appropriate volume of 
agarose (6 ml if a single and 3 ml if two antibody 
containing gels were to be used). The concentration 
of antiserum used was dependant on their different 
avidities for the antigens tested. Gel containing 
10% (v/v) of the sheep anti-rat me t. a 1 1 o th i one i n 
antiserum was then poured onto the remainder of the
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plate containing the electrophorectically separated 
metallothionein. The process was repeated using a 2% 
(v/v) sheep anti-rat metallothionein in agarose gel 
with the plate containing the electrophoretically 
separated Chick gamma globulin. With the plates 
containing the electrophoretically separated liver 
and kidney cytosol samples the gel was cut as 
previously described. However agarose containing 2% 
(v/v) sheep anti-rat meta11othionein was poured onto 
half the remainder of the plate and to the other half 
of the plate agarose containing rabbit anti-rat liver 
cytosol (4.8V, v/v), was added.
The plates were repositioned in the tank with the 
'sample track' next to the negative electrode and 
electrophoresed for 16-18 hr at a constant voltage of 
40 volts.
Figure 2.1 Layout of gels during e 1ectrophoresis
1st Dimension 2nd Dimension
Sample Bromophenol 
bl ue
i
I I
Gels containing 
tjwo different 
j antisejra
I I
I i
1 i i
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c) Washing and staining of the agarose gels
The gels were pressed dry by covering with layers of 
filter paper and applying pressure (thick gloss 
plates were ideal) for 10-15 min. They were then 
washed again in saline for at least 2 hr. Finally 
they were washed in distilled water for no less than 
30 min and dried by means of a hair dryer.
The gels were stained by immersion in Coomassie Blue 
for about 10 min and destained in 3-4 rapid changes 
of the destainer. The destaining was complete in 
about 6 min. The solutions of stain and destainer 
were of exactly the same composition as described in 
section 2.2.3 B <i).
i i) Western blotting technique
This technique, which e1ectrophoretica11y transfers 
proteins from a polyacrylamide gel to a 
nitrocellulose sheet, can be used to examine the 
reactivity of a primary antibody towards an antigen. 
Using peroxidase-conjugated antibodies, to bind the 
primary antibody, the method is sensitive enough to 
detect small amounts (about 100 pg) of electro- 
phoretically separated antigen. However, this is 
dependent on the affinity of the primary antibody 
towards the antigen.
a) Reagents
1. Stock electrode buffer
Tris base (300g) , glycine (1440g) and sodium azide 
(0.5g) were dissolved in distilled water to a final 
volume of 10 litres. This was stored at room 
temperature.
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2. Electrode buffer
Stock electrode buffer (250 litres) was diluted with 
distilled water to a final volume of 10 litres. This 
was stored at room temperature.
3. Phosphate buffered saline (PBS)
Disodium hydrogen phosphate (1.78g) and sodium 
chloride (9.0g) were dissolved in distilled water to 
a final volume of 1 litre. This solution was stored 
at room temperature.
4. Wash buf fer
Horse serum (10 ml) and Triton x 100 (0.2 ml) was 
added to PBS to give a final volume of 1 litres.
This buffer was freshly prepared before use.
5. Developing solution
Diamino benzidene chloride (100 mg) was dissolved in 
200 ml of 0.1 M Tris-HCl, (pH7.5) containing hydrogen 
peroxide (30 vol) at 1:5000. This solution was 
freshly prepared before use.
b) Electrophoretic blotting procedures
The SDS-polyacrylamide gels (10 and 20%) containing 
the e 1ectrophretica11y separated proteins (as 
described in section 2.2.3 (b)) were incubated with
gentle shaking in 500 ml electrode buffer. The gels 
were blotted onto nitrocellulose paper using the 
method described by Towbin et a 1 (1979). By applying
a voltage of 40 V (5 V/cm, constant voltage) across 
the gel and nitrocellulose paper (in a Biorad trans­
plot apparatus) for 16 hr, the proteins were
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transferred from the gels to the nitrocellulose 
paper.
c) Immunological detection of protein on 
nitrocellulose
The nitrocellulose paper containing the transferred 
proteins was given three 15 min washes with wash 
buffer at room temperature. The nitrocellulose was 
then incubated for 60 min with sheep anti-rat 
metallothionein antiserum (1:100 in wash buffer).
This was followed by a further three 15 min washes 
with wash buffer. The nitrocellulose paper was then 
incubated for 60 min with donkey anti-sheep 
Immunoglobulin-G conjugated to horse radish 
peroxidase (1:600 in wash buffer). Following a 
further three washes with wash buffer and one with 
PBS, the nitrocellulose paper was exposed to the 
developing solution. The colour which develops in 
seconds, was stopped by washing the nitrocellulose 
paper with distilled water.
To examine the extent of colour development due to 
non-specific binding of either antibody towards the 
transferred proteins, the above procedure described 
in sections (ii) and (iii) was repeated using heat- 
inactivated sheep serum (1:100 in wash buffer) 
instead of sheep anti-rat metal 1othionein antiserum 
at the primary antibody incubation stage.
2.2.5 Preparation of 1 :-s I-1 abe 1 1 ed Cd.Zn rat liver 
meta11othionein-I and determination of its 
immunoreactivitv towards the sheep anti-rat 
meta11othione1n antiserum
Cd, Zn-metal lothionein I was labelled with 1 “E:1SI using 
a modification of the method described by Bolton and 
Hunter (1973). This modification was incorporated to
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limit the extent of exposure and possible risk of 
contamination with The immunoreactivity of
this labelled protein was assessed to ensure that 
metallothionein still retained its affinity for the 
antibody.
A) Preparat i on
i) Buf f ers
a) 0.05 M Phospate buffer (pH7.5)
To 84 ml of a 68 g/1 solution of dipotassium hydrogen 
phosphate (K^HPO*), was added 16 ml of an 87. 1 g/1 
solution of potassium dihydrogen phosphate (KH^PO^). 
Distilled water was then added and the pH of the 
buffer was adjusted to pH7.5 prior to being made up 
to a final volume of 1 litre. The buffer was stored 
at 4c,C.
b) 0.05 M Phosphate buffer (pH7.5) + 0.10 or 0.25% 
gelat in
To 0.1 (or 0.25) g of gelatin and 0.01 g of sodium 
azide was added 80 ml of 0.05 M phosphate buffer, 
(pH7.5) at 37c,C and the resulting mixture was stirred 
until the gelatin dissolved. The buffer was then 
filtered using Whatman No. 1 filter paper and allowed 
to cool. Once cool, 0.05 M phosphate buffer (pH7.5) 
was added to a final volume of 100 ml. The buffer 
was stored at A-tz,C.
c) 0.05 M phosphate buffer. (pH7.5) -f 2% horse
serum
To about 90 ml of 0.05 M phosphate buffer (pH7.5) was 
added 2 ml horse serum and 0.01 g of sodium azide.
The buffer was stirred until the sodium azide had
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dissolved and then 0.05 M phosophate buffer was added 
to a final volume of 100 ml. The buffer was stored 
at 4~C.
d) Borate buffered saline (125 mM borate-NaOH. 
pH8.3 with 75 mM NaCl)
To 250 ml of a stock borate-saline solution (0.5 M 
boric acid and 0.3 sodium chloride) was added 0.5 M 
sodium hydroxide (dropwise) to establish a pH of 8.3. 
Then distilled water was added to the solution to a 
final volume of 1 litre. The borate buffered saline 
was stored at .
i i ) Method
Radioiodination of Cd,Zn-metal1othionein I was 
performed using a modification of the conjugation 
method of Bolton and Hunter (1973). The first stage 
involved the conjugation of N-hydroxysuccinimide 
hydroxyphenylpropionate (NSHPP) with the protein. A 
fresh solution of NSHPP in redistilled toluene: 
ethylacetate (1:1) solution (10 mg/ml) was prepared, 
of which 6.6 ul was added to a small dry peai— shaped 
flask containing a mini stirrer. The solution was 
then evaporatd to dryness under nitrogen. A solution 
of hepatic Cd, Zn-metallothionein I in borate-buffered 
saline (4.5 mg/ml) was added to the pear— shaped flask 
and mixed continuously for 20 minutes at 4c-'C. Then
87.5 ml of 0.05 M phosphate buffer (pH7.5) was added 
to the flask. The conjugated protein was then 
separated from the NSHPP on a Sephadex G25 1 x 10 cm 
(PD10) column, equilibrated with 0.05 M phosphate 
buffer (pH7.5). Fractions of 1 ml were collected and 
monitored at 254 nm for the meta11othionein peak.
The fract ions corresponding to rnetal lothionein were 
pooled and lyophilysed.
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The second stage involved the iodination of the 
conjugated protein. Into a plastic LP3 tube 
containing a mini-shaker, was added 10 ml of the 
NSHPP-metallothionein conjugate (reconstituted to 
200 ul in distilled water). Additions of 20 ul 
(lmCi) of Na1s:SiI and 10 ml of Chloramine T (5 mg/ml 
in distilled water) were made and the solutions were 
mixed for 20 seconds, after which 10 ul of sodium 
metabisuphite solution (12 mg/ml in distilled water) 
and 10 ul of potassium iodide solution (200 mg/ml in 
distilled water) were added. Then 955 ul of 0.05 M 
phosphate buffer (pH7.5) containing 0.25% gelatin was 
added to the reaction tube. This mixture was then 
separated on a Sephadex G25 column (1 x 10 cm) (PD10) 
equilibrated with 0.05 M phosphate buffer (pH7.5) 
containing 0.1% gelatin. This column had been 
previously saturated with 500 ul of 10% (w/v) bovine 
serum albumin and well washed afterwards. After the 
elution of 2.5 ml, fractions of 500 pi were collected 
into LP3 tubes containing 500 pi of 0.05 M phosphate 
buffer (pH7.5) containing 2% (v/v) horse serum. The 
elution buffer was changed from the 0.05 M phosphate 
buffer with 0.1% gelatin to that containing 2% horse 
serum after the iodinated protein had eluted. The 
i i r a c j j oac t ivity in each of fracti ons f rom the 
Sephadex G25 column was measured using a Wallac gamma 
counter.
B) Determination of immunoreactivitv
i) Reagents
Diluent buffer
A 0.05 M phosphate buffer (pH 7.5) was made as 
described in section 2.2.5 a (1) except that 0.01 g 
sodium azide and 10 g of bovine serum albumin were
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added prior to it being made up to the final volume 
of 1 litre.
i i) Method
1. Each of the eluate fractions containing 1:2£*I 
radioactivity obtained from the PD10 column in 
section 2.2.4, were diluted in diluent buffer to give
100,000 cpm.
2. Samples of each fraction (lOOul) were added to
3 sets of duplicate LP3 tubes.
3. 100 ul of sheep anti-rat metallothionein
antiserum at a dilution of 1:1000 (in diluent buffer) 
and 100 ul of diluent buffer were added to one set of 
duplicate tubes for each fraction. These are classed 
as the 'specific binding' tubes.
4. 100 ul of heat inactiviated normal sheep serum
(1:1000) and 100 ul of diluent buffer were measured 
into a second set of duplicate tubes for each 
fraction, classed as the 'non-specific binding' 
tubes.
5. No further additions were made to the final set 
of duplicate tubes for each fraction classed as the 
'total activity' tubes.
6. All tubes were then incubated for 24 hr at room
temperature.
7. Additions of 100 ul of heat inactivated normal 
sheep serum (1:500 in diluent buffer) and 10 ul of 
donkey anti-sheep Immunoglobulin G (IgG) (1:20 in 
diluent buffer) were made to all the non specific and 
specific binding tubes.
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8. The tubes were then incubated for 18 hr at 4-^C.
9. The "antibody bound" 12®l was separated from
the "free" by centrifugation of the tubes at
2600 g for 20 min, following which the supernatant 
was discarded and the pellet retained in each tube.
10. The pellets retained in step 9 were washed with 
diluent buffer <1 ml) and recentrifuged at 2600 g for 
20 min.
11. Again from each tube the supernatant fraction 
was discarded and the pellet retained for the 
measurement of 1=asi radioactivity using a Wallac 
gamma counter.
The data was presented graphically as percentage 
bound (corrected for non-specific binding) of total
radioactivity versus fraction number (see figure
2.8 ) .
2.2.6 Development of an RIA for meta 11othionein
A) Assessment of titre. avidity and specifitv of
the sheep anti-rat liver meta11othione1n 
ant iserum
As not all antibodies produced are suitable for use 
in RIA procedures an assessment of their usefulness 
is made in terms of the antibody titre, avidity and 
spec if i c i ty.
a) Ti tre
The titre of this antibody was defined as the 
dilution of the anti serum which bound 50% of the 
immunoreactive metal 1othionein added. The method for 
its determination is given below:-
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i) Reagents 
Diluent buffer.
Details of composition are given in section 2.2.5 (a)
i i > Method
1. To sets of three duplicate LP3 tubes was added
100 ul of the 1 I-1 abe 11 ed metal lothionein at either 
50, 100 or 200 pg/tube.
2. Further additions of 100 ul of sheep anti-rat 
metallothionein antiserum at dilutions of 1/50,
1/100, 1/200, 1/400, 1/1000, 1/2000, 1/4000 or 1/8000
(in diluent buffer) were made to one set of duplicate 
tubes for each concentration of radio-label (the 
'specific binding* tubes).
3. Heat inactivated normal sheep serum (100 ul) at 
the appropriate dilution was added to another set of 
duplicate tubes for each concentration of radio-label 
(the 'non-specific binding' tubes).
4. No further additions were made to the final set 
of duplicate tubes for each concentration of radio­
label (the total activity tubes).
5. An addition of 200 ul of diluent buffer was 
made to each of the 'specific binding* and 'non­
specific binding' tubes.
6. The tubes were incubated for 24 hr at room 
temperature.
7. Additions of 100 ul of heat inactivated normal 
sheep serum at concentrations of 1/100 (for anti­
metal lothionein antiserum concentrations of 1/50 to
100
1/400) and 1/500 (for anti-metallothionein antiserum 
concentrations of 1/1000 to 1/8000) were made to each 
'specific binding' and 'non-specific binding' tube.
8. Donkey anti-sheep Immunoglobulin-G (Ig-G) at 
concentrations of 1/100-1/400 and 1/20 (for first 
antiserum concentrations of 1/1000-1/8000), was added 
to each tube described in stage 7.
9. The tubes were then incubated for 18 hr at 4c:,C .
10. The " ant i body-bound" 1 I was separated from the 
"free"'1215! by cent r i f ugat i on as described in section
2.2.5 (b) stages 9-11.
So as to show the displacement of the 1 2:31-1 abe 11 ed 
metallothionein by the unlabelled metallothionein the 
above procedure was repeated, except that an addition 
of 100 ul of 10 ug/ml metallothionein standard was 
made to each specific-binding tube. The label 
concentration used was 50 pg/tu,be and only 100 ul of 
diluent buffer was added to each tube.
The data is presented graphically as percentage 
antibody bound (corrected for non-specific binding) 
of total 1:2151 radio activity versus the dilution of 
sheep anti-rat metallothionein used.
b) Avid i tv
The avidity of the antiserum was defined as the 
energy of binding of the antibody for its antigen.
It was determined by means of a Scatchard plot in 
which the ratio of the molar concentration of "bound" 
to "free" antigen was plotted against the total molar 
concentration of bound antigen. The Scathchard plot 
enables the determination of the number of binding 
sites present in the antibody solution (nmol/1) and
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Indicates how may populations of antibodies to 
metallothionein exist.
i) Reagent
D i1uent Buffer
Details of composition are given in section 2.2.5 
(a).
i i ) Method
1. To duplicate sets of ’specific-binding* LP3
tubes, 100 ul of 1 2:&I-label led meta 11 othionein (50 pg
per tube) was added, followed by 100 ul of the sheep
anti-rat metallothionein antiserum (1:1000).
2. Further additions of meta11othionein (100 ul)
at concentrations of 0.01, 0.02, 0.04, 0.06, 0.08,
0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 2.0 or 4.0 ug/ml were
made to each set of duplicate tubes.
3. A duplicate set of 'total activity' tubes 
(containing solely the 100 ul of 11 se;-label led 
metallothionein) and 'non-specific binding' tubes, 
(containing 100 ul of heat inactivated normal sheep 
serum and not the sheep antiserum) were also 
incorporated into the assay.
4. The tubes were incubated for 24 hr at room 
temperature.
5. The "antibody-bound" meta 11othionein was 
separated from the "free" metallothionein and 
measurement of 11 215 radioactivity was made as 
described in section 2,2=5 b> stages 7-11.
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c) Spec 1f 11 v
The specifity of the antiserum was assessed by 
deriving cross-reactivity curves for particular 
compounds which may be found in samples measured in 
the RIA. These were albumin (rat, sheep and human) 
and haemoglobin (rat, sheep and human) up to 1 mg/ml 
and rat P2 microglobulin up to 10 ug/ml (Carter, 
unpublished observations). Rat liver and kidney 
metal 1othioneins I and II were also assessed and 
found to give equal cross-reactivity to the sheep 
anti-rat metallothionein antiserum (Carter 
unpublished observations). The cross reactivity 
studies were continued using glutathione and cysteine 
and also their cadmium salts. An assessment of the 
cross-reactivity of human metallothionein II (which 
was kindly donated Prof. J. H. Kagi, Univ. of Zurich, 
Switzerland) with the sheep anti-rat metallothionein 
was made. This was performed to confirm the ability 
of the antibody to react with metallothionein in 
human plasma and urine (for studies performed in 
Chapter 6).
The method used to determine the cross reactivity of 
these substances is described in the following 
section (2.2.6 B)). The range of concentrations of 
the test compound used were 0.01-30.0 ug/ml for the 
glutathione and cysteine (and their cadmium 
complexes) and 0.01-10.0 ug/ml for human 
metallothionein II.
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B) Detection of metallothionein bv RIA
1) Reagent
Dlluent Buffer
Details of the composition of the buffer are given in 
sect ion 2.2.5 a).
i i) Method
1. 100 ul of test samples or meta 11 othionein
standards (0.01-10.0 ug/ml) were placed in LP3 tubes 
in triplicate and 100 ul of sheep anti-rat
metal lothionein antiserum (1:1000) and 100 ul of 1-*eil 
labelled metallothionein (50 pg/tube - equivalent to 
approximately 12,000 d.p.m.) was added. These were 
classed as the 'specific binding' tubes.
2. Incorporated into the assay, in triplicate,
were:-
'zero binding' tubes which contained the antiserum in 
stage I but contained 100 ul of diluent buffer 
instead of test material or metallothionein 
standards;
'non-specific binding' tubes which contained 200 ul 
of diluent buffer instead of the sample and antiserum 
aliquot;
'maximum-binding' tubes which incorporated all 
additions made to the 'zero-binding* tubes, except 
that the antiserum was diluted (1:50); and
'total' tubes which only contained 100 u.1 ot 1 -c" I - 
labelled metallothionein.
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3. All the tubes were incubated for 24 hr at room 
temperature.
sheep serum (1:500) and 100 ul of donkey anti-sheep 
Immunoglobulin G (IgG), (1:20) were made to all the 
'non-specific binding' and 'specific-binding' tubes. 
The heat inactivated normal sheep serum was diluted 
1:100 and the donkey anti-sheep IgG was diluted 1:5 
for additions to the "maximum binding" tubes,
5. The tubes were then incubated for 18 hr at 4°.
6. The "antibody-bound"1^I-label led
metallothionein was separated from the "free"ia5I- 
labelled metallothionein by centrifugation of the 
tubes at 2600 g for 20 min, following which the 
supernatant fractions were discarded and the pellet 
fractions retained.
7. The pellet fractions retained in step 6. were
washed with diluent buffer (1 ml) and recentrifuged 
at 2600 g for 20 min.
8. Again the supernatant fractions were discarded
and the pellets retained for the measurement of ',:3:&l 
radioactivity using a Wallac gamma counter.
All dilutions were made using the diluent buffer.
The percentage binding of the label was calculated 
from the equation.
Ciqq-n sB x 100 = “ ft
4. Additions of 100 ul of heat inactivated normal
where C100 = mean counts/100s of the 'specific 
binding* tubes
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Co100 = mean counts/100s of the 'zero-binding' tubes
NSB = mean counts/lOOs of the 'non-specific binding* 
tubes
B = mean binding of the radio label to the antibody 
in a set of 'specific-binding' tubes
Bc. = mean binding of the radio label to the antibody 
in the 'zero-binding* tubes.
Data was expressed graphically as B
B
versus logarithm of the concentration of
metallothionein, or as logit y versus the logarithm
of the concentration of metallothionein, where:-
Logit y = log [(100 x B)/(BC-B>]
C . Effect of components of the tissue supernatant 
fractions, urine and bile of the rat on the 
standard RIA curve for the metallothionein
The supernatant fractions of the liver, kidney and 
intestine, urine and bile are composed of complex 
mixtures of proteins, peptides and salts, all of 
which may interfere with the antibody-antigen binding 
observed in an RIA. This interference was assessed 
by performing the RIA procedure described in section
2.2.8 (b) in the presence of the supernatant 
fractions of the liver, kidney and small intestine 
from young male rats (250 g) not previously exposed 
to cadmium. Details of preparation of these tissue 
supernatants are described in Chapter 3 (section
3.2). The dilution of each of these samples was made 
up so as to give concentrations of metallothionein 
that were on the limit of detection of this RIA 
procedure. The standard metallothionein solutions
106
CO.01-10.0 ul/ml) used in the assay were made up in 
the appropriately diluted supernatant fraction at 
1/10, 1/25 and 1/50 (in diluent buffer). The diluted
supernatant fraction was also added to the 'non­
specific', 'zero' and 'maximum-binding' tubes. The 
RIA procedure was repeated incorporating urine and 
bile samples from control male rats (at neat, 1/5 and 
1/10 dilutions).
The RIA standard curve for each of the tissue 
supernatant fractions, urine and bile was compared to 
that incorporating the buffer diluent, and examined 
for linearity over the working range.
The analytical recovery of standard meta11othione in 
additions (0.05, 0.4 and 0.9 ug/ml) to each of the 
tissue supernatant fractions, urine and bile were 
also measured by the RIA procedure, incorporating the 
modificat ions described previously in this section.
2.3 Results
2.3.1 Isolation of metallothionein I and II
Table 2.1 shows the values for recovery and 
purification of metallothionein from a typical liver 
homogenate of a rat exposed to cadmium by sub­
cutaneous injection using a modification of the 
method used by Vander Mai lie and Garvey (1978).
About 82% of the total cadmium found in the 
homogenate was located in the 106,000 g supernatant, 
and about 15% of this was lost following the heat 
treatment. The heat treated supernatant was 
fractionated by gel filtration using Sephadex G75 
(figure 2.2). Fractions 50-70 corresponding to a 
Ve/Vo ratio of 2.0-2.5 were taken as the the crude
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metallothionein sample. The reconstitued sample 
after lyophi1ization contained 47% of the total 
cadmium content of the liver homogenate. 
Mercaptoethano1 (5 mM) or dithiothreitol (5 mM) was
added to the ammonium formate buffer, so as to 
breakdown the metallothionein polymers in the liver 
cytosol sample, prior to fractionation by gel 
filtration. Although these compounds produced a 
better resolution of the metallothionein peak on the 
Sephadex G75 profile, 30% of the cadmium bound to 
metallothionein was lost in the presence of 
mercaptoethano1; and 20% of the metallothionein bound 
cadmium was lost in the presence of dithiothreitol 
(see table 2.2). As the loss of metal ions increases 
the sensitivity of the protein to oxidation (once 
these thiol-compounds are removed), and because of 
loss in yield, it was decided not to add either of 
these reducing agents to the fractionation buffer in 
future preparations.
The further isolation of Sephadex G75 separated 
metallothionein by ion-exchange chromatography into 
metallothionein I and II, required a methodological 
refinement prior to obtaining the profiles shown in 
figure 2.3 and 2.4. Ammonium formate buffer was 
thought to be present in the crude metallothionein 
sample after 1yophi1ization. This buffer was 
believed to affect the ionic gradient of the Tris 
buffer system used with the DEAE cellulose ion- 
exchange gel, giving rise to poorly resolved protein 
peaks. This problem was rectified by the desalting 
of the lyophilized (Sephadex G75) separated 
metallothionein on a PD10 column, followed by 
lyophi1ization, prior to ion-exchange chromatographic 
separation of the two metallothionein isoforms. This 
step was thus incorporated into the method (see 
sec t i on 2.2.3 A).
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Separation of the crude rnetal lothionein into two 
components, designated metallothionein I and II, 
using either DEAE Sephadex CLB6 or DEAE cellulose was 
performed (figure 2.3 and 2.4). The meta 11othionein 
I and II contained 30.4 and 31.8 ugCd/mg protein 
respectively (table 2.1). Using cadmium content as a 
measure of purification, a 15 fold purification of 
the protein was obtained by this method of isolation. 
This is an artificial measure of purification, as 
cadmium is also lost at each stage of purification. 
However, the percentage recovery and measure of 
purification observed in table 2.1 is comparable to, 
although slightly lower than, that obtained by Vander 
Mai lie and Garvey (1978).
Both DEAE-cellulose and DEAE-Sepharose CL6B were used 
to separate the metallothionein isoforms. However 
the DEAE-Sepharose CL6B was found to tolerate higher 
flow rates without subsequent packing of the gel and 
provide a more stable ionic gradient that the DEAE 
cellulose. For these reasons, the DEAE-Sepharose 
CL6B was used to isolate the two meta 11othionein 
isoforms on a routine basis.
A second method of isolation of metallothionein using 
Diaflow ultrafiltration membranes was investigated to 
increase the capacity and yield of metallothionein 
from the liver cytosol by the previous method. Table
2.3 shows that 11% of the total homogenate cadmium in 
the liver homogenate was found in the filtrate 
following ultrafiltration using a YMIO membrane 
(excluding the filtration of molecules of greater 
that 10,000 dal tons). No further cadmium was found 
in the filtrate after an addition of 5 mM 
dithiothreitol, thus the recovery of meta11othionein 
(as assessed by cadmium content) was not improved.
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Figure 2.2
Fractionation of a heat-treated liver supernatant on 
an 80 x 2.6 cm column of Sephadex G75 (fine) eluted 
with 15mM ammonium formate (pH 8.0), at a flow rate 
of 1.1 ml/minute. The supernatant was obtained from 
rats injected with 10 doses of 1.5 mg Cd^/kg body 
we i gh t
Ultraviolet scan at 254 nm is shown as (— — ) . 
Cadmium shown as (o— O) , zinc as (A— .— A) and copper 
as (□-— -□) were determined by taking aliquots of 
certain eluted 5 ml fractions. The protein markers 
(a-h) with their respective molecular weights are 
given below:
a-Albumin (bovine serum) 
b-Ovalbumin (hen egg) 
c-Chymotrypsinogen A (bovi 
d-Ribonuclease A (bovine) 
e-Cadmium, zinc metallothi 
f-Insulin (bovine) 
g-Myoglobin (fragment III) 
h-5' Adenosine monophospha
(66,250 dal tons)
(45,000 dal tons)
ne) (23,200 dal tons)
(12,600 da1 tons)
one i n (6,700 da1 tons)
(5, 700 dal tons)
(equine) (2,510 da1 tons)
te (equine) (344 dal tons)
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F igure 2.3
Separation of Cadmium, zlnc-metallothionein fraction 
obtained from Sephadex G-75 filtration by ion 
exchange chromatography using DEAE Sepharose CL6B. A 
flow rate of 1 ml/min was used and 4.8 ml fractions 
were collected from the 0.01-0.03 M Tris-HCl (pH8.0) 
gradient elution
The conductivity of selected fractions C —  •■) was 
measured. Ultraviolet absorbtion scan at 254 nm 
(—  ■■ > was obtained by monitoring the eluant.
Cadmium CO— — -O) and zinc (A— ...A) concentrat ions were 
monitored on selected fractions.
Peaks I and II are designated metallothionein I and
II.
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Figure 2.4
Separation of Cadmium, zinc-metallothionein fraction 
obtained from Sephadex G-75 filtration by ion 
exchange chromatography using DEAE cellulose. A flow 
rate of 1 ml/min was used and 3.8 ml fractions were 
collected from the 0.01-0.3 M Tr.is-HCl (pH8.0) 
gradient elution
The conductivity of selected fractions (■———■) was 
measured. Ultraviolet absorbtion scan at 254 nm 
C—  ) was obtained by monitoring the eluant.
Cadmium (O O) and zinc (A-.— A) concentrations were
monitored on selected fractions.
Peaks I and II are designated metallothionein I and
II.
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The separation of the components of the filtrate from 
the YM10 membrane on a YM5 membrane (which removes 
all substances less than 5000 daltons), showed that 
only 2% of the cadmium in the cytosol fraction was 
found in the residual fraction. A further 7% of the 
cadmium in the cytosol fraction was found in the 
filtrate from this membrane. As the recovery of 
metallothionein (assessed by cadmium measurement) was 
very low, this method was not used for the isolation 
of metallothionein.
The final method of metallothionein isolation from 
the liver cytosol was a modification of the method 
used by Winge et al (1981). This incorporated a 
chloroform/ethanol addition to remove many of the 
proteins and fats of the liver cytosol before 
fractionation by gel filtration using Sephadex G75.
An outline of the procedure and the recovery of 
cadmium at each stage of preparation is shown in 
table 2.4. Following the ethanol/chloroform 
extraction and precipitation with acetone, most 
cytosolic cadmium (about 75%) was lost together with 
the cytosolic proteins. Fractionation of the 
solubilized acetone precipitated proteins on Sephadex 
G75 showed the removal of many of the cytosolic 
proteins but a marked loss of metallothionein was 
also indicated. This was measured by an increased 
loss of cadmium and yet a similar cadmium:protein 
weight ratio (see table 2.4), as compared to these 
values, was obtained by the modified method of Vander 
Mai lie and Garvey (see table 2.1).
2.3.2 Characterisation of the metallothioneins
Samples from various stages of isolation of this 
protein from the liver homogenate using the modified 
method of Vander Mai lie and Garvey, were subjected to 
non-denaturing polyacrylamide gel electrophoresis.
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The stained gel showed that two main components of 
different electrophoretic mobility were present in 
the pooled metallothionein I peak eluted from the 
ion-exchange column (figure 2.5, track 5), whereas 
the pooled metallothionein II peak (track 6) was 
resolved into one rather diffuse component on the 
gel. Both these purified metallothioneins appear to 
be rather diffuse, whereas metallothionein in the 
liver cytosol (track 2) appears as a distinct band. 
The mobility of the metallothioneins in this 
polyacrylamide gel also appear to be similar to a 
stained fraction ahead of albumin in the separated 
control rat serum (tracks 1 and 7). This stained 
fraction may be pre-albumin.
The purified metallothionein I and the cytosolic 
fractions of the liver, kidney and small intestine, 
as well as the urine (from a rat exposed to 300 ppm 
Cd2-* in the diet for 16 weeks) were subjected to SDS 
polyacrylamide gel electrophresis using 10% (figure 
2.6) and 20% (figure 2.7) gels. From these gels, the 
purified metallothionein I had an apparent molecular 
weight of about 12,000 (calculated from a mixture of 
proteins of known molecular weight as a standard 
reference in the 10% and 20% gels). The presence of 
this protein can be observed particularly well in the 
liver and kidney cytosolic fractions and urine, in 
the 20% gel. No positive staining was observed in 
the cytosolic fraction of the intestine. This may be 
due to the concentration of protein in this sample 
being below the limit of detection for the Coomassie 
Blue staining procedure. Intense staining was seen 
in the electrophoretic pattern of the urine. This 
has an apparant molecular weight of about 20,000 
daltons and may be microglobulin, as this is 
reported to be present in the urine of rabbits 
(Piscator et a 1. 1981) and man (Kjellstrom et a 1.
1977: Stewart et a 1. (1981)) exposed to cadmium.
121
Figure 2.5
Electrophoresis in a 10% polyacrylamide gel (0.2% 
cross 1inkage) to show the main steps in the isolation 
of the two metallothioneins from rat liver
Track:
1, 7 - Control rat serum
2 - Liver cytosol fraction (106,000g
supernatant of a 10% liver homogenate)
3 Supernatant from the liver cytosol 
following heat treatment
4 Semi purified metallothionein fraction 
following the separation of the supernatant 
from the heat-treated liver cytosol by 
Sephadex G-75 filtration
5 Purified metallothionein I isolated from 
the sample shown in track 4, by DEAE ion- 
exchange chromatography
6 Purified metallothionein II isolated from 
the sample shown in tract 4 by DEAE ion- 
exchange chromatography
122
123
Figure 2.6
SDS electrophoresis using a 10% polyacrylamide gel 
(0.2% crosslinkage) of tissue cytosol and urine 
samples from a rat exposed to 300 ppm Cd'^ "* in the 
diet for 16 weeks
Tracks:
1, 2 - molecular weight markers (12,300 - 78,000
dal tons)
3 - purified rat liver metallothionein I
4 - liver (from a 10% homogenate)
5 - kidney (from a 10% homogenate)
6 - intestine (from a 5% homogenate)
7 - urine
8 - molecular weight markers (12,300 - 78,000
dal tons)
9 purified rat liver metallothionein I.
The molecular weight markers used were:
Cytochrome c (equine) 
Myoglobin (equine) 
Chymotrypsinogen A (bovine) 
Ovalbumin (hen egg)
Albumin (bovine serum) 
Ovotransferin (hen egg)
(12,300 daltons)
(17,200 daltons)
(26,000 daltons)
(45,000 daltons)
(66,250 daltons)
(78,000 daltons)
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Figure 2.7
SDS electrophoresis using a 20% polyacrylamide gel 
(1.1% crosslinkage) of tissue cytosol and urine 
samples from a rat exposed to 300 ppm Cd2^  in the 
diet for 16 weeks
Tracks:
1 - Molecular weight markers (2,512 - 16,494
dal tons)
2 - Purified rat liver metallothionein I
3 - Liver (from a 10% homogenate)
4 - Kidney (from a 10% homogenate)
5 - Small intestine (from a 5% homogenate)
6 - Urine
7 - Molecular weight markers (2,512 - 16,494
daltons)
8 - purified rat liver metallothionein I.
The molecular weight markers used were:
Myoglobin III (2,512 daltons)
Myoglobin II (6,214 daltons)
Myoglobin I (8,159 daltons)
Myoglobin I + II (14,404 daltons)
Myoglobin (16,495 daltons)
The myoglobin and eyeinogen-bromide cleaved 
components were obtained from equine heart
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Cadmium, zinc and copper content of the purified 
samples of metallothionein I and II gave the molar 
ratios for Cd:Zn:Cu of 90:40:1 for metallothionein I 
and 100:30:1 for metallothionein II. When the 
protein concentration was determined by drying 
metallothionein samples to constant weight, the molar 
ratio of Cd:Zn:Cu:metallothionein was 4.5:2.0:0.05:1 
for metallothionein I and 5.0:1.5:0.05:1 for 
metal 1othionein II. However, using the Lowry method 
for the determination of protein concentration the 
values obtained for metallothionein I and 
metallothionein II were between 1.5 and 2.0 fold 
greater than those obtained by drying to constant 
we i gh t.
2.3.3 Affinity of the 1 :ai5I-label led metal lothionein I 
for the sheep anti-rat metallothionein 
ant iserum
Iodination of the 3-(4-hydroxypheny1) propionyl- 
metal lothionein I conjugate with Na13L,£;I incorporated 
about 50% of the added 1::2eI radiolabel. The specific 
radioactivity of the 1 ^ ’I-labelled protein was 
generally 100 jiCi/ug protein which was equivalent to 
0. 3 3 3 protein. Figure 2.8 shows the 
radioactivity and immunoreactivity of the eluate 
fractions following separation of the radio-labelled 
proteins from the free 122611. The radio-labelled 
protein (fractions 1 to 4) were highly immunoreactive 
towards the sheep anti-rat metallothionein antiserum, 
fractions 5-10 were less reactive towards the 
antibody and contained no radioactivity.
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Figure 2.8 Assessment of the immunoreactivitv of each of 
the fractions of a Sephadex G-25 column 
following iodination of metallothionein.
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The immunoreactivity of the conjugate designated 
(□---- □) in each fraction, was calculated as follows:
B-NSB x 100 
T
where B is the mean radioactivity of the anti­
body bound radiolabelled metallothionein in 
counts per 100s.
NSB is the mean radioactivity of the non-
specifically bound radiolabelled metallothionein 
in counts per 100s.
T is the total radioactivity present in counts per 
100s.
The radioactivity in each fraction is given by (• •) .
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Figure 2.9 Patterns for precipitin lines after 
crossed Immunoelectrophoresis of rat 
liver metallothionein I against sheep 
anti-(rat metallothionein I) antiserum
i
SARM
Mt
W
\
The antigen (rat liver metallothionein I) was placed 
in the well (bottom right) and e 1ectrophoresed in the 
first dimension (to the left of the well). Electro­
phoresis in the second dimension (upwards) was 
against the split antibody containing gel. The exact 
conditions and the method of staining are described 
in Section 2. The samples marked on the gel represent 
Mt - rat liver metallothionein I 
SARM - sheep anti-(rat metallothionein I)
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2.3.4 CharacterlsatIon of the sheep anti-rat 
metallothionein antiserum
Using crossed Immunoelectrophoresis, the antigenicity 
of the rat liver metallothionein I towards the sheep 
anti-rat metallothionein antiserum was shown by the 
existence of two immunoprecipi tat ion peaks (figure 
2.9). The relative mobility (rm) of metallothionein 
A and B peaks with respect to the Bromophenol blue 
was between 0.37 and 0.45 and between 0.49 and 0. 62 
respectively. The cross reactivity of chick gamma 
globulin towards this antibody was also measured by 
this method. As figure 2.10 shows there is an 
immunoprecipi tat ion peak at the origin. The strong 
reaction indicates the presence of either a highly 
avid or high titre antibody towards chick globulin in 
the antiserum. The presence of these antibodies is 
not surprising as this protein was conjugated to rat 
metallothionein I to evoke the antibody to 
metallothionein in the sheep. This is discussed 
further in section 2.4.
The presence of metallothionein in the cytosol 
fraction of the liver and kidney of cadmium exposed 
rats, and its detection by this antibody was further 
demonstrated by crossed Immunoelectrophoresis. As 
figure 2.11 and 2.12 show, there is a single 
immunoprecipitat ion peak towards proteins in the 
liver and kidney cytosols, in each of the anti-rat 
metallothionein antiserum containing gels. The rm 
values for each of the precipitation peaks for the 
liver and kidney are between 0.41 and 0.56, and 
between 0.36 and 5.5 respectively. The anti-rat 
cytosol antiserum cross reacted with 5 proteins in 
both the liver and kidney cytosol.
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Figure 2.10 Patterns of precipitin lines after
crossed 1mmuno-e1ectrophores1s of chick 
gamma globulin against sheep ant 1-(rat 
metallothionein I) antiserum
The antigen (chick-gamma globulin) was placed in the
well (bottom right) and e 1ectrophoresed as described
in the legend beneath figure 2.9. The samples marked
on the gel represent
CGG - Chick gamma globulin
SARM - Sheep anti-(rat metallothionein I)
SARM
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Figure 2.11 Patterns of precipitin lines obtained 
aft er crossed Immunoelectrophoresis of 
the liver cvtosollc contents (from a 
rat exposed to 300 ppm CcP~*~ in the diet 
for 16 weeks) against two antisera 
(indicated on the plate)
RARC
SARM
( LC
The antigen (rat liver cytosol) was placed in a well 
(bottom right) and electrophoresed as described in 
the legend beneath figure 2.9. The samples marked on 
the gel represent.
LC - liver cytosol
SARM - sheep anti-(rat metallothionein I)
RARC - rabbit anti-(rat cytosol)
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Figure 2.12 Patterns of precipitin lines obtained 
after crossed Immunoelectrophoresis of 
the kidnev cytosolic contents (from a 
rat exposed to 300 ppm Cd2"- in the diet 
for 16 weeks) against two antisera 
(indicated on the plate)
RARC
SARM
I C KC
\ . ■
r
The antigen (rat kidney cytosol) was placed in a well 
(bottom right) and e 1ectrophoresed as described in 
the legend beneath figure 2.9. The samples marked on 
the gel represent 
KC - kidney cytosol
SARM - sheep anti - (rat meta 11othione 1n-I)
RARC - rabbit anti-(rat cytosol)
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Further characterisation of the sheep anti-rat 
metallothionein antiserum was undertaken by assessing 
the reaction of this antibody to proteins present in 
the liver, kidney and intestinal cytosols and urine, 
(electrophoretically separated by SDS 10% 
polyacrylamide gel Immunoelectrophoresis) using the 
Western Blot technique (see section 2.2). As figure 
2. 13A shows, there was intense staining observed in 
the low molecular weight region of the gel, 
particularly in the purified metallothionein fraction 
(tracks 3%$ ), but also in the liver, kidney and 
intestinal cytosol fractions. However, staining was 
also observed in other parts of the gel, particularly 
where the proteins were in higher concentrations. 
Althought the clarity of the protein fractions needs 
improvement by modifying the test procedure, the 
standard proteins of known molecular weight, and 
certain of the low molecular weight proteins 
(particularly metallothionein) may be depicted. 
Repeating the technique using normal sheep serum 
instead of the anti-metallothionein antiserum, no 
staining in the low molecular weight region was 
revealed but there was intense staining in the high 
moleular weight region of the gel particularly in the 
liver cytosol fraction (figure 2.13B). The reason 
for this is not known, but it follows that further 
work is required to make this a practicable test of 
cross reactivity of a compound for the antibody. The 
Western Blot technique is not an easy technique to 
master and as time spent on this technique was 
limited, the photographs of the electrophoretic 
transfer of protein by the Western Blot technique 
presented in this thesis are the results of 
preliminary work. Further work needs to be performed 
to ascertain i) the most appropriate concentration of 
sheep anti-metallothionein antiserum and donkey anti­
sheep antibody (conjugated to horseradish peroxidase) 
to use for this technique, ii) to limit the non-
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Figure 2.13 Immuno-b1ottlng of electrophoretical1v 
separated proteins from a 10% SDS 
polvacrvlamlde gel using the Western 
Blot technique
Photograph A - Immunoblotting using a sheep anti­
rat metallothionein I antiserum.
Tracks:
1,2, - Molecular weight markers (12,300-78,000
dal tons)
3.9 - Purified rat liver metallothionein-I
4 - Liver cytosol (from a 10% homogenate)
5 - Kidney cytosol (from a 10% homogenate)
6 - Small intestinal cytosol (from a 5%
homogenate)
7 - Urine
Photograph B - Immunoblotting using heat -
inactivated normal sheep serum.
Tracks:
1„2,8 - Molecular weight markers (12,300-78,000 
dal tons)
3.9 - Purified rat liver metallothionein-I
4 - Liver cytosol (from a 10% homogenate)
5 - Kidney cytosol (from a 10% homogenate)
6 - Small intestinal cytosol (from a 5%
homogenate)
7 - Urine
The molecular weight markers used have been presented 
in figure 2.6.
Tissue cytosol and urine samples were obtained from a 
rat exposed to 300 ppm Cd^-4" in the diet for 16 weeks.
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specific binding by adding chick-gamma globulin to 
the first antibody solution or heat inactivated 
normal sheep serum to the second antibody solution 
for example.
2.3.5 Quantitative assessment of the sheep anti-rat 
liver metallothioneln antiserum for R.I.A.
The antibody titration curve for the sheep antiserum 
is shown in figure 2.14, revealing that 54% of the 
tracer was bound at a dilution 1/1000 of the 
antiserum (antiserum titre). The weight of labelled 
antigen which gave no further increase in titre was 
50 pg/tube. Displacement of the 11231-label led 
metallothioneln from the antibody by unlabelled 
metallothionein (1 ug/tube) is shown in figure 2.15.
A displacement of 24% of the 12SI labelled 
metallothionein bound to the antiserum (at a dilution 
of 1:1000) was observed by the addition of the 
standard metallothionein (1 ug/tube). This 
illustrates that competition between the labelled and 
unlabelled protein for the antibody exists.
A more accurate method for determining the avidity of 
the sheep anti-rat metallothionein antiserum is by 
means of a Scatchard plot (figure 2.16). The line of 
steeper slope represents an antibody population with 
high avidity for the metallothionein. The line of 
shallower slope represents an antibody population 
with low avidity for metallothionein. The 
concentration of binding sites/ml of antiserum 
present as the population of high avidity antibody 
sites was 18.5 nmol/1 and of low avidity antibody 
sites was 72.0 nmol/1 by extrapolation. From the 
slope of each line on the Scatchard plot, the 
association constant (K> of metallothionein with the 
antibody population can be calculated. This is a 
quantitative measure of the stability of the antigen-
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Figure 2.14 Antibody titration curve of the sheep anti-
frat nietallothionein I) antiserum.
80
60
40
20
Dilution of antiserum
The antibody titration was measured using ^25j_2abelled
metallothionein I at 50 (•- -•), 100 (a a) and 2 00
(□____□) pg/tube so as to determine the concentration of
radiolabel that would produce the most sensitive radio­
immunoassay.
The definition of B-NSB/T is given in the legend of 
figure 2.8.
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_ Figure 2.15 Displacement of the antiserum dilution
curve by rat liver metallothionein I.
80
60
40
20
Dilution of antiserum
The concentration of ^25j_iabelled metallothionein I used 
was 50pg/tube. Displacement of the antiserum dilution
curve (•_____•) occured by the addition of lOOug/ml
(lug/tube) rat liver metallothionein I (a_ * - _ a).
B/
F
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Figure 2.16 Determination of the avidity of the sheep 
anti~(rat metallothionein-1) antiserum 
using a Scatchard plot.
o.8r
0.6
0.4
-K
-K
0.2
4024 328 16
C - B/F
1+(B/F)
The avidity of the antiserum was determined by means of a 
Scatchard plot, in which the ratio of molar concentration 
of bound to free antigen is plotted against the total 
molar concentration of bound antigen where 
B - radioactivity associated with "antibody bound"
125I- radiolabelled metallothionein (counts/lOOs).
F - radioactivity associated with "free" 3-25I-radio- 
labelled metallothionein (counts/lOOs).
C - concentration of the antigen added (nmol/ml).
The slopes of the lines -K^ and -K2 are 3.7 x 10”2 
litres/mole and 7.2 x 10”3 litres/mole respectively.
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antibody complex. These values were 3.7 x 10-2 and 
7.2 x 10~3 nmol/1 for the high and low avidity 
antibody respectively. Thus it appears that the 
sheep anti-metallothionein antiserum may contain 
either two antibody populations or a single antibody 
with low and high avidity binding sites, reacting 
with metallothionein.
Although certain compounds have been assessed for 
their cross reactivity to the antibody, (see section 
2.2.6) glutathione and cysteine and their cadmium 
complexes have not been previously assessed. As 
shown in figure 2.17 both glutathione and cysteine 
did not exhibit cross reactivity with the antiserum 
up to 20 ug/ml. However, the cadmium complex of 
glutathione did show significant reactivity towards 
the antiserum at high concentrations, showing 15% 
cross-reactivity at 30 ug/ml. Also shown in figure 
2.17, human metallothionein II showed 100% cross 
reactivity with rat liver metallothionein I using the 
sheep anti-rat metallothionein antiserum.
2.3.6 Use of the sheep anti-rat metallothionein
antiserum for the detection of metallothionein 
bv RIA.
The standard curve for metallothionein is depicted in 
figure 2.18. It is linear over the range 0.08-
1.0 ug/ml. By using the logit log transformation 
(Rodbard and Lewald, 1970) as modified by Bremner
et al. (1983) shown in figure 2.19, linear plots over
the range 0.04-6.0 ug/ml were then obtained. Intra- 
and inter-assay coefficients of variation were about 
3% and 15% respectively for 3 samples containing 0.5,
1.0 or 4.0 ug/ml metallothionein. A decrease of 20- 
30% in the sensitivity of this assay occurred 2 weeks 
after iodination of metallothionein and hence the
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Figure 2.17 Cross reactivity of glutathione, cysteine 
(and their cadmium salts! and human kidney 
metallothionein II.
100r
80-
60
40
20
1000.10.01 1.0 10
(Concentration (ug/ml) 
(logarithmic scale)
The above competitive binding assay used the following as 
competitive inhibitors: glutathione, cysteine and
cysteine-Cd complex, all represented as (■-----■);
glutathione-Cd complex as (a a) and human kidney
metallothionein II as (• •) .
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Figure 2.18 Standard curve for rat liver
metallothionein I
lOOr
80
60
40
20
100.01 1.00.1
Concentration of metallothionein(ug/ml) 
(logarithmic scale) 
where for each sample
Bq - the mean radioactivity of the antibody bound
radiolabelled metallothionein in the absence of standard 
or unknown concentrations of metallothionein, in counts 
per 100s.
B - the mean radioactivity of the antibody bound 
radiolabelled metallothionein in the presence of standard 
or unknown concentrations of metallothionein, in counts 
per 100s.
NSB - the mean radioactivity of the non-specifically 
bound radiolabelled metallothionein, in counts per 100s.
T - the total radioactivity in counts per 100s.
Figure 2.19 Standard curve for rat liver
metallothionein I.
4.0
3.0
.2.0
1.0
0.01 1.00.1 10
metallothionein concentration (ug/ml) 
(logarithmic scale)
B, Bq and NSB are defined in the legend of figure 2.18.
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radio-label was only used within 8-10 days of its 
production.
The immunoreactivity of compounds in the urine, bile 
and cytosolic fractions of liver and kidney from 
control rats was assessed.
As shown in figure 2.20, the components of the liver 
and kidney cytosols at a 1:25 dilution interfered 
with the antigen-antibody complex, displacing the 
standard curve to the right, and decreasing the 
sensitivity of the assay. Thus the percentage 
binding of the radio-label led antigen, on addition of 
0.4 ug/ml metallothionein for example, was reduced by 
12 and 17% in the diluted liver and kidney cytosol 
fractions respectively, when compared to control 
buffer dilutent. The dilutions of 1/5 and 1/10 of 
liver and kidney cytosol (not shown graphically) 
showed a decrease in sensitivity with increasing 
concentration of liver or kidney cytosol. The 
detection limit for metallothionein in the assay 
using the liver cytosol at dilutions 1/5 and 1/10 
were 0.5 and 0.1 ug/ml respectively, and in the assay 
using kidney cytosol at dilutions of 1/5 and 1/10 
were 0.9 and 0.25 ug/ml.
There was no displacement of the standard curve for 
metallothionein in urine at concentrations greater 
that 0.1 ug/ml (figure 2.21). However, there was an 
apparent increase in sensitivity in the urine at 
concentrations between 0.01 and 0.1 ug/ml, and the 
detection limit for metallothionein in the assay was 
reduced from 0.04 to 0.02 ug/ml. There seemed to be 
a considerable affect on the standard curve for 
metallothionein when bile from control rats was used 
as a diluent (figure 2.22). The detection limit was 
increased to 0.2 ug/ml. However, the standard error 
about the mean percentage bound value particularly at
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Figure 2.20 Standard curve for metallothionein
measurement in the rat liver and kidney 
cvtosol fractions.
100i
80
60
40
20
0.01 0.1 1.0 10
Concentration of metallothionein(ug/ml) 
(logarithmic scale)
Standard curve for the measurement of metallothionein in
a) liver cytosol (diluted 1:25 in diluent buffer) p □) ,
b) kidney cytosol (diluted 1:25 in diluent buffer) (■——■) 
and c) diluent buffer (0.05M phosphate buffer, pH 7.5 + 
0.1% Bovine serum albumin) (•--- •).
B, Bq and NSB are defined in the legend of figure 2.18
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Figure 2.21 Standard curve for metallothionein 
measurement in rat urine.
co 100
pH
rH
•H
40
•H 20
0.01 0.1 1.0 10
Concentration of metallothionein(ug/ml) 
(logarithmic scale)
Standard curve for metallothionein measurement in urine
( q  □) compared to the standard curve obtained in
diluent buffer (• •) .
B, B0 and NSB are defined in the legend of figure 2.18.
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Figure 2.22 Standard curve for metallothionein 
measurement in rat bile^
100
80
60
40
20
0.01 1.00.1 10
Concentration of metallothionein (ug/ml) 
(logarithmic scale)
B, Bq and NSB are defined in the legend of figure 2.18.
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the lower concentrations was large and varied. Apart 
from cross-reacting proteins this may also be due to 
the detergent effect of the bile interferring in the 
formation of antigen-antibody complex.
The analytical recovery of metallothionein in urine, 
kidney and liver cytosol was determined by the 
addition of purified liver metallothionein to the 
sample (table 2.5). It shows that the addition of 
metallothionein at 0.05, 0.4 and 0.9 ug/ml gave an 
analytical recovery of between 79 and 98%, However, 
in the bile, the analytical recovery of 
metallothionein additions of 0.4 and 0.9 ug/ml was 70 
and 90%.
2.4 Discussion
2.4.1 Isolation and purification of metallothionein
Using the isolation scheme shown in figure 2.2, rat 
hepatic metallothionein was resolved into two peaks 
with characteristic ultraviolet absorbtion at 254nm 
(see figures 2.3 and 2.4) and a cadmium:protein ratio 
(w/w) of 30.4 and 31.8. These respective components, 
designated metallothionein I and II were similar to 
the metallothionein components described by Vander 
Mai lie and Garvey (1978). An apparent ten fold 
purification of metallothionein from the liver 
cytosol was calculated. The 35% recovery of these 
proteins from the rat liver as measured by cadmium 
content was slightly lower than the 48% attained by 
Vander Mai lie and Garvey (1978). The major loss of 
cadmium in the purification scheme occurred in the 
heat treatment step. As metallothionein has been 
reported to be heat stable (Webb, 1972a; Cherian, 
1974), this loss of the cadmium could have occurred
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by the dissociation of cadmium from the protein or 
loss of metallothionein during the formation of 
coagulated protein precipitate.
The time taken to isolate metallothionein by 
fractionation using gel filtration chromatography can 
be 18-24 h; in an attempt to increase the rate of 
production of this protein, ultrafiltration membranes 
were used. However, as shown in figure 2.6, this was 
not successful as only 2% of the cadmium in the 
cytosol was present in the fraction of molecular 
weight between. 5 and 10 kilodaltons. Using this 
method most of the cadmium in the cytosol fraction 
was retained by the YMIO membrane (which witholds 
constituents above 10 kilodaltons). This may either 
be explained by metallothionein being polymerised or 
parts of the membrane occluded by other protein 
constituents of the cytosol. The latter possibility 
is more likely as dithiotheitol was used to maintain 
the metallothionein in its monomeric form during 
ultrafiltration. A further noteworthy point which 
may explain the cadmium retention in the YMIO 
ultrafiltration membrane is that monomeric 
metallothionein appears to have a molecular weight of
10,000 daltons on electrophoretic profiles. For this 
reason, it is likely that this protein will also act 
similarly and be retained by the YMIO membrane.
Further work (using ultrafiltration membranes which 
retain proteins of greater than 25,000 daltons for 
example) may provide evidence for the above 
explanation for the poor recovery of metallothionein 
by the method using ultrafiltration membranes.
Seven percent of the cadmium in the cytosol was 
present in the fraction containing constituents of 
less than 5 kilodaltons suggesting that either the 
cadmium was also bound to low molecular weight 
constituents of the liver, such as glutathione, or
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the metal had become dissociated from the thionein 
moiety during the course of the isolation process.
The latter is more probable as the use of 
dithiothreitol in the isolation of metallothionein 
does lead to metal losses from the protein (see table 
2) .
The use of an aqueous/organic phase separation step 
similar to that used by Winge et al. (1981), to
remove all lipophilic constituents of the cytosol 
before fractionation by gel filtration, was less 
successful than the method which did not incorporate 
this step (figure 2.7). The cadmium losses may have 
been due to the inability to remove all the aqueous 
layer from the organic phase and the difficulty in 
reconstituted proteins following acetone 
precipi tat ion.
Mercaptoethanol has been used in the isolation of 
metallothionein from rat liver to reduce the protein 
to its monomeric form (Minkel et a 1. 1980). However,
unlike the results observed by Minkel et a 1. (1980),
the findings of this study showed that, although 
mercaptoethanol and dithiothreitol decreased the 
polymerisation of metallothionein, in so doing these 
reducing agents seemed to remove cadmium from the 
metallothionein. Thus the use of these thiols was 
not incorporated into the isolation procedure for 
cadmium metallothionein.
The purity of rat liver metallothionein I and II 
isolated in the present study was assessed 
quantitively by the metal content and protein weight 
of each protein and qualitatively by electrophoresis. 
When based on the mass of the protein (1yophi1ized to 
constant weight), the molar ratio of Cd: 
metallothionein was 4.5:1 and 5.0:1 for isoforms I 
and II respectively. Zinc was the major secondary
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metal bound to these proteins. The values for the 
cadmium:metallothionein II molar ratio is in good 
agreement with findings of Winge et a 1. (1975), and 
Tohyama and Shaikh (1978) who related metal content 
of metallothionein to protein content of 
metallothionein determined by quantitative amino acid 
analysis of the purified protein. (The latter 
procedure yielded a protein content of 50% relative 
to the value obtained by the Lowry procedure).
Single crystals of Cd, Zn-metallothionein II from rat 
liver have since been obtained (Mel is et al. 1983)
using the preparative procedure described by Winge et. 
a!_ (1975). Vander Mallie and Garvey (1979) report a 
slightly lower cadmium:metallothionein I molar ratio 
of 3.76:1 when the protein content was calculated 
from total nitrogen content. Again the latter 
procedure yielded a protein content of 40% of the 
value obtained by the Lowry procedure.
According to the electrophoretic profile (figure 
2.5), the metallothionein II (which is more tightly 
bound to the DEAE Sepharose column) was more pure 
than the metallothionein I, the latter protein having 
perhaps three other constituents. It appears that 
metallothionein II may be one of these constituents.
Alternatively these constituents could be 
metallothionein I molecules of differing charge.
This may be brought about by the higher concentration 
of copper in certain hepatic metallothionein I 
species. Copper thionein contains 9 g Cu/mole 
metallothionein (Winge et a1. (1981) in comparison
with the 7 metal atoms of Cd,Zn-metallothionein. The 
presence of copper in Cd,Zn-metal1othionein could 
affect the change of the overall molecule and thus, 
the binding of the protein to the E>EAE Sepharose 
column.
156
Impurities have also been reported In metallothionein 
I following its isolation from rat liver (Vander 
Mai lie and Garvey, 1978). The nature of these other 
constituents in the purified protein were not 
resolved by these workers.
According to Vasak et al. (1984), the conformational
state of the protein (measured by an increase in 
Stokes radius) is suggested to change on decreasing 
the ionic strengths. These effects are thought to be 
attributed to changes in intramolecular repulsion 
between the strongly negatively charged metal- 
thiolate clusters of the protein. This may effect 
the elution properties of metallothionein, and could 
also help to explain the 'impurities' found in the 
present study and also found by Vander Mai lie and 
Garvey (1978). However, the SDS (denaturing) 
electrophoretic profiles of rat liver metallothionein 
I showed only one distinct band of staining. This 
provides evidence for the hypothesis that the 
'impurities' in the electrophoretically separated 
non-denatured metallothionein I profile are 
metallothionein I molecules of differing charge.
The presence of proteins of similar molecular weight 
to metallothionein (about 12,000 daltons by the use 
of molecular weight markers) were observed in the 
liver, ki6ney and urine of a rat exposed tp dietary 
cadmium (figure 2.7). Very low concentrations of 
these proteins were detected in the small intestine 
of these animals. This provides qualitative evidence 
for the existance of metallothionein as detected by 
RIA.
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2.4.2 Characterisation of the sheep anti-rat 
metallothionein antiserum
Using crossed Immunoelectrophoresis, it was shown 
that the sheep anti-rat metallothionein antiserum 
cross reacted with two components in the purified 
sample of rat hepatic metallothionein. It is 
believed that these components are metallothionein I 
(giving the larger peak - see figure 2.9 ) and 
metallothionein II (the smaller peak - see figure
2.9 ). Non-denaturing electrophoresis of the 
metallothionein I sample also revealed the presence 
of another protein of similar electrophoretic 
behaviour as metallothionein I (see figure 2.5). As 
the two isoproteins elute within close proximity 
following DEAE Sepharose ion exchange chromatography, 
cross-contamination could occur upon isolation. No 
other cross-reactive peaks to any impurities in the 
metallothionein sample were observed, despite the 
presence of a minor protein band in addition to the 
metallothionein protein bands upon the electro­
phoretic separation of the protein in the 
metallothionein sample (figure 2.5). To explain this 
difference, the protein 'contaminant' may have been 
absent from the preparation used for Immuno­
electrophoresis, or more likely, the protein was of 
low concentration and undetectable by formation of a 
precipitin peak in the immunoelectrophoretic 
technique, or the precipitin peak was masked by the 
peak observed as due to metallothionein I-antibody 
binding.
The faint preciptin lines found in the cross- 
immunoelectrophoretic separation of metallothionein I 
at high antibody concentrations does provide 
information as to the nature of the protein antibody 
binding. These faint precipitin lines may suggest 
that an antibody-antigen lattice structure, with
158
multiple antibody-antigen interactions, is not formed 
unlike most protein-antibody complexes which form an 
intense precipitin line in crossed immunoelectro- 
phoresis (eg. see chick gamma globulin figure 2.11). 
This indicates that there are a low number of 
interactions between metallothionein and the sheep 
anti-metallothionein antibody. Further evidence of 
an unusual antigen-antibody complex with 
metallothionein and its antibody is provided by the 
results of the precipitation experiment by Winge and 
Garvey (1983). They indicated that stable complexes 
of metallothionein and a rabbit anti-rat liver 
metallothionein were formed at combining ratios of 
approximately 1.5 mol metallothionein to 1 mol of 
antibody. This was explained on the basis of one 
dominant immunogenic site and one weakly immunogenic 
site. As the antigenic reactivity of the rat 
metallothionein with the rabbit antisera resides 
predominantly in the amino-terminal domain of the 
molecule (Winge and Garvey, 1983), and the protein is 
comparitively small compared to the antibody, it is 
not surprising the metallothionein antibody combining 
ratio is low.
Antibodies to chick gamma globulin (the protein to 
which metallothionein I was conjugated to evoke the 
anti metallothionein antibody) were also observed 
(figure 2.11). This indicates that the sheep 
antiserum contains a mixed population of antibodies 
towards each of the constituents of the conjugate.
The presence of a single cross-reacting peak towards 
the sheep antiserum was found in both the liver and 
kidney cytosols of a rat exposed to cadmium in the 
diet, upon using crossed immunoelectrophoresis 
(figure 2.13 and 2.14). These peaks have similar 
electrophoretic mobility to the metallothionein I 
peak but also overlap into the metallothionein II
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peak (figure 2.10). Thus the precipitin lines 
observed may be due to metallothionein in liver and 
kidney cytosol fractions reacting with sheep anti­
metal lothionein antiserum. This is supported by the 
cross-reaction of a protein in the liver and kidney 
cytosol fraction, which is electrophoretically 
similar to liver metallothionein, with the sheep 
antiserum by the Western Blot technique (see figure 
2.15). Although this technique is not entirely 
specific for metallothionein, it does lend support to 
the results obtained by crossed 
Immunoelectrophoresis.
From the Scatchard plot (figure 2.19), the sheep 
antiserum contains two major populations of 
antibodies which react towards metallothionein. One 
population is low in concentration but high in 
avidity for the protein, the other population is high 
in concentration but low in avidity. This agrees 
with the findings of Winge and Garvey (1983) which 
suggest the presence of two antigenic determinants in 
the metallothionein molecule - one dominant and one 
weakly antigenic site. As previously stated, these 
workers also found that the amino-terminus of 
metallothionein (residuals 1-29) was more antigenic 
than the carboxyl-terminus (residuals 30-61). The 
low avidity and the apparent amino-terminus specific 
binding of the sheep anti-rat metallothionein 
antibodies in the antiserum may be explained by any 
of the following reasons:
a) The carboxyl-terminus section of 
metallothionein generally contains more lysine 
residues than the amino terminus section. Therefore 
the binding of a radiolabelled 'tag* such as N- 
succinimyl (hydroxypheny1) propionate, which binds to 
the lysine residues of the protein, may interfere
160
with the avidity of binding a metallothionein for the 
anti-metallothionein antibody used in this study.
b) Chick gamma globulin (which is linked to the 
protein by glutaraldehyde) binds to the amino groups 
via the C-N=CH(CH2)3-CH=N-3 linkage of the amino acid 
residues in the protein. Thus the gamma globulin 
could be bound to amino acid residues throughout the 
metallothionein molecule, and therefore antibodies to 
these conjugates could be evoked. Also, by 
conjugating metallothionein with another protein such 
as chick gamma globulin, a more antigenic determinant 
could be introduced into the system.
A structural similarity in metallothioneins has been 
found in many mammalian species (Kojima et al. 1979,
Kimura et al. 1979a, Kissling and Kagi, 1977, Huang
et al. 1981). Thus a metallothionein from one
mammalian species may evoke a low antibody response 
because the proteins contain few antigenic 
determinants when injected into another mammal. One 
method which may produce an anti-metallothionein 
antibody of higher titre and specifity would be to 
inject metal1othionein from one animal class, eg. rat 
(mammal), into an animal of a different class, eg. 
chicken/turkey (avain), as the metallothionein of 
these species may be significantly different in 
structure to be immunologically distinct from one 
another.
2.4.3 Radioimmunoassay of metallothionein
As previous work (Carter, 1982) and this study
suggests, the sheep anti-rat metallothionein antibody
is not specific for individual forms of
metallothiunein. The antibody has been shown to
cross-react equally with rat and human
metallothionein, liver or kidney meta 11othione in,
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either of the two major isoproteins and does not seem 
specific for metallothionein of different or zero 
metal content. _ In these respects the antibody is 
similar to that described by Vander Mai lie and Garvey 
(1978). However, although the antibody was raised in 
sheep in a similar manner to that described by Mehra 
and Bremner (1983), the antibody produced by these 
workers was very specific, reacting to only 
metallothionein I. The radioimmunoassay described in 
this study offers an advantage over that described by 
Mehra and Bremner (1983) in that it can be used to 
measure total metallothionein in liver, kidney and 
urine and metallothionein in rat and man (and 
probably other species as well).
The antibody titre is low (1:1000) compared to that 
reported by Mehra and Bremner (1983) ie. 1:35,000 for 
50% binding of the antigen, or by Garvey et al.
(1982), or Garvey (1984) ie. 1:20,000 at 30% binding 
of the antigen. However, as the antibody was raised 
in sheep, the supply of antiserum is far greater than 
in rabbits. The titre used in the study is greater 
than that reported by Tohyama and Shaikh (1981), who 
used a dilution of 1:2500 for 25% binding of the 
ant igen.
As the antibody titre in this study is far lower than 
that reported by Garvey et a1 (1982) or Garvey (1984)
and Mehra and Bremner (1983), the detection limit and 
linear working range which is 0.04-0.6 ug/ml (6.6 ng-
1.0 ug) (see figure 2.21) is higher than that 
described by these workers (1 pg-100 ng/tube and 100 
pg-10 ng/tube respectively). However, the linear 
working range of the assay in this study is of the 
same order but covers a larger range of 
concentrations than that described by Tohyama and 
Shaikh (1981).
162
Another factor affecting the sensitivity of the 
radioimmunoassay is the quality of the radio labelled 
tracer. About 75% of the tracer was bound by excess 
antibody, and the non-specific binding to the 
radiolabel was always about 10%. This may be a 
contributing factor- to the wide linear working range 
accomplished by this assay.
2.4.4 Application of the radioimmunoassay for the
measurement of metallothionein in blologicial 
samples
The standard curves for meta11othionein were 
displaced by the addition of the diluted cytosolic 
samples to the assay tubes, thus decreasing the 
sensitivity of the assay (see figure 2.24). This 
could be due to three possible factors. Primarily 
the cytosolic component of the liver and kidney of 
rats not exposed to Cd or excess zinc (or copper) is 
believed to contain metallothionein (Bremner and 
Davies, 1972; Stonard and Webb, 1976). The kidney 
cytosol has a higher concentration of metallothionein 
than the liver from rats not previously exposed to 
cadmium or excess zinc (Shaikh and Smith, 1975). 
Secondly other constituents in the cystolic 
compartment of these tissues could interefere with 
the antigen-antibody interactions. Compounds such as 
albumin, haemoglobin and rat microglobin have been 
assessed individually and showed no cross-reaction 
with the radioimmunoassay (Carter, unpublished 
observations) .
This study has demonstrated that cysteine and 
glut athione up to 30 ug/ml (5 ug/tube) also showed a 
slight cross-reaction (about 12%) at this 
concentration, whereas a cysteine-cadmium complex 
showed no such cross-reaction at this concentration. 
Glutathione in the liver is present at concentra­
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tions of about 3.0 mg/g wet tissue weight the 
approximate concentration of this compound in a 20% 
(w/v) liver cytosol would, therefore, be 0.36 mg/ml. 
Thus in each assay tube, the diluted liver cytosol 
may contain about 1.4 ug of glutathione, and so if a 
cadmium-glutathione complex is formed in vivo, this 
complex should not significantly interfere with the 
assay of metallothionein (see figure 2.19). No 
evidence for the existence of a glutathione-cadmium 
complex in the liver cytosol of the rat is included 
in the work presented in this thesis (see chapter 3). 
Nevertheless other cadmium protein complexes located 
in the cytosol of both the liver and kidney may 
intefere with the RIA by binding to the anti­
metal lothionein antibody. This problem may be 
resolved by the purification of the antiserum by 
affinity chromatography.
The standard curve in urine for the measurement of 
metallothionein by radioimmunoassay also showed a 
marked change from the standard curve obtained in 
buffer (figure 2.25). There seemed to be an apparent 
increase in sensitivity at low concentrations (0.02- 
0.1 ug/ml) and this may be an effect of 
metallothionein present in the urine of rats 
previously unexposed to metals such as cadmium. 
Urinary meta11othionein has been reported in control 
unexposed rats (Tohyama and Shaikh 1983).
The constituents of bile also appear to affect the 
standard curve for metallothionein, showing a marked 
decrease in sensitivity at the lower concentrations 
(figure 2.26). It appears that the detergent effect 
of the biliary constituents such as deoxycholic acid 
could interfere with the binding of antigen to the 
antibody.
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2.5 Summary
Rat liver Cd,Zn-metallothionein I and II have been 
isolated and found to be of comparable purity to that 
obtained by other workers (Winge et al. 1975, Vander
Mai lie and Garvey 1978, Toyhama and Shaikh 1978).
The cadmium:metallothionein molar ratio was found to 
be 4.5:1 and 5.0:1 in isoform I and II respectively. 
Zinc was the major secondary metal bound to this 
prote in.
Sheep anti-rat metallothionein antiserum was shown to 
contain antibodies to Cd, Zn-metallothionein I (and 
possibly Cd,Zn-metallothionein II), chick gamma 
globulin (the protein to which metallothionein I was 
conjugated to evoke the anti-rat metallothionein 
antibody), and probably a single protein in each of 
liver and kidney cytosol fractions from a rat 
(exposed to cadmium in the diet) by crossed 
immunoelectro-phoresis. The Western Blot technique 
also provided evidence for the presence of antibodies 
to rat liver metallothionein I in this antiserum.
From the Scatchard plot, it was ascertained that two 
major populations of metallothionein antibodies exist 
in the sheep antiserum. One population low in 
concentration, is high in avidity; the other high in 
concentration, is low in avidity.
By the use of the isolated rat liver metallothionein 
and the sheep anti-rat metallothionein antiserum a 
radioimmunoassay for metallothionein has been 
developed. The assay is capable of measuring the 
total metallothionein concentration in the tissues 
and body fluids of rat, man and possibly most 
mammals. It has a large linear working range which 
means that very high dilutions are not required for 
the measurement of the protein in tissues from 
biological samples such as diluted liver and kidney
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cytosol. Thus despite its lower sensitivity this 
radioimmunoassay for metal 1othionein has a major 
advantage of flexibility and measurement of total 
metallothionein values in biological samples.
CHAPTER 3
An investigation between metallothionei 
cadmium, zinc and copper in the rat
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3.1 Introduction
The present understanding of the metabolism and 
toxicology of cadmium involves the critical organ 
concept described in section 1.10. Fundamental to 
this concept is the "threshold dose" for the 
occurrence of adverse effects within an organism.
The basis for such a "threshold dose" lies in the 
interference of cadmium with certain biochemical 
processes and structural components CNordberg, 1976).
The development of renal damage is the principal 
result of chronic environmental exposure to the ionic 
form of cadmium in humans (Friberg, 1974: Ewers et a 1 
1985) and in experimental animals (Nomiyama et al. 
1975, Kotsonis and Klaassen, 1978). The mechanism by 
which cadmium induces this toxicity is at present 
unclear, in view of the variety of toxic effects 
produced in experimental studies in animals. The 
induction of metallothionein synthesis principally in 
the kidney and liver, and subsequent binding of 
cadmium causes the steady accumulation of the metal 
in these tissues. This accumulation is probably 
responsible for the attainment of a critical 
concentration as the protein sequesters cadmium. The 
sequestration of the metal by metallothionein does 
infer a storage role for this protein in cadmium 
exposure.
The existence of cadmium, zinc-metallothionein in the 
plasma upon exposure to cadmium (Suzuki, 1981; Garvey 
and Chang, 1981) suggests a role for this protein in 
the transport of the metal, presumably to the kidney, 
as circulating cadmium-meta1lothionein is 
specifically targetted to this organ. Certain 
workers are of the opinion that the nephrotoxic 
effects of cadmium are mediated by meta 11oth1 onein,
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if not directly CCherian, 1978), then by the delivery 
of the toxic ion (Cain and Holt 1983). Therefore 
although the intracellular storage of cadmium in the 
metallothionein-bound form may initially represent 
detoxification, the possible release of the cadmium 
may be the cause of the nephrotoxicity. Hence there 
is difficulty in ascertaining a precise role for this 
protein. Cadmium is also excreted into urine bound 
to metallothionein following the onset of renal 
damage. However, little is known of the clinical 
significance of the urinary excretion of 
metallothionein prior to the onset of renal damage.
Metallothionein concentrations in the small intestine 
are reported to be increased by dietary 
administration of cadmium to rats (Stonard and Webb, 
1976). Engstrdm and Nordberg, (1979) observed that 
cadmium pretreatment in mice increased subsequent 
retention of an oral dose of 10S,Cd. However, no 
intestinal metallothionein levels were reported. 
Squibb et a1. (1976) suggested that metallothionein
may be involved in mucosal trapping of cadmium, from 
experiments in which mice were given large oral doses 
of CdCl^. Kello et a1. (1979) found that in rat
jejunum mucosa in situ, a several fold increase in 
metallothionein content did not affect either cadmium 
absorbtion from the lumen into the mucosa or transfer 
of cadmium from mucosa to the body. From further 
work using isolated rat jejunum segments, Foulkes and 
McMullen (1986) concluded that at low cadmium 
concentrations (40-50 nmol/g), the endogenous cadmium 
binding capacity sufficed to trap most of the cadmium 
taken up in the mucosa. At higher concentrations of 
cadmium, induction of metallothionein synthesis by 
zinc was reported to increase fractional trapping of 
cadmium. These reports, therefore, do suggest that 
metallothionein acts to sequester cadmium and 
eliminate the metal by desquamation of the mucosal
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epithelium and, also, an increase in meta11othionein 
concentrations in the small intestine would increase 
the oral "threshold dose" required for the onset of 
renal damage.
As metallothionein binds zinc and copper, the 
homeostasis of these metals could be altered. Zinc 
and copper may also interact to affect the threshold 
dose level and modify the toxic response to cadmium. 
More recently, Scheuhammer et a 1 (1985) have
suggested that zinc may play a more integral role in 
the induction of hepatic metallothionein upon 
exposure to cadmium. This conclusion was supported 
by the findings that the effectiveness of cadmium to 
initiate new metallothionein synthesis is much 
reduced in the presence of pre-existing zinc- 
metallothionein, and the high correlation of hepatic 
metallothionein with zinc concentrations, whether 
metallothionein is induced by zinc or cadmium. From 
this study and that of others (Brady et a 1. 1979), it
appears the zinc may be a primary inducer of hepatic 
metallothionein upon cadmium exposure. However, 
further work is required to elucidate this response 
in other organs and following low level chronic 
exposure to cadmium.
The measurement of metallothionein in urine has led 
certain workers to show that this parameter can be 
used as a good indicator of tissue burden of cadmium 
in man (Chang et al. 1980a) and in animals (Tohyama
et a 1. 1981). Thus metallothionein in urine has been
used as a diagnostic tool in the assessment of 
exposure to cadmium.
This study was performed to investigate the role of 
metallothionein in the absorption, distribution and 
excretion of cadmium, zinc and copper upon dietary 
administration of cadmium. The relationship between
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urinary excretion of metallothionein and tissue 
burden of cadmium was also investigated.
3.2 Exper i men t a1
3.2.1. Materials
All metal salts were obtained from BDH Chemicals Ltd, 
Poole, Dorset. Nitric and perchloric acids (used in 
atomic absorption spectrophotometry) were also 
supplied by BDH Chemicals Ltd. All chemical 
compounds were of Analar or equivalent grade except 
nitric acid which was of Aristar grade. Sodium 
pentobarbitone 'Sagatal' (60 mg/ml) was supplied by 
May and Baker, Dagenham, Essex. All materials used 
for the radioimmunoassay of metal 1othionein have been 
previously described in section 2.2.1.
3.2.2. Methods
Urinary creatinine was measured by the method of 
Bartels and Bohmer (1971). Cadmium, zinc and copper 
were measured by atomic absorption spectrophotometry 
using an SP9 spectrophotometer (Philips, Cambridge, 
U.K.), with deuterium background correction. For the 
measurement of cadmium, a slotted tube atom trap 
accessory was incorporated. This accessory is a 
double slotted quartz tube which is supported above 
the air/acetylene flame from a conventional burner.
A 3 to 5 fold increase in sensitivity over 
conventional methods has been reported (Milner,
1983).
A) - Metal measurement in tissues
The concentration of cadmium, zinc and copper in 
liver and kidney, and cadmium in the small intestine
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were measured after digestion of 0.5 g tissue with a 
mixture of concentrated nitric and perchloric acids 
(5.1) by the method of Delves et al. (1971). This
method gave recoveries of greater than 98% for zinc 
and copper at a concentration of 0.4 ug/ml with a 
coefficient of variation of less than +8% at a 
concentration of 0.1 ug/ml. Incorporation of a 
slotted tube atom trap gave a recovery of greater 
than 98% for cadmium at a concentration of 0.02 ug/ml 
with a coefficient of variation of less than +10% at 
a concentration of 0.01 ug. Further practical 
details are given in Appendix 11.
B) Metal measurement in urine
The concentration of cadmium in urine was measured by 
the discrete sampling of 100 ul of urine using the 
slotted tube atom trap accessory. This method gave a 
recovery of greater than 98% for cadmium at a 
concentration of 0.05 ug/ml and a coefficient of 
variation of less than +10% at a concentration of 
0.05 ug/ml. Urinary zinc and copper concentrations 
were measured after digestion of 3.0 ml with a 
mixture of nitric/perchloric acids as described above 
for the digestion of tissues. A recovery of greater 
than 95% was also obtained at concentrations of 0.1 
ug/ml and a coefficient of variation of less than 
+10% was obtained at 0.1 ug/ml. Further practical 
details are given in Appendix II.
C) Metal measurement in eluate fractions from the 
Sephadex G75 column
The concentrations of cadmium, zinc and copper in the 
eluate fractions following the separation of 
components in the cytosolic fraction of liver, kidney 
and small intestine were measured using the method
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described in Appendix II. Dilutions were made in 1% 
nitric acid in deionized water as appropriate.
D) Metallothionein measurement in the tissues, 
urine and pooled eluate fractions from the 
Sephadex G75 column
The cytosolic fractions of the liver, kidney and 
small intestine and the pooled eluate fractions from 
the Sephadex G75 column, following separation of 
these cytosols, were diluted with 0.05 M phosphate 
buffer (pH7.4) + 0.1% BSA. Urine samples were 
diluted with urine from a control male rat in which 
levels of meta11othionein were undetectable.
Metallothionein concentrations were then measured 
using the radioimmunoassay procedure described in 
sect i on 2.2.6 B .
E) Statistical analysis
All data was expressed as group mean and standard 
error of the mean. Statistical comparison of group 
control and treatment mean values were made using the 
Student's t-test. The homogeneity of variance was 
made using Barletts Test.
3.2.3 Experimental Design
A) The effects of repeated dietary administration
of cadmium; a dose response study
Male Wistar albino rats (University of Surrey 
strain), initial body weight 195 ±_ 5 g, caged in 
groups of 5, were fed standard powdered rodent diet 
(Spatts No. 2), ad 1i bi turn. The composition of the 
diet is detailed in Appendix III. Test groups of 
animals received a dietary supplement of 75 ppm Cd2-*' 
150 ppm Cd2"" or 300 ppm Cd'2-*" as cadmium chloride. A
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further control group was fed the normal powdered 
diet. Body weights were recorded periodically. At 
intervals of 3 and 8 days, 4, 16 and 62 weeks, 24
hour urine samples were collected from 3 animals in 
each dose group. The urine collections were made by 
placing the rats in glass metabolism cages with 
stainless steel mesh bases. The animals from each of 
these dose groups were then anaethetised with 
'Sagatal'. The liver, kidneys and sections of the 
small intestine (consisting of the duodenum, jejunum 
and ileum) were removed and weighed. The small 
intestinal segment taken was washed with 15 mM 
ammonium formate buffer (pH8.0) and blotted dry 
before weighing. Samples of urine and tissues were 
stored at -20e=>C for cadmium, zinc and copper 
determinat ion.
Samples of liver were homogenised with 20 vol (w/v) 
of 15 mM ammonium formate buffer (pH8.0). Kidney and 
small intestine samples were homogenized with 10 vol 
of the same buffer. The homogenates were centrifuged 
at 106,000 g (40,000 rev/min) for 1 hour and the 
cytosol (supernatant) fractions were assayed for 
metallothionein content. Samples of the cytosol 
fractions from each tissue were stored at -20<:,C.
The effect of repeated dietarv administration
of cadmium on the disposition of cadmium, zinc
and copper i n the tissue cvtosol and urine:
relationship with meta11othionein
To study the time dependant relationship between 
metallothionein and the metals in the urine and 
tissue cytosol fractions, the samples of urine and 
cytosol fractions obtained in the previous section 
(3.3.3 A) were defrosted (at 4,=,C) , centrifuged (.2000 
g for 10 mins) and then fractionated on a Sephadex 
G75 column (80 x 2.6 cm). (Further practical details
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are given later in this section). However, cadmium 
was found not to be associated with the metallo­
thionein fractions as expected but with other higher 
and lower molecular weight components in each of the 
tissue cytosol or urinary profiles (profiles are not 
shown). Whether the observed cadmium distribution 
may have been caused by long term freezing (greater 
than 6 months) or thawing/re-freezing of samples 
following a temporary breakdown of the freezer, is 
not known. Thus it was decided to examine the 
relationship between metallothionein and the metals 
in fresh samples of tissue cytosol and urine to 
eliminate any effects of freezing/thawing. Due to 
limited equipment and time, the experiment was 
performed on the urine and tissue samples of one rat 
at one time point.
Male Wistar albino rats (University of Surrey 
strain), initial body weight about 200 ±_ lOg, caged 
in groups of 5, were fed standard powdered rodent 
diet (Spratts No. 2), ad libitum, containing a 
dietary supplement of 300 ppm C d ^ ‘ as cadmium 
chloride. After 16 weeks, 24 hour collections or 
urine were taken from 1 rat as described previously 
(Section 3.3.3 A). The liver, kidneys and sections 
of the small intestine (consisting of the duodenum, 
jejunum and iIleum) were removed and weighed. The 
small intestinal segment taken was washed in 15 mM 
ammonium formate buffer (pH8.0) and blotted dry 
before weighing. The cytosolic fraction of the liver 
and kidney were prepared as described previously in 
section 3.3.3 A. The small intestine segment was 
homogenized with 5 vol (w/v) of 15 mM ammonium buffer 
(pH8.0). The homogenate was centrifuged at 106,000 g 
for 1 hour, and the cytosol fraction was retained. A 
sample of urine and each of the cytosol fractions ot 
the liver, kidney and small intestine were taken for 
the analysis of metal 1othionein and trace metals
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(cadmium, zinc and copper). Samples (10 ml) of the 
urine and each of the cytosols were fractionated by 
means of gel exclusion chromatography. (Urine, kidney 
and intestinal cytosols were fractionated as 
described for liver in Chapter 2, section 2.2.3 A). 
Each of the protein fractions eluted from the column 
were pooled, (see figures 3.4, 3.5, 3.7, 3.11 for
typical profiles), lyophilysed and reconstitued in 10 
ml of 15 mM ammonimum formate buffer (PH8.0), Each 
of these pooled fractions was analysed for 
immunoreactivity to the radioimmunoassay for 
metallothionein, and cadmium content.
3.3 Results
3.3.1 The effects of repeated dietary administration 
of cadmium: a dose response study
A) Body weight and organ/body weight ratio
Figure 3.1 shows the increase in body weight of the 
different groups of rats. There was no significant 
difference in body weight gain between test and 
control groups up to 16 weeks dietary exposure to 
cadmium; with the exception of the 300 ppm Cd^"1" dose 
group which showed a significantly lower gain in body 
weight. At the termination of the experiment (62 
weeks), the 75, 150 and 300 ppm cadmium treated rats
had body weights which were 77%, 78% and 65% of the
control animals. In addition, cadmium treatment 
resulted in significant increases in liver weight 
relative to body weight from 4 to 16 weeks exposure 
(table 3.1). Increases in kidney weight relative to 
body weight were also observed during this period.
By 62 weeks decreases in liver and kidney weight in 
the cadmium treated groups relative to the control
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group were seen. The liver/body weight ratio 
increased and the kidney/body weight ratio decreased 
in comparison to that of the control group. However 
these changes were not significant.
B Cadmium, zinc and copper concentrations in the
liver and kidney
From table 3.2, it is seen that cadmium accumulated 
in the liver and kidney in relation to dose. The 
cadmium concentrations in each of the tissues did not 
markedly differ in the 75 and 150 ppm dose groups up 
to 16 weeks exposure and in the 300 ppm dose group up 
to 4 weeks. By 62 weeks exposure there was a higher 
cadmium concentration in the kidney in all dose 
groups. Cadmium concentrations were 3.0, 2.2 and 1.5
times greater in kidney than in liver for the 75,
150, and 300 pm dose groups respectively. 
Interestingly at 16 weeks in the 300 ppm dose group, 
the pattern was reversed such that a higher 
concentration of cadmium was found in the liver.
Zinc also accumulated in the liver and kidney 
following cadmium exposure (table 3.3). Although an 
initial dose dependent fall in hepatic zinc 
concentration was observed up to 8 days of cadmium 
exposure, an increase in zinc concentration of 9.5, 
43.5 and 20.3% compared to the control group by 4 
weeks was seen in the 75, 150, and 300 ppm dose
groups respectively. This increase was maintained 
throughout the experiment. The hepatic zinc 
concentrations were lower in the 300 ppm dose group 
as compared to the 150 ppm dose group up to 16 weeks 
of cadmium exposure. In the kidney, a significant 
increase in zinc concentration was apparent in the 
150 and 300 ppm dose groups by 4 weeks. Although no 
such increase was observed after 16 weeks, a
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significant increase in renal zinc concentrations in 
the test animals of up to 60% above controls was 
shown after 62 weeks. A 50% reduction in renal zinc 
concentrations was observed in the control group 
after 16 weeks which may be a result of dietary or 
other environmental changes. This may explain the 
apparent decrease in renal zinc concentrations 
between 4 and 16 weeks in the test groups.
Hepatic copper concentrations significantly increased 
after 4 weeks in the 150 ppm dose group and 16 weeks 
in the 75ppm dose group (table 3.4). There was no 
such increase in the 300 ppm dose group, and no 
significant difference was found in the 75 and 150 
ppm dose group from controls after 62 weeks. Cadmium 
treatment also caused the accumulation of copper in 
the kidneys up to 16 weeks in all 3 dose groups 
(table 3.4). However, a subsequent decrease in renal 
copper concentration was observed after 62 weeks in 
each of the respective dose groups. It may also be 
noted that the renal copper concentrations of the 
control group increased 4 fold between 4 and 16 weeks 
and decreased 60% between 16 and 62 weeks of cadmium 
exposure. These observations may be a result of a 
change in copper content of the diet, and as such are 
difficult to interpret.
C) Metallothionein concentrations in the liver and 
k idnev
As shown in figure 3.2, hepatic metallothionein 
concentrations increased about 5 fold in all 3 dose 
groups compared to the control group (1.2 ±_ 0.5 
nmol/g), after just 3 days exposure to cadmium. The 
liver metallothionein concentrations then increased 
in a dose-related manner to concentrations of 333 +_ 
94, 394 + 66 and 423 + 66 nmol/g in the 75, 150 and 
300 ppm dose groups respectively by 62 weeks. The
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Figure 3.2 Effect of dietary cadmium on the
concentration of metallothionein in the 
11 ver
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Figure 3.3 Ef fect of dietary cadmium .qji -the 
concentration of metallothionein in the 
M .dney
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mean renal metallothioneln concentration for the 
control group was 6.8 +. 1.3 nmol/g, about 6 fold 
higher than that found in the liver. As figure 3.3 
shows, there was a dose-related increase in renal 
metallothioneln concentrations after 8 days, and by 4 
weeks, this was significant in all 3 dose groups 
compared with the control group. After 62 weeks a 
further 5-10 fold increase in renal metal 1othionein 
concentrations was seen in all dose groups as 
compared to the respective values obtained after 16 
weeks cadmium exposure.
D) Relationship between meta11othionein and
cadmium, zinc and copper concentrations in the 
liver and kidnev
As shown in table 3.5, there was no dose- or time-
related increases in the calculated molar ratio of
cadmium to protein for metallothioneln in the liver 
and kidney between 8 days and 62 weeks exposure to 
cadmium. The molar ratio ranged from 2.2 to 3.5.
However, there was a significant increase in the
molar ratio between 3 and 8 days in all 3 dose groups 
in both organs. There was also a trend towards a 
higher molar ratio in the kidney as compared to the 
liver in all 3 dose groups at each time interval.
The cadmium and metallothionein concentrations in the 
liver and kidney were strongly correlated, the 
correlation coefficient values (r) were 0.97 
<p<0.001>, 0.91 (p<0.001) and 0.84 (p<0.001> for the
75 ppm, 150 ppm and 300 ppm dose groups respectively. 
A significant correlation between the percentage 
increase in hepatic zinc concentrations above 
control, and metallothionein concentrations was 
observed. The correlation coefficient value (r) was 
0.62 (p<0.01>. However, no significant correlation
between percentage increase in zinc concentration
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above control, and metallothionein concentration was 
observed in the kidney Cr = 0.1, p>0.1). In 
addition, no significant correlation was found 
between percentage increases in copper concentrations 
above control, and metallothionein concentrations in 
either liver or kidney although it appeared that zinc 
and copper concentrations were related to the 
concentration of metallothionein in each tissue. The 
low correlation observed between percentage increases 
in zinc or copper and metallothionein concentrations 
appears to be as a result of the variance in the zinc 
and copper concentrations in the control group.
E) Relationship between cadmium and
metallothionein concentrations in the small 
intest ine
As shown in Table 3.6, cadmium accumulated in the 
small intestine in a time- and dose-dependent manner 
from 8 days to 62 weeks exposure. The concentration 
of cadmium in this tissue between 8 days and 16 weeks 
was about twenty fold less than the corresponding 
cadmium concentrations found in the liver and kidney. 
However, by 62 weeks, the cadmium concentration in 
the liver and kidney was only 2-3 times greater than 
that found in the small intestine.
Metallothionein was undetectable in the small 
intestine of control animals. However, after 8 days 
exposure to cadmium, metallothionein was observed 
(0.2-0.4 nmol/g). Although no induction of 
metallothionein was detected in the 75 ppm dose group 
until 62 weeks exposure, a significant induction of 
metallothionein was seen after 4 and 16 weeks in the 
150 and 300 ppm dose groups respectively (figure 
3. 4) .
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As there was no induction of metallothionein in the 
75 ppm dose group until 62 weeks exposure, no 
relationship between cadmium and the protein was 
seen. However, in the 300 ppm dose group, where 
metallothionein was induced after 4 weeks exposure, a 
good correlation (r = 0.96, p<0.001) between cadmium
and metallothionein was observed (see figure 3.4).
The cadmiurn:protein molar ratio for metallothionein 
showed no time-related difference and was 5.2 +_ 1.3. 
Likewise, there was a marked correlation (r = 0.97, 
p<0.001) between the metal and protein in the 150 ppm 
dose group after 16 weeks exposure; however, the 
rat io was higher (12.1 +.5.3).
F) Cadmium, zinc and copper concentrations in the 
ur ine
From figure 3.5 it can be seen that cadmium is 
detectable in the urine after 3 days exposure to the 
metal in all 3 dose groups. In the lower two dose 
groups, cadmium excretion remained low (less than 0.1 
pmol/mmol creatinine). However, in the 300 ppm dose 
group, a marked elevation to 0.2 pmol/mmol creatinine 
was observed after eight days. Between 4 and 62 
weeks exposure, the cadmium excretion .in this dose 
group remained high at about 0.3 pmol/mmol 
creatinine. The effect of dietary cadmium on the 
urinary excretion of copper and zinc in the urine was 
not clear in this study (table 3.7). There seems to 
have been a general increase in the excretion of 
copper and zinc in comparison with controls in the 
150 and 300 ppm dose groups up to 4 weeks exposure, 
and in the 75 ppm dose group up to 8 days exposure. 
Thereafter the concentration of copper and zinc in 
the urine was not different from control levels, 
except in the high dose group where a significant 
decrease in both zinc and copper concentration was 
seen after 16 weeks exposure.
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G) Metallothioneln concentrations In the urine:
relationship with urinary cadmium
concentrat ions
As shown in figure 3.6, metallothionein was 
detectable in the urine of control rats, at a mean 
concentration of 1.25 +. 0.2 nmol/mmol creatinine 
(equivalent of 0.9 ±_ 0.02 pg/ml) over the 
experimental period. However, an increase in 
concentration of metallothionein in these animals was 
observed between 4 and 62 weeks. The dietary 
administration of cadmium significantly increased the 
excretion of metallothionein to 3.5 ±.0.2 nmol/mmol 
creatinine, after 3 days exposure in all 3 dose 
groups. Metallothionein excretion continued to 
increase gradually until at 62 weeks, values of 
24.0, 37.0 and 55.0 nmol/mmol creatinine were seen in
the 75, 150 and 300 ppm dose groups respectively.
The correlation between cadmium and metal 1othionein 
concentrations in the urine of the low dose group was 
marked (r = 0.96, p<0.001) as the excretion of both 
is low. However, in the 150 ppm dose group there was 
less marked correlation between these two parameters 
(r = 0.75, p<0.005). In the 300 ppm dose group 
there was a poor correlation (r = 0.62, p<0.005).
H) Relationship between urinary meta 11othionein 
and liver and kidnev cadmium concentrations
There was a marked correlation between urinary 
metallothionein and liver and kidney cadmium 
concentrations in all dose groups. In the liver, the 
r values were 0.87 (p<0.001>, 0.90 (p<0.001) and 0.87 
(p<0.001) for the 75, 150 and 300 ppm dose groups
respectively. The r values in the kidney were 
calculated as 0.91 (p<0.001), 0.88 (p<0.001) and 0.97
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(p<0.001) for the 75, 150 and 300 ppm dose group
respectively. The relationship between tissue 
cadmium and corresponding urinary metallothionein 
values are shown in the form of a scatter plot (see 
figure 3.7).
3.3.2 The effects of repeated dietary administration 
of cadmium on the concentrations of 
metallothionein. cadmium, zinc and copper in 
the tissue cytosol fractions and urine
A) L i ver
Figure 3.8 shows the distribution of cadmium, zinc 
and copper in the freshly prepared liver cytosol 
fraction of a rat exposed to 300 ppm in the diet for 
16 weeks upon fractionation using a Sephadex G75 
column (80 x 2.6 cm). The metallothionein fraction 
(fractions 50-70) revealed the presence of both zinc 
and copper, and contained about 87% of the total 
cytosolic cadmium content. The remaining 20% was 
associated with higher molecular weight fractions. 
Measure of immuno-reactive metallothionein in the 
pooled column fractions 1, 2, 3 and 4 (see table 3.8)
showed a percentage recovery of about 80% of the 
cytosolic content. Around 70% of the total 
immunoreactivity in the cytosol was present in the 
metallothionein fraction (pooled fraction 3). A 
further 8% of the total immunoreactivity was found 
associated with higher molecular weight fractions, 
but only negligible amounts of immunoreactivity were 
associated with the low molecular weight fractions.
B) Kidney
Fractionation of freshly prepared kidney cytosols 
from a rat exposed to dietary cadmium for 16 weeks 
(figure 3.9) showed the presence of cadmium, zinc and
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Figure 3.7 Relationship between urinary
metallothionein and liver (A) and 
kidney (B) cadmium concentrations In 
rats exposed to dietary cadmium
loop
10 0.1o.oi
Liver cadmium concentration (pmol/g wet weight)
10
1.00.10.01
Kidney cadmium concentration (praol/g wet weight)
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Figure 3.8 Separation of the cytosol fraction of a
liver from a rat exposed to 300 ppm
cadmium in the diet for 16 weeks, on an
80 x 2.6 cm column of Sephadex G75 
(fine) eluted with 15 mM ammonium 
formate (pH8.0>, at a flow rate of 1.1 
ml/minute
Ultraviolet scan at 254 nm is shown as ( ).
Cadmium shown as (•--- •), zinc as ( A  A )  and copper
as (□---□ ) were determined by taking aliquots of
certain eluted 5 ml fractions. The protein markers 
(a-h) with their respective molecular weights are 
given below:
a-Albumin (bovine serum) 
b-Ovalbumin (hen egg) 
c-Chymotrypsinogen A (bovi 
d-Ribonuclease A (bovine) 
e-Cadmlum, zinc metallothi 
f-Insulin (bovine) 
g-Myoglobin (fragment III) 
h-5' Adenosine monophospha
(66,250 da 1 tons)
(45,000 da 1 tons)
ne) (23,200 da1 tons)
(12,600 dal tons)
onein (6,700 dal tons)
(5,700 dal tons)
(equi ne) (2,510 dal tons)
te (equine) (344 dal tons)
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Figure 3.9 Separation of the cytosol fraction of 
kidneys from a rat exposed to 300 ppm 
cadmium in the diet for 16 weeks, on an 
80 x 2.6 cm column of Sephadex G75 
(fine) eluted with 15 mM ammonium 
formate (pH8.0>, at a flow rate of 1.1 
ml per minute.
(A further explanation of this figure
is given in the legend to Figure 3.8)
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copper in the metallothionein fraction (fractions 50- 
63). This fraction also contained about 90% of the 
total cytosolic cadmium content. The remaining 
cadmium in the cytosol was found to be associated 
with the high molecular weight fractions (-5%). As 
table 3.8 shows, 78% of the total immunoreactivity of 
the kidney cytosol was associated with the 
metallothionein fraction. A further 11% of the total 
immunoreactivity was found in the high molecular 
weight fractions.
C) Small Intestine
Figure 3.10 shows the fractionation of freshly 
prepared cytosol of the small intestine from a rat 
exposed to dietary cadmium for 16 weeks. Analysis 
of the metal content of each fraction showed the 
presence of cadmium, copper and zinc in the 
metallothionein fraction (fractions 45-62) in each 
cytosol. These fractions contained around 45% of the 
total cytosolic cadmium. The remainder was found 
mainly associated with higher molecular weight 
proteins. Assessment of the immunoreactivity of each 
of the pooled fractions (table 3.8) showed that 56.6% 
of the total immunoreactivity of the intestinal 
cytosol was associated with the metallothionein 
fraction at 16 weeks. A further 27.6% was found in 
the lower molecular weight region of the cytosol.
The immunoreactivity of the higher molecular weight 
proteins towards the antibody was negligible.
D) Ur ine
Fractionation of a fresh urine sample collected from 
a rat exposed to 300 ppm cadmium in the diet for 16 
weeks (figure 3.11) showed that 88% of the urinary 
cadmium was associated with constituents of that 
molecular weight between 1400 and 6600 daltons.
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Figure 3.10 Separation of the cytosol fraction of 
the small intestine from a rat exposed 
to 300 ppm cadmium in the diet for 16 
weeks on an 80 x 2.6 cm column of 
Sephadex G75 (fine) eluted with 15 mM 
ammonium formate (pH8.0), at a flow 
rate of 1.lml/minute.
(A further explanation of this figure
is given in the legend to figure 3.8)
Fi
gu
re
203
Metal concentration (pg/fraction)
o
«H
n
o
uiufrgz qe aoueqjosqv
o
04
e
o
in
a)nq
rH
o
>
-p
c
idq
rH
o
p
0)
sq
c 
c 
o
•H
-p
o
qp
204
Figure 3.11 Separation of the urine from a rat
exposed to 300 ppm cadmium in the diet 
for 16 weeks on an 80 x 2.6 cm column 
of Sephadex G75 (fine) eluted with 15 
mM ammonium formate (pH8.0>, at a flow 
rate of 1.lml/minute.
(A further explanation of this figure
is given in the legend to figure 3.8)
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Twelve percent of the total urinary cadmium was on 
the metallothionein fraction and around 6% was in the 
high molecular weight fraction. The predominant 
metal present in the metallothionein fraction was 
copper which was in 40 fold greater concentration 
than cadmium. Most of the zinc was associated with 
the low molecular weight fraction.
Assessment of the immunoreactivity of the 
fractionated urine (see table 3.8) revealed that 69% 
of the total immunoreactivity of the urine was found 
in the metallothionein peak. Between 9 and 12% of 
the immunoreactivity was found in the low molecular 
weight fraction and a further 5.6% was associated in 
the high molecular weight fraction.
3. 4 Discussion
Exposure to cadmium leads to the accumulation of this 
metal in the tissues, particularly the liver and 
kidney, causing disturbances in the normal metabolic 
handling of zinc and copper. These effects appear to 
be related to the induction of metallothionein. The 
change in the tissue distribution of cadmium and the 
development of critical concentrations of this metal 
in target tissues may also be related to the 
properties of this protein.
3.4.1 Relationship between metallothionein and 
cadmium in the liver and kidney
After continual ingestion of cadmium, the metal 
accumulation in both the liver and kidney are 
generally dose and time related (table 3.2); although 
at the 300 ppm dose level this relationship became 
less significant. An explanation of the lower
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significance is the significant decrease in growth 
rate of the rats fed this dose of cadmium (figure 
3.1). It has also been reported that this decrease 
in growth rate may be brought about by a 20% lower 
food consumption in this strain of rats fed 300 ppm 
Cd2-1" compared to the corresponding control group.
The 75 ppm and 150 ppm Cd2"*" dose groups showed no 
significant difference (Bonner, unpublished 
observations). Therefore it is possible that the 
300 ppm Cd2'*" dosed animals in this study did not 
receive a cadmium intake twice that of the 150 ppm 
Cd2^  dosed rats.
Cadmium accumulated to its highest concentration in 
the kidney and highest content in the liver. This is 
in accordance with previous dietary studies showing 
that steady state concentrations of cadmium in the 
liver are attained, while the kidney tends to 
accumulate the metal (Stonard and Webb, 1976; Weigel 
et al. 1984, 1984a). In the present study the ratio
between cadmium concentration in the kidney and that 
found in the liver decreased with increasing dose, 
i.e. the higher the dose, the higher the cadmium 
concentration in the liver. This was most apparent 
after 62 weeks exposure where the ratio in the low 
dose group was 3.5 compared to 1.5 in the high dose 
group. This is in agreement with reported values of 
between 2.0 and 1.3 after oral cadmium doses of 25- 
100 ppm (Prigge, 1978; Anwar et a1 . 1961).
A decreased rate of hepatic cadmium accumulation 
between 4 and 62 weeks was observed in all 3 dose 
groups. This may be explained by either the 
increased retention of cadmium observed in the small 
intestine, together with a possible time-dependent 
decrease in absorption of cadmium at this site, or a 
loss of this metal bound to meta11othionein which 
would be *targetted* to the kidney as suggested by
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Cherian (1983). The rate of renal cadmium 
accumulation at 16 weeks compared to 4 weeks appears 
to be less in the 300 ppm dose group than the 75 and 
150 ppm dose groups. This corresponds to an 
increased urinary excretion of cadmium observed in 
the 300 ppm dose group compared to the other dose 
groups. An increased rate of renal cadmium 
accumulation observed between 16 and 62 weeks in the 
75 and 150 ppm dose groups suggests a re-distribution 
of cadmium from other organs in particular the liver 
and small intestine. This cadmium may be bound to 
metallothionein which in circulation would be 
targetted to the kidney. The absence of this 
observable effect in the 300 ppm dose group may again 
be explained by the increased urinary excretion of 
cadmium in this dose group.
Metallothionein concentrations in the liver and 
kidney also increased with cadmium exposure in a 
dose- and time-related manner, increasing by about 20 
fold in the liver and by about 30 fold in the kidney 
after 4 weeks exposed to 300 ppm Cd^-*" (figures 3.2 
and 3.3) compared to control values <5 nmol/g).
The significant increase in liver:body weight and 
kidney:body weight ratios observed in the 150 and 300 
ppm dose groups compared to the control group by 4 
weeks exposure (table 3.1) may reflect an increase in 
cellular constituents such as metallothionein.
However, the increase in the kidney:body weight ratio 
at 16 weeks is no longer significant. The dose 
dependant decrease in the kidney:body weight ratio 
observed at 62 weeks may reflect a loss of cellular 
constituents, which may include metallothionein, 
indicated by the 10-100 fold increase in urinary 
metallothionein concentrat ions between 16 and 62 
weeks exposure (figure 3.7). The rate of increase in 
hepatic and renal metallothionein also decreased
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between 4 and 62 weeks in all dose groups which may 
also indicate a cellular loss of this protein. (The 
results in Chapter 4 provide evidence that cadmium- 
metallothionein is released from the liver prior to 
hepatic damage).
Gel exclusion chromatography revealed that 90% of 
cadmium was associated with the metallothionein 
fraction of cytosolic fractions of the liver and 
kidney samples in this present study (figures 3.8 and
3.9). The metallothionein fraction accounted for 
about 70% and 80% of the total cytosolic 
metallothionein-immunoreactivity found in the liver 
and kidney respective1y. Thus the cadmium: 
metallothionein molar ratio calculated from the whole 
cytosol measurements of this protein is a good 
indicator of the true ratio found in the 
metallothionein fraction of the cytosol.
The accumulation of cadmium in the liver and kidney 
correlated well with metallothionein upon dietary 
exposure to cadmium in both tissues, giving a ratio 
of 3.0 g ion cadmium/mole metallothionein which does 
not significantly change with length of exposure from 
8 days to 62 weeks. However, there was a significant 
increase in the cadmium metallothionein molar ratio 
from 3 to 8 days exposure. The lower cadmium: 
metallothionein molar ratio at day 3 suggests that 
another metal such as zinc, may be inducing 
metallothionein in the liver and kidney. This is 
further discussed in section 3.4.2.
It has been suggested that the cadmium content of 
metallothionein governs the extent of renal toxicity, 
once in the plasma and targetted to the kidney 
(Suzuki at al, 1979), Thus* the ratio of cadmium (g 
ion) to metallothionein (mole) in the liver may be 
important in the onset of renal toxicity, especially
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as the following chapter (chapter 4) provides 
evidence of the hepatic release of metallothionein.
As the cadmium:metallothionein molar ratio does not 
significantly change in the liver throughout the 
exposure period (except during the first week) in any 
of the dose groups, the potential nephrotoxicity of 
hepatic cadmium-meta1lothionein released into the 
plasma does not appear to increase with length of 
exposure or in a dose dependent manner.
3.4.2 The relationship between metallothionein and 
zinc in the liver and kidney
The other major component of hepatic meta11othionein 
induced by cadmium, is zinc (Webb 1975). The present 
study does reveal a definite correlation between the 
percentage increase in zinc concentration and 
metallothionein concentration in the liver from 4 to 
16 weeks exposure to cadmium (correlation coefficient 
r = 0.62; pCO.OOl). This correlation is not as high 
as that between cadmium and metallothionein 
concentrations between the same time points 
(correlation coefficient r = 0.87, p<0.001). Zinc is
also observed in the fractionated liver cytosol from 
a cadmium exposed rat (figure 3.8) which further 
suggests a relationship between zinc and 
metallothionein in this organ.
From the results of the present study, it would 
appear that zinc may play a role in the induction of 
metallothionein, as shown by the correlation between 
percentage increases in hepatic zinc and 
metallothionein concentration, and the lower hepatic 
cadmium:metallothionein molar ratio on day 3 in 
comparison with the other time points. However, the 
correlation between cadmium and metallothionein in 
the liver is high, and the hepatic molar ratio 
between this metal and protein does change
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significantly. If zinc was the major inducer of 
metallothionein, the cadmium:protein molar ratio 
would be expected to increase as zinc becomes more 
limited and the correlation between zinc as well as 
cadmium metallothionein would be high. From the 
results of the present study, the correlation between 
cadmium is higher than that for zinc and in the 
kidney, where zinc concentrations are limited, no 
change in the cadmium: metallothionein molar ratio is 
observed. Therefore, it appears that cadmium does 
play a major role in the induction of metallothionein 
following dietary exposure to this metal. This 
conclusion differs from the conclusions of 
Scheuhammer et a 1. (1985), who suggest that zinc
plays a major role in the induction of 
metallothionein (after both zinc and cadmium 
administration) as hepatic metallothionein 
concentrations are highly correlated with hepatic 
zinc concentrations after either zinc, cadmium or 
cadmium and zinc administration (r = 0.97, p<0.001).
The difference in this correlation and that observed 
in the present study may be due to the different 
route of administration (intraperitoneal) and the 
larger dose of Cd2-*- used by Scheuhammer et a 1.
(1985). The present study also does not provide
evidence for Scheuhammer's other suggestion that in
the presence of pre-existing hepatic zinc-
metai1othionein, the ability of cadmium to induce new
metallothionein is greatly reduced and that cadmium
is sequestered in the pre-existing metallothionein,
as this would also increase the cadmium:
meta11othionein molar ratio with length of exposure.
No significant correlation was found between the 
percentage increase in zinc and meta11othionein 
concentrations in the kidney. This finding is in 
agreement with other workers (Dalgarno, 1972; Stonard 
and Webb, 1976; Ashby et a 1. 1980; Weigel et a 1.
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(1984a, 1984b), despite the lower dose regimens of
less than 20 ppm Cd=;H" in the diet used by some 
authors (Dalgarno, 1972; and Weigel et al. 1984a,b)
or different route of administration (Ashby et al. 
1980). However, zinc was found to be associated with 
metallothionein in the kidney cytosol of a 300 ppm 
dosed rat, which does suggest a relationship between 
this metal and meta11othionein in the kidney.
3.4.3 Relationship between metallothionein and copper 
in the liver and kidney
Increases in hepatic copper concentration upon 
exposure to cadmium were observed especially in the 
lower dose group. Small amounts of copper were 
observed in the metallothionein peak of a 
fractionated cytosol sample from the liver of a 
cadmium exposed rat (figure 3.8). However, the 
copper concentrations did not appear to correlate 
with metallothionein concentrations in the liver (r= 
0.18, p>0.1). It has been shown that dietary
administration of cadmium caused a marked inhibition 
of biliary copper excretion leading to an 
accumulation of copper in the liver, (Ashby et a 1. 
unpublished observations), and it may be this 
inhibition and resultant hepatic accumulation of 
copper which masks the increased copper concentration 
associated with metallothionein. The copper 
concentration in the kidney increased with the dose 
and length of exposure up to 16 weeks; even though 
possible changes in dietary copper content may have 
masked the significance of this effect at 16 weeks 
(table 3.4). The low correlation between percentage 
copper concentration increases and metallothionein 
concentration in the kidney (r = 0.12, p>0.01) may
also be explained by this peculiar variation in renal 
copper concentration shown in the control group. 
However, the fractionated cytosol of the kidneys from
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a rat exposed to 300 ppm Cd (figure 3.9) did show 
that most of the cytosolic copper was associated with 
the meta11othione!n peak. This provides evidence of 
a relationship between copper and meta11othionein in 
the kidney - a finding originally described by 
Stonard and Webb (1976).
3.4.4 Relationship between metallothionein and 
cadmium in the small intestine
The accumulation of cadmium in the small intestine in 
a dose- and time-dependent manner as observed in this 
study (table 3.6), suggests that this tissue takes 
part in the sequestration of cadmium and possibly 
contributes to the time dependant decreased rate of 
cadmium accumulation between 4 and 62 weeks in all 3 
dose groups.
The results of this present study also show that only 
about 42% of the total small intestinal cytosolic 
cadmium is bound to metallothionein; the remaining 
cadmium is bound to higher molecular weight proteins 
(figure 3.10). Both these intestinal components 
which sequester cadmium may be responsible for 
limiting cadmium absorption. It is believed that 
metallothionein serves to limit absorption of low 
levels of cadmium (Taguchi and Nakamura 1982), or 
high levels of copper and zinc (Richard and Cousins 
1977), maintaining a balance between uptake of these 
metals and eventual transfer to the portal 
circulation, and excretion by desquamation of 
mucosal cells. Evidence that intestinal 
metallothionein may increase the "trapping" of 
cadmium was provided by perfusion experiments using 
isolated segments of rat jejunum in situ (Faulkes and 
McMullen, 1986)s However, if meta11othionein is able 
to cross cell membranes as suggested in Chapter 4, 
then upon chronic dietary exposure a certain
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proportion of cadmium would be bound to intestinal 
metallothionein and be expected to enter the portal 
circulation, where upon it would be "targetted" for 
the kidney. This is in agreement with the findings 
of Cherian (1983).
The isolation of metallothionein from the small 
intestine of adult rats following oral cadmium 
ingestion has been reported (Ta'guchi and Nakamura, 
1982). In the fractionation of the small intestine 
cytosol sample obtained in the present study two 
immuno-reactive species were identified, 1) a protein 
of about 10,000 daltons - found at the same position 
as hepatic meta11othionein; 2) a low molecular weight
component of between 1,000 - 6,500 daltons (figure
3.10). The first component, which contained cadmium, 
is believed to be metallothionein as its properties 
are similar to that described by Taguchi and Nakamura
(1982). The second immunoreactive component, which 
contains mainly zinc and copper, may be similar to 
the copper complex found in the soluble fraction of 
the neonatal rats as described by Holt and Webb
(1983). From their experiments they postulate that 
this complex could be involved in the intestinal 
excretion and not in the intestinal absorption of 
cadmium. This may also explain why no cadmium was 
found in the second immunoreactive component from the 
intestinal cytosol observed in these studies (figure 
3. 10, Table 3.8),
3.4.5 Relationship between metallothionein and trace 
metals in the urine
The loss of cadmium in the urine (about 3.4 pg/day) 
between 4 and 16 weeks in the high dose group is far 
higher than that observed in the low and medium dose 
groups (about 0.3 pg/day) over the same time period. 
However, in all three dose groups the meta11othionein
215
excretion is low up to 16 weeks exposure. As the 
cadmium in the kidney cytosol from the rat exposed to 
300 ppm cadmium, was mainly bound to metallothionein 
(about 90%), any urinary cadmium derived from the 
kidney would be expected to be bound to 
metallothionein. However, most of cadmium in the 
fractionated urine sample was not bound to 
metallothionein, but was bound to a lower molecular 
weight component (1,000 - 6,500 daltons, figure
3.11). The major metal constituent of the 
metallothionein was copper. However no definite 
trends were seen in the copper or zinc excretion 
(table 3.6) and certainly by 16 weeks in the 300 ppm 
dose group, a significant decrease in excretion of 
these metals compared to control was observed. An 
explanation of this apparent discrepancy may be that 
the role metallothionein plays in urinary copper 
excretion is probably small at this stage of cadmium 
exposure, and any trend in copper and zinc excretion 
may have been effected by the peculiar variation in 
copper and zinc concentrations observed in the 
kidney.
Metallothionein in urine is thought to be only 
associated with copper before the onset of 
proteinuria, and the presence of cadmium in the 
protein is claimed to be an early indicator of 
nephrotoxicity (Suzuki and Yoshikawa, 1981). The low 
metallothionein excretion observed in the study 
provides evidence for the absence of renal tubular 
dysfunction up to 16 weeks cadmium exposure. The 
existence of cadmium in the high molecular weight 
region of the urinary profile from cadmium exposed 
rats indicate possible glomerular dysfunction. 
Electrophoretic studies could be used to further 
substantiate this proposed explanation. Certainly 
reports have shown that chronic exposure to cadmium
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does lead to glomerular nephitis (Kazantis, 1975; 
Axelsson and Piscator, 1966).
About 70% of the total immunoreactivity of the 
fractionated urine was found in the metallothionein 
region of the profile. However, a further 9% was 
found in the lower molecular weight region, in the 
same position as cadmium on this profile. It follows 
that these components may be metallothionein 
degradation products from the kidney. This 
suggestion is supported by evidence of renal 
degradation of.exogenous metallothionein Injected 
intravenously in rats - a subject discussed further 
in Chapter 5, Bremner (1980) reports the existence 
of metallothionein degradation products in the bile 
of cadmium exposed rats. These degradation products 
may also be eliminated from liver and excreted in the 
urine following glomerular filtration. A 
glutathione-cadmium complex of about 1,400 daltons 
has been isolated from human and rat liver cytosols 
and human haemolysate, following cadmium exposure to 
each respective animal (Katoh et a 1. 1984). The
previously described low molecular weight and/or 
degradation products may explain the observed urinary 
cadmium binding substances in the present study 
(figure 3.11). However, the fractionation of the 
liver and kidney cytosols did not show any detectable 
cadmium concentrations in the low molecular region of 
these profiles (figures 3.8-3.9) and, therefore, does 
not support this suggestion.
The presence of metallothionein in the serum of 
cadmium exposed rats has also been indicated by 
Garvey and Chang (1981). Once in the blood, cadmium 
metallothionein is "target ted" to the kidney, where a 
proportion of the protein is taken up (Cherian and 
Shaikh, 1978; Cain and Holt, 1983). This is 
particularly significant as it suggests that cadmium
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metallothionein uptake into the kidney is a saturable 
process. Measurements of plasma/whole blood cadmium 
and plasma metallothionein concentrations would have 
been useful for determining the clearance of this 
protein and metal.
Replacement of zinc and some of the cadmium bound to 
hepatic metallothionein by copper is believed to 
occur in the blood (Bremner et al. 1978: Cain and
Holt, 1983). The increase in copper content of the 
kidneys, observed upon exposure to dietary cadmium, 
may be due to this replacement by copper and 
subsequent absorbtion of a cadmium, coppei—  
meta11othionein. This replacement would also explain 
why copper metallothionein is present in the urine 
before the onset of tubular dysfunction, and 
indicates that the origin of urinary metallothionein 
may also be the liver before the onset of tubular 
dysfunction. This is also supported by the lack of 
zinc in the metallothionein fraction of the urine 
despite its presence in association with cadmium and 
copper in the metallothionein of the kidney cytosol. 
Fractionation of plasma samples from these cadmium 
exposed rats may have provided evidence of a possible 
metal replacement of metallothionein whilst in the 
blood, and of the origin of urinary metallothionein.
A similar replacement of cadmium and zinc in 
metallothionein by copper may also occur in the 
peritubular space of the nephron or other part of the 
urinary tract following loss from renal tubular 
cells. This would lead to the occurance of urinary 
copper metallothionein and cadmium in the low 
molecular weight region of the urinary profile. The 
origin of the urinary copper metallothionein may also 
be from the small intestine. Evidence for this 
hypothesis comes from the observation that cadmium, 
copper-metallothionein exists in the small intestinal
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cytosol of cadmium exposed rats and the results of 
Cherian's study (1983), which suggests transport of 
this protein to „the kidney following gastro­
intestinal absorption. Likewise as suggested for the 
liver and kidney metallothionein, a replacement of 
cadmium and zinc by copper may occur.
Therefore, the origin of urinary metallothionein 
prior to renal tubular dysfunction is still not 
certain, but it is possible that the urinary 
metallothionein may be derived from either the liver, 
kidney and small intestine or all these tissues 
following the high level dietary exposure.
3.4.6 Relationship between urinary metallothionein 
concentrations and tissue burden of cadmium
Dietary cadmium treatment for 62 weeks was sufficient 
to give renal accumulation of 152, 209 and 203 p.g 
Cd^/g tissue in the 75, 150 and 300 ppm
respectively. Since the concentration of the metal 
is about 50% higher in the renal cortex where the 
estimated critical concentration for cadmium is 
believed to be 200 pg/g (Friberg et al. 1974); renal
dysfunction is to be expected in the 150 and 300 ppm 
dose groups. The urinary metallothionein 
concentrations were observed to significantly 
increase in all dose groups after 62 weeks (figure 
3.8), suggesting possible renal dysfunction in these 
animals. Slight elevations in urinary cadmium 
concentrations were also observed (figure 3.6). 
However, whether these elevations are due to a rise 
in urinary excretion of cadmium bound to 
metallothionein is not known.
A marked correlation between urinary metallothionein 
and liver or kidney cadmium contents was observed in 
all 3 dose groups. Thus from this study, the urinary
219
meta11othionein concentrations appear to be a 
reasonable index of hepatic and renal cadmium burden 
prior to the attainment of the cadmium critical 
concentration in the kidney. This finding is in 
agreement with the findings of Tohyama et a 1. (1981).
A dose dependent decrease in correlation between 
urinary cadmium and metallothionein was observed.
This may reflect the increase in non-metallothionein 
bound cadmium with increasing dose (if a similar 
profile for the distribution of cadmium, copper and 
zinc in the urine is seen in the 75 and 150 ppm dose 
group as was observed from the 300 ppm dose group).
From two studies using workers occupationally exposed 
to cadmium, Lauwerys et a 1. (1976, 1979) concluded
that cadmium in the urine reflected body burden when 
exposure was low, and recent exposure when exposure 
was high. In the present study, cadmium exposure to 
rats was high, and increases in urinary 
metallothionein concentrations were detected after 
only 3 days of exposure to cadmium at dietary levels 
of 75, 150 and 300 ppm, indicating urinary
meta11othionein concentration may be used as an index 
of recent cadmium exposure.
3. 5 Summary
Chronic dietary administration of cadmium at doses of 
75, 150 and 300 ppm lead to cadmium and
meta11othionein accumulating in the liver and kidney 
in a time- and dose-related manner. There was an 
inverse relationship in the ratio of liver to kidney 
cadmium concentrations and dietary dose of the 
cadmium but of the two organs, the metal reached 
higher concentrations in the kidney although a higher 
total cadmium content was found in the liver. About
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90% of the cadmium was associated with 
metallothionein in the fractionated liver and kidney 
cytosol of the rat exposed to 300 ppm Cd*-*' and 70%- 
80% of the total cytosolic immuno-reactivity measured 
by the radioimmunoassay was found in the 
metallothionein fraction.
A decreased rate of hepatic cadmium and 
metallothionein concentration between 4 and 62 weeks, 
may be due to either a loss of hepatic cadmium- 
met a 1 1 oth i one in to the kidney (together with an 
increased rate in renal cadmium accumulation), 
increased cadmium retention by the small intestine or 
a decreased absorbtion of cadmium in the gastro­
intestinal tract.
The average cadmiurn:meta11othionein molar ratio was 
calculated to be 3.0 g ion Cd-^/mole metal lothionein 
throughout the study except within the first week of 
dietary feeding when this ratio was lower. It has 
been suggested that this latter finding may result 
from the involvement of another metal 'such as zinc)
in the induction of metallothionein.
Percentage increases in zinc correlated with
metallothionein in the liver between 4 and 16 weeks
and zinc was observed in association with
metallothionein in the cytosol fraction of a liver
from a rat exposed to 300 ppm C d ^ , suggesting
involvement but not a major role of this metal in the
induction of hepatic meta11othionein.
Most of the copper was associated with 
meta11othionein in the kidney cytosol of a rat 
exposed to 300 ppm. However, the correlation between 
percentage increases in copper and increases in 
metallothionein concentrations did not correlate 
wel 1.
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In the small intestine taken from a rat exposed to 
300 ppm Cd2:"*", 42% of the cytosolic cadmium was
associated with metallothionein. The remainder was 
found in the high molecular weight fractions.
Cadmium in the small intestine increased in a time- 
and dose-related manner - a supporting explanation of 
the decreased rate of hepatic cadmium accumulation. 
The radioimmunoassay identified two immunoreactive 
components in the small intestine. One is suggested 
to be metallothionein and the other a low molecular 
weight protein which may function in the excretion of 
cadmium.
Excretion of cadmium in the urine (between 4 and 16 
weeks) amounted to 3-4 ug/day in the 300 ppm dose 
group but only 0.3 ug/day in the 75 and 150 ppm dose 
groups. From the fractionation profile of a urine 
sample from a rat exposed to 300 ppm Cd2+, nearly all 
of the cadmium was associated with low molecular 
weight constituents and the major metal constituent 
of the metallothionein fraction was copper. Most 
(70%) of the immunoreactivity detected by the 
radioimmunoassay was found in the metallothionein 
fraction. However, a further 9% was found in the low 
molecular weight fraction suggesting either 
degradation products of metallothionein or other 
cross-reactive materials.
The urinary copper metallothionein has been suggested 
to be of mixed tissue origin but probably liver, 
kidney and small intestine. Further evidence of this 
possibility is provided in the next two chapters.
The cadmium and zinc associated with meta11othionein 
in these organs may be replaced by copper present in 
body fluids.
Urinary meta11othionein concentrations appear to be a 
good indicator of cadmium burden in the body and also
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of recent exposure in rats after dietary 
administrat ion.
CHAPTER 4
Handling of cadmium metallothionein 
by the isolated perfused rat liver
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4. 1 Introduct ion
The liver appears to play a key role in the tissue 
disposition of cadmium upon exposure to the metal. 
This is not only due to the inducibility of 
metallothionein (as discussed in Chapter 3) but also 
to the rapid uptake of the metal by the liver 
(Frazier and Kingsley, 1976; Panemanga1 ore and Brady, 
1979).
The uptake of cadmium (as Cd^"1") , by isolated 
hepatocytes from the liver of a previously unexposed 
rat appears to be a biphasic response with an initial 
rapid uptake, followed by a second phase of slower 
uptake (Stacey and Klaassen, 1980). The kinetics of 
hepatic cadmium transport have been studied in the 
isolated perfused rat liver by Frazier and Kingsley 
(1976), who concluded that cadmium uptake into the 
liver may occur by a combination of simple diffusion 
and a carrier-mediated process. Support for the 
involvement of a carrier in the uptake process comes 
from: (a) with high cadmium concentrations in the
medium (where passive diffusion would play a large 
role in the uptake process) , cadmium uptake rate 
constants are lower than at low cadmium 
concentrations (where a facilitated mechanism would 
contribute more to uptake) (Frazier and Kingsley 
1976); (b) Zinc interferes with the rate of cadmium
uptake by an isolated rat liver (Frazier and 
Kingsley, 1979) and in isolated rat hepatocytes 
(Stacey and Klaassen, 1980) and other mammalian cell 
lines (Huang et al.1980; Corrigan and Huang, 1981). 
These cations appear to demonstrate competitive 
kinetics of uptake (Kingsley and Frazier, 1979;
Stacey and Klaassen, 1980, 1981), and a common
transport system that may consist of multiple
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components may also exist at least in Chinese hamster 
ovary (CHO) cells (Corrigan and Huang, 1981).
The uptake of both cadmium and zinc by isolated 
hepatocytes has been suggested to involve a 
sulphydry1-dependent carrier mechanism (Fail la et a 1. 
1979; Gerson and Shaikh, 1984). These hypotheses are 
supported by the finding that Sulphydryl (SH) 
blockers are able to reduce significantly the uptake 
of both cadmium and zinc while metabolic inhibitions 
have little or no effect on metal uptake (Failla and 
Cousins, 1978; .Fai1 la et a 1. 1979).
The cadmium clearance in both the isolated liver 
perfusion system and in vivo were very similar 
(Frazier, 1980). Thus the isolated perfused liver is 
a preferable model system for studying metal kinetics 
in the liver as it eliminates complications due to 
multiple competing processes found in vivo, ie. 
without the interference of other organs such as the 
k idney.
Stacey and Klaassen (1980) showed that 
metallothionein induction appears to increase the 
rate of biphasic uptake of cadmium in isolated rat 
hepatocytes. They further suggested that the second 
phase may be related to the binding of cadmium to 
intracellular components, in particular 
meta11othionein, since elevation of hepatic 
metallothionein was found to increase the uptake 
velocity of only this phase. However, Din and 
Frazier (1985) reported that pre-induction of 
metallothionein in isolated hepatocytes had no effect 
on the cellular uptake of cadmium but the range of 
cadmium concentrations used in the medium incubating 
the hepatocytes (up to 18 pM> was far smaller than 
that used by Stacey and Klaassen (1980) (up to 800 
pM) .
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The rate of cadmium accumulation by rat liver 
parenchymal cells (hepatocytes) has been reputed to 
be ten fold higher than non-parenchyma 1 cells (mainly 
Kupffer and endotheial cells) in v i tro (Cain and 
Skilleter, 1983). This result was also found in v 1vo 
(Caperna and Failla, 1984), but the concentration of 
cadmium (calculated on the basis of total cellular 
protein concentration) in the endothelial cells was 
about two fold higher than that in both the 
parenchymal and Kupffer cells. The increase in 
metal 1othionein concentration in the endothelial 
cells was also.about 2 fold higher than other cell 
types following exposure to cadmium in vi tro and i n 
vivo (Caperna and Failla, 1984). However, these 
workers observed that no induction' of metallothionein. 
in the Kupffer cells occurred following exposure to 
cadmium in vitro. It was suggested that this may be 
caused by (a) one or more components of the plasma 
membrane required for transfer of the metals into the 
cell may be irreversibly lost or altered during the 
cell isolation procedure, (b) since Kupffer cells are 
phagocytic, they may preferentia 11y accumulate metals 
bound to aggregates and particles. Skilleter and 
Cain, (1981) have found that monolayers of Kupffer 
cells accumulated markedly more cadmium when the 
metal was presented as colloidal cadmium-dithiol 
complexes. Similar results were subsequently 
observed in vivo (c) accumulation of heavy metals by 
Kupffer cells is dependant on interactions with other 
liver— cell types.
The isolated liver perfusion system may therefore 
present advantages by aiming to resolve the 
discrepancy between Kupffei— cell uptake and 
metabolism of cadmium in vivo and in vitro, although 
on balance these results do not conflict with overall 
uptake into the liver in view of the greater number 
of hepatocytes.
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As described in the previous chapter, after chronic 
exposure, cadmium is mainly bound to metallothionein 
in the liver and kidney. A time-dependent increase 
in concentration of cadmium is found in the kidney in 
contrast with a steady loss from the liver. This 
suggests that cadmium as metallothionein may be 
eliminated by the liver and subsequently accumulated 
in the kidney. As the release of cadmium 
metallothionein from the liver is relatively slow and 
the kidney uptake is avid, the cadmium- 
metallothionein concentrations in the blood remain 
virtually undetectable (Frazier, 1982). It is, 
therefore, difficult to demonstrate the transport of 
cadmium from liver to kidney in vivo and thus the 
role metallothionein may play in this process. With 
the use of an isolated rat liver perfusion system, it 
could be possible to detect any release of cadmium 
metallothioneinfrom the liver of a rat previously 
exposed to cadmium, as there will be no avid uptake 
by the kidney. Thus, provided no significant 
reabsor[)tion of cadmium metallothionein occurs in the 
liver, this meta11o-protein would continue to 
increase in the perfusion medium in a time dependant 
manner.
The aim of the present work is to study the release 
and uptake of cadmium metallothionein in an isolated 
perfused rat liver in order to examine the mechanisms 
of release and uptake of this meta 11o-protein by the 
liver, and ascertain a possible role for this protein 
in these mechanisms.
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4.2 Experimental
4.2.1 Ma ter i a1s
Tissue culture medium 199 without phenol red was 
obtained from Flow Laboratories, Uxbridge, Middlesex, 
U.K. Phenol red was supplied by Difco Laboratories, 
Detroit Michigan, U.S.A. Bovine serum albumin 
(fraction V), herparin, gentamycin, collagenase (type 
IV) and protease (type XIV - bacterial pronase E from 
streptococcus) were all supplied by Sigma Chemical 
Co., Poole, Dorset, U.K. The erythrocytes used in 
the perfusion medium were collected from an adult 
female Swiss alpine goat, a few hours before use and 
washed with isotonic saline.
Metallothionein was obtained from the liver of a male 
rat and isolated by the procedure described in 
section 2.2.3 A. The radiolabels used were 1 °,:;,Cd and 
N-succinimidy1 [2.3-3HI propionate which were 
supplied by Amersham International pic, Amersham, 
Bucks, U.K. All materials required for the 
determination of metallothionein by radiommunoassay 
are described in section 2.2.1.
Nitric acid (used in electrothermal atomic absorbtion 
spectropotometry) was of Aristar grade, the propan-2- 
ol and hydrogen peroxide (30% v/v) (used in the 
solubilization of the red cell lysate) were all 
supplied by B.D.H. Chemical Co., Poole, Dorset, U.K. 
Soluene 350, also used in the solubilization of the 
red cell lysate and the scintillation fluid 
(Picofluor 30) were obtained from Packard 
Instruments, Reading, U.K.
The bolting cloth for filtering the cell suspension 
was supplied by Henry Simon, Stockport, Cheshire UK. 
Sephadex G75 was obtained from Pharmacia, Stockholm,
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Sweden. All reagents for the determination of 
enzymes were supplied by Sigma Chemical Co. Sodium 
pentobarbitol (Sagatal, 60 mg/ml) was obtained from 
May and Baker, Dagenham, Essex, U.K. All other salts 
used were of Analar or equivalent grade.
4.2.2 Methods
A) The isolated liver perfusion technique
i > Preparation of perfusion medium
The perfusion medium used in this technique comprised 
two fractions, the erythrocyte fraction and the 
perfusate supernatant. The erythrocyte fraction was 
prepared by separating the erythrocytes from 100 ml 
whole goat blood by centrifugation <2600 rpm for 10 
min). The erythrocytes were then washed several 
times in PBS (details of composition are given in 
section 2.2.6 B) and resuspended in tissue culture 
medium 199 without phenol red, to a final volume of 
33 ml. The perfusate supernatant comprised 100 ml of 
tissue culture medium 199 without phenol red, 2.5% 
<w/v> bovine serum albumin, 335 units of heparin and 
50 mg of gentamycin. Then 67 ml of perfusate 
supernatant was added to the 33 ml of goat 
erythrocytes to make a final volume of 100 ml. The 
remaining perfusate supernatant was used in the 
preparation of in situ infusion of the liver as 
described in the following section.
i i ) Surgical methods
An adult male Wistar albino rat (body weight 200-250 
g) was anaesthetised with sodium pentobarbitone 
(Sagatal, 60 mg/kg body weight). After opening the 
body cavity, the bile duct and hepatic portal vein
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were cannulated with pp25 and pp60 propylene tubing 
respectively. An in situ infusion of the liver with 
perfusate supernatant at a flow rate of 10 ml/min was 
performed during hepatectomy. The liver was 
connected to the pertuslon system depicted in figure
4.1 and perfused with the perfusion medium according 
to the procedure described by Brewster et a 1. (1977).
The liver perfusion system was allowed to equilibrate 
for 15 min, before samples of the perfusion medium 
were taken. The surgical work described above was 
performed by Dr R. Jones and Mr M, Singh.
B) Radio- 1 abe 1 1 incr of rat liver metallothionein I 
with 1c:,9Cd and N-succinimldvl £2.3-3H3 
prop i ona te
Rat liver metallothionein I (11,6 mg) was dissolved 
in 5 ml of borate buffered saline (pH8.5) (details of 
composition are given in section 2.2.4) and 300 pCi 
(300 pi) of 1°*CdC1= were added. The pH of the 
mixture was adjusted to 5.0 with 1M HC1 and the 
solution was left to stir for 3.5 hr at 4l-,C . Then 
the pH of the mixture was adjusted to 8.0 and the 
sample was fractionated on Sephadex G25 (PD10)
disposable columns, (10 x 1.0 cm) equilibrated with 
borate buffered saline (pH8.5). The eluate fractions 
were collected and the fractions containing 
metallothionein from each column were pooled. A 5 pi 
sample was taken for the assay of the “-'-'Cd 
radioact ivi ty.
Seven hundred pCi of N-succinimidyl £2,3- 
3H1propionate in toluene was placed in a glass vial. 
The toluene was then evaporated under nitrogen 
leaving the radiolabelled ester behind. The 
remaining 1°3Cd-metallothionein solution in borate 
buffered saline (pH8.5) was then added to the glass
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Figure 4.1 The dlegramatic representation fo the
apparatus used In the Isolated perfused 
liver experiments
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1. reservoir, 2. filter, 3. pump, 4. heat exchanger, 
5. 37*C water bath, 6. oxygenator, 7. humidifier,
8. constant head device, 9. three-way valve, 10. 
perfusion pump, 11. liver, 12. bile vial, 13. liver 
support and flow meter, 14. heating bars,
15. thermostat 16. magnetic stirrer.
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vial and the resulting mixture was left to stir for 
2.5 hr at room temperature. The sample was again 
fractionated using PD10 columns equilibrated with 
borate buffered saline (pH8.5). The eluate fractions 
containing metallothionein from each column were 
collected and pooled. A 5 pi sample was taken for 
the assay of 1osCd and 3H radioactivity.
C) Isolation of rat liver hepatocvte and non-
hepatocvte cells
Rat liver hepatocytes and non-hepatocytes were 
isolated by the method of Dobrota (1983) with some 
minor modifications. The method, which involves 
perfusion of the liver with collagenase, was used in 
preference to the "slicing method" of Fry et a 1 
(1976) because it gives much higher yields of viable 
cells (70-80% against 20%).
i) Solut ions
The solutions required for the procedure are 
summarised in the table below:-
1 2 3 4
Ca1c i um-f ree Bicarbonate Hanks PBS1 A
bi carbonate 
buf f er
buf fer + 
250mM CaCls:
saline
(S> (g) (g)
Phenol red 0. 02 0. 02 0. 02 0. 02
NaCl 8. 3 8. 3 8.0 8.0
KC1 0. 33 0. 33 0. 4 0. 2
MgC 1,,. 6He0 0. 13 0. 13 - 0. 1
MgSO^ j . 7H30 0. 15 0. 15 0.2 -
Na^HPO* . Ht.0 - - 0. 06 0. 2
KH-sPO* 0. 17 0. 17 0. 06 0.2
NaHC03. 2. 02 2.0 0. 35 -
CaCl 2Hffi0 - 0. 12 - -
Glucose — — 1 . 0 —
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i i ) Procedure
1. Following the perfusion of the liver with the
perfusion medium containing 1 osCd-and 3H- 
labelled metallothionein, calcium-free 
bicarbonate buffer (solution 1) was perfused 
until about 80 ml had passed through the liver.
2. The liver was perfused with 0.05% (w/v)
collagenase in bicarbonate buffer and 250 mM 
CaC 1 (Solution 2) for about 15 min allowing 
about 50 ml of enzyme solution to pass through.
3. The liver was carefully removed from the
perfusion system, weighed and transferred onto 
a glass plate. It was combed with a stainless 
steel comb to form a slurry.
4. The slurry was transferred to a 250 ml concical 
flask with about 50 ml 0.05% collagenase in 
solution 2, and incubated at 37,r,C for 20 min.
5. The cell suspension was then filtered through a
bolting cloth (150 mesh) and the filtrate was 
centrifuged for 20 min at 250 g (1400 rev/min 
on a DIGIFUGE).
6. The supernatant and the upper part of the
pellet were removed (and kept) without 
disturbing the lower part of the pellet.
7. The pelleted cells were resuspended gently in
Hanks saline (solution 3) and were again 
pelleted by centrifugation for 2 min at 250 g.
8. The cells were resuspended and pelleted a
further twice as in step 7. The washes were 
discarded.
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9. After discarding any striated layer at the top 
of the pellet, the pellet was resuspended in a 
small volume of solution 3 and kept at 4°C.
This was the 'Hepatocyte' preparation.
10. The supernatant and upper layer of the pellet, 
removed and kept in step 6, were now 
centrifuged for 10 min at 400 g (1800 rev/min 
on a DIGIFUGE).
11. The pellet was resuspended in PBS 'A' (solution 
4) and pelleted again as in step 10.
12. The pellet was resupended in 0.25% protease in 
solution and incubated for 1 hr at 37^0.
13. The cells were pelleted as in step 10.
14. The cells were resuspended in solution 4 and 
pelleted a further two times as in step 10.
15. The final pellet, representing the 'Non 
Hepatocytes' was resuspended in a small volume 
of Hanks saline and kept at 4c:,C.
iii) Examination of the Cells
Cells from the original slurry (step 3), hepatocytes 
(step 9) and 'non hepatocytes' (step 15) were placed 
on a microscope slide mixed with an equal amount of 
Trypan blue (0.5% in saline) and examined under phase 
contrast with a Leitz SM-Lux microscope at x 400 
magnification. The trypan blue exclusion dye 
indicated a viability of about 84% in the three 
preparations examined.
In the study employed, the prepared cells were not 
cultured but were quickly examined for integrity, by
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phase contrast light microscopy, and viability, by 
the trypan blue exclusion method, before 
homogenisation for subsequent assay of 10‘*Cd and 3H 
radioac t i vi ty.
D) Meta 11othionein measurement in the perfusate 
supernatant, bile and liver cytosol
The metallothionein concentrations in perfusate 
supernatant samples from the medium perfusing the 
isolated livers from rats previously exposed to 
cadmium, were measured by the radioimmunoassay 
procedure described in section 2.2.6 B. Control 
perfusate supernatant (not used in the isolated liver 
perfusion experiment) was used as the dilutent for 
the metallothionein standards to be used in this 
assay. Dilution of the experimental samples were 
made as necessary using the control perfusate 
supernatant.
The bile samples and cytosol fraction from the 
isolated perfused rat liver were also assayed for 
metallothionein using the radioimmunassay procedure 
described in section 2.2.6 B but modified in line 
with section 2.2.6 C for bile and liver cytosol 
samples.
E) Cadmium measurement in the perfusate 
supernatant and liver
Cadmium concentrations in the perfusate supernatant 
samples from the medium perfusing the isolated liver 
from rats previously exposed to cadmium, were- 
measured by atomic absorbtion spectrophotometry using 
electrothermal atomization. The analytical method 
used is described in Chapter 6, section 6.2.3. The 
calibration curve for cadmium standard in perfusate 
was linear between 0 and 3 ug/1 with diminuation in
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signal at higher concentrations. Samples containing 
greater than 3 ug/1 were diluted and assayed again. 
Analytical recovery varied from 94.0-103.0% with an 
overall average recovery of 97.3 +_ 3.7% (SEM) when
0.5, 1.0 and 2.0 ug/1 of cadmium were added. The 
coefficient of variation for 12 samples was found to 
be 7% at cadmium concentrations of between 0.7 and
1. 65 ug/1.
The cadmium concentration in the liver was measured 
by flame atomic absorbtion spectrophotometry, after 
digestion of 0.5 g tissue with a mixture of 
concentrated nitric/perchloric acids (5:1) by the 
method of Delves et a 1 (1971).
Analytical recovery was >98% with a coefficient of 
variation of <+. 10% at a concentration of 0.02 ug/ml. 
Further practical details are given in Appendix III.
F) Measurement of 1 °3Cd and 3H isotopes in the 
supernatant and ervthrocvte fractions of the 
perfusion medium, and liver homogenate. cvtosol 
and bile
The radio-activity of ' °3Cd and 3H isotopes in the 
perfusate supernatant and erythrocyte samples of the 
medium (perfusing the isolated rat liver exposed to 
lo3Cd, 3H-labelled meta11othionein), and intei—  
homogentate, cytosol and bile samples of this liver 
were all measured by (3-sc int i 1 lat ion counting.
Aliquots of perfusate supernatant samples (0.5 ml) 
and bile samples (400 ml) were suspended in 4 pi of 
Picofluor 30 scintillation fluid. Aliquots of 
erythrocyte lysate of the perfusion medium, 
homogenate or cytosol fraction of the isolated 
perfused liver (0.2 ml) were diluted with 1.8 ml of 
distilled water in a glass scintillation vial.
236
Soluene 350 (0.5 ml) was then added. The mixure was 
agitated for about 15 min and left to stand until the 
biological sample had dissolved. Subsequent 
additions of 0. 1 ml propan-2-ol, followed by 0. 1 ml 
of 30% (v/v) hydrogen peroxide were made. The 
solubilized samples were left overnight, with the 
vial capped loosely. After which 0.1 ml of conc. HC1 
was added dropwise to achieve an acidic pH. An 
aliquot of each sample (1.0 ml) was then suspended in 
4 ml of scintillation fluid (Picofluor 30).
Counting of the.1c,s,Cd and 3H isotopes was achieved 
using an LKB Rackbeta Spectral (Model 1219). 
Correction for overlap between spectra of 103Cd and 
3H was computed by automatic correction. At the 
start of each batch of samples for counting, test 
standards, one of 1°9Cd and one of 3H were included. 
After selecting a suitable window for the 1°3Cd and 
3H channels, the instrument automatically calculated 
the overlap between the two channels and subsequently 
corrected all the unknown samples in the batch. 
Because no authentic standard of precisely known 
1°^Cd activity was available, no correction for 
disintegrations per minute (dmp) were made.
G) Measurement of enzvme activity in the perfusate 
supernatant
Enzymes were assayed on fresh samples within 3-4 days 
of collection. Lactate dehydrogenase activity was 
determined by the method described by Bergmeyer 
(1974). The quantitative kinetic determination of 
gamma glutamyl transpeptidase was made based on the 
optimized method of Szasc (1971). L-Alanine 2 oxo- 
glutarate amino transferase (Glutamic pyruvate 
trsnssrfiinssc.' set 1 vi tv wss determined by the method 
of Bergmeyer and Bernt (1974).
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4.2.3 Experimental Design
A) Release of cadmium and meta 11othionein from 
the liver of rats previously exposed or 
unexposed to cadmium
The isolated technique was performed on two male 
Wistar-albino rats, which had previously been exposed 
to cadmium. One of these rats (body weight 275 g) 
had been subcutaneously injected with 1.5 mg Cd:;:‘f/kg 
body weight/day for twelve days prior to the isolated 
liver perfusion. The other rat (final body weight = 
750 g) had been exposed to 300 ppm Cd2"* as the 
chloride in the diet for 12 months prior to the liver 
perfusion. Finally, the isolated liver perfusion 
technique was performed on a male Wistai— albino rat 
(body weight about 250 g) which was previously 
unexposed to cadmium.
The liver from each animal was isolated (on separate 
occasions) and perfused as described in section 4.2.2 
A. After the system was allowed to equilibrate for 
15 min, a sample of bile and perfusion medium were 
taken as the zero time samples. Samples of perfusion 
medium (1.0 ml) were then collected at 15 min 
intervals from a post hepatic sampling port during 
the following 180 min. Perfusate supernatant was 
separated from the erythrocytes by centrifugation at 
2,500 rpm for 10 minutes, the former was removed and 
retained at 4c:,C. The volume of this sample was 
noted. The goat erythrocytes were washed in PBS 'A' 
and recentrifuged at 2,500 rpm for 10 min. The PBS 
’A' was removed and added to the perfusate plasma 
sample and the total volume noted. Bile samples were 
also collected at 15 min intervals for 180 min. 
Aliquots of both perfusate supernatant/PBS 'A' 
mixture and bile were retained for determination of 
cadmium and metal 1othionein concentration. After ISO
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min the isolated perfused liver was removed from the 
perfusion apparatus and weighed. Small sections of 
each lobe (about 0.5 g) were taken for cadmium 
analysis. The remainder of the liver was reweighed 
and the cytosolic fraction prepared as described in 
section 2.2.3 A. Meta 11othionein content of the 
cytosolic fraction was then determined.
B) Uptake distribution and excretion of 1G9Cd and 
3H-labelled metallothionein bv an isolated 
1iver.
The isolated perfusion technique was performed on the 
liver of an adult, male Wistar-albino rat (about 
250 g), previously unexposed to cadmium. The liver 
was isolated and perfused as described in section
4.2.2 A. After the system was allowed to equilibrate 
for 15 min, a sample of bile and perfusion medium 
were taken. Following this, 150 pi of *°-'Cd,3H- 
labelled-metallothionein (0.6 mg/ml) was added to the 
medium. After 60 s, a sample of
perfusion medium (2.0 ml) was taken from a post- 
hepatic sampling port. Perfusion medium (1.0 ml) and 
bile samples were collected at 15 min intervals for a 
further 180 min. The perfusate supernatant and 
erythrocyte samples were prepared as described in the 
previous section, and aliquots of each sample were 
retained for subsequent assay of 10,*Cd and 3H 
radioactivity.
After the isolated liver had been perfused for 180 
min, the perfusion medium was flushed out of the 
system (and retained) and replaced with calcium-free 
bicarbonate buffer, prior to the isolation of 
hepatocytes and non hepatocytes cells as described in
4.2.2 B. However, a small section of liver (2.0 g) 
was removed and retained following the removal of the 
tissue from the perfusion apparatus. The portion of
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liver retained was used in the preparation oi the 
cytosolic fraction as described in section 2.2.3 A.
Aliquots of both homogenate and supernatant 
fractions were analysed for ' °3Cd and 3H. A sample 
(10 ml) of the cytosolic fraction was subjected to 
gel filtration using Sephadex G75 on an 80 x 2.6 cm 
column equi1ibrated with 15 mM ammonium formate 
buffer (pH8.0). The eluate fractions were also 
analysed for 1osCd and 3H radioactivity.
C) The distribution of 1 °3Cd and 3H-1abel1ed
metallothionein between the supernatant and 
erythrocyte fractions of the perfusion medium
To establish the distribution of 1 °3Cd and 3H between 
the perfusate supernatant and erythrocyte fractions 
(without the involvement of an isolated perfused rat 
liver), an experiment was performed in v i tro as 
described below.
A sample of perfusion medium (10 ml) was incubated 
in a 25 ml conical flask (placed in water bath at 
37^0 . The medium was continuously stirred using a 
low spread magnetic stirrer, and oxygenated by a 
moist continuous stream of 95% oxygen and 5% carbon 
dioxide. The system was allowed to stabilize for 10 
min, before a sample (0.5 ml) of the medium was taken 
as the zero sample. Following this, 20 ul of 'osCd 
and 3H-labelled meta11othionein (0.6 mg/ml) was added 
to the perfusion medium. Samples (0.5 ml) of the 
medium were withdrawn every 15 min for 180 min. The 
perfusate supernatant and erythrocyte samples were 
prepared for the analysis of 1°3Cd and 3H 
radioactivity as described in section 4.2.2 F.
Samples of perfusion supernatant (1.0 ml) and 
erythrocyte lysate (0.1 ml diluted to 1.0 ml with 
distilled water) from the final time point (180 min)
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were fractionated by gel filtration chromatography 
using Sephadex G75 columns (24 x 1.0 cm) equilbrated 
with 15 mM ammonium formate buffer (pH8.0). Aliquots 
of the eluate fractions were analysed for 1 °3Cd and 
3H radioactvity.
4. 3 Results
4.3.1 Release of cadmium and meta 11othionein from the 
liver of .rats previously exposed to cadmium
A) Release of hepatic cadmium meta11othionein into 
the perfusion medium
Metallothionein was detected in the perfusate 
supernatant 15 min after the commencement of the 
perfusion, at a concentration of 0.7 pg/ml and 
0.48 pg/ml from the livers of rats subcutaneous 1y and 
orally exposed to cadmium respectively (figures 4.2 
and 4.3). Metallothionein concentrations in the 
perfusate supernatant from the liver of the rat 
subcutaneously exposed to cadmium, reached a plateau 
of about 1.1 pg/ml by 75 min. A more gradual 
increase in the perfusate supernatant concentration 
of metallothionein was observed between 15 and 150 
min from the liver of the rat orally exposed to 
cadmium. However, no plateau was observed; instead 
the meta11othione in concentration increased almost 
linearly to 1.2 pg/ml after 165 min of perfusion.
The total amount of metallothionein present in the 
perfusate supernatant after 180 min was 71.3 and
69.4 jig in each of the respective experiments using 
the livers’ of rats subcutaneous 1y and orally exposed 
to cadmium (table 4.1). This was calculated to be
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Figure 4.2 Release of metallothionein and cadmium into 
the perfusate supernatant from an isolated 
perfused liver of a rat subcutaneouslv 
injected with cadmium.
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Figure 4.3 Release of metallothionein and cadmium into 
the perfusate supernatant from an isolated 
perfused liver of a rat orally exposed to 
cadmium.
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0.5 and 0.14% of the total hepatic metallothionein 
content in each of the respective experiments.
The appearance of cadmium in the perfusion 
supernatant from the livers of both subcutaneous1y 
(figure 4.2) and orally (figure 4.3) exposed animals 
was also observed 15 min after the commencement of 
perfusion. The release of cadmium increased until 
reaching a plateau at approximately 150 min after the 
start of the perfusion in both rats. The total 
amount of cadmium present in the perfusate 
supernatant after 180 min in the subcutaneous 1y 
exposed animal was 6.9 pg and that in the orally 
exposed animal was 1.7 pg; whilst the total cadmium 
content in the liver of each animal after 180 min, 
was 1134 and 282 pg respectively (see table 4.1). 
These values represent some 0.6 and 0.5% of the total 
cadmium content of the liver from each respective 
animal being released into the plasma by 180 min.
Following the perfusion of a liver from a control rat 
(not exposed to cadmium) no cadmium was detected in 
the perfusate plasma throughout the 180 min 
experimental time interval. In contrast, 
metallothionein was detected in the plasma between 30 
and 60 min, but the concentration never rose above 
0.06 pg/ml. As this concentration of metallothionein 
was on the detection limit of the radioimmunoassay, 
the presence of metallothionein in the perfusate 
following the perfusion of a control rat liver 
remains in some doubt.
In both perfusion experiments using livers of rats 
exposed to cadmium, the cadmium and metallothionein 
concentrations in the perfusate plasma showed very 
similar profiles. The correlation coefficient (r) 
between these two parameters were 0.83 and 0.82 for 
the subcutaneous 1y and orally exposed animals
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respectively. The molar ratio of cadmium to 
metallothionein in the plasma showed a marked degree 
of similarity at all time points in each experiment. 
The cadmium:metallothionein molar ratio in the 
perfusate sypernatant was higher (5.4 +. 0.9) in the 
subcutaneously exposed rate as compared to the 
orally exposed rat (2.2 + 0.6).
B) Excretion of hepatic metallothionein into the 
bile
Metallothionein was detected in bile 15 min after 
commencement of’ perfusion of the livers of both 
subcutaneously and orally exposed rats. The rate of 
metallothionein excretion in the bile was relatively 
constant up to about 120 min in both experiments, 
(figure 4.4 A and 4.4 B). However, between 120 and 
150 min, the rate of metallothionein excretion in the 
bile seemed to increase. Cumulative biliary 
excretion of metallothionein was about 30 fold 
greater in the rat subcutaneously exposed to cadmium 
as compared to the rat orally exposed to cadmium, by 
the end of the experimental period. The total 
content of metallothionein excreted in bile was 2.3 
and 0.075 pg in each of the respective experiments.
If these figures are compared to the total content of 
metallothionein in the liver for each experiment, the 
toal amount of metallothionein excreted by this route 
is 0.02 and 0.001% for the subcutaneously and orally 
exposed animals respectively. Metallothionein was 
not detected in the bile of an isolated perfused 
liver from a rat previously unexposed to cadmium.
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C) Time dependent change In lactate dehydrogenase 
activity in the perfusate supernatant
As figure 4.5 shows, the lactate dehydrogenase 
activity in the perfusate supernatant in the 
experiment using the liver of a control rat (not 
previously exposed to cadmium) increases sharply 
between 0 and 15 min but the increase thereafter is 
gradual, reaching 870 IU/L by 180 min. In the 
experiment using the liver of a cadmium exposed rat, 
the lactate dehydrogenase activity in the perfusate 
supernatant increased in a similar manner to that in 
the previous experiment, reaching a value of 1100 
IU/L by 180 min.
It should be noted that perfusate lactate 
dehydrogenase activity is not specific to the liver, 
and that the erythrocyte fraction will contribute to 
the total activity of this enzyme in the perfusion 
supernatant. An ideal enzyme to use as an index of 
hepatic damage is sorbitol dehydrogenase, but this 
enzyme requires to be measured immediately and time 
was not available to do this. Haemolysis also 
interferes with the sorbitol dehyrogenase assay. As 
certain samples to be analysed were haemolysed, no 
clear profile of enzyme release from the liver would 
have been shown. Other enzymes such as glutamic 
pyruvate transaminase or gamma glutamyl transferase 
could have been used as more specific indicators of 
liver damage'. These enzymes were in fact used in the 
further isolated liver perfusion experiments (section
4. 3.3).
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Figure 4.5 Lactate dehydrogenase activity in the 
perfusate supernatant perfusing the 
isolated rat livers
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4.3.2 Radiolabelling of rat liver metallothionein-1 
with -^Cd and 3H
Rat hepatic metallothionein I was labelled with 1osCd 
(6.0 pg/mCi). Following desalting with a G25 
Sephadex (PD10) disposable column, the 1 os*Cd was 
bound to metallothionein with a specific activity of
36.4 pCi/mg protein. This gives a calculated 
concentration of 1 °3Cd of 0.22 pg/mg protein. The 
approximate molar ratio of cadmium-109 to 
metallothionein was calculated as 1:77. Conjugation 
of the 1 os,Cd labelled hepatic metallothionein I with 
C2, 3-3H-propiony11, propionyl succimidyl ester gave 
a specific activity of 16.3 pCi 3H/mg protein. The 
1 os*Cd and 3H radioactivity was 48,500 cpm/pl and 
21,700 cpm/pl respectively.
4.3.3 Uptake, distribution and excretion of 1oaCd and 
3H labelled metallothionein bv an isolated 
perfused liver.
A. Time dependent change in 1°3Cd and 3H radio­
activity in the perfusate medium
An addition of 200 pi of 0.6 mg/ml 1 °3Cd and 3H- 
labelled metallothionein I was made to the perfusion 
medium, perfusing an isolated liver from a control 
rat (not previously exposed to cadmium). This gave a 
concentration of 1.2 pg metallothionein/ml perfusate; 
estimated as 1.8 pg metallothionein/ml perfusate 
supernatant (the perfusate compartment was estimated 
as about 2/3 of the total perfusate volume).
After 60 s, the 3H radioactivity of the perfusate 
supernatant was found to be 290387 cpm/ml perfusate 
(figure 4.6). This was estimated as 0.8 pg 
metallothionein/ml perfusate. The radioactivity of 3H 
in the perfusate supernatant decreased steadily with
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Figure 4-. 6 Time dependent change In lc,^ Cd and 3H 
radloactivitv in the perfusate 
supernatant after the addition of 
1 c,g»Cd. 3H-1 abel 1 ed metallothionein I
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time to 13516 cpm/ml perfusate (estimated as about 
0.37 pg metallothionein/ml perfusate) by 180 min.
Figure 4.6 also shows that the 1°^Cd radioactivity in 
the perfusate supernatant decreased in an exponential 
manner from 42200 cpm/ml perfusate (calculated as 
0.114 ng ^ ’^ Cd/ml perfusate) by the termination of 
the experiment. As figure 4.7 reveals, the 
exponential elimination of 1 °-'Cd from the perfusate 
supernatant showed 3 components with elimination 
constants of 0.29 (ke, ) , 0.072 (ke;:) and 0.049 (ke:;:;) 
min-1. The respective half lives of each component 
were 2.4, 9.6 and 14.1 min. As the elimination
constant (ke,) is determined from only two 
experimentally determined points, the validity of 
this elimination constant must be in some doubt.
The 3H radioactivity in the erythrocyte fraction was 
198250 cpm/ml perfusate; estimated as 0.365 pg 
metallothionein/ml perfusate (approximately 68% of 
that found in the supernatant fraction after 60 s) . 
The 3H radioactivity decreased to 154500 cpm/ml by 15 
min and remained around this level until 165 min from 
the commencement of perfusion (figure 4.8)
Also shown in figure 4.8 is the time course profile 
for ‘°3Cd in the erythrocyte fraction of the 
perfusate following the addition of 1 °--:'Cd, 3H 
labelled metallothionein. The concentration of 1°3Cd 
decreased markedly by 83% after 15 min perfusion from 
15800 cpm/ml perfusate (calculated as 53 pg 103Cd/ml 
perfusate) to 4250 cpm/ml perfusate (calculated as 
14 pg 10':-'Cd/ml perfusate). A less dramatic decrease 
in 1 os*Cd activity was observed thereafter until the 
end of the experiment.
252
Figure 4.7 Kinetics of los*Cd radioactivity In the 
perfusion supernatant after the 
addition of 1 os»Cd. 3H- label led 
metallothionein I
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The decay constants and half life of the *°^Cd 
radioactivity are calculated as follows:
KeCl) = 0.29 min-1; tteCl) = 2.4 min
Ke <2) = 0.072 min-1; tK>(2) = 0.6 min
Ke (3) = 0.049 min-1; t&(3> = 14.1 min
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Figure 4.8 Tlroe dependent change In 1 °^Cd and 3H 
radloactivltv in the erythrocyte 
fraction of the perfusion medium after 
the addition of 1°^Cd.aH-1abe11ed 
metallothionein I
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B) Distribution of 1°'?lCd and in the Isolated 
perfused liver
The 1 radioactivity in the 10% homogenate of the
2g portion of the isolated perfused rat liver after 
180 min perfusion was found to be 93604 cpm/ml (or 
936040 cpm/g hepatic wet weight). Further 
calculations showed that an estimated 26.2 ng of 
1 °3Cd was taken up by the liver, at the end of the 
experiment (about 99% of the total 1 °,?'Cd added to the 
perfusate). The cytosolic fraction of this liver 
homogenate contained 75782 cpm 1°3Cd/ml cytosol (an 
estimated 21.3 ng lo3Cd). This was 81% of the total 
1 °3Cd found in the liver.
Also shown in table 4.2, the same 10% liver 
homogenate contained 98000 cpm 3H radioactivity/g wet 
liver which was calculated to be 23.4% of the total 
3H radioactivity added to the perfusion medium. The 
cytosolic fraction of this liver homogenate contained 
21420 cpm of 3H radioactivity/g wet liver, which was 
calculated to be 5. 1% of the total 3H added to the 
perfusion medium. Thus the estimated 3H-labelled 
metallothionein content of the liver (whether in a 
degraded or intact form) was calculated to be 29 pg. 
From further calculations 6.2 pg 3H-labelled 
metallothionein appear to be associated with the 
cytosol fraction.
Separation of this cytosol fraction by gel filtration 
using Sephadex G75, revealed that most of the 1 °?’Cd 
was associated with the fraction corresponding to 
metallothionein in the liver (figure 4.9). It is 
also interesting to note that 3H is present as two 
approximately equal peaks in this cytosol fraction. 
The first peak is eluted at the same postion in the 
elution profile as that expected of hepatic cadmium, 
zinc-metallothionein; and also the same position as
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Figure 4.9 Distribution of 10‘*Cd and 3H in the 
cytosol fraction of the isolated 
perfused liver (taken 180 mins after 
addition of cadmium-meta 1lothionein) 
following fractionation on a 80 x 2.6 
cm column of Sephadex G75 (fine) eluted 
with 15mM ammonium formate (pH8.0).
The flow rate was 1. 1 ml/min.
1°^Cd and 3H radioactivities represented as (•--- • )
and (A— — a ) respectively, were measured in certain 
5 ml fractions. The protein markers (a-e) shown have 
the following molecular weights.
a Ovalbumin (hen egg) 45,000 daltons
b Chymotrypsinogen A (bovine pancreas) 23,200 daltons
c Ribonuclease-I (bovine pancreas) 12,600 daltons
d Cd, Zn-metallothionein-1 (rat liver) 6,700 daltons
e Insulin (bovine) 5,700 daltons
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the 1°-='Cd. The second peak was found in a fraction 
of lower molecular weight than metallothionein and 
contained only a small amount of 1°'3Cd.
Upon comparing the radioactivity of 1 °'3Cd in the 
hepatocyte and non-hepatocyte fractions (table 4.3), 
it was noted that the 1°9Cd radioactivity in the 
latter fraction was 15 fold greater than the former 
on a cellular concentration basis. However, the 
total radioactivity in the non-hepatocyte fraction 
was only slightly greater than the hepatocyte 
fraction. The. percentage recovery of '* °3Cd 
radioactivity upon isolating these fractions was low; 
the hepatocyte fraction contained 3.2% of the total 
hepatic 1 °-3Cd activity (a calculated 0.84 ng of 
lo~’Cd), and the non-hepatocyte fraction contained 
5.0% of the total hepatic ' os,Cd activity (a 
calculated 1.31 ng of lo'"'Cd). The non-hepatocyte 
fraction also contained the greater 3H radioactivity 
on a cellular concentration basis (table 4.3). 
However, the total 3H radioactivity was greater in 
the hepatocyte fraction; 62% of the total hepatic 3H 
radioactivity as compared to 11.1% in the non- 
hepatocyte fraction. Thus a percentage recovery of 
about 73% of the 3H radioactivity was calculated 
following the isolation of these fractions.
The percentage content of each radioisotope within 
the hepatocyte and non-hepatocyte fractions can be 
calculated on the estimated percentage of each of 
these cell types in a rat liver. These values were 
calculated assuming that a rat liver comprises 65% 
perenchymal (hepatocyte) and 35% non-parenchyma 1 
(non-hepatocyte) cells (Blouin et a1. 1977). Using
this estimation, calculations show that 91% of the 3H 
radioactivity found in the liver would be associated 
with the hepatocyte fraction, whereas the 1 °3Cd 
content would be approximately equal in both
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hepatocyte an non-hepatocyte fractions (55% and 45% 
respec t i ve1y).
C) Excretion of 1osCd and 3H in the bile
Figure 4. 10 shows the cummulative excretion of '■ osCd 
and 3H into the bile. The cummulative excretion of 
both these radio-isotopes increased with time. 
However, the rate of excretion of 1osCd and 3H 
appears to decrease after about 60 min and 90 min 
respectively. A definite formation of a plateau was 
observed with the 1°3Cd profile by 180 min, but the 
3H radioactivity continued to rise even at the end of 
the experiment. Only 0.0007% of total 'osCd added to 
the perfusate was found in the bile. Likewise only a 
small amount of the total 3H radioactivity added to 
the perfusate (0.006%) was found in the bile after 
180 min. The total estimated excretion of 1 ,:>3Cd and 
metallothionein (as calculated from 3H activity) was 
0.02 ng and 0.73 pg respectively. The calculated 
meta 11othionein:cadmiurn molar ratio was also found to 
be 612:1 which is far greater than that calculated 
for the protein prior to injection (see section 
4. 3. 4) .
D) Recovery of 1osCd and 3H in the isolated liver 
perfusion system
The 1°3Cd and 3H-label led meta 11othionein sample 
added to the perfusion medium at the start of the 
isolated perfused liver experiment contained'about 
120 pg of protein and 26.4 ng of 1 °,:;:*Cd. As shown in 
table 4.4, 1 min after the addition of this protein,
66.7% of the 3H and 43.2% of the '°3Cd radioactivity 
was present in the perfusate supernatant fraction.
Most of the remaining 3H radioactivity was associated 
with the erythrocyte fraction. The low recovery of 
109Cd in the erythrocyte fraction suggest that much
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Figure 4. 10 Cummulative excretion of 3H and lc,-~*Cd 
into the bile from the Isolated 
perf used 11ver
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of the 1 °3Cd radioactivity (about 36%) is already 
associated with the liver (not measured for 
radioactive isotopes at the 1 min stage). By 180 
min, the percentage of 3H found in the perfusate 
supernatant had decreased to 30.8%, whereas only very 
low levels of the 1 °3Cd radio activity were found in 
this fraction. The erythrocyte fractions contained 
slightly lower 3H radioactivity after 180 min when 
compared to the 1 min time point, but the 1 °-*Cd 
radioactivity had decreased to very low levels during 
this time period. Table 4.4 also shows that 
approximately 99% of the 1 os,Cd radioactivity was 
found in the isolated perfused liver by the end of 
the experiment, although only 23.3% of the 3H 
radioactivity was associated with this tissue.
E) Time dependent changes in enzyme activities in 
the perfusate supernatant following addition of 
i°9Cd. 3H-labelied metallothlone in I
Lactate dehydrogenase and alkaline phosphatase 
activities in the perfusate supernatant increased 
from 15 min until the end of the experiment 
by 2.7 and 2.0 fold respectively (figure 4.11 A and
C). However, the concentrations of gamma glutamyl 
transferase decreased by 46% during this time 
interval (figure 4.11 B).
4.3.4 The distribution of 1Q9Cd and 3H labelled
metallothionein between the supernatant and 
erythrocyte fractions of the perfusion medium
Following the incubation of 20 pi of 0.6 mg/ml 1GSCd, 
3H-labelled metallothionein I with 10 ml of 
perfusate, a time-dependant increase in 3H activity 
in the perfusate supernatant was observed (figure 
4.12). The 1°9Cd activity in the perfusate 
supernatant showed no overall change during the 180
264
Figure 4.11 Changes in enzyme activity In the.
pprfusate supernatant after the 
addition of 1 os*Cd. 3H-1 abe 1 1 ed 
fnpta 1 1 oth i oneln I
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Figure 4.12 Time dependent change in 109Cd and 3H
radioactivity in the perfusate supernatant 
(in the absence of the perfused liver).after 
the addition of 109Cd. 3H labelled 
metallothionein.
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min time period. The d i s ifr i but i on of 1 °¥*Cd and 3H, 
upon fractionation of the perfusate supernatant after 
180 min on a Sephadex G75 column (figure 4.13), 
revealed that most of 3H radioactivity was 
associated with two peaks. The first peak was 
located in the high molecular weight fraction and the 
second was found in the fraction where hepatic Cd,Zn 
metallothionein is located. Virtually no 1 °3Cd 
activity was associated with the latter fraction.
The 3H radioactivity of the erythrocyte fraction, one 
min after the addition of the l03Cd, 3H-label led 
protein was about 26% of the total 3H radioactivity 
added. Although an initial increase in 3H 
radioactivity was observed, there was a time- 
dependent decrease after 60 min (figure 4.14). There 
was no significant change in 1osCd activity in the 
erythrocyte fraction throughout the experiment, 
remaining at about 15600 cpm/ml perfusate. The ,03Cd 
and 3H in the erythrocyte fraction after 180 min, 
upon separation with Sephadex G75 is shown in figure 
4.15. About 2/3 of the lo"=,Cd was associated with the 
high molecular weight fraction. The remainder was 
associated with the metallothionein fraction. The 3H 
radioactivity was broadly distributed from the high 
to the low molecular weight range. Most of the 3H 
radioactivity was associated with a fraction of 
molecular weight greater than 14,000 dal tons but a 
small percentage was associated with the 
metallothionein fraction.
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Figure 4.13 Fractionationation of the perfusate 
supernatant bv Sephadex G-75 chromatography, 
180 minutes after the addition of 109Cd. 3H- 
labelled metallothionein fin the absence of
the perfused liver).
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Figure 4.14 Time dependant change in 109Cd and 3H
radioactivity in the erythrocyte fraction 
fin the absence of the perfused liver). 
after the addition of 10^Cd.3H-labelled 
metallothionein.
20
r>
•H
•H
•H
12
10
60 120 180
Time after addition (minutes)
3H radioactivity - O O
l°9Cd radioactivity - a ---a
269
Figure 4.15 Fractionation of the erythrocyte fraction by 
Sephadex G-75 chromatography. 180 minutes 
after the addition of lQ9Cd, 3H-labelled 
metallothionein fin the absence of the 
perfused liver).
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4.4 Discussion
4.4.1 Release of hepatic cadmium metallothionein into 
perf usate
Chronic exposure to cadmium eventually leads to 
higher concentrations of the metal In the kidney than 
In the liver. This was observed In the previous 
chapter (section 3.3) and has been reported elsewhere 
(Stonard and Webb, 1976). The reason for the 
difference in the cadmium concentrations in these 
organs is believed to be due in part to the transient 
passage of cadmium through the liver and a steady 
accumulation of this metal in the kidney (Frazier, 
1982). However, the release of cadmium from the 
liver and the role metallothionein plays in this 
inter-organ transport is a matter of some conjecture.
Evidence that cadmium bound to metallothionein is 
released into circulation and transferred to the 
kidney from the liver of cadmiurn-treated rats with 
liver injury caused experimentally with hepatotoxins 
such as Aflatoxin (Cain and Griffiths, 1980) or 
carbon tetrachloride (Tanaka et a1. 1981) has been
reported. However, with the use of an isolated liver 
perfusion system, the results of this study have 
shown that both cadmium and metallothionein are 
released from the liver of cadmium exposed rats 
(without the use of hepatotoxins) (figure 4.1 and
4.2).
Metallothionein concentrations in the perfusate 
supernatant increased in a time dependant manner 
reaching about 1.1 pg/ml after 120 min in the liver 
from the rat subcutaneously dosed, and after 160 min 
in the liver from the rat orally dosed with cadmium. 
The total amount of metallothionein released by the
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end of each experiment was about 70 pig, even though 
the total metallothionein content of the liver from 
the orally dosed rat was about 3.5 times that of the 
liver from the parenterally dosed rat. This implies 
that intracellular concentration of metallothionein 
may not effect the release of the protein from the 
liver of a cadmium exposed rat; suggesting that 
metallothionein may be actively and not passively 
transported out of this organ. In support of this 
suggestion, there was no observable difference in 
lactate dehydrogenase activity in the perfusate 
supernatant between the livers of control and cadmium 
treated rats (figure 4.4). This provides evidence 
that the livers of the cadmiurn-treated rats are not 
damaged, indicating that metallothionein release from 
the liver cannot be due to loss of membrane integrity 
due to hepatocellular injury. It should be noted 
that red blood cells in the perfusate may contribute 
to the perfusate supernatant lactate dehydrogenase 
concentrations as the enzyme is also present in red 
cells. Lactate dehydrogenase is thus not an ideal 
indicator of hepatic injury. In view of its 
exclusively hepatic localisation, sorbitol 
dehydrogenase would have been a more sensitive 
indicator of hepatic injury (Zimmerman and Sloff, 
1970), but this was not measured for technical 
reasons. The measurement of hepatic specific enzymes 
(eg. glutamic pyruvate transaminase and gamma 
glutamyl transpeptidase) in the perfusate and a 
histological examination of the liver should be made 
in future isolated liver perfusion work, to further 
assess the hepatic integrity.
Further evidence as to the existence of an active 
mechanism for the release of metallothionein from the 
liver, is provided by the appearance of a 'plateau' 
in the perfusate concentrations of this protein.
This is particularly apparent in the experiment using
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the liver from the subcutaneously exposed rat (figure
4.2). Such an observation suggests saturation of a 
possible transport mechanism from liver to perfusate 
supernatant and/or perfusate supernatant to 
erythrocyte compartments, and an equilibrium in 
metallothionein concentration between these 
compartments. The 'plateau' in concentrations of 
metallothionein may also be explained by an 
equilibrium between release and uptake of the protein 
by the liver and/or erythrocyte fraction of the 
perfusate. Hepatic uptake of metallothionein (as 
measured by tritium) from the perfusate has been 
observed in this study using a liver from a rat not 
previously exposed to cadmium, an observation which 
is discussed later (section 4.4.4).
However, further explanations as to the difference in 
the rate of release of metallothionein from the liver 
of the subcutaneously dosed rat as compared to the 
orally dosed rat; and the lack of relationship 
between metallothionein content of the liver and 
hepatic release of this protein quite possibly may 
be: (i) the difference in ages of the two animals,
the subcutaneously dosed rat was 2 months old whereas 
the orally dosed rat was 14 months old. ii) the 
difference in the dosing schedules followed which may 
bring about different effects upon the liver. These 
differences could be manifested as an increased 
‘resistance to the cellular release of metallothionein 
in orally as compared to subcutaneously dosed rats.
The perfusate plasma cadmium concentration-time 
profile was similar to that for plasma 
metallothionein in each of the respective isolated 
liver perfusion experiments (figure 4.1 and 4.2).
The correlation coefficient between metallothionein 
and cadmium concentrations in the perfusate
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supernatant at each time point was 0.83 and 0.82 for 
the subcutaneously and orally dosed rats 
respectively. This suggests that cadmium may be 
released into the perfusate supernatant from the 
isolated perfused liver bound to metallothionein.
CThe idea that metallothionein could act as a carrier 
of cadmium in blood has also been suggested by Garvey 
and Chang (1981) and Frazier (1982)1. The molar 
ratio of cadmium to metallothionein in the plasma was
5.4 +. 0.9 in the parenterally dosed rat and 2.2 +0 . 6  
in the orally dosed animal. These values for the 
cadmium/metallothionein molar ratio are roughly 
consistant with values calculated from the liver in 
vlvo (Winge et a1. 1975, Vander Mai lie and Garvey,
1979). From the calculations made from the results 
in table 4.2, the molar ratio of
cadmium/metallothionein in the liver of the orally 
dosed rat (3.5) and the liver of the subcutaneously 
dosed rat (5.0) were similar to the respective 
cadmium/metallothionein molar ratios calculated in 
each perfusate supernatant. This further suggests 
that cadmium may be released from the liver into the 
plasma bound to metallothionein. The difference in 
the cadmium/metal1othionein molar ratio in these 
livers probably reflects the difference in this molar 
ratio observed in the perfusate supernatant in each 
of the respective experiments.
Further calculations show that the release of 
metallothionein from the liver was about 0.55 and 
0.33 ug/hr in the subcutaneously and orally exposed 
rats respectively. If the release of metallothionein 
from the liver is in equilibrium with, and dependent 
on the perfusate concentrations of this protein as 
suggested earlier, and it is presumed that kidney 
uptake of this protein is rapid; then the rate of 
release of metallothionein from livers of the
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parenterally and enterally dosed animals can be 
calculated as 13.2 and 8.0 pg/day respectively.
The respective equivalent hepatic cadmium release was 
calculated to be 1.21 pg/day and 0.29 pg/day. Now 
the total hepatic cadmium and metallothionein content 
of the orally dosed rat is greater than the 
subcutaneously dosed animal (table 4.1), and the 
hepatic cadmium/metallothionein ratio is greater in 
the latter as compared to the former animal. An 
interesting conclusion from the above findings is 
that the hepatic cadmium/metallothionein ratio and 
not the total hepatic cadmium and metallothionein 
content may be important in the hepatic release of 
cadmium metallothionein.
It is recognised that these preliminary findings 
suggesting that cadmium-metallothionein may be 
released form the liver by an active transport 
mechanism, and that the release of this protein may 
be dependent on the cadmium/metallothionein molar 
ratio, need to be verified by further work. This 
work should include performing isolated perfusion 
experiments on the livers of rats of similar ages and 
lengths/routes of exposure to establish whether the 
findings of this study were significant. If the 
results were confirmatory of the preliminary 
findings, then it would be of interest to pursue 
further studies to establish how a cytoplasmic 
protein, metallothionein may be transported across 
the hepatocellular membrane into the perfusate. One 
possible mechanism for the transport of 
metallothionein across the hepatocellular membrane 
may include a secretory pathway as described by 
Wheland et al. (1982), whereby proteins synthesised
on the ribosomes of the ’rough* endoplasmic reticulum 
follow a pathway to the 'smooth' stacks of the golgi 
body and finally to the cell surface. Such an
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example Is the release of albumin from hepatocytes 
(Yokota and Fahimi, 1981). An exponential release of 
newly synthesised albumin from an isolated perfused 
rat liver (measured by rocket Immunoelectrophoresis) 
has been observed (Mullock and Hinton 1982) and 
supports the possible mechanism described for 
metallothionein. However, metallothionein appears to 
be synthesised on the free polysomes in the cytosol 
of the liver (Cherian et a1. 1981) so the cytosolic
protein would have to enter the endoplasmic reticulum 
golgi cisternae to participate in this secretory 
pathway. One suggestion may be that newly 
synthesised metallothionein in vivo possesses a 
signal sequence which permits entry into these cell 
organelles, and in the process the signal sequence is 
removed. The metallothionein may bind to the 
cytoplasmic side of the endoplasmic reticulum and 
appear on the external surface of the plasma membrane 
by means of reorientation as suggested for the 
hepatic release of 5 nuc1eotidase (Widnell and 
Little, 1977).
4.4.2 Hepatic uptake of cadmium-meta11othionein
Cadmium-metallothionein is very actively taken up by 
the renal proximal tubule cells (Cherian and Shaikh, 
1975; Cain and Holt, 1983) as discussed further in 
Chapter 5. However, there have been no reports on 
active hepatic uptake of cadmium-metallothionein.
Using the isolated perfusion system, this hepatic 
uptake has been examined without the interference 
from other tissues - especially the kidney.
From the 3H and 1 os*Cd rad i oac t i vi ty/t ime profile 
(figure 4.6) and the results from table 4.2, the rate 
of uptake of metallothionein (as measured by tritium 
activity) appeared to be fairly constant. Whereas 
hepatic uptake of '°3Cd was exponential, such that 23%
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of the metallothionein and 99% of the cadmium added 
to the perfusate was present in the liver after 180 
min. The difference in the perfusate clearance 
profiles for 3H and 1°9Cd activity suggests that 
either hepatic uptake of metallothionein and cadmium 
occurs by separate mechnisms, or that the mechanism 
of uptake of these two components is the same but the 
3H (perhaps as metallothionein) is also being 
released by the liver into the perfusate. It should 
be noted that evidence as to the stability of the 
metal 1othionein-bound tritiated propionic acid N- 
hydroxy-succinimide ester is provided in the 
fractionation profile of the liver cytosol (figure 
4.9), a matter which is further discussed in section 
4.4.3. If cadmium and metallothionein uptake occur 
by different mechanisms, the 10,3,Cd may be lost from 
the protein whilst in the circulating perfusate or 
prior to the addition to the perfusate. From the 
results of Law and Stillman (1980), the stability of 
the cadmium following its in vitro addition to the 
metallothionein molecule appears to be as stable as 
the in vivo induced cadmium bound metallothionein. 
However, whether the stability of cadmium binding to 
metallothionein decreases if any binding of 
metallothionein to the hepatocellular or the 
erythrocyte membranes occurs is not known. If the 
stability of cadmium binding to metallothionein was 
affected, then hapatic cadmium uptake would be 
similar irrespective of whether it is in the form of 
cadmium-metal lothionein, cadmium-albumin or Cd22^  for 
example. However, the results of this study suggest 
that there are 3 distinct expoential components in 
the clearance of 1 os*Cd (as cadmi um-metal lothionein) 
in the plasma with rate constants 0.29 (—kel), 0.072 
(ke2) and 0.049 min (-ke3) . These three 
components are yet to be confirmed by more frequent 
measurements of 3H and 1 os,Cd between the time points 
0-15 min.
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The elimination constant (-ke3) is quantitively 
similar to the elimination constant (0.035 min-') 
calculated by Frazier and Kingsley (1967) following 
the addition of cadmium chloride to an isolated 
perfused liver. However, the cadmium uptake in this 
study was reported to follow first order kinetics. 
This suggests that some of the 1osCd may be behaving 
as non-thionein bound cadmium in the perfusate. The 
mechanism of uptake of this non-metallothionein bound 
Cd may be similar to that described by Stacey and 
Klaassen (1980) in isolated hepatocytes; and is 
believed to be .mediated by simple diffusion and a 
mediated transport process involving the net 
secretion of hepatic zinc. The existence of two 
other exponential components in the plasma clearance 
of ' os,Cd suggests other mechanisms of cadmium uptake 
are taking place. These mechanisms may also include 
the uptake of cadmium, together with metallothionein 
by endocytosis. The endocytic vesicles, may fuse 
with lysosomes, and dissociation of cadmium from the 
metallothionein may then occur as reported in vitro 
with lysosomal extracts at a pH below 5 (Meulenaar et_ 
a 1. 1985). The dissociation of cadmium is reported
to increase degradation of the protein by the 
lysosomal extract (Feldman et a 1. 1978a, Meulenaar et_
a1. 1985). Whereas cadmium may be transported into
the cytosol, the tritiated breakdown products may 
then be eliminated from the cell by means of 
exocytosis. Further evidence for this mechanism of 
uptake of cadmium-meta1lothionein is presented in the 
following section.
The dissimilar perfusate supernatant clearance 
profiles observed with 3H and 1°3Cd (see figure 4.6), 
could also be explained by a hepatic release of the 
3H-labelled metallothionein and/or breakdown products 
into the plasma, and the hepatic retention of “-***Cd. 
Evidence for the release of metallothionein from the
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liver of cadmium-exposed rats has been given in the 
previous section (4.4.1), but both cadmium and 
metallothionein were released into the perfusate in 
these experiments in the apparent absence of liver 
inj ury.
However, further work to establish whether (or not) 
the 3H radioactivity is metallothionein bound may 
provide information as to the hepatic release of 
metallothionein.
4.4.3 Distribution of metallothionein and cadmium in 
the 1i ver
Of the 23% of metallothionein (as measured by 3H 
activity) taken up by the liver over the 180 min 
period, only 5% was located in the cytosol (table
4.2). The remainder appeared in association with the 
membrane compartment. Further analysis of the 
cytosol by fractionation using Sephadex G75, revealed 
that the 3H associated with two peaks of similar 
activity - (1) metallothionein and (2) a degradation 
product of this protein. The profile , (figure 4.8) 
also reveals the apparent absence of tritium in the 
low molecular weight region (5.7 kilodaltons) 
indicating that if complete degradation of 
metallothionein has taken place, then the products 
have been removed from liver, perhaps by means of 
exocytosis. An explanation as to the existance of 3H 
labelled metallothionein and its degradation products 
in the cytosol may be their release following lysis 
of endocytosic lysosomal vesicles during the 
preparation of the cytosol fraction. A further 
explanation as to the presence of metallothionein in 
the cytosol is that this protein may have bound to 
the cell surface and a small fraction of the protein 
was released into the cytosol upon its preparation. 
These explanations may also help to explain why only
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5% of the total hepatic 3H actually was located In 
the cytosol, whereas about 73% of the total hepatic 
3H activity was recovered in the preparation of 
hepatocyte and non-hepatocyte cells.
Unlike the 3H activity, 1osCd activity in the liver 
is found mainly in the cytosol fraction (81%). The 
majority of the 1 os*Cd is associated with the 
metallothionein fraction and a small proportion of 
the lc>3Cd peak is found in the peak of 3H activity in 
the lower molecular weight region (figure 4.8). The 
estimated 1‘-‘^ Cd: metal lothionein molar ratio also has 
increased from 1:77 in the synthesis of the 1 ‘-‘^ Cd 
labelled metallothionein (see section 4.3.4), before 
addition to the perfusate, to 3.5:1 in the cytosol 
upon the hepatic uptake of this protein. These 
results imply that most of the 1°9Cd in the cytosol 
is being sequestered by endogenous metallothionein. 
This may result from either uptake of "free" '“-*s,Cd 
from the perfusate or release of lo3Cd following the 
lysosomal degradation of metallothionein. Evidence 
for the existance of the latter mechanism is provided 
in Chapter 5 which describes the uptake of cadmium 
metallothionein in the renal cortex.
The uptake of metallothionein (as measured by 3H 
activity) by the hepatocyte and non-hepatocyte 
fractions was found to be 1325cpm/10*- cells and 
5700cpm/10*'=- cells respectively, calculated to be 62 
and 11% of the total calculated hepatic ,c,'*Cd 
radioactivity respectively. Likewise the 
concentration of the 1 os*Cd in the hepatocyte fraction 
(1006cpm/106 cells) was lower than the hepatocyte 
fraction (15750 cpm/10*5 cells). However, the 
recovery of 1osCd radioactivity by the isolation of 
the hepatocyte and non-hepatocyte fractions was less 
than 10%. This suggests that ,0'*Cd is being released 
from these cells upon their isolation.
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Using the estimation that the liver comprises of 65% 
parenchymal and 35% non-parenchymal cells (Blouin e_t_ 
al. 1977), the hepatocyte fraction contains an
estimated 91% of the 3H activity in the liver (about
29 pg metallothionein) in comparison to the 9.9% 
(about 3 pg metallothionein) in the non-hepatocyte 
fraction. However, of the total 1 os*Cd radioactivity 
retained by the hepatocyte and non-hepatocyte 
fractions using the same estimation, 55% and 45% was 
present in each respective fraction, (table 4.4). 
However, if the efficiency of accumulation of '°3Cd 
and 3H in each-of the hepatocyte and non-hepatocyte 
fractions is calculated (this calculation would be 
based on a cell volume or cell protein content), the 
distribution of these radioactivities would be 
somewhat different.
The volume and protein content of hepatocytes are 10-
30 times greater than that of non-hepatocytes (Blouin 
et al. 1977; Wisse and Knook 1979). When calculating
the efficiency of both 1 os,Cd and 3H accumulation by 
each of these cell types per unit cell volume, it may 
be seen that both these radio isotopes are 
accumulated more efficiently in the non-hepatocyte as 
compared to the hepatocyte fraction per unit volume - 
at least 98% of both radioisotopes have accumulated 
in the non-hepatocytes on a unit cell volume basis. 
Caperna and Fail la (1984) also report a more 
efficient uptake of cadmium by the non-hepatocyte 
(endothelial and Kupffer cells) when compared to 
hepatocytes when calculated per mg of cell protein, 
following subcutaneous injection of CdCl;£ in the rat.
The observed 1 os,Cd distribution following cadmium 
metallothionein administration to an isolated 
perfused liver system is in contrast to the almost 
exclusive accumulation of cadmium by the parenchymal 
cells when exposed to cadmium chloride in vivo (Cain
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and Skilleter, 1980) and In vitro (Skilleter and 
Cain, 1981). However, the results of this study 
compare well with the results of Skilleter and Cain 
(1981) when cadmium is administered with dithiol 
agents such as 2.3 dimercaptopropanol (BAL) or 
dithiothreitol, An explanation of this observation 
was that either the dithiol/cadmium complexes enhance 
the normal cellular uptake mechanism, or that 
colloidal complexes of cadmium may be taken up by 
endocytosis particularly in Kupffer cells.
The endothelial and Kppffer cells (non hepatocytes) 
are reported to contain about 3 fold more 
metallothionein per mg of cytosolic protein than the 
parenchymal cells from a liver of an exposed rat 
(Caperna and Failla, 1984). This may also effect the 
distribution of 1 °3Cd between the hepatocyte and non- 
hepatocyte fractions in the present study; by 
increasing the sequestration of cadmium by the higher 
concentration of metallothionein in the latter as 
compared to the former fraction.
The differential distribution of 1 °~'Cd and 3H between 
hepatocyte and non-hepatocyte may be explained by 
either of two possible mechanisms.
i) a differential uptake of metallothionein bound 
cadmium and non-metallothionein bound cadmium, 
the former being taken up by the hepatocyte- 
and the latter by the non-hepatocyte fractions.
ii) similar uptake of cadmium-metallothionein by 
both cellular fractions but relatively low 
proportion of 3H in the non-hepatocyte may be 
due to the more active lysosomal system and, 
therefore, higher catabolism of metallothionein 
in this fraction and its subsequent release 
into the perfusate.
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The results of this study do not refute either 
mechanism, in fact both mechanisms may be occuring 
simultaneously. Certainly the polymerised 3H- 
labelled metallothionein, observed following the 
incubation of this protein with the perfusion-medium 
(figure 4.12), would probably be taken up by the 
Kupffer cells as Skilleter and Cain (1981) proposed 
for the uptake of cadmium/di thiol complexes - 
providing support for the second mechanism. It is 
also likely that 1 os*Cd bound to the proteins such as 
albumin [observed following the incubation of lo^Cd, 
3H-labelled metallothionein with the perfusion medium 
(figure 4.12)3 would also be taken up by Kupffer 
cells lending support to the first mechanism.
4.4.4 Biliary excretion of metallothionein and 
cadmi um
Chromotographic evidence for the presence of 
metallothionein in bile from rabbits injected with 
large amounts of cadmium has been obtained (Nomiyama 
and Nomiyama, 1982). More recently, metallothionein 
and metallothionein fragments have been detected in 
the bile of control and copper-dosed rats by a 
radioimmunoassay procedure (Sato and Bremmer, 1984). 
These workers also noted up to a 30 fold increase in 
the concentration of their protein in the bile upon 
induction of metallothionein by copper.
The results of this study also demonstrate the 
presence of metallothionein in the bile of cadmium 
dosed rats, by a radioimmunoassay procedure, 
described in Chapter 2. However, unlike the 
radioimmunoassay procedure used by Sato and Bremner 
(1984), the radioimmunoassay procedure used in this 
study was unable to detect metallothionein in the 
bile of control rats.
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The biliary release of metallothionein over the 180 
minute period was very low (less than 0.5%'of total 
hepatic metallothionein content) in the isolated 
perfused liver from both orally and parentally, 
cadmium dosed rats. This indicates that the bile is 
not a major route of excretion for metallothionein. 
This is a finding which has been demonstrated in 
copper dosed rats (Sato and Bremner, 1984), where 
only 1-2% of the hepatic metallothionein is excreted 
in the bile.
The billiary excretion of metallothionein (as 
measured by 3H radioactivity) and cadmium from a 
isolated perfused control rat liver exposed to 1°--='Cd, 
3H labelled metallothionein, was negligible (0.007% 
and 0.0006% of the respective totals of 3H and 1 os*Cd 
activity added to the perfusate, after 180 min. The 
calculated concentration of metallothionein and 
cadmium excreted in the bile was 0.72 pg and 0.18 ng 
respectively after 180 min. The average 
cadmium:metallothionein molar ratio was calculated 
from the 10,3Cd and 3H radioactivity of the bile 
samples from each time point and found to be 1:57. 
This is totally different to the cadmium: 
metallothionein molar ratio of 3.5:1 calculated in 
the liver cytosol (section 4.4.3) - suggesting that 
the cadmium may not be excreted into the bile bound 
to metallothionein. This is supported by evidence 
provided by Cherian and Vostal (1977) and Cirkt and 
Havrdova (1979) that cadmium may be excreted in the 
bile as a low molecular weight substance, possibly as 
a glutathione-cadmiurn complex (Cherian and Vostal , 
1977), or as a degradation product of meta11othionein 
(Sato and Bremner, 1984).
As the chromatographic studies of the liver cytosol 
reveal, 3H is associated with two peaks of activity 
i) metallothionein, ii) possible degradation products
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of metallothionein. It seems likely that both of 
these compounds account for the radioactivity of 3H 
in the bile. The 3H radioactivity in the bile may 
also be due to polymerised 3H-labelled 
metallothionein.
The 1 °-*Cd: metal lothionein ratios in the bile are 
wildly different from that found in the liver 
cytosol. This may be explained by the existence of 
degradation product(s) of metal 1othionein and/or 
polymerised metallothionein in the bile, as (i) low 
1 os,Cd radioactivity was associated with the 
degradation productCs) of metallothionein located in 
the liver cytosol (figure 4.8) and (ii) poly­
merisation of metallothionein would give rise to loss 
of metal ions (including lc,55,Cd). The existence of 
degradation products of metallothionein and 
polymerised metallothionein in bile have been 
suggested by Sato and Bremner (1984) following their 
chromatographic studies of the bile from a copper 
exposed rat.
4.4.5 Distribution of metal 1othloneln and cadmium 
between the perfusate supernatant and 
ervthrocvte compartments of the perfusion 
med i urn
The incubation of 1 osCd,3H-label led metallothionein 
in the perfusion medium without the interference of 
an isolated liver was performed to analyse the 
behaviour of metallothionein in the perfusate: so as
to aid the understanding of the cadmium- 
metallothionein handling by the liver. The results 
suggest that the 1°^Cd is fairly labile, with about 
72% of the total added to the perfusate finally 
recovered in the perfusate supernatant fraction. The 
majority (61%) of meta11othionein (as measured by 3H 
activity) added was recovered in the perfusate
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supernatant fraction. However, a small degree of 
transfer of metallothionein from the erythrocyte to 
the plasma fraction over the 180 minute period was 
observed. This may be explained by increased 
erythrocyte lysis.
Fractionation of a supernatant sample, taken 180 min 
after addition of the metallothionein to the 
perfusate (figure 4.12) revealed the presence of two 
peaks of 3H radioactivity. One peak was believed to 
be metallothionein and the other, of higher molecular 
weight, may be.a polymer of metallothionein. There 
were no peaks of 3H radioactivity in the low 
molecular weight range indicating that 
metallothionein has not been degraded in the 
perfusate supernatant. Most of the 1 os,Cd is found in 
the high molecular weight fraction and very little 
associated with the metallothionein fraction.
This again demonstrates the lability of '°3Cd. It 
seems that the los*Cd may be associated with albumin 
or polymerised metallothionein in perfusate 
supernatant. As very little 10i?,Cd is associated with 
the metallothionein fraction, it would seem feasible 
to suggest that loe,Cd is bound to albumin and not the 
metallothionein polymer.
Fractionation of an erythrocyte sample taken 180 min 
after addition of the 1°3Cd,3H-1abe11ed 
metal lothionein revealed that the majority of 10S>Cd 
and 3H is assocated with higher molecular weight 
fraction and very little is associated with the 
metallothionein fraction (figure 4.12). Assuming the 
stability of the 3H moiety bound to the protein 
[supported by evidence that most of the 3H is 
associated with metallothionein in the liver cytosol 
(figure 4.9)], it appears that most of the 
metallothionein may be bound to the high molecular
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weight proteins of the erythrocyte fraction. These 
proteins may include haemoglobin or cell membrane 
fragments, or again the metallothionein may be 
polymer i sed.
The results of the present study would suggest that 
after 180 min the 1 os,Cd is labile in the perfusate 
and does not remain bound to metallothionein. It 
also appears that metallothionein may have a high 
tendency to polymerise or bind to other constituents 
such as albumin, haemoglobin or erytrocyte membranes. 
The lability of the 1°3Cd bound to metallothionein 
may be related to the binding of metal 1othionein to 
other constituents, but also due to the oxidation of 
the disulphide bonds of metallothionein brought about 
by the high oxygen tension in the perfusate.
S n m m n r y
From the results using the isolated liver perfusion 
system, it appears that cadmium and metallothionein 
are actively released from the liver of cadmium 
exposed rats; and that this process is not 
attributable to cellular turnover. The mechanism of 
release of metallothionein is not known but may 
involve a secretory pathway similar to that described 
for albumin. As the perfusate supernatant 
cadmium:metallothionein molar ratio at each time 
point is similar to that found in each respective 
liver, it is proposed that the cadmium and 
metallothionein are released together. An observed 
'plateau' in the concentration time profile for 
metal 1othionein and cadmium suggest a possible 
equilibrium in concentration of cadmium and 
metallothionein between the liver, perfusate 
supernatant and erythrocyte compartments.
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Uptake of 1osCd,3H-label led metallothionein by the 
isolated liver from a rat not previously exposed to 
cadmium, was also observed. Ninety nine per cent of 
the 1 os*Cd and 23% of the metal lothionein (as measured 
by 3H radioactivity) added to the perfusate, was 
located in the liver after 180 min. Although hepatic 
3H uptake was fairly constant, los,Cd uptake by the 
liver was exponential. The 3 experimental components 
in the perfusate clearance of 109Cd observed in this 
study, have been proposed to indicate 3 different 
mechanisms of uptake of Cd (one of these mechanisms 
may also include hepatic release of Cd).
Most of hepatic 3H radioactivity was estimated to be 
in approximate equal amounts in the hepatocyte (55%) 
and non-hepatocyte fractions (45%). However, the 
efficiency of uptake (estimated uptake per unit cell 
volume) of both radioisotopes was greater in the non- 
hepatocytes. Subcellular fractionation of the liver 
after 180 min into membranous and cytosol components 
revealed that most of the hepatic 3H radioactivity 
was associated with the membranous fraction, whereas 
most of the 1 os,Cd radioactivity was found in the 
cytosol fraction. Both radioisotopes were found 
associated with the metallothionein fraction 
following cytosolic fractionation by gel filtration 
chromatography. About 50% of the 3H radioactivity 
was also found in a fraction of lower molecular 
weight (<5.7 kilodaltons) suggesting that the: 
protein is degraded. These results imply that 
hepatic uptake of 3H-labelled metallothionein occurs 
by endocytosis and metallothionein and its 
degradation products are released into the cytosol 
following lysis of the endocytic/lysosomal vesicles 
during the preparation of the cytosol fraction. 
los'Cd may be taken up by the same mechanism as 
metallothionein, particularly if it is protein bound. 
However, the "free" ion may be taken up directly into
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the hepatic cytosol by a membrane carrier mechanism.
A further possiblity is that ‘°*Cd,3H-label led 
metallothionein may have been taken up directly into 
the cytosol by some unknown mechanism.
Biliary excretion of cadmium and metallothionein 
(and/or metallothionein degradation products) was 
negligible. The 1°-3*Cd:3H radioactivity ratios were 
wildly different in the bile as compared to the liver 
cytosol, which may be explained by the existence of 
3H-labelled degradation products and/or polymerised 
metal lothionein or albumin. The ' °'*Cd also appears 
to be associated with the high molecular weight 
proteins of the erythrocyte fraction such as 
haemoglobin or erythrocyte membrane components as 
well as possible metallothionein aggregates, (as the 
3H also appears to be found in the high molecular 
weight region). The aggregation/polymerisation of 
the metallothionein or the binding to other proteins 
may explain the lability of the lc,3Cd. The lability 
Qf 10-3Q c| jn perfusate may aid an explanation of
(i) the multi-component nature of the exponential 
1 c,9Cd clearance in the perfusate supernatant, (ii) 
the differential distribution between hepatocyte and 
non-hepatocyte and (iii) the differential 
distribution between membranes and cytosolic 
fractions of the liver.
CHAPTER 5
Renal handling of Intravenously administered 
cadmium metallothionein in the rat
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5. 1 Introduct ion
Chronic oral exposure of rats to cadmium, gives rise 
to a time-dependent increase in renal concentration 
of the metal with respect to the liver concentrations 
(Stonard and Webb, 1976; Nordberg, 1978), although 
this finding was not observed at the highest dose 
regimen used in Chapter 3. It has been suggested 
that Cd-metallothionein is released from the liver 
(Nordberg, 1972; Tanaka et al. 1978; Garvey and
Chang, 1981; Frazier, 1982). Evidence for this 
release is presented in Chapter 4 (section 4.3.1), 
where a time-dependent increase of Cd-metallothionein 
from the isolated liver of rats previously exposed to 
cadmium into the perfusate was observed. Uptake of 
circulating Cd-metallothionein by the proximal 
tubular cells of the renal cortex, following 
glomerular filtration has also been reported (Squibb 
et a1, 1976, Nordberg et a1. 1975) and it appears to
be similar to the well established fate of 
circulating low molecular weight proteins and their 
catabolism (Stober and Waldman, 1974). Thus the very 
low or undetectable serum levels of metallothionein 
observed may be due to the relatively slow release of 
metallothionein from liver and avid uptake of this 
protein by the kidney.
The renal metabolism of Cd-metallothionein has been 
reported to lead to complete degradation of the 
protein within 48 hr followed by at least partial 
neutralization of the amino acids (Cherian and Shaikh, 
1975; Webb and Etienne, 1976). The degradation of 
the injected cadmium-meta1lothionein having a much 
shorter half life of 4 hr (Cain and Holt, 1983) than 
the endogenous renal Cd-metallothionein (3-5 days) 
(Squibb et al. 1979). The renal handling of
circulating cadmium-metallothionein with respect to
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mechanisms of nephrotoxicity is not yet fully 
understood. Webb and Etienne (1976) suggest that the 
toxic action on the kidney is due to the release of 
cadmium intracellularly upon the lysosomal 
degradation of the reabsorbed protein. Cherian 
(1978) believes that the Cd-metallothionein is the 
toxic species. This hypothesis is based mainly on 
his observation that the Cd2"* is bound to 
metallothionein at all times and therefore is 
unatainable for interactions leading to toxicity.
Cherian (1978) also demonstrated that 10S)Cd did not 
accumulate in the renal lysosomes upon injection of 
1°^Cd-metallothionein. As over 90% of the cadmium was 
metallothionein bound at all times, even though some 
degradation of the protein occurred, he concluded 
that the role of the lysosomal system in the renal 
Cd-metallothionein toxicity was minimal. However, 
the behaviour of 1c,3Cd may not be indicative of 
i °s=»Cd-metal lothionein within the proximal tubular 
cel Is.
Studies by Cain and Holt (1983) using cadmium, 3H- 
labelled metallothionein have shown that 
intravenously injected cadmium 3H-1abe11ed 
metallothionein is taken up rapidly into the rat 
kidney. However, they also showed that the 3H- 
labelled protein was rapidly degraded (within 4 hr of 
injection) without a concomittant loss of 
mi tochrondr ia 1 / 1 ysosomal cadmium. Upon subeel l'ular 
fractionation, a lack of 3H was found in the 7800g_ av 
fraction. 3H was found in the particulate (3100 g. 
av) fraction and contamination of this fraction by 
lysosomes may occur due to the heterogenity in size 
and density of these organelles. Cain and Holt 
(1983) concluded that their results did not rule out 
the involvement of the lysosomal system in the 
degradation of metallothionein. The. cadmium from Cd-
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metallothionein was found mainly in the particulate 
fraction (containing nuclei.and cell membranes) up to 
4 hours post injection, prior to the accumulation of 
the metal in the cytosol fraction thereafter. Upon 
disruption of the endocytic vesicles of the 
particulate fraction, degradation products of the 3H- 
metallothionein were found by 30 min following 
injection of the protein.
U1trastructural studies by Squibb et a1. (1984)
showed an increase in small lysosomes of the proximal 
tubular cells 1 hr after an intraperitonea1 injection 
of Cd-metal lothionein (0.6 mg Cd^'/kg) . The number 
of small vesicles increased dramatically by 4 hr.
The mechanisms by which these early ultrastructural 
alterations occur has not been clearly identified. 
However, these workers suggest an inhibition of 
primary lysosomal formation and decreased fusion of 
these lysosomes with pinocytotic vesicles. This 
suggestion is supported by the findings of Cain and 
Holt (1983) in that 3H from the 3H-1abe11ed 
metal lothionein (at a dose of 0.8 mg Cd:-“Vkg), is 
present in the particulate fraction and not in the 
mitrochrondria1/lysosomal fraction. However, Cain 
and Holt provide evidence that the meto11othionein in 
the particulate fraction (which may also contain 
lysosomes) is degraded completely by 4 hr after 
injection. This does not support further findings by 
Squibb et a 1. (1984) that the inhibition of- lysosomal
cathespsin D and acid phosphatase occured in the 
kidney following administration of Cd- 
metal 1othionein.
Subfractionation studies on the renal cortex 
following intravenous injection of 0.3 mg. of 1c,3Cd- 
metallothionein (equivalent to a dose of 0.1 mg 
Cd3i+'/kg) (Dobrota et a 1 . 1982) showed that 31% of
1c,3Cd is associated with the organelles, and 37% with
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the cytosol fraction 30 min after injection. A time- 
dependent movement of 1°-=,Cd from the organelles to 
the supernatant fraction was observed until at 24 hr, 
when about 60% of the ' 0-*Cd was supernatant 
associated, further subfractionation of the 
mitochrondrial/lysosomal (10,000 gav) fraction 
revealed that the 1 °-*Cd was associated with the large 
lysosomes. By 1.5 hours, the 1 °**Cd associated with 
large lysosomes decreased and was undetectable by 
24-hrs. These studies also showed that the 1 ‘•‘■*Cd 
associated with the small lysosome fraction after 30 
min, doubled by 1.5 hr but decreased in this fraction
by 20% after 24 hr.
These results suggest movement of 1u9Cd from the
large lysosomes to the small lysosomes and finally to
the cytosol, following uptake of ‘^ C d -  
metal lothionein. The first steps of their pathway 
are well established as the catabolic route of 
reabsorbed low molecular weight proteins, and the 
appearance of ' °'*Cd in the cytosol may be explained 
by the rapid intralysosomal breakdown of 
metal lothionein. It was also noted that the Cd^ "* 
release may be due to the intralysosomal acid pH. 
Another finding of this study was a slight 
redistribution of 5* nucleotidase, as shown by a 
decrease in enzyme activity in the mitrochrondria1/ 
lysosomal fraction in the renal cortex of the control 
as compared to Cdi:_t-treated rats, and an increase in 
enzyme activity in the microsomal fraction of the 
renal cortex of the Cd-treated as compared .to control 
rats. This was suggested to indicate alterations in 
the distribution of brush-border membranes which are 
possibly associated with membrane binding sites for 
Cd-metallothionein reported by Selenke and Foulkes. 
(1981). The change in distribution may also indicate 
damage to the brush border membranes, an observation 
made in vivo (Cherian et a 1. 1976) and, in vltro
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(Cherian, 1982) during cellular uptake of Cd- 
metal lothionein in the kidney.
The results presented by Dobrota et a 1. (1982) do
indicate the involvement of the lysosomal system as 
the mode of entry for Cd-metallothionein into the 
cortical cells and in the degradation of the protein. 
To ellucidate further the fate of intravenously 
injected Cd-metallothionein in the renal cortex of 
the rat, experiments were performed to study the 
distribution of '°~*Cd and 3H for 103Cd, 3H-1 abe 11 ed
metallothionein in:-
a) the classical fractions from a renal cortex
homogenate that is nuclear, mitrochrondrial/ 
lysosomal, microsomal (including the P3 
fraction) and supernatant.
b) the subfractionated mitrochrondria1/1ysosoma1
and P3 fractions to assess the association of 
Cd and metallothionein with lysosomes and 
membrane vesicles.
c) the fractionated supernatant fraction, so as to
show with which cytosolic proteins, cadmium and 
tritium are associated.
5.2 Exper i men t a1
5.2.1 Mater i a 1s
Hepatic Cd,Zn-metallothionein was isolated from male 
Wistar albino rats as described in section 2.2.3 A. 
The radiolabels used were cadmium-109 and N- 
succinimdyl C2,33H1 propionate, supplied by Amersham 
International pic, Amersham, Berks, U.K., Sucrose 
(mineral water sugar) was supplied by Tate and Lyle,
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and Percol used in the density gradients for 
subfractionation were obtained from Pharmacia, 
Stockholm, Sweden. Reagents for the enzyme assays 
were also supplied by Sigma Chemical Co. Poole,
Dorset U.K. and B.D.H., Poole, Dorset, U.K.
(Picofluor 30) was obtained from Packard Instruments, 
Reading, U.K. Sephadex G75 was supplied by 
Pharmacia. Sodium pentobarbitone (Nembutal, 60mg/ml) 
was obtained from May and Baker, Dagenham, Essex,
U.K. All other salts used were of Analar or 
equivalent grade.
5.2.2 Preparative and Analytical Methods
A) Preparation of 1oa»Cd. 3H-label led 
metallothionein and measurement of 
radioact ivi tv.
The losCd, 3H-label led rat liver metallothionein I 
was prepared as described in section 4.2.3. The 
specific activity for each of the radioisotopes was 
21.8 pCi/ml for 1°®Cd and 9.8 pCi/ml for 3H. 3H and 
'• ossCd were determined as described in section 4.2.2.
B) Protein concentration and enzyme activity 
measurement
Protein concentrations were measured by the method 
described by Hinton and Norris (1972).
Acid phospatase, 5-nucleotidase, glucose-6- 
phosphatase, and succinate dehydrogenase activties 
were measured by the methods described by Dobrota and 
Hinton (1980) and Hultberg and Uckerman (1972).
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5.2.3 Experimental Design'
Four groups of six anaethetised Wistar albino rats 
were intravenously injected into the jugular vein 
with 0.2ml of lo3Cd, 3H- label led
metallothionein/animal. After 10 min, 30 min, 1.5 hr 
or 24 hr, the body cavity of each animal was -opened
and a blood sample from each of the six animals at
each time point was taken from the vena cava. (The 
series of experiments undertaken at each time point 
were performed on separate occasions and not 
sequentially within a 24 hr period). The animals
were killed, the kidneys removed and the kidney
cortices excised.
A) Subcellular fractionation of the kidney cortex
1. Kidney cortices from all six rats from each 
time point were transferred into ice-cold 
0.25 M sucrose containing 5 mM Tris HC1 buffer, 
pH 7.4 (0.25 M buffered sucrose) (in a 
preweighed beaker) and the combined weight of 
the tissues was recorded.
2. The tissues were then homogenised with 2-3 
strokes of a Potter-Elving homogenlzer and made 
up to 10% w/v with isotonic buffered sucrose.
A 2ml aliquot was retained as the homogentate 
(H) reference fraction.
3. The remaining homogenate was centrifuged at
500g. (1600 rpm) for 3 min. The pellet was
resuspended in 0.25 M 'buffered' sucrose and
recentrifuged at 1600 g for 3 min.
4 s bupernatants i row both these centrl i u.-rss were
recombined and stored at 4'~'C.
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5. The 500g_ pellet from step 6 was resuspended in
about 30 ml 0.25 M buffered sucrose and 
retained as the nuclear <N) fraction.
6. The pooled supernatant was centrifuged at
10,000g_ (11,000 rpm) for 3 min and the 
subsequent supernatant was removed and stored 
at 4,=,C .
7. The remaining pellet was resuspended in about
15 ml of 0.25 M sucrose and retained as the 
mitochrondrial/lysosomal (ML) fract-ion,
8. The supernatant obtained in step 6 was then
centrifuged at 18,000 (13,500 rpm) for
15 min.
9. A white "fluffy layer" above the pellet 
obtained in step 8 was removed and retained as 
the (P3) fraction.
10. The supernatant and pellet obtained in step 8 
were then centrifuged at 106,000 g (40,000 rpm) 
for 1 h. The subsequent supernatant was 
retained as the supernatant (S) fraction.
11. The pellet obtained in step 10 was then 
resuspended in 0.25 M sucrose.
B) Density gradient centrifugation of the 'ML' and
* P-^ ' reference fractions.
Zonal rotors were used for the subfractionation of 
subcellular organelles. The advantages of zonal 
rotors and the principles of their operation will not 
be covered in this thesis as this has been described 
in detail by Hinton and Dobrota (1976), Cline, and 
Ryel (1971), and Chervenka and Elrod (1972).
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The 'ML* fraction, obtained in the previous section 
(5.2.3A) was further subfractionated by rate zonal 
sedimentation in an CHS) zonal rotor (MSE Scientific 
Instruments) leaving a 2 ml sample as the 'ML' 
reference fraction.
The density gradient used was made with sucrose. A 
stock solution of 2 M sucrose (68.54% w/v) was 
treated with activated charcoal (34g/l) to remove 
traces of nuclease and other protein contaminants 
(Steel and Busch, 1967). This stock solution was 
diluted with distilled water to make the precise 
dilutions required for making gradients and the 
isotonic 0.25 M sucrose for homogenising.
The density gradients used in this study were all 
linear with volume and were made with the apparatus 
described by Hinton and Dobrota (1969).
The HS zonal rotor contained 550 ml of experimental 
sucrose gradient ranging from 0.5 M to 1.7 M and 
150 ml of 2 M as the “cushion".
The experimental gradient was made as follows: 300 ml
of 0.5 M sucrose was stirred in a mixing vessel, to 
this was added 1.8 M sucrose at 40 ml/min whilst the 
resultant gradient was withdrawn and pumped into the 
rotor at 40 ml/min. The 'ML' fraction was 
resuspended in approximately 25 ml of 0.25 M sucrose 
and loaded into the HS zonal rotor which was then 
spun at 8,000 rev/min for 1 hr. At the end of the 
spin 20 ml fractions were collected for the various 
assays.
To isolate the basolateral and luminal (brush border) 
membrane fractions, the ,P.•;==:, reference fraction 
obtained in the previous section (5.2.3. (a)), was 
further fractionated by percol density gradient
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centrifugation, leaving a 2 ml sample as the 'p^ ,* 
reference fraction. This was performed as previously 
described by Boumendil et al. 1983 except that a high
speed 'swing-out' rotor (Beckman - RIIC Instruments) 
was used.
C) Fractionation of the supernatant (S) fraction 
by gel filtration chromatography
A proportion of the supernatant fraction (10 ml) was 
fractionated on a Sephadex G75 column (1 x 24 cm) 
using 15 mM ammonium formate buffer pH 8.0 as the 
eluant. A flow rate of 14 ml/h was used and 2.0 ml 
fractions were collected.
5.3 Results
5.3.1 Distribution of 3H and 1osCd in the renal 
cortex and plasma
Each rat was injected with 0.2 ml of 10^Cd, 3H 
labelled metallothionein. This is equivalent to 0.72 
mg metallothionein and 0.115 ug 1°9Cd as taken from 
the specific activity (section 4.3.3). The values 
for the renal cortex presented below are measurments 
made from a pooled sample of the homogenate from the 
renal cortices of 6 animals for each time point.
The values for the plasma are an average measurement 
made from six animals for each time point.
Of the injected dose, only 25% of 3H (0.18 mg 
metallothionein) was in the plasma after 10 min. A 
time dependent decrease in. 3H was observed, until, by 
24 hr none was detectable. The 3H also decreased 
rapidly in the cortex so that only 0.43% remained by 
24 hr (table 5.1). Of the injected dose, 26% of the
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' °3Cd (0.03 ug 103Cd) was present in the renal cortex 
after 10 min.
At this time only 12.3% of 1 °3Cd was present in the 
plasma; thereafter a time dependent decrease in ,G9Cd 
was observed - reaching undetectable levels by 24 hr. 
However, although renal cortex 1 °3Cd decreased to 
15.3% of total after 30 min, it increased thereafter 
reaching about 29% of total radioactivity by 24 hr.
5.3.2 Distribution of 3H and 1 °‘3Cd in the classical
subfractions of the renal cortex
The distributions of 3H and l03Cd in the classical 
subfractions are shown in table 5.2. Subfractions of 
the renal cortex 10 min after injection of 'lo3Cd,3H- 
labelled metallothionein revealed that 25.7% of the 
3H in the homogenate was found in the 'ML' fraction 
and 22.7% was found in the supernatant fraction. The 
remaining 37% was found in the other fractions, 
giving a total percentage recovery of 86.2% of the
activity found in the homogenate. By 30 min the 3H
activity appears mainly in the 'ML' fraction (35.4%) 
and supernatant fraction (51.6%) of the kidney 
cortex. The 3H activity after 1.5 hr was mainly 
associated with the 'ML' fraction (79.8%). A smaller 
percentage of the total 3H was found in the nuclear 
fraction (18.7%) at this time point. The 3H was 
undetectable in the other fractions by 1.5 hr, and by 
24 hr, 3H activity was undetectable in all the 
classical subfractions.
The distribution of 1 °'3Cd in the classical 
subfractions after 10 min, showed a similar profile 
to the 3H distribution, with 26.4% in the 'ML' 
fraction and 26.6% in the supernatant. At 30 min 
these values increased to 29.4% and 54.7% in the 'ML* 
and supernatant fractions respectively. However, by
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Table 5. 2
Change in the total radioact1vity and percentage of 
homogenate radioactivity of 3H and 1 os*Cd in the 
classical subfractions of the kidney cortex after 
intravenous injection of 1°'5'Cd, 3H labelled 
metallothionein. Values presented at each time point 
are from single experiments. The percentage 
recoveries are the original observations and are not 
corrected to 100% in each column.
Subcellular fractions are denoted;
N - nuc1 ear
ML - mitochrondria1/1ysosoma1 
P3 - partially purified membrane fraction 
MIC - microsomal (less the P3 fraction 
SUP - supernatant.
ND - not detectable
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1.5 hr, the 1°^Cd was found mainly in the supernatant 
fraction (76.°%), increasing to 82.9% by 24 hr.
The 1 ‘,;*Cd/3H ratio of the ' osCd, 3H labelled 
meta 11othionein prior to injection was calculated to 
be 2.2. This ratio was found to be similar to that 
found in the 'ML' and supernatant fraction of the 
renal cortex 10 min post injection. However, by 30 
min, the ,03Cd/3,H activity ratio had increased to 3.4 
and 4.4 in the 'ML' and supernatant fractions 
respectively. The ratio in the 'ML' fraction after
1.5 hr had decreased to 2.9. No other estimates of 
the '°^Cd/3H activity ratio could be made from the 
other classical subfractions .
5.3.3 Distribution of total protein content and
marker enzymes in the classical subfractions of 
the renal cortex
The distribution of each of these parameters in the 
classical subfractions and their variance with time 
following intravenous dnjection of lo^Cd,3H labelled 
metal 1othione in, are shown in table 5.3.
The percentage of total homogenate protein in each of 
the subfractions showed only minor fluctuations over 
the 24 hr period. However, the supernatant fraction 
did show a 30% decrease at the 10 min time point when 
compared to control values. From 30 min, a time 
dependant increase in this percentage was observed, 
finally reaching control values by 24 hr.
The greatest percentage of acid phosphatase activity 
in the homogenate was found in the 'ML' fraction of 
the renal cortex of control rats (39% of total 
homocsnate activity). In comparison to the 
percentage of total homogenate acid phosphatase 
activity observed in the 'ML' fraction from control
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cortices, a lower percentage was seen in this 
fraction 10 min after injection of 1 os,Cd, 3H-label led 
metallothionein. This was followed by about a 1.5 
increase in the percentage by 30 min, remaining at 
this level thereafter up to 24 hr. In contrast, 
overall decreases in the percentage of total 
homogenate acid phosphatase activity in both the ' P3' 
and 'MIC' fractions were observed between the 10 min 
and 24 hr time points. An increase in the percentage 
of total homogenate acid phosphatase activity (about 
26%) was also observed in the supernatant fraction 
between the 10. min and 24 hr time points.
5'- nucleotidase was found in the nuclear, 
mitochrondrial/lysosomal and microsomal fractions 
(18.1, 26.3 and 39.5% of the total activity found in
homogenate of the control renal cortex respectively). 
The percentage of total 51 nucleotidase activity 
found in the 'ML' fraction after 10 min was 35.7% 
(about 70% higher than that found in the control 'MIC’ 
fraction). This percentage decreased in a time- 
dependent manner to 6.5% at 1.5 hr increasing 
slightly to 17.7% at 24 hr. In contrast, the 
percentage of this enzyme found in the microsomal 
fraction after 10 min was about 9.1% of total 
homogenate activity and this percentage increased in 
a time-dependent manner to 24 hr. Time-dependant 
fluctuations in the percentage of 5'— nucleotidase 
activity of the 'P3 ' fraction were only minor, 
following injection of 1 or*Cd, 3H-label led 
metallothionein. Likewise, no major fluctuations in 
the percentage of this enzyme were found in the 
supernatant and nuclear fractions between 10 min and
1.5 hr, but a small decrease in percentage in the 
nuclear fraction, and a small increase in percentage 
in the supernatant fraction was observed at 24 hr.
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Table 5.3
Percentage recoveries of protein and marker enzymes 
from the classical subtractions of the rat kidney 
cortex after intraveous Injection of “-*‘r*Cd, ^ ‘H- 
labelled metallothionein. The control values are 
averages of 12 observations and have been previously 
reported by Dobrota et al. (1982), whilst the 10 min,
30 min, 1.5 hr and 24 hr values are from single 
experiments. The percentage recoveries are the 
original observations and are not corrected to 100% 
in each column.
Enzymes are denoted;
Acid P: Acid-glycerophosphatase
5 NT : 5' Nucleotidase
G-6-P : Glucose-6-phosphatase
SDH : Succinate dehydrogenase
Subcellular fractions are denoted;
N : nuclear
ML : mi tochrondrial/lysosomal
P3 : partically purified membrane fraction
MIC : microsomal (less the P3fraction)
SUP: : supernatant
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Glucose-6-phosphatase was mainly located in the 
micosomal fraction of the renal cortical homogenate 
from control animals (53.6%), but a significant 
percentage was also found in the nuclear (19%) and 
'ML' (20%) fractions of these animals. Following 
injection of 1 os,Cd,3H labelled metal 1 othionein, the 
percentage of glucose 6-phosphatase in the nuclear 
fraction was around 36-38% between 10 min and 30 min, 
somewhat higher than that found in the control 
nuclear fraction. This percentage then decreased in 
a time-dependent manner to 16.5% at 24 hr. After 10 
min the percentage of glucose-6-phosphatase in the 
microsomal fraction (including the 'P3 ' fraction) was 
observed to be less than half the percentage found in 
the microsomal fraction from control renal cortices. 
Thereafter the percentage of total glucose-6-
phosphatase activity in the microsomal fraction 
increased, reaching a maxima of 48.6% at 1.5 hr. A 
slight decrease in this percentage was noted at 24 hr.
Succinate dehydrogenase was found mainly in the 'ML' 
fraction of the renal cortical homogenate from 
control animals (66.4%). The distribution of this 
enzyme in the classical subfractions showed only 
slight fluctuation throughout the 24 hr period, 
following injection of 'osCd,3H-1abel1ed 
metal 1othionein.
5.3.4 Distribution of 3H and 1oaCd in the cortical 
’ML1 samples subfractionated bv rate 
sedimentation (zonal) centr1fugation
Subfractionation of the cortical 'ML' samples 
separates different populations of lysosomes and 
microsomes as well as separating mitochrondria from 
lysosomes. Figure 5.1 shows the time-dependent 
distribution of 3H and ’ os*Cd associated with each of 
these particular fractions following injection of
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Figure 5.1 Distribution of 3H and 1Q9Cd in the cortical 
"ML11 samples, subfractionated bv rate 
sedimentation centrifugation.
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109,Cd, 3H labelled metal lothionein. After 10 min, a 
sharp peak of the 3H and 1 os,Cd activity was found 
between fractions 2 and 5 Csmall lysosome fraction) 
and a broad peak of 3H and 10S,Cd activity was found 
between fractions 10 and 25 ('mltochrondrlal' 
fraction). A further small peak of activity of 3H 
and 103Cd was found between fractions 30 and.35 
(large lysosome fraction). 109Cd and 3H are closely 
associated in this profile and the radioactivity of 
10,£>Cd is about 2 fold greater than that of 3H.
By 30 min, the 3H and 1 °~'Cd decreased between 
fractions 2 and 5, and 10 and 25 by about 70-80%. 
However, the 3H and 1C9Cd activity between the 
fractions 30 and 35 increased slightly. A time- 
dependent decrease in 3H and 1 os,Cd activities in both 
the first two peaks was observed up to 24 hr. The 
third peak of 3H radioactivity (fraction 30-35) 
increased by about 2 fold, whereas the lo-'Cd in this 
peak decreased slightly. By 24 hr the 3H and 1osCd 
in fraction 30-35 decreased to almost undetectable 
levels.
5.3.5 Distribution of total protein content, acid 
phosphatase, glucose-6-phospatase. 5* 
nucleotidase and succinate dehydrogenase in the 
cortical "ML11 samples subfractionated bv rate 
sedimentat ion
The total protein content of the subfractionated 
cortical ML is shown in figure 5.2. As shown in the 
10 min profile, 3 peaks of protein content are 
observed between fractions 2-6, 12-24 and 30-34. The
respective peaks in the profile were 15.0, 10.1 and
5.25 mg/fraction respectively. The first peak showed 
a time-related decrease until 24 hr to a measured 
peak of 12.0 mg/fraction. The other peaks in the
311
protein profile showed no significant change over the 
24 hr period.
As shown in figure 5.3, the acid phosphatase activity 
10 min after injection of 'l03Cd, :E'H labelled
metallothionein was distributed between one peak in 
fractions (1-4) and two very broad peaks covering the 
remaining fractions. By 30 min, the acid phosphatase 
activity was mainly distributed in two peaks 
(fractions (2-8) and (3.1-35). The activity in the 
first peak was found to be about 2 fold greater 
(3.0 umole/min/fraction) after 30 min than after 10 
min, but then decreased by about 30% by 1.5 hr. No 
significant changes in acid phosphatase activity were 
observed in the second two peaks (fractions 31-35) 
from 30 min to 24 hr; remaining between 1.0 and 1.5 
umole/min/fraction.
The 5'-nucleotidase activity in the subfractionated 
'ML' samples are shown in figure 5.4. The profile 
shown after 10 min, reveals one sharp peak (fraction 
1-3) and two broad peaks of activity between 
fractions (8-18) and (20-36). These had peak 
activities of 1.76, 0.84 and 1.8 umol/min/fraction 
respectively. By 30 min, the profile revealed the 
presence of only two peaks of activity, between 
fraction 2-8, and 16-21, with peak activities of 1.4 
and 1.1 umol/min/fraction respectively. The 
activites in each of these respective peaks had 
decreased by about 20 and 40% by 1.5 hr, increasing 
again after 24 hr.
The time-dependent distribution of glucose-6- 
phosphatase in the cortical 'ML' fraction following 
subfractionation is shown in figure 5.5. The 
activity of this enzyme is found mainly in fractions 
1-10 after 10 min. By 30 min a sharp peak of 
activity of 0.6 umole/min/fraction was observed
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Flgure 5.2-5.6
Distribution pattern of protein and marker enzymes 
from a subfractionated 'ML' fraction of a rat kidney 
cortical homogenate after exposure to 1 °'*Cd, -=,H- 
labelled meta11oth1 onein for between 10 min and 24 
hour. This was undertaken by centrifuging the 'ML' 
fraction for 45 minutes at 9000 rev, in an HS zonal 
rotor.
The protein is given as mg/fraction; phosphatases and 
succinic dehydrogenase as umo1/min/fraction.
Every fraction was assayed but points were simply 
joined up with a smooth line for clarity.
The sucrose density gradient is shown as
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Figure 5.2 Distribution of the protein content in the
cortical "ML" samples, subfractionated by-
rate sedimentation centrifugation.
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Figure 5.3 Distribution of acid phosphatase activity in
the cortical "ML11 samples, subfractionated bv
rate sedimentation centrifugation.
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Figure 5.4 Distribution of 5/nucleotidase activity in
the cortical >fM L fl samples, subfractionated bv
rate sedmentation centrifugation.
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Figure 5.5 Distribution of glucose-6-phosphatase 
- activity in the cortical "ML" samples. 
. subfractionated by rate sedimentation 
centrifugation
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Figure 5.6 Distribution of succinate dehydrogenase 
activity in the cortical "ML" samples, 
subfractionated by rate sedimentation 
centrifugation.
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between fractions 2 to 6 and a broad peak of activity 
of about 0.13 umole/min/fraction between fractions 10 
to 20. The activity in these peaks did not change 
until after 24 hr when about a 2 fold increase was 
observed in both peaks.
Figure 5.6 shows the time-dependent distribution of 
succinate dehydrogenase in the subfractionated 
cortical ML fraction. The 10 min profile shows a 
single peak of activity of 0.3 umol/min/fraction 
between fractions 12 to 24. The activity of this 
enzyme shows a time-related increase, reaching 0.85 
umole/min/fraction by 24 hr.
5.3.6 Distribution of 3H and 1 °3Cd in the luminal and 
basolateral membrane vesicles by percoll 
density gradient centrifugation
The P3 fraction which contains the luminal and 
basolateral membrane vesicles was separated by 
density gradient centrifugation. Figure 5.7 reveals 
a time-dependent distribution of 3H and ' °3Cd in 
membrane vesicles throughout the gradient following 
injection of 1c,3Cd, 3H-label led metal 1 othionein. The 
position of the luminal and basolateral membrane 
vesicles are marked on each profile. These membrane 
vesicles were distinguished by the increase in 
specific activities of the enzymes - Na4' + K'4 ATPase 
with the baso-lateral membrane fraction and alkaline 
phosphatase for luminal (brush border) fraction, as 
described by Boumendi1-Podevin and Podevin (1983).
After 10 min, there is a broad peak of radioactivity 
of both 3H and 1°3Cd between fractions 5 and 15. 
However, the resolution between the luminal and 
basolateral membrane vesicles using 3H or 1 u':v,Cd 
profile was poor. The activity of 3H showed a time- 
dependent decrease from around 4000 cpm/traction
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after 10 min to undetectable levels by 1.5 hr. A 
time-dependent increase in 1 °^Cd activity from about 
6000 cpm/fraction by 10 min to about 11,000 cpm/ 
fraction by 1.5 hr. At any of the time points 
measured, there appeared to be very little difference 
in the 1°9Cd and 3H content of the luminal as 
compared to basolateral membrane vesicles.
5.3.7 Distribution of 3H and 1osCd in the cvtosol 
samples fractionated on Sephadex G75.
Figure 5.8 reveals the time course of 3H and 1 °3Cd 
distribution in the fractionated cytosols.
The major peak of activity at 10 min of both 3H and 
ici^Cd appears in the metallothionein fraction 
(20-30). However, 1 os*Cd is also found in the high 
molecular weight fractions 10-15 (about 60% of that 
found in the metallothionein fraction). There is 
also a small proportion of the 3H found in the high 
molecular weight fraction and as a shoulder in 
fractions 30-35 of molcular weight slightly lower 
than metallothionein. The 103Cd/3H ratio found in 
the metallothionein peak (fractions 20-30) of the 
cytosol fraction after 10 min was 2.2. This ratio is 
the same as the 103Cd/3H ratio of the cadmium 
metallothionein intravenously injected into the rats.
By 30 min, the 1°3Cd in the metallothionein* peak 
showed about a 4 fold increase to 1550 cpm/fraction. 
The 1°3Cd activity also increased about 3 fold to 
7200 cpm/fraction in the high molecular weight peak. 
After 1.5 hr, the 1°3Cd activity decreased in the 
metallothionein fraction but increased slightly in 
the high molecular weight fraction. However by 24 hr 
the lo3Cd activity had decreased in the high 
molecular weight peak but increased in the 
metallothionein peak.
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Figure 5.7 Distribution of 3 H and los*Cd In luminal
and basolateral membrane vesicles bv 
percoll density gradient centrifugation
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Figure 5.8 Distribution of 3H and 109Cd in the cvtosol 
samples, fractionated bv Sephadex G-7 5 
chromatography.
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From 30 min the 3H profile revealed an increase in a 
fraction of molecular weight, slightly lower than 
metallothionein with time, until by 24 hr the 3H 
radioactivity in the cytosol was undetectable. The 3H 
radioactivity of this low molecular weight fraction 
probably represents breakdown products of 
metallothionein catabolism. Thus even as early as 30 
min, metallothionein breakdown products are evident in 
the cytosol fraction. The exact origin of these 
breakdown products is not known but it is believed to 
be the lysosomes. However, presently we have no data 
on the catabolism of metallothionein in the lysosomes.
5. 4 Discussion
5.4.1 Distribution of nosiCd.3H labelled
metallothionein between the renal cortex and 
plasma with time
From the results shown in figure 5.1, 1 °‘3Cd,3H labelled
metallothionein uptake into the kidney cortex as 
assessed by the activity of each radiolabel is a very 
rapid process. The maximum levels of 1 °-*Cd and 3H were 
achieved only 10 min after the intravenous injection of 
the radiolabelled protein. Levels of 3H decreased 
after this time point, while the 1°9Cd levels were more 
or less maintained for the 24 hr period. It was 
surprising that only 26% of 3H and 1 °'3Cd were found in 
the renal cortex after 10 min. However, Cherian and 
Shaikh (1975), using similar intravenous doses of 
cadmium (as metallothionein) reported 48% of total 
injected cadmium was found in the kidney. This is 
equivalent to about 25% in the .renal cortex, and is 
similar to the values obtained in the present study.
The level of 3H radioactivity was estimated to be 
equivalent to 0.18 mg of metallothionein binding a 
maximum of about 21 ug of cadmium. Thus the 
concentration of cadmium in the renal cortex is about 5
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ug/Cd^/g (approximat ing to 7.5 ug/Cd'-+/g for the whole 
kidney). This value is approaching the calculated 
critical concentration for cadmium (10 ug/g whole 
kidney) causing renal dysfunction following a single 
intravenous injection of cadmium-meta1lothionein 
(Maitani et a 1. 1986).
Renal dysfunction may be one explanation as to the 
lower than expected cadmium content of the kidneys 
giving an increase in cadmium content of the urine. 
Unfortunately urine 1°9Cd and 3H radioactivity were not 
monitored. However, Cherian and Shaikh (1975), have 
shown that between 35% and 42% of intravenously 
injected [ 3:2S3 or C 1 ^ Cl from metallothionein was found 
in the urine by 3 hours using doses of between 0.5 and
4.0 mg of protein. Most of this radioactivity was 
associated with metallothionein. These workers also 
found that between 23% and 32% of the injected 103Cd 
from metallothionein was found in the urine at doses of 
between 0.37 and 2.5 mg of the protein. All of the 
1°9Cd was associated with metallothionein. This does 
suggest the onset of proximal tubule dysfunction, as the 
exogenous protein "leaks out" following its uptake by 
the kidney. Some metallothionein may also pass 
directly to the urine following glomerular filtration 
particularly if the renal uptake of this protein is a 
saturable process. Selenke and Foulkes (1981) have 
located two distinct binding sites for cadmium 
metallothionein on the luminal membrane by studies 
using brush border membranes in vitro. It is possible 
that these binding sites in vivo may become saturated 
following the intravenous administration of a large ex 
vivo bolus of cadmium-metallothionein leading to 
increased urinary concentrations of the protein.
A further explanation as to the lower than expected 
' °'3Cd and 3H in the renal, cortex may be due to 
erythrocyte uptake or binding of metallothionein 
whilst in the blood. Certainly from in vitro studies
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using oxygentated perfusion medium, it may be seen that 
approximately one third of the 1°3Cd and 3H is 
associated with the erythrocyte fraction of the 
perfusion medium (section 4.3, Chapter 4).
Metallothionein may also exist in the plasma as a 
polymer as well as a monomer. From the results of 
Chapter 4 (section 4.3, figure 4.13), it would appear 
that metallothionein may polymerise when in the 
perfusion medium. However, the ratio of 103Cd/3H in 
the intravenously injec-ted metallothionein (2.2) was 
similar to the 10sCd/3H ratio found in the renal cortex 
and plasma at 10 min. This does suggest that the 3H 
label does not dissociate from the metallothionein 
molecule in the plasma and renal cortex at this time. 
From fractionation studies of metallothionein in the 
oxygenated perfusion medium in vitro (section 4,3, 
Chapter 4), it would appear that the 3H-label is not 
labile for up to 3 hr. Cherian et al (1983) report 
that when intravenously injected, the cadmium bound to 
polymerised metallothionein is cleared more slowly from 
the plasma then the monomeric form and higher 
concentrations of the former accumulate.in the liver 
and spleen and lower concentrations in the kidney.
This further establishes the complexicity of interorgan 
relationships with circulating metallothionein, and may 
account for why only 37% and 33% of total respective 3H 
and 1osCd activities are in either the renal cortex or 
plasma.
The decrease in 3H observed in the renal cortex with 
time (table 5.1) reveals a rapid rate of degradation of 
the tritiated metallothionein. The 3H content 
decreased by about 60% between 10 and 30 min after 
injection. In comparison, the half life of endogenous 
renal metallothionein is far slower (2 days) (Webb, 
1979), than the N-succinimidy1 C2,3-H3] propionate 
injected metallothionein in this study. Using 
radiolabelled metallothionein revealed a faster rate of
325
degradation than the integral 1 ^ C, 3SS, or 3H labelled 
cysteine moieties used to label metallothionein 
(Cherian and Shaikh, 1975; Webb and Etienne 1977; Cain 
and Holt, 1983). This may illustrate a difference in 
the rate of degradation due to either the position of 
the radiolabel of the protein, or to different chemical 
radio-isotopes used and not necessarily the rate of 
metallothionein degradation per se. The 
reincorporat ion of 3aiS (following the degradation of 
the labelled metallothionein) into cysteine or other 
sulphur containing aminoacids, (particularly when naive 
renal metallothionein is induced following cadmium 
exposure) would give rise to a different biological 
half life to 3H which may not necessarily be 
incorporated into the same metabolic pathway.
Elimination of 3H radioactivity from the renal cortex 
into the urine and blood may occur. Evidence that 3H 
may be released into the plasma is given by the changes 
in 1 °'3Cd/3H radioactivity ratio from 2.2 to less than
1.0 and the increase in 10-^ Cd/3H in the renal cortex to
4.1 after 30 min. Cherian and Shaikh (1975) showed 
that small amounts of 3BS and 1AC radioactivity from 
metallothionein were present as low molecular weight 
constituents of fractionated urine samples from rats 
intravenously injected with metallothionein. This 
indicates that the degradation products of 10'T'Cd,3H 
labelled metallothoinein are also excreted in the 
urine.
Cadmium uptake into the renal cortex appears to be 
extremely rapid. The maximum radioactivity, (just as 
for 3H) is attained after 10 min but this remains 
constant up to 24 hr. A similar although not such an 
avid renal uptake of cadmium following intravenous 
injection of cadmium-meta1lothionein has also been 
reported by Cain and Holt (1983) - attainment of 
maximum cadmium concentrations occured at 4 hr although 
near maximum levels were found after 1 hr. Such
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differences in the kinetics of renal uptake may be due 
to the different doses of cadmium used (0.8 mg/ animal 
by Cain and Holt, about 0. 1 mg/animal in the present 
study) or differences in the extent of polymerisation 
of metallothionein, between the two studies, which has 
been reported to affect the time profile of renal 
uptake of this protein and therefore cadmium. 
Nevertheless in this study, as also shown by Cain and 
Holt (1983), cadmium unlike tritium is retained in the 
kidney cortex for up to 24 hr following injection 
(Table 5.1).
The retention of cadmium and degradation of 
metallothionein following uptake in the renal cortex is 
discussed further in the following section (5.4.2, 
5.4.4).
5.4.2 Time course of 1c,'aCd.3H labelled metallothionein 
in the classical fraction of the renal cortex
From the results in table 5.2, it appears that 3H and 
1°9Cd are found mainly in the particulate fraction of 
the renal cortex, 10 min after injection of 1°9Cd, 3H 
labelled metallothionein. About 63% and 61% of the 
total homogenate 3H and 1 °’aCd content respectively was 
found in this fraction after 10 min. Of this 11.7% and 
10.3% of the total homogenate 3H and 1°3Cd content 
respectively, is found in the P3 fraction (containing 
membrane vesicles). This suggests that an active 
receptor for metallothionein is located in the 
membraneous fraction. The presence of two distinct 
binding sites for cadmium-meta 11othionein on the 
luminal surface of brush border membranes in vi tro 
provide evidence for the suggested receptor sites. 
(Selenke and Foules, 1981). However, it is possible 
that labile cadmium released from the exogenous 
metallothionein, binds non-specifical1y to all 
subcellular particulates, especially those rich in 
thiol groups.
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By 10 min the supernatant fraction contains 22.7% and 
26.6% of the total 3H and 103Cd activity injected 
respectively. The 103Cd/3H ratio in each of the 
particulate and supernatant fractions are similar to 
the 103Cd/3H ratio of injected metallothionein (2.2). 
These results suggest that the metallothionein is 
primarily taken up by endocytosis following membranous 
binding, and may remain intact up to 10 min post 
injection. However most of the 22.7% of 3H in the 
cytosol by this time is located as metallothionein (as 
the 1 os,Cd and 3H peaks coincide exactly with the 
position expected for metallothionein in this gel 
filtration profile - see figure 5.8). This suggests 
either that the protein is transported intact across 
the plasma membrane or this result is artefactual, and 
caused by disruption of endocytic vesicles during 
homogenisation and the release of endosomal contents 
into the “cytosol" fraction.
Of the total particulate 3H and 1 °‘3Cd after 10 min, 
some 25.7 and 26.5% of the respective isotopes are 
found in the 'ML' fraction. The remaining radio­
activity is evenly spread between the other particulate 
fractions. Acid phosphatase activity (table 5.3) is 
high in the 'N' fraction after 10 min when compared to 
the control group, but it is not clear if this might 
indicate an increase in proportion of large secondary 
lysosomes. Although with time, there is a loss of 3H 
from the cortex* is notable that at 1.5 hr, the 
'ML' fraction contains nearly 80% of total homogenate 
3H, These observations, together with the distinct peak 
of 3H in the large lysosomes (figure 5.1) at 1.5 hr, 
strongly suggest that the metallothionein which reaches 
the ‘lysosome compartment' is degraded relatively 
slowly. In contrast, the initial metallothionein 
degradation which begins in the endosome compartment 
appears to be extremely rapid, with the low molecular 
weight 3H components at 30 min indicating almost 
complete degradation of the thionein molecule (figure
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5.8)- The amino acids and^peptides formed from this 
degradation will readily pass out of the kidney and 
enter the circulation, leading to undetectable levels 
of 3H in the cortex by 24 hr. An increase in 3H (from 
3H labelled metallothionein) in the particulate 
fraction up to 2 hr following intravenous injection of 
the labelled protein has also been reported by Cain and 
Holt (1983). This was followed by a decrease in 3H in 
the particulate fraction up to 48 hr.
Considerable amounts of the 1osCd which are associated 
with the particulate fraction are transferred to the 
supernatant fraction, after 30 min, reaching 83% at 24 
hr. This transfer may occur via 1ysosoma1/endocytic 
vesicle 'leakage' following degradation of the 
tritiated metallothionein or upon acidification of the 
contents of a vesicle by adjoining lysosomes. Cain and 
Holt (1983) presented evidence that metallothionein is 
degraded in the particulate fraction such that no 3H or 
1c>sCd exists by 4 hr. However, the mechanism of 
transfer of the 1°3Cd from the particulate to the 
supernatant fraction is still unknown and possibly 
unique.
5. 4. 3 Time course distribution of the 3H and 1osCd in 
the subfractionated rat kidney cortex 'ML' 
f rac t i on
From the distribution patterns presented in figure 5.1, 
it is clear that 10 min after injection, both the 3H 
and 1°3Cd are mainly associated with the slow 
sedimentary peak which contains small lysosomes 
(determined by the acid phosphatase activity figure
5.2) and endocytic membraneous vesicles (determined by 
the 5'-nucleotidase activity - figure 5.3) as well as 
mi tochrondria (determined by the succinate 
dehydrogenase activity is figure 5.5). There appears 
to be movement of 3H activity from small to large 
lysosomes up to 1.5 hr (figure 5.1 and 5.2). This may
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represent the transfer of metallothionein from small 
lysosomes, which are precursors to large lysosomes.
1 °-,Cd is not a suitable marker for studying the 
handling of metallothionein in lysosomes because of it 
is a labile moiety of this protein.
The presence of 5'-nuc1eotidase activity in the early 
and central regions of the subfractionation (figure
5.3) also suggests that the losCd and 3H are also 
associated with endocytic membranous vesicles. There 
appears to be a major loss of large endocytic vesicles 
after 10 min in the 'ML* fraction, without any increase 
in the 5'-nuc1eotidase activity of the other region of 
the ‘ML' fraction. However, 5'-nuc1eotidase cannot be 
used as a specific indicator of endocytic vesicles and 
so no conclusions can be made from this result.
The loss of 103Cd from the lysosomes with time is not 
followed by an increase in radioactivity in other 
organelles, but an increase in that of the supernatant 
fraction. It appears, therefore, that a proportion of 
cadmium is transfered from the lysosomes (and other 
particulates) to the cytosol - as discussed elsewhere 
section 5.4.2. However the loss with time of 3H from 
the lysosomes is not followed by any increase in 
radioactivity in the other organelles or cytosol, and 
at 1.5 hr, the lysosomal fraction contains most of the 
remaining 3H (80%). It follows that the degradation 
products of metallothionein exit from the renal cortex 
and possibly pass into circulation.
5.4.4 Time course distribution of 3H and 103Cd.in the 
luminal and basolateral membrane vesicles
These distribution profiles (Figure 5.7) reveal that 
metallothionein (as measured by 3H) appears to be 
associated with both luminal and basolateral membranes, 
and that the concentration of protein associated with 
these membranes decreases in a time-dependent manner.
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The 1osCd radioactivity reveals an increase in 
concentration associated with the basolateral and 
luminal membranes as compared to the remainder of the 
P3 fraction.
The results of the P3 subfractionation profiles suggest 
a movement of cadmium from denser vesicles such as 
small lysosomes to the luminal and basolateral membrane 
vesicles and thus a time related movement of cadmium 
from the renal cortical cell to the lumen or capillary. 
However, it should be noted that the cadmium associated 
with these vesicles is less than 10% of the total 
homogenate 10S*Cd. Thus, if this movement represents a 
possible route of elimination of 1‘•>‘3Cd from the tubular 
cells, it is likely to be a small proportion of total 
cortical Cd content.
5. 4. 5 Time course distribution of 3H and 1°9Cd in the 
cvtoso1
The fraction patterns shown in figure 5.8 reveal that 
after 10 min most of the 1 os,Cd and 3H which was present 
in the cytosol was associated with metallothionein.
The 10-^Cd/3H ratio calculated in the metallothionein 
peak at this time was the same as that calculated for 
the intravenously injected 10S*Cd,3H metallothionein.
This suggests that the 'intact' radio1abelled 
metallothionein has entered the cytosol. Whether this 
has occurred by a direct passage of metallothionein 
across the membrane or as a methological artifact 
brought out by the lysis of endocytotic vesicles upon 
their isolation, is not known. Evidence suggesting the 
transfer of metallothionein across membranes in the 
liver has been presented and discussed earlier in this 
thesis (section 4.4.2 and 4.4.3, Chapter 4). The 
presence of renal epithelial 'receptor' binding sites 
for metallothionein have also been demonstrated.in 
vitro (Selenke and Foulkes, 1981). This further 
supports the idea that the intravenously injected
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metallothionein may cross the renal tubular epithelial 
membranes in a similar manner to the liver.
In addition to the presence of 10~’Cd,3H labelled 
metallothionein, there is evidence that some 
polymerised metallothionein is present in the cytosol 
after 10 min. The decrease in 3H of the 
metallothionein peak and increase in 3H of the low 
molecular weight peak with time from 30 min, and the 
complete absence of 3H at 24 hr, indicates the 
appearance of metallothionein degradation products in 
the cytosol and eventual loss of these products 
(aminoacids and peptides) from the renal cortex.
Between 10 and 30 min, 1 °3Cd in the metallothionein 
region increased but then decreased by 1.5 hr.
However, by 24 hr, los,Cd associated with the 
metallothionein region increased. This indicates that 
upon the degradation of 3H labelled metallothionein, 
the 10'3Cd released from this exogenous protein may bind 
the 'intact' exogenous metallothionein (by a 
replacement of zinc by 103Cd) and the endogenous 
metallothionein which exists in the kidney cytosol. 
However, possibly by 1.5 hr, available binding sites on 
the existing metallothionein molecules have been 
saturated accounting for an increasing proportion of 
10-’Cd bound to high molecular weight proteins occuring 
by 30 min (an observation also reported by Cain and 
Holt (1983) who undertook a similar experiment).
Endogenous renal metallothionein is induced about 4 hr 
after cadmium adminisration thus by 24 hr, cadmium 
would also bind the naive metallothionein that had been 
induced within the previous 20 hr. This would account 
for an increase in the proportion of 10,5,Cd present in 
the metallothionein region of a fractionation profile 
of the renal cortical cytosol.
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5.5 Summary
It appears that between 30 and 40% of the intravenously 
injected 10‘aCd,3H labelled metal lothionein was taken up 
by the renal cortex. The uptake of this protein is 
extremely fast (within about 10 min) with the same 
proportions of 1 °3Cd at 10 min and 24 hr. The 
remainder of the exogenous metallothionein at 10 min 
may have been distributed between the urine and liver, 
particularly if the metallothionein was polymerised. 
Calculations of the 1c>3Cd/3H ratio also showed that the 
10-*Cd,3H labelled metal lothionein was taken up intact. 
The half-life of the injected metallothionein was much 
shorter (between 10-30 min) than the endogenous renal 
metallothionein (about 2 days) and upon intra-lysosoma1 
degradation of the injected protein it appears that 
cadmium leaves the lysosomes and redistributes to 
endogenous metallothioneins in the cytosol.
The majority of the 3H labelled metallothionein taken 
up by the kidney after 10 min appeared to be 'trapped* 
in the endosomal compartment, following which it was 
degraded so that most of tritiated degradation products 
had left the renal cortex. The intravenously injected 
metallothionein molecule also appeared to be 
transported intact across the plasma membrane, as 
concluded by the appearance of 10S*Cd,'3H labelled 
metallothionein in the cytosol after 10 min. However, 
whether this protein would cross the membrane barrier 
is not known; but possible suggestions are discussed.
CHAPTER 6
Absorption, retention and excretion of cadmium 
following dietary exposure of cadmium contaminated 
'brown crabmeat* in humans - role of metallothionein
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6. 1 IntroductIon
Food and food stuffs are the principal source of 
environmental cadmium for most people (except 
smokers). The daily intake from food is about 20-50 
pg/day but this may vary considerably because of 
variations in local cadmium concentrations and in 
local dietary habits (Fleischer et al. 1974; Fox,
1976; HMSO, 1983; Bernard and Lauwerys, 1984).
Rice from cadmium polluted areas of Japan, where the 
Itai-Itai disease is common, contains an average 
2.5 pg/g whilst the mean content for rice from 
unpolluted areas is 0.075 pg/g. The daily intake may 
be significantly elevated in humans who habitually 
eat some types of mushrooms which may contain 50
pg/g, or leafy vegetables such as lettuce and
spinach, which readily accumulate cadmum from soil.
Whilst the UK national average dietary intake of
cadmium is 140 pg/wk the intake in polluted regions, 
such as Shipham, is 200 pg/wk. A small proportion of 
the Shipham inhabitants, however, had intakes in 
excess of 400-500 pg/wk, which is the recommended 
tolerable level for man (WHO, 1972).
A high percentage of cadmium in certain foodstuffs is 
protein bound. That in mammalian liver and kidney 
(Kagi and Nordberg 1979) and crab hepatopancreas, 
(brown crabmeat) (Overnall and Trewhella 1979) is 
metallothionein-bound, whilst in oysters (Nordberg et_ 
al. 1986), mussels (Noel-Lambot, 1976) and- whelk
(Dohi et a1. 1986) it is bound to a ' metallothionein-
like' protein.
Gastrointestinal absorbtion of dietary cadmium in 
experimental animals is now widely accepted as being 
in the region of 3-5% (Bremner, 1979). However, this
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can be influenced by many factors* for example, age 
Cas more cadmium is absorbed in new born animals 
(Sasse and Farboe, 1977; Engstromn and Nordberg, 
1979)1; dietary factors such as iron deficiency 
(Valberg et al. 1976), calcium status (Koo et a 1.
1978; Washko and Cousins, 1977) and fibre content 
(Kiyozumi et al. 1982). In addition the physical
form of cadmium may affect its absorption; Maitani et. 
al. (1984) showed that less cadmium was absorbed in
mice after acute oral administration of cadmium 
metallothionein than cadmium chloride when 
administered in saline. However, in these animals 
gastro-intestinal absorption of cadmium from rat 
liver homogenate was higher when in the form of 
cadmi um-metal lothionein than as CdCl^. In contrast, 
other acute oral studies (Cherian et al. 1978 have
shown that absorption of cadmium from the gastro­
intestinal tract in mice is not dependent on the 
chemical form cadmium metallothionein or cadmium 
chloride. Subchronic and chronic oral studies 
(Muller et a1. 1986; Cherian, 1983) also suggest that
the chemical form of cadmium does not seem to 
significantly affect its absorption.
The tissue distribution of cadmium after the 
oral/dietary administration of cadmium 
metallothionein is very different from that seen 
following the administration of cadmium as chloride 
or acetate after acute (Maitani et al. 1984)
subchronic (Muller et al. 1986) or chronic (Cherian,
1983) dosing. Cherian (1983) reported that 74% of 
the cadmium absorbed is present in the liver and 16% 
in the kidney after chronic dietary administration of 
cadmium chloride, but with cadmium metallothionein 
there is an increased deposition in the kidney (70%) 
and considerably less in the liver (18%). Muller 
et a 1. (1986) found a similar tissue distribution
pattern in rats following ingestion of:cadmium
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acetate or cadmium metallothionein. However cadmium 
concentrations in the smal1•intestine were reduced 
after cadmium administration of. the latter compared 
to the former chemical form. These workers also 
reported a marginally higher, but not significant, 
cadmium deposition in the kidneys with cadmium- 
metallothionein than with cadmium acetate. Cadmium 
in the form of metal 1othionein thus appears to be 
preferentia11y targeted to the kidney and may 
therefore, represent a particular hazard to this 
organ.
From a number of reports (Nordberg, 1976; Shaikh and 
Smith, 1980) it appears that gast.ro- intest ina 1 
absorption of cadmium in man is similar, to that found 
in experimental animals. This has recently been more 
accurately quantified for cadmium from brown 
crabmeat, and found to be 2.7% of the ingested dose 
(Newton et al. 1984). This study also provided
useful estimates of the excretion of cadmium in urine 
(0.01% of body content/day) which was consistent with 
other reports (Ellis et a 1. 1979). Although much
information on dietary cadmium is available, eg. in 
Japan - from Itai-Itai sufferers, and in Shipman (see 
Chapter 1, section 1.9.9)., these data are not 
strictly relevant since the chemical form or dose did 
not represent 'normal range' dietary intake. Indeed, 
very few chronic studies with elevated normal dietary 
cadmium have been carried out under strictly 
controlled conditions. Cadmium intake was recently 
investigated in a group of New Zealanders enjoying a 
high oyster consumption (Sharma et a I. 1983).
Although their intake was high (30-300 fig Cd'^'/day) 
the blood and urine cadmium levels were not. greatly 
elevated, cigarette smoking did significantly elevate 
blood cadmium in this study. However, the lack of 
correlation between cadmium intake (via oysters) and 
blood or urinary cadmium concentrations-' in certain
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groups within this study illustrates well the problem 
of employing blood and urinary cadmium as indices of 
body and tissue burden of this toxic metal.
Results from studies on experimental animals and man 
suggest that urinary metallothionein is a better 
indicator of the tissue (especially kidney) burden of 
cadmium (Chang et a1. 1980; Tohyama et a 1. 1981) than
blood or urinary cadmium. It has also been reported 
that urinary meta11othionein correlates well with 
blood cadmium concentrations (Chang et a 1. 1980) and
the latter measurement is regarded as an index of 
recent exposure. Thus, urinary metallothionein may be 
a good indicator of recent exposure to cadmium. 
However, as reported by Roels et a1. (1983), under
moderate chronic exposure to cadmium the fraction of 
cadmium in the urine which is directly influenced by 
recent exposure (blood cadmium) is small in
comparison with that influenced by body burden. As
most of the cadmium in urine is believed to be
associated with meta11othionein in man when exposed
to cadmium (Mitane et a1 . 1986), it appears that
urinary meta11othionein is probably a good indicator 
of recent cadmium exposure only after acute or 
subacute administration prior to the accumulation of 
high tissue cadmium concentrations.
The objectives of the study described in this chapter 
were to establish whether urinary and blood cadmium 
and meta11othionein levels in man increased in 
response to dietary intake of" brown crabmeat 
containing elevated levels of cadmium. Brbwn. 
crabmeat was chosen because the gastrointestinal 
absorption of cadmium from this source is now fairly 
accurately quantified and also because this material 
from specif ic regions of the UK (eg. Lihet lends.-’ 
contains reliably high levels of cadmium. With 
carefully controlled intake of cadmium and the
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established rate of absorption it was also intended 
to produce an accurate balance sheet and from this 
derive elimination and retention values. However, 
attempts to analyse urine samples for meta11othionein 
were thwarted by unforseen methodological problems.
6. 2 Exper i men t a1
6.2.1 Mater ials
Brown crabmeat Chepatopancreas) was supplied in 
frozen blocks directly from the Shetland Fisheries 
(supply arranged via Dr G Topping, DAFS Marine Lab, 
Aberdeen). Rectangular microwave oven dishes were 
obtained from Village Mill, New Barnet, Herts,
Polythylene tubes for blood plasma storage were 
purchased from Nielsen and Griffiths, Sussex, U.K. 
and the 2.5 litre urine bottles used for urine 
storage were purchased from Azlon, London, U.K. The 
LP^ , tubes used in the preparation of plasma samples 
for cadmium analysis were supplied by Luckham Ltd. , 
Burgess Hill. Aristar nitric acid (70%) and the 
cadmium nitrate solution (in 1 mol/1 HC1) was 
purchased from B.D.H. Chemicals, Ltd., Poole, Dorset, 
U.K. Creatinine, hydrochloric acid, sodium 
hydroxide, sodium chloride and picric acid solution 
used in the measurement of creatinine were also 
obtained from B.D.H. Chemicals Ltd.
N-succinimidy1 3-(4 hydroxypheny1) propionate (NSHPP) 
was obtained from Sigma Chemical Co., Pocle, Dorset, 
U.K. unless otherwise stated Sephadex and DEAE 
Sepharose CL 6B were obtained from Pharmacia (G.B.)• 
Ltd; YM5 and YM10 Diaflo ultrafiltration membranes 
were obtained from Amicon Corp. , Stonehou.se, Glos. , 
U.K. All materials used in the radioimmunoassay of
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metallothionein are recorded in section 2.2.1. The 
Dowex mixed bed self indicating resin AG501-810 was 
obtained from BIO-RAD Labs, Richmond, California,
U. S. A.
6.2.2 Experimental Design
A) Preparation of brown crabmeat
Brown crabmeat Chepatopancreas) , was thawed out and
immediately homogenised in an industrial food mixer. 
The blended crabmeat was prepared in 100 g portions 
and kept at 4°C. The portions were placed in 
rectangular microwave oven dishes and sealed with 
cling film. Each 100 g portion was "microwaved" for 
30 seconds and cooled to 4°C before being frozen at - 
80°C. Samples were taken before and after 
"microwaving" for microbial analysis (Public Health 
Labs., St. Lukes Hospital, Guildford) and for 
measurement of cadmium content.
B) Feeding Study
i) Volunteers
The protocol of the feeding study outlined below 
(table 6.1) was approved by the University of Surrey 
Ethical Committee. The 12 volunteers (9 male, 3 
female) consisting of members of staff and students 
who were non-smokers, were given details of the study 
and subsequently provided signed statements 
consenting to take part.
ii) Feeding protocol
Each volunteer consumed 100 g of brown crabmeat per. 
week for 12 weeks. The 'majority of the. volunteers 
ate 50 g of crabmeat containing 5.5 ug cadmlum/^g
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crabmeat in white bread sandwiches twice weekly 
(usually Tuesdays and Fridays).
iii) Sample collection
Urine (volume noted) and blood samples (10 ml) were 
collected twice before the start of the feeding 
period, to provide control values of cadmium.
Samples were collected at the end of weeks 1, 2, 4,
6, 8, 10 and 12 after starting the crabmeat diet and
also 6 and 16 weeks after finishing the diet 
(corresponding to weeks 18 and 28 of the study). The 
volunteers provided their samples on a Monday morning 
(except on weeks 4 and 6), having collected the 
urines during the preceding 24 hr. The exact dates 
of sample collection, with some variations in the 1 
and 2 week intervals caused by holidays are shown in 
the timetable (table 6.1).
C) Sample Preparation
Of the 10 ml of blood taken from each subject, 1 ml 
was stored in blood tubes containing EDTA at -20°C 
and the remaining 9 ml was placed into heparinized 
tubes and centrifuged (2800 rpm, 5 min). The plasma 
was removed and stored at -20°C in polyethylene tubes 
previously washed in 10% nitric acid rinsed in 
reverse osmosis/deionised (RO/DI) water and dried in 
an oven at 80*C. The 24 hr urine collection from 
each subject was made in acid washed, RO/DI water 
rinsed 2.5 1 urine bottles. After noting the volume, 
250 ml was retained and stored at -20'C in 
polyethylene bottles for further measurements. 
Aliquots (5 ml) of each urine were also taken for 
cadmium and creatinine analysis, and stored at. -2’0 ‘C 
on polyethylene tubes, as used for plasma storage.
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Table 6.1 Timetable of crabmeat feeding to and sample 
collection from the human volunteers
Month Dates for Blood Dates of the Week No
and Urine crab meat (of Study)
Collection feeding
November 13th Mon Control
19th Mon Tue 20th Nov Samp1es
26th Mon ' 1
December 3rd Mon 2
19th Thur 4
J anuary 2nd Wed 6
14th Mon 8
28 th Mon \f 10
February 11th Mon Fri 8th Feb 12
March 25th Mon 18
J une 3rd Mon 28
6.2.3 Analytical methods
A) Measurement of cadmium in whole blood and
p1asma
i ) Appara t us
The analyses were performed on a Pye-Unicsm SPG 
atomic absorbtion spectrophotometer, equipped with a 
graphite furnace, autosampler and background 
corrector. A cadmium hollow cathode lamp was used, 
operating at a lamp current of 4.5 mA. The 
measurement wavelength was 228.8 nm, with a band 
width of 0.5 nm. Uncoated graphite tubes were used.
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i i) Reagents
The water used was reverse osmosis/deionised (RO/DI). 
Standard cadmium solutions were made from a 
commercial 1.00 g/litre cadmium nitrate solution in 1 
M HC1. Standard solutions consisting of 0, 0.25, 0.5
and 1.0 ppm Cd::5:H" were made up in RO/DI water.- All 
solutions were prepared in polyethylene bottles, 
previously nitric acid-washed and RO/DI water-rinsed. 
Working standards of 0, 0.5, 1.0 and 2.0
pg/1 (ppb) Cd-""*" were made f rom the addition of 10 ml of 
each respective standard solutions in 5 ml of pooled 
human plasma/whole blood. These working standards 
were stored at -20°C in 0.5 ml aliquots.
iii) Procedure
To 250 pi of plasma was added 750 pi of 5% nitric 
acid into acid-washed, RO/DI watei— rinsed LP4 tubes. 
Immediately the tubes were gently but thoroughly 
mixed on a Whirlimixer, and centrifuged at 2000 rpm 
for 5 min. The clear supernatant was transferred 
into acid-washed, RO/DI water-rinsed sample cups (2 x 
250 pi).
A standard temperature programme was used as shown in 
table 6.2. The integration time was 2.0 seconds and 
measurements were made in the peak height mode. A 
100 ms signal damping and deuterium background 
correction were implemented. The injection volume 
was 10 pi. Duplicate measurements were made on each• 
sample. The same procedure was used for the analysis 
of cadmium in whole blood.
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Table 6.2 Standard temperature programme for the 
measurement of cadmium In whole 
blood/plasma
Phase Temp
CC)
Time
(secs)
Ramp Other
cond i t i ons*
Dry 1 90 o o 7
Dry 2 120 30. 0 9
Ash 400 30. 0 7
Atomize 1500 3.0 0 TC, PT, RC, AZ
Clean 2700 3. 0 1
* TC - Temperature controlled programme 
PT - Peak timer 
RC - Recorder 
AZ - Autozero
B) Measurement of Cadmium in Urine
i) Apparatus and Reagents
The apparatus and reagents are described in section 
6.2.3. A).
The working standards of 0, 0.5, 10.0, and 2.0 pg/1
(ppb) Cd22"*" in 55 nitric acid were made from a 1.0 
mg/1 (ppm) Cd22*" standard (also in 5% nitric acid) on 
the day of analysis. All solutions were made up in 
polyethylene bottles previously washed with 10% 
nitric acid and rinsed in RO/DI water.
ii) Procedure
250 pi of each urine sample was added to the 
autosampler sample cups containing 250 pi of 5% 
nitric acid with additions of 0, 0.5, 1.0 and
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Table 6.3 Standard temperature programme for the 
measurement of cadmium In urine
Phase Temp Time Ramp Other
CC) (secs) condi t ions*
Dry 1 105 20. 0 7
Dry 2 150 10. 0 9
Ash 400 30. 0 7
Atomize 1200 2. 0 0 TC, PT, RC, AZ
Clean 2700 3..0 1
* TC, PT, RC, AZ - See footnote to Table 2
The integrat ion time was 20 seconds , and measurements
were made in the peak height mode. A 100ms signal
damping and deuterium background correction were 
implemented. The injection volume was lOpl, and 
duplicate measurements were made on each sample.
2,0 ug/1 Cd2"* . As described in the Results (section 
6.3.3) it was necessary to employ the method of 
standard additions for analysing cadmium in urine. 
Duplicate measurements were made on each urine 
sample. The sample cups had been previously washed 
in 10% nitric acid and rinsed in RO/DI water. The 
temperature programme which was found most suitable 
for urine samples is shown in table 6.3. The 
integration time was 20 seconds, and measurements 
were made in the peak height mode. A 100 ms signal 
damping and deuterium background correction were 
implemented. The injection volume was 10' pi and 
duplicate measurements were made on each sample.
• C) Measurement of creatinine in the urine
Creatinine was measured with an autoanalyser system 
using the Jaffe reaction (Bartels and B'ohmer, 1971).
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i > Reagents
Stock creatinine solution of 20 mM/1 was made in 0.1 
M HC1, and used to prepare the working standards - 
100, 200, 400, 600, 800 and 1000 mol/1 in 0.02 M HC1.
ii) Procedure
Urine samples were diluted 1:40 with RO/DI water and 
placed in autoanalyser cups for subsequent creatinine 
analyses.
D) Measurement of meta11othionein in urine— and.
p 1 a s m a
i) Procedure
The measurement of metallothionein was carried out 
using the radioimmunoassay procedure described in 
section 2.2.4. Plasma samples (100 ul) or urine 
samples (100 ul) were concentrated as described in 
section 6.2.2 D) ii) and then were used as test 
samples.
i i) Validation of urine and plasma concentration 
and of the metallothionein assay in the 
concentrates
The reported values for metallothionein in the urine 
and plasma of unexposed persons are <0.2 ng/ml and 
<2.0 ng/ml respectively (Chang et a1. 1980). As the
lower limit of our radioimmunoassay is 20 ng/ml, 
samples of urine were concentrated in order to bring 
levels into the detection range of our assay.
Before attempting to concentrate the urine samples, 
they were firstly desalted on a mixed bed self- 
indicating resin - AG - 501 x 810 (1: 1 mixture of
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Dowex 1-XB and 50W-XB). Desalted urine samples were 
then lyophylized and redissolved in l/20th of the 
volume in order to achieve a concentration required 
for the detection limits of our meta11othionein RIA.
6.3 Results
6.3.1 Cadmium and microbiologica1 analysis of the 
brown crabmeat
To ensure representative sampling of the crabmeat for 
cadmium analysis, two samples were taken immediately 
after thorough blending. The two samples were 
carefully weighed and digested in the nitric/ 
perchloric acid mixture. Each sample was analysed in 
duplicate by flame atomic absorbtion spectro­
photometry. The cadmium content of both samples was 
found to be 6.6 ppm (6.5 pg/g).
The crabmeat samples before and after microwaving 
were kindly analysed by Professor Cartwright's group 
at the Public Health Labs, and found to contain the 
following total viable counts:
10e/g total viable 
count
8 x lO'Vg total viable 
count
<500/g total viable count ' 
(after thawing out).
It was confirmed that the crabmeat sample after the 
third stage of treatment was satisfactory for human 
consumption.
1. Untreated blended
2. Blended, "microwaved"
3. "Microwaved" again
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6.3.2 Measurement of cadmium in whole blood and 
plasma
Figure 6.1 shows the calibration curve for cadmium 
standards in plasma. The plot is linear between 0 
and 3 pg/1 with a diminution in signal at higher 
concentrations. A similar curve was also obtained 
for cadmium standards in blood. Samples containing 
>3 pg/1 cadmium were diluted and assayed again.
Analytical recovery was assessed by the addition of 
standard concentrations of cadmium to 3 samples of 
human plasma to check the effect of sample matrix on 
cadmium determination. The recovery varied from 
94.0-103.0% with an overall average recovery of 97.3 
± 3.7% (SEM), when 0.5, 1.0 and 2.9 pg/1 of cadmium
were added.
The absolute sensitivity of an e1ectrotherma1 
atomizer is defined as the mass or concentration of 
an element that will give a peak absorbance value of 
0.00426. We found that 0.4 pg of cadmium had an 
absorbance of 0.00426. This expressed in terms of 
concentration is 40 ng/1 for a 10 pi sample. The 
detection limit was 0.2 pg/1 (when calculated using 
the formula 2 x standard deviation x cadmium 
concentration in a sample divided by mean observed 
cadmium concentration in that sample), in blood 
samples low in cadmium (eg. 1.4 pg/1).
The coefficient of variation for 12 samples measured ' 
on two occasions (between batch) was found to be 7% 
at cadmium concentrations of between 0.7 and 
1.65 pg/1. Likewise, the coefficient of variation 
(C.V.) for 7 replicate injections of the same sample 
solution (from the same sample cup) was 0.5%, and for 
7 separate measurements of the same sample (from 
separate sample cups) in the same run was 3.0%.
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Figure 6.1 Standard curve for the analysis of 
cadmium In plasma
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The accuracy of this method was determined by the 
assay of whole blood samples provided by the 
Guildford trace elements QC scheme (Robens Institute, 
University of Surrey, Guildford, U.K.). Samples 42 
and 44 were assayed and found to contain 4.4 and 6.5 
pg cadmium/1 respective1y . The actual values given 
were 4.7 and 6.6 pg/1 respectively.
6.3.3 Measurement of cadmium in the urine
Because of the complex, chemical nature of the urine 
samples, it was necessary to employ the method of 
standard additions. This method assumes that added 
analyte reacts in exactly the same way during 
analysis as analyte present in the sample. The 
urine samples were diluted with 5% nitric acid (1:1) 
which decreased the background absorbtion by about 
60%. Using the method of standard additions, the 
calibrating plot was linear up to 0.2 absorbance 
units (figure 6.2). The detection limit was 0.5 pg/1 
in urine samples containing small amounts of cadmium 
(eg. 1.25 pg/1).
Analytical recovery was assessed by the addition of 
standard concentrations of cadmium to 3 samples of 
human urine to check the effect of sample matrix on 
cadmium determination. The recovery varied from 92.7 
to 112% with an overall recovery average of 100.3 ± 
5.9% when 1.0 pg/1 of cadmium was used. Figure 6.2 
shows the slope of each calibration plot on the 
addition of cadmium to a urine sample taken from 
subject number 10. This shows that the added cadmium 
reacts in the same way during analysis as the analyte 
already in the sample. The slope of the calibration 
plots for the urine samples measured was 24.3 ± 4.7 
absorbance units./ppb Cd-*"'".
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Between-day precision gave a coefficient of variation 
(C.V.) of 8% (figure 6.3.) whilst the within-run 
precision gave a C.V. of 3%. The accuracy of this 
method was determined by the assay of urine samples 
provided by the Guildford trace element Q.C. scheme 
(Robens Institute, University of Surrey, Guildford). 
Samples 43, 51, and 59, were assayed and found to 
contain 0.5, 2.6 and 2.3 pg/1 respectively. The 
respective values given were 0.5, 2.5 and 2.5 pg/1. 
Table 6.4 shows a comparison of the urinary cadmium 
results obtained by this electrothermal atomization 
technique described above with results obtained by a 
plasma source mass spectrometry (kindly performed by 
Dr Gray, Chemistry Department, University of Surrey). 
With the exception of subject 3 (3/12), there was 
good correlation and no systematic differences were 
seen in samples containing <1 pg/1. It is not known 
why the cadmium values measure in subject 3 by the 
two methods were so different.
Table 6.4 Comparison of cadmium concentrations in 
urine determined bv palsma source mass 
spectrometry (1) and e1ectrotherma1 atomic 
absorbtion spectrophotmetrv (2)
Volunteer No 
and Date
CCD1 pg/1 
(1 )
CCdl pg/1 
(2)
2 (3/12)
3 (3/12)
6 (2 / 1)
7 (19/11)
8 (19/11) 
12 (26/11)
2. 28 
0. 72 
2. 33 
0 . 6 
0.. 61 
0. 65
3. IS
4. 90 
3. 36 
0. 7 
0. 64 
0 . 6
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6.3.4. Measurement of metallothionein in urine
Metallothionein was isolated from the livers of rats 
exposed to cadmium by fractionating the heat-treated 
cytosol on Sephadex G75. The metalloprotein-enriched 
region from the G75 fractionation was subjected to 
ion-exchange chromatography. Purified 
metallothionein I was used in the radioimmunoassay 
for the standard curve as well as in the validation 
of the urine concentration procedure (for further 
details see Chapter 2,. section 2.2.3).
A control urine sample (from subject No. 8) was
spiked with Cd,Zn-metallothionein to give a
concentration of 0.13 pg metallothionein/ml. This 
was used to assess the analytical recovery of Cd,Zn- 
metallothionein after desalting on the mixed bed 
resin. By analysis of cadmium content, this was 
found to be 86%. As table 6.5 reveals, by desalting 
the urine, the recovery of metallothionein was 110%, 
whereas the implementation of a filtering step with a 
PM30 membrane or heat treatment step (60°C, 2 mins),
reduced the measured metallothionein value by 45 and
80% respectively. A hundred fold concentration of 
the urine was not possible because the lyophylised 
urine would not dissolve in l/100th of the original 
volume. The urine was therefore concentrated only 
twenty fold. Concentrating the urine twenty fold,, 
gave a measured value for metallothionein 2.1. times 
greater than the actual value of the spiked 
metallothionein. Besides the inaccuracy ,of the 
measurement of metallothionein under these, 
conditions, the sensitivity of the assay was also 
decreased such that the detection limit was ten times 
greater than in the assay of unconcentrated urine.
The loss of accuracy and sensitivity was probably due 
to the increased concentration of urinary solutes, 
such as urea, interfering with the antigen-antibody
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binding of the assay. Thus despite the desalting and 
concentrating of the human urine samples, it was 
concluded that metallothionein.measurement would not 
be possible. Therefore, the measurement of 
metallothionein by the RIA method was not attempted 
in unspiked urine samples which had been 
concentrated.
Table 6.5 The analytical recovery of spiked '
meta11othionein in urine following various 
procedures
Analytical Procedure Metal lothionein (jig/ml.)
Measured Actual
Value Value
Neat urine + metallothionein 
(0. 135 jig/ml) 0.13 0. 135
Desalting the urine on a
mixed bed resin 0. 16 0. 135
Desalting and filtering the
urine on a PM30 membrane 0. 12 0. 135
Desalting, filtering and
heat-treating the urine 0.02 0.135
Concentrated neat urine and 
metallothionein spike
(0.135 pg/ml) (x 20) '5.2 2.7
Desalting the urine followed
by concentration (x 20) ' 5.7 2.7
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6.3.5 Measurement of meta 11oth1one1n in plasma
Preliminary analysis of meta11othionein in plasma on 
subjects 2 and 9 at the time points measured failed 
to show detectable levels of meta11othionein using 
the radioimmunoassay. Therefore the measurement 
metallothionein in the remaining plasma samples was 
not attempted.
6.3.6 Changes in plasma and urine cadmium during the
intake of brown crabmeat bv a group of
volunteers
The profiles showing urine and plasma cadmium 
concentrations of each of the subjects (in order 1-
12) before, during and after the crabmeat feeding are 
shown in figures 6.4-6.15. In addition figure 6.12 
shows the whole blood cadmium profile for subject No 
9. The values used to plot the profiles are as 
presented in table 1, 2 and 3 in Appendix IV. For
the sake of clarity errors are not shown in figures 
6.4-6.15, but these are shown in tables 6.5, 6.6, and
6.7. Figure 6.16 shows the profiles for the mean 
urine and plasma cadmium concentrations of 11 of the 
12 subjects.
The mean plasma cadmium concentration was 1.04 pg/ml 
(standard deviation of 0.22,n = 10) and the mean 
urinary cadmium cadmium concentration was 1.31 pg/g 
creatinine (standard deviation of 0.46, n = 10) 
before exposure to the dietary cadmium. In most of 
the subjects there seemed to be a consistent pattern 
in plasma and urine cadmium concentrations upon 
exposure to the brown crabmeat'. Elevations in 
cadmium concentrations in plasma and urine were 
observed at 2 weeks in S/12 subjects, and 6/11 of
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Legend to Figures 6.4 and 6.16
Figures 6.4 to 6.15 show the urine and plasma cadmium 
profiles of the 12 volunteers Cin order 1-12) before, 
during and after the crabmeat feeding. Fig 6.12 in 
addition, shows the whole blood cadmium profile. the 
values used to plot the profiles are as presented in 
Tables in Appendix IV. For the sake of clarity 
standard deviations are not shown in Figs 6.4-6.15, 
but these are shown in Tables 1, 2, and 3. Figure 
6.16 shows the profiles of average urine and plasma 
values of our 12 volunteers. The horizontal bar on 
each figure indicates the duration of the crabmeat 
f eeding.
Plasma cadmium concentrations are shown as (O— —  O) 
and urinary cadmium concentrations as (a— — a ) . Whole 
blood cadmium concentrations in Figure 6.12 are shown 
as (O---O ) .
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subjects at 6 weeks during the 12 week exposure. In 
3 of the subjects, urinary cadmium concentrations 
were significantly elevated after only one week of 
exposure. Following severe nausea and stomach 
cramps, subject 3 withdrew from the trial after the 
fourth week. However, this subject did provide blood 
and urine samples at the later timepoints and for 
this reason these results were not incorporated into 
the mean data in figure 6. 16. Even this subject (No. 
3) showed the distinct peak of plasma and urinary 
cadmium at week 2.
As shown in figure 6. 16, mean plasma cadmium 
concentrations of the subjects significantly 
increased above control concentrations to 2.95 ± 1.45 
jig/1 (n=ll; p<0.002) at 6 weeks, although the latter 
peak was less well defined. Mean urinary cadmium 
concentrations revealed a significant increase after 
2 weeks to 2.5 ± 0.98 pg/g creatinine (n=ll; p<0.01> 
and a less significant peak after 6 weeks (p<0.05) 
which was due to the marked individual variation.
For most of the volunteers the cadmium concentrations 
in plasma and urine, did not correlate well. The 
linear correlation coefficient was 0.55 (p<0.001>.
However, a good correlation (r = 0.97, p<0.001)
between the plasma and urine concentrations was 
observed in subject 2 (This subject although 
consuming 100 g crabmeat/week, did so, by eating 
smaller quantities on a more regular basis than other 
volunteers. Thus the intervals between consumption 
and sample collection are all shorter than the other 
volunteers) and a significantly better than average 
correlation was also found in subjects 1-4 between 
cadmium concentrations in plasma and urine (r = 0.81, 
P<0.001).
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The cadmium concentrations in the urine samples of 
one subject (No. 9) measured individually in 
different daily runs were compared with the values 
obtained when all 11 urine samples from this subject 
were measured in one daily run. The results 
presented in table 6.6 indicate that there was no 
significant difference between the urine samples 
measured in the two different ways. This shows that 
the elevations in cadmium concentrations 
observed in urine are not a manifestation of ' 
methodological problems.
The net cumulative excretion of cadmium (ie, 
cumulative total cadmium excreted - cumulative total 
basal cadmium excreted) in the urine in each subject 
over the 12 week exposure period ranged from 4-147 pg 
with a mean of 79 ± 49 pg for the 11 subjects (table 
6.7). The percentage difference between net (total- 
basal) cumulative cadmium excreted and total 
cumulative cadmium content excreted over the 12 week 
exposure in 8 of the 12 subjects, ranged from 34 to 
55%. However, in subjects 1, 7 and 8 this percentage
difference was 13.5, 7.0 and 13,2%. The excretion of
cadmium in the urine of these three subjects was not 
significantly higher than basal urinary cadmium 
concentrations prior to the 12 week exposure.
6.3.7 Relationship between whole blood and plasma 
cadmium concentrations
The time dependent fluctuations in cadmium . 
concentrations of the whole blood in subject No. 9 is 
somewhat similar to that of the plasma cadmium (see 
figure 6.12) although the whole blood does not show a 
distinct peak in week 6. Increases in plasma cadmium 
concentration are observed after 2 and 6 weeks of 
exposure to the crabmeat; but the whole blood values 
increase steadily after week 4. However, plasma
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Table 6.6 A comparison of the cadmium concentrat1ons 
In urine sampl.es - from subject No. 9 
determined bv the analysis of Individual 
samples in different daily runs Cl) with 
values obtained when all 11 urine samples 
were analysed in one daily run (2)
Date of sample Urinary cadmium
collection concentration (pg/1)
.1 2
13.11.84 1. 55 + 0.01 1 . 50 + 0. 05
19.11.84 0. 72 + 0. 07 0. 87 + 0. 10
26.11.84 2. 31 + 0. 00 2. 28 + 0. 02
03.12.84 2. 10 + 0. 1 2. 05 + 0. 10
19.12.84 2. 39 + 0. 00 2. 44 + 0. 15
02.01.85 2. 90 + 0. 13 2. 92 + 0. 10
14.01.85 3. 96 + 0. 05 3. 85 ± 0.01
28.01.85 2. 80 ± 0. 17 2 . 65 ± 0. 15
11.02.85 1. 72 ± 0 . 1 1 . 64 ± 0. 08
25.03.85 1. 26 ± 0. 05 1 . 24 ± 0. 05
03.06.85 1. 73 ± 0. 15 2. 57 ± 0. 10
Values given are mean ± SEM of 4 observations.
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Table 6.7 Cumulative excretion of cadmium In the
urine over the.12 week period attributable 
to crabmeat intake
Subject No Net cumulative excretion 
of Cd (pg>*
1 23
2 70
4 94
5 100
6 28
7 4
8 40
9 147
10 121
11 101
12 142
♦Net cumulative excretion of cadmium (pg> =
Cumulative total cadmium excreted in a cadmium 
exposed subject <Mg>~ Estimated cumulative total 
basal cadmium <pg>. Cumulative total cadmium 
excretion in a cadmium exposed subject was calculated 
from the addition of total cadmium excretion in 24 hr 
at the 7 points during the exposure period (weeks 1-
12) and multiplying by 12 for the number of weeks 
exposure.
Cumulative total basal cadmium excretion (p.g) was 
estimated from the average of the two control values 
for each subject, expressed per 24 hr and then 
multiplied by 7 and 12 to give the total amount of 
cadmium excreted in the urine of these subjects.
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Table 6.8 A comparison of whole blood cadmium
concentrations, with ^equivalent plasma 
cadmium concentrat 1ons in subject 9
Week
No
Whole blood ^Equivalent plasma 
cadmium cadmium 
concentration concentration 
(pg/1) Cpg/1)
% P1asma [ i 
whol e 
b1ood [cdl
0 1. 27 ± 0. 02 0. 3 23
0 1. 27 ± 0. 02 0.63 50
1 1 . 27 ± 0.025 0. 51 40
2 1. 50 ± 0.05 1. 16 77
4 1. 13 ± 0. 16 0, 79 70
6 1.31 ± 0.04 1. 09 83
8 1. 47 ± 0. 07 0. 73 50
10 1 . 4 ± 0.00 0. 46 33
12 1. 45 ± 0. 05 0. 41 28
18 1.8 ± 0. 00 0. 9 50
*Equi va1ent plasma Cd concentration (pg/1) = 2/3
plasma Cd concentration (p.g/1) (to give the amount of 
cadmium in the plasma fraction of the whole blood 
sample). This assumption is based upon average 
haematocrit values for erythrocyte concentration of 
45% for males and 41% for females.
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cadmium expressed as a percentage of the total blood 
cadmium concentration shows an increase from 37.5%. 
(Mean weeks 0, 0.1) to 76.7% (mean of weeks 2, 4, 6). 
This increase is short lived and after week 8 
decreases to 33.0% (see table 6.8).
6.4 Discussion
6.4. 1 Cadmium and metallothionein measurement in the 
blood and urine
As concentrations of cadmium in normal human blood 
and urine are very low, external contamination of 
samples can be an obvious source of analytical error 
(Kjellstrom, 1979; Stoeppler and Brandt, 1980). 
Because of this, a procedure was developed by which 
cadmium was determined directly (without any 
extraction procedures), using highly pure nitric acid 
as a diluent and protein precipitant, before analysis 
by electrothermal atomic absorbtion. Matrix 
interferences are reduced in the presence of nitric 
acid and the resulting specific background absorbance 
during atomization is only 0.05-0.2 units. This can 
be completely compensated for by simultaneous 
background correction.
The accuracy of the methods of determining cadmium 
concentrations in urine and plasma were assessed by 
participation in a trace element quality control 
scheme. The determinations of the plasma and urine 
quality control samples gave values within 10% of the 
mean obtained by other laboratories througout Europe. 
The mean cadmium concentrations in the control 
samples of plasma and urine were 1.04 ± 0.22 pg/i and 
1.31 ± 0.46 pg/1 creatinine. These values are 
consistent with those reported by other workers 
(Chang et a1 1980, Ellis et a 1. 1983).
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Attempts to measure endogenous levels of 
metallothionein by RIA in human plasma/serum or urine 
have proved successful and concentrations of O.OIjj.g/1 
were detected (Garvey, 1984). Therefore, a procedure 
involving concentration and desalting of urine, in 
order to detect this protein by our radioimmunoassay 
was attempted. This approach proved unsuccessful as 
the increased solute concentration of the urine 
interfered with the assay (table 6.4). Despite the 
desalting step, it is considered that the removal of 
all constituents except metallothionein by 
fractionation on Sephadex G75 prior to concentration, 
is needed for reliable meta11othionein measurements in 
plasma or urine using this RIA method. Alternatively 
a more sensitive RIA capable of detecting such low 
levels of metallothionein should be employed.
6.4.2 Plasma and whole blood cadmium kinetics
An unusual profile was observed in plasma cadmium 
concentration during and after consumption of the 
brown crabmeat. Elevations above control were seen 2 
and 6 weeks after starting the crabmeat diet in 8 of 
12 and 6 of 11 subjects respectively. The return to 
control levels between and after elevations in cadmium 
concentrations in the plasma suggest a possible 
'cycling* or movement of cadmium (which may be bound 
to plasma proteins, such as metallothionein) from one 
organ to another. For example, the release of cadmium 
from the gastro-intestina1 tract (where the metal is 
absorbed) into the circulation where upen it may be 
bound to plasma proteins such as albumin prior to its 
uptake by the liver (one of the main storage organs 
for the metal) and the release of cadmium- 
metallothionein by the liver into circulation prior to 
its uptake by the kidney. Thus plasma cadmium 
concentrations are elevated upon exposure as the metal 
is shuttled from the intestinal absorbtion site to the
376
liver in association with the plasma proteins, 
reflecting recent exposure (described by Lauwerys ejt. 
al. 1976 and Bernard et a 1. 1980). This would depend
upon the kinetics of absorption which is discussed 
later (section 6.4.4). The elevations in plasma 
cadmium concentrations seen 2 and 6 weeks after 
starting the crabmeat diet could also be due to an 
efflux of the metal from the liver. This efflux could 
be attributable to an increased cellular turnover 
although the results presented in this thesis using 
the isolated perfused liver system (Chapter 4, section
4.3.1) would indicate that cadmium is actively 
released from the liver bound to metallothionein.
These results also suggest that the amount of cadmium 
released into the perfusate is related to the total 
cadmium content of the liver. This is in agreement 
with the postulate that a fraction of the cadmium in 
the blood reflects body burden (Nordberg and 
Kjellstrom, 1979). Other causes for these elevations 
in plasma cadmium concentrations observed, could be 
due to changes in dietary habits over the 
Christmas/New Year period (when the elevations in 
plasma cadmium concentrations occurred)-. This could 
also explain why such elevations in cadmium 
concentrations in the plasma were seen on exposure to 
such low concentrations of cadmium.
The results for subject No. 9 showed that whole blood 
cadmium concentrations also showed a marked elevation 
similar to that in plasma, after 2 and 6 weeks 
exposure to the form of cadmium present in brown 
crabmeat, but the magnitude was not as great as the 
respective elevations in plasma cadmium 
concentrations. However, whole blood cadmium 
concentrations increased thereafter, as did plasma 
cadmium after week 12. Although only 20-50% of the . 
total blood cadmium was found in the plasma in control 
samples, up to 70-80% was found in the plasma
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between 2 and 6 weeks exposure to the brown crabmeat. 
The concentrations of cadmium in the plasma as a 
percentage of those in whole blood decreased 
thereafter. This is in agreement with other workers 
who found whole blood cadmium to be more of an index 
of recent exposure and plasma cadmium an index of 
body burden of the metal. It is unfortunate that we 
were unable to confirm this by the measurement of 
plasma metallothionein. However, it has been 
recently shown that cadmium is bound to glutathione 
in normal (control) human blood (Katoh et a1. 1982).
These workers analysed the haemolysate, as most of 
the glutathione in blood is associated with 
erythrocytes (Meister, 1975). Katoh*s work is in full 
agreement with the results obtained in our study, 
showing that up to 80% of the cadmium in control 
human blood is associated with erythrocytes. These 
workers also found no evidence of cadmium in 
association with metallothionein following 
fractionation of the haemolysate by gel filtration. 
This is not surprising as studies have shown that 
normal control human plasma/serum contains very low 
concentrations of metallothionein (0.01 pg/l)
(Garvey, 1984).
6.4.3 Urinary cadmium kinetics
It is interesting to note that a marked increase in 
the urinary cadmium was observed during the 12 weeks 
of crabmeat feeding in most of the 12 subjects. This 
is somewhat surprising in view of the report by 
Sharma et a 1. (1983) that subjects consuming much
larger amounts of cadmium from oysters showed no 
significant increase in urinary cadmium.
The time course of urinary cadmium excretion during 
and after the intake of the brown crabmeat shows an 
unusual profile which reflects that of the plasma
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cadmium. Peaks of elevated urinary cadmium at week 2 
and 6 after starting the crabmeat diet, are shown by 
almost all the 12 volunteers although a few peaks 
were found in weeks 8 and 10 (see figures 6.11 and 
6.13). If this profile is a true reflection of the 
dietary exposure of cadmium from crabmeat it 
represents a most unusual pharmacokinetic model, 
since the plasma profile peaks would suggest frequent 
'cycling'. An expected model would perhaps be an 
exponential increase over the twelve weeks 
representing accumulation followed by an exponential 
decrease representing elimination. Advice from the 
resident pharmacologist suggested that neither the 
plasma nor the urine cadmium profiles could be fitted 
to any known model of absorbtion or elimination and 
that statistical approaches to smoothing out the 
profiles would not necessarily be valid. The 
'cycling' hypothesis is proposed because of the 
distinct dip, back to control levels, at about week 
4-5 and also because the level returns, again to 
contol at 12 weeks, when it might be expected to be 
highest. The 'cycling' could be explained by 
critical threshold absorption levels which require to 
be reached before the peak in urinary cadmium (and 
indeed plasma) is expressed. The interval to the 
peak may reflect the time needed to reach the 
threshold value. The rapid decay after the peak 
suggests significant elimination which is then 
followed by the lag period. The alternative 
explanation to the 'cycling' may be a complex balance 
between threshold values and a possible contribution 
of the liver in the enterohepatic circulation of 
cadmium. The urine (and plasma) peaks thus may 
represent cadmium which as been 'recycled' and added 
to that absorbed from the crabmeat. From the results 
of Chapter 5 and from other workers (Cherian, 1983; 
Selenke and Foulkes, 1981), renal uptake of cadmium 
metallothionein in rats appears to be a saturable
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process. Thus the fluctuations of urinary cadmium 
concentrations found inman may also reflect a 
saturable uptake of cadmium-metallothionein, 
particularly as urine and plasma cadmium 
concentrations do tend to follow similar profiles for 
most subjects.
We have also considered the possibility that the 
peaking may be due to methodolgical artefacts. The 
excellent correlation between the urinary cadmiums of 
subject 9 assayed on a batch basis (as the samples 
from all 12 volunteers were collected) and repeated 
in a single batch (see table 6.8) clearly shows that 
the 'peaks' are not due to day to day variations in 
sensitivity.
Because the 'dip' to control levels coincided with 
the Christmas holidays, we investigated the 
possiblity that the fluid and food intake during this 
period might have influenced the absorption. The 
'dip' was found to be be equally pronounced in 
teetotalers (low/normal fluid intake) and in 
relatively heavy drinkers, thus indicating that the 
'dip' was not attributed to dilution or "washout" 
associated with high fluid intake. Whilst most of 
the volunteers admitted to eating too much during the 
Christmas holidays detailed accounts of their eating 
habits revealed no clearcut correlations (eg. 
subjects eating predominantly brown bread produced 
the same profile of urinary cadmium as those eating 
mainly white bread, those eating the crabmeat at home 
had the same profile as subjects consuming ;the 
crabmeat on Tuesdays and Fridays in the lab). It is 
thus considered unlikely that the variations in diet 
in our volunteers had influenced the absorbtion of . 
cadmium. Although we can most probably discount the. 
contribution of individual eating habits the . 
possibility remains that the dip may be caused by
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excessive food intake adversely affecting the 
absorbtion of cadmium.
Another possibility which may explain the dip in the 
urinary and plasma cadmium concentrations is the 
interval between the crabmeat intake and the sample 
taking. Whilst at most of the time points, the 
crabmeat was eaten on a Friday and samples taken on 
the following Sunday/Monday, on week 4 the samples of 
urine and blood were collected two days after the 
crabmeat intake. On week 6 the sampling interval may 
be even shorter since the volunteers were at liberty 
to consume their 100 g weekly portions how they 
wished over the Christmas holiday. The possiblity 
therefore exists that the 'dip* may be due to low 
values attributable to the short interval between 
intake and sampling. If this is the case it suggests 
that the absorbtion is not just inefficient but also 
very slow.
Although there is a possibility that the unusual 
profile of the urinary cadmium may be caused by 
artefacts we would conclude that on balance it is 
more likely that the profile is real.. The main 
reason for this conclusion is that the urinary 
cadmium tends to follow that of blood/plasma cadmium 
closely, in spite of the different methodology used 
to prepare blood/plasma (via extraction) and urine- 
(via standard addition techniques) for cadmium 
measurement using atomic absorption 
spectrophotometry.
6. 4. 4 Gastrointestinal absorbtion of cadmium
From the reported values of cadmium absorption from 
brown crabmeat (Newton et a 1, 1983) we may calculate-
the total cadmium absorbed by our 12 volunteers 
during the 12 weeks of the crabmeat feeding study.
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The crabmeat was found to contain 6.5 ppm (see
section 4.1). This means that the volunteers who 
consumed 1.2 kg of brown crabmeat took in 7.8 mg of 
Cd'2-*". Allowing for an absorption of 2.7% the total 
Cd^ "*' absorbed is about 200 pg per subject. This is 
comparable with absorbed intake of cadmium amongst 
oyster consumers in New Zealand (68-680 pg, assuming 
the same 2.7% absorption value) and in comparison to 
the uptake in moderate smokers (170 pg) over a 
comparable period.
An approximate index of the elimination of cadmium in 
the urine of our subjects (see Table 6.9) suggests 
that an average of 79 pg Cd^-*' has been excreted by 
each volunteer in the 12 weeks. In comparison to the 
estimated total absorbed this represents 38%. Sharma 
et a 1 (1983), in their oyster study estimated the
excretion of cadmium in urine to be 0.01% total body 
Cd^^/day. Applying their excretion value to our 
total absorbed Cd^2 over the 12 weeks gives an 
estimated total eliminated as 1.76 pg. This 
calculation provides a much lower estimate of total 
cadmium eliminated and suggests that the excretion of 
oyster-derived C d ^  is considerably lower that the 
excretion of C d ^  originating from the brown 
crabmeat. This in turn suggests that the chemical 
forms of Cd^ "*" from these two sources are very 
different or that they may be metabolised very 
dif ferently.
6.4.5. Cadmium retention in the body
From the above estimated value of total Cd12'* 
eliminated it appears that some 62% (of the cadmium 
absorbed from the gastro-intestina1 tract) has been 
retained. Thus, although the total amount of.cadmiurn 
absorbed is extremely small it would seem that a 
significant proportion of this has been retained in
382
the body. Urinary cadmium values do not indicate a 
clear phase I rapid elimination of cadmium as 
described by Newton et a 1. (1983). It would
therefore appear that the elimination of cadmium from 
our subjects would proceed extremely slowly according 
to the very long elimination half life of 170 d. If 
this is the case our data would suggest that subjects 
who habitually consume brown crabmeat may steadily 
accumulate cadmium since there is a clear discrepancy 
between the elimination and the estimated total 
absorbed cadmium. A round estimate of the possible 
retention is 60% of the absorbed dose (2.7%) or about 
1.7% of the ingested dose.
6. 5 Summary
A group of twelve human subjects (non-smokers) 
consumed 100 g of brown crabmeat/week for up to 12 
weeks. Eleven of the twelve subjects completed the 
trial. Cadmium concenrations in the plasma and urine 
were found to be elevated after 2 and 6 weeks 
exposure to the crabmeat in the majority of subjects. 
This suggested a 'cycling' of cadmium possibly 
brought about by the efflux of cadmium (bound to 
metallothionein or another protein found in the 
plasma) from the liver or gastrointestinal tract upon 
the attainment of a critical threshold from each 
organ. It would have been useful to substantiate the 
above suggestion by the measurement of plasma and 
urinary meta11othionein concentrations; this was not 
possible using the present method. However the . 
percentage of whole blood cadmium concentrations in 
the plasma increased at weeks 2 and 6 (in the one 
subject where whole cadmium-values were measured) .
This also suggests that the cadmium is being released' 
into the circulation from the organs - possibly bound 
to metallothionein which would be targetted to the
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kidney. The urinary cadmium concentration profiles 
may either reflect the saturation of the renal uptake 
process for cadmium (bound to metallothionein) or the 
attainment of a critical cadmium concentration for 
this organ.
Although the retention of cadmium in man following 
ingestion of the crabmeat was similar to that 
reported by other workers. Compared with other 
studies in man following ingestion of cadmium 
containing oysters, the- urinary excretion of cadmium 
in this study appears somewhat different. This 
suggests that either cadmium in oysters is in a 
chemically different form or metabolised differently 
compared to cadmium in brown crabmeat.
CHAPTER 7
General Discussion
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Although a plethora of literature has been published 
concerning the disposition, metabolism and toxicity 
of cadmium in experimental animals and man, our 
understanding of the role played by metallothionein 
and the biological changes produced by cadmium 
exposure is not clear. The experiments described in 
this thesis were designed to provide more information 
on the role metallothionein plays in the disposition 
of cadmium. Thus mechanisms for the absorption, 
distribution, excretion and toxicity of cadmium may 
be ascribed. The use of metallothionein measurements 
as an index of exposure and tissue burden, together 
with risk assessment of cadmium exposure, is 
evaluated.
7.1 Characterisation of metallothionein and anti­
metal lothionein antiserum for use as 
experimental tools
The method utilized in this thesis for purifying rat 
liver metallothionein I and II was a modification of 
the procedure used by Vander Mai lie and Garvey 
(1978), and produced rat liver metallothionein I and 
II, of similar purity to other workers (Vander Mai lie 
and Garvey, 1978; Tohyama and Shaikh, 1978 and Winge 
et al. 1975 - see also table 2.12 in Chapter 2). The
purity of these proteins in the present study was 
assessed quantitatively by the cadmium, zinc and 
copper together with mass of the purified protein 
(lyophilysed to constant weight); and qualitatively 
by electrophoresis. Although non-denaturing 
polyacrylamide electrophoresis indicated 
metallothionein I to contain two "impurities", no 
impurities were observed in the metallothionein I 
sample using SDS (denaturing) electrophoresis. The 
purity of metallothionein I from the calculated 
metal:protein molar ratio; 4.5 (Cd):1.4 (Zn):0.1
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(Cu):1 (metallothionein) was equivalent to that 
calculated by other workers (Vander Mai lie and 
Garvey, 1978) thus it was concluded that the 
"impurities" observed in the electophoretic profile 
of purifled metallothionein I were metallothionein 
molecules of differing charge ie. metallothionein II 
or polymers of these proteins. Work on the further 
purification of metallothionein I was not pursued for 
the following reasons:
a) The antibody utilized in the radioimmunoassay 
for metallothionein (used in this thesis) 
appreared to bind metallothionein I and II with 
equal avidity and thus the radioimmunoassay was 
unable to distinguish between these two
isof orms.
b) The experiments described in this thesis using 
radioisotopes required that only
metallothionein was to be radio-label led, thus 
a metallothionein sample containing no other 
proteins was required. The elimination of 
other isoforms from a metallothionein I sample 
was of secondary importance.
In Chapter 2 of this thesis, the antiserum used in 
the radioimmunoassay was shown to react with rat 
liver metallothionein I and II (figure 2.10), chick 
gamma globulin (figure 2.11) as well as a single 
species in each of the cytosol fraction of the liver 
and kidney from a rat clinically exposed to cadmium 
in the diet (figure 2.12) using Immuno- 
electophoresis. The radioimmunoassay also revealed 
the antibody to be of low titre (1:1000) and the 
Scatchard plot (figure 2.19) indicated two 
populations of antibodies - one population was more 
avid towards metallothionein than the other. This 
may be explained by an existance of two antigenic
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determinants in the metallothionein molecule - a 
suggestion made by Winge arid Garvey (1983). These 
workers found that the residues 1-29 (amino terminal 
section) were more antigenic than the carboxy- 
terminal section (residues 30-61). However, 
conjugating metallothionein with chick gamma globulin 
prior to immunization to produce the antibody (used 
in this radioimmunoassay) may also explain the two 
populations of antibodies. This conjugation may also 
explain the low avidity of the antiserum for 
metallothionein as there appears to be an antibody 
population which reacts to the chick gamma globulin.
The detection limit and linear working range of (6.6 
ng - 1.0 mg/tube) the RIA for metallothionein 
described in this thesis (see figure 2.21) is higher 
than that described by Vander Mai lie and Garvey 
(1978) of 200 pg-10 mg/tube, and Mehra and Bremner 
(1983) of 100 pg-10 mg/tube. However, the linear 
working range of the assay presented in this thesis 
covers a larger range of concentrations - useful when 
metallothionein measurement may vary widely eg. 
between tissues and body fluids. The assay is of 
great value in high level and/or long term exposure 
to cadmium such as the chronic dietary cadmium 
feeding study in rats (Chapter 3) but is of somewhat 
limited use (only because of sensitivity) in sudies 
of very low level exposure to cadmium such as the 
dietary feeding of cadmium containing crabmeat to man 
(Chapter 6) .
Further work to increase the sensitivity of the 
radioimmunoassay for metallothionein is recommended 
for future objectives. The following suggestion may 
be worthy of consideration:
Raising anti-rat-metallothionein I antibodies in an 
avian species such as a turkey or chicken for
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example. The difference between mammalian and avian 
metallothioneins (see Chapter 1, section 1.4) may 
produce a more avid antibody, as these differences 
may be sufficient to permit the avian immune system 
to detect this otherwise interspecies structurally 
similar protein, as "foreign". However, the antibody 
may be too specific reacting to only the rat 
metallothionein administered. This may be overcome 
by producing an avid antibody in an avian form to a 
mixture of metallothionein I and II from the rat 
liver or kidney for example. This method of antibody 
production may also increase the titre of the 
antibody - decreasing the interference problems 
associated with the remaining constituents of the 
anti-serum and the need for further purification of 
an anti-metallothionein antibody using affinity 
columns.
7.2 Role of metallothionein In the absorption
transport distribution and excretion of c a d m i u m
Little is known of the mechanisms of cadmium 
absorption in the gastro-intestinal tract, and the 
role metallothionein plays in this process remains 
controversial. The induction of metallothionein in 
the gastrointestinal tract has been reported to 
increase cadmium absorption (Engstromn and Nordberg,
1979), limit absorption of cadmium (Washki and 
Cousins, 1977; Squibb et al. 1976; Faulkes and
McMullen, 1986) or have no effect on absorption 
(Kello et al. 1979). Work in this thesis (Chapter 3)
has shown that following chronic cadmium exposure, 
this metal accumulates in the small intestine in a 
time- and dose-related manner (table 3.6). Binding 
of cadmium to metallothionein was also observed at 
the 300 ppm dose level and dose- and time-dependent 
induction of this protein in the intestine was also 
seen at both 150 and 300 ppm suggesting a role for
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metallothionein in cadmium absorption. As no such 
induction of metallothionein in this tissue was 
observed at the 75 ppm dose level, this also suggests 
a 'no effect* level. As high molecular weight 
proteins in the cytosol of the small intestine also 
appear to bind cadmium, these proteins may bind all 
cadmium absorbed in the lower dose group but the 
binding capacity may be saturated in the high dose 
group, leading to the induction of metallothionein.
The actual role of metallothionein in cadmium 
absorption is still difficult to ascertain from 
experiments presented in this thesis. However, the 
observed increase in small intestinal metallothionein 
content may be acting as part of a homeostatic 
control mechanism, serving to limit cadmium 
absorption in rats and may contribute to the observed 
decreased rate of accumulation of cadmium in the 
liver after 4 weeks, and kidney between 4 and 16 
weeks exposure to 150 and 300 ppm Cd^-*.
Metallothionein has also been proposed to sequester 
high dietary levels of zinc (Richards and Cousins, 
1976; Smith et al♦ 1980) and copper (Sayer et al.
1980; Evans, 1979; Bremner, 1980). However, as such 
high concentrations of these metals are used to 
observe the induction of metallothionein, it may be 
argued that this protein does not serve as part of a 
homeostatic control mechanism but is perhaps more 
likely to be a reflection of a breakdown of 
regulatory control. This hypothesis is further 
supported by the observation that upon 
gastrointestinal absorption cadmium utilizes and 
interferes with intestinal transfer systems, for 
example iron (Valberg et al. 1976; Flanagen et_
al_, 1979, 1980) and calcium (Hamilton and Smith, 1978;
Tsuruki et al.1978. and Yuhas et a1. 1978); which may
indeed lead to a breakdown of the regulatory control 
of metal absorption.
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Thus metallothionein in the gastrointestinal mucosa 
appears to sequester the cadmium absorbed. However, 
whether cadmium from the intestinal mucosa enters the 
portal circulation, bound to intestinal 
metallothionein in a similar manner as has been 
inferred for intestinally absorbed exogenous cadmium 
metallothionein (Cherian, 1983), is still to be 
resolved. If metallothionein is able to cross cell 
membranes as proposed from isolated liver perfused 
experiments performed in this thesis, some doubt must 
be cast on a role for metallothionein in limiting 
cadmium absorption.
Long term dietary feeding studies suggest that 
cadmium accumulates in the liver and kidney in a 
dose-dependant manner. This accumulation also 
correlates with the tissue metallothionein 
concentrations (Chapter 3). Cadmium accumulates to 
its highest concentration in the kidney, which 
suggests movement of cadmium from other sites to this 
organ. The transport of cadmium bound to 
metallothionein in the blood has been suggested 
(Chang and Garvey, 1981; Frazier, 1982) although not 
definitely proved. Using the isolated perfused liver 
system, the results of this thesis (Chapter 4) have 
shown the release of cadmium-metallothionein from the 
liver of a cadmium-dosed rat. This release appears 
to involve an active rather than a passive transport 
mechanism. The mechanism is not known but may 
involve a secretory pathway such as that described 
for albumin (Yokota and Fahimi, 1981) or the cadmium- 
metal lothionein may be co-released with another 
cellular component such as albumin.
This mechanism of release of albumin involves protein 
synthesis in the ribosomes of the 'rough' endoplasmic 
reticulum followed by glycosylation (addition of 
signal sequences) in the 'smooth' endoplasmic
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reticulum and golgi apparatus before exocytosis at 
the cell surface. However, metallothionein appears 
to be synthesised on the free polysomes in the 
cytosol of the liver in vitro at least (Cherian et_ 
al. 1981) so this cytosolic protein would have to
enter the endoplasmic reticulum/golgi cisternae to 
participate in the secretory pathway. One suggestion 
may be that newly synthesised metallothionein in vivo 
possesses a signal sequence which permits entry into 
these cell organelles, and in the process the signal 
sequence is removed. A further explanation of the 
hepatic release of metallothionein is that the 
protein may bind to the cytoplasmic side of the 
endoplasmic reticulum and appear on the external 
surface of the plasma membrane by means of 
reorientation as has been suggested for the hepatic 
release of 5* nucleotidase (Widnell and Little,
1977). However, further experimental work to repeat 
these preliminary findings and to look further at the 
mechanism of release of cadmium-metallothionein 
should be performed. One direction may be to examine 
the mechanism by subfractionation centrifugation and 
chromatographic procedures as described in Chapter 5 
(section 5.2.3).
The uptake of cadmium-metallothionein has been 
demonstrated by the isolated perfused liver 
technique, using a liver from a rat not previously 
exposed to cadmium (Chapter 4). A distinct 
difference between perfusate clearance profiles of 
cadmium and metallothionein was observed. Whether 
this reflects a difference in hepatic uptake between 
cadmium and metallothionein is unkown. However, the 
multicomponent nature of the lc,,*Cd clearance profile 
may suggest the existance of different cadmium 
species eg. as the 'free' ion, cadmium- 
metal lothionein or cadmium-albumin. Each form of 
cadmium may undergo a different route of hepatic
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uptake. Meta11othloneln bound-cadmium may be taken 
up by the Kupffer cel Is of the liver, metabolised and 
the degradation products (included tritiated 
products) expelled into the perfusate cadmium being 
retained by these non-hepatocytes. This would 
explain the high content of 1Q9Cd and low content of 
3H (metallothionein) in these cells. In the . 
hepatocytes, where levels of 3H and 10,3Cd were both 
high, cadmium-metallothionein may be absorbed by 
these cells as revealed by the presence of cadmium 
metallothionein in the cytosol. Thus the hepatic 
uptake of cadmium-metallothionein may be different 
for hepatocytes and non-hepatocytes. Whether 
metallothionein entered the hepatic cytosol by 
directly crossing the membrane, by endocytosis or 
some other mechanism is yet to be determined.
Intravenously injected 1 os,Cd, 3H-label led 
metallothionein was present in the cytosol of the 
renal cortex after only 10 mins (Chapter 5, section
5.3.1) indicating a rapid uptake and suggesting a 
possible transmembrane passage for this protein. The 
mechanism for such a transmembrane transport in the 
renal cortex may involve two distinct binding sites 
for cadmium-metallothionein on the luminal surface of 
the brush border membranes located using in vitro 
preparations of these membranes (Selenke and Faulkes, 
1981). Similar binding sites may also exist on the 
hepatocellular membranes. Studies in Chapter 5 of 
this thesis do suggest that cadmium-metallothionein 
is taken up by large endocytic vesicles and promptly 
degraded within 3 hrs by lysosomes, releasing the 
cadmium into the renal cortical cytosol. The process 
of metallothionein degradation described in the renal 
cortex may be similar in the liver. This could 
explain why a large proportion of 3H was associated 
with the 'membrane' fraction of the isolated perfused 
rat liver after 3 hours exposure. Subfractionation/
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time course studies (as described in Chapter 5) are 
needed to provide further evidence of this pathway. 
However, the results of Chapters 4- and 5 in this 
thesis do provide evidence for the hepatic release 
and uptake, and renal uptake of metallothionein, 
inferring that metallothionein may play a major role 
in the transport and distribution of cadmium.
The presence of metallothionein in the tissues and 
the sequestration of cadmium suggests that this 
protein is responsible for the long half life of 
cadmium. The liver and kidney are the two major 
storage organs for cadmium (Cherian, 1983; Kotsonis 
and Klaassen, 1977, 1978), accounting for 60% of the
body burden (Decker et a 1. 1957). This is believed
to be due to the greater induction of metallothionein 
in these tissues as compared to other tissues 
(Onosaka and Cherian, 1981). A time dependent 
increase in hepatic and renal cadmium content and 
metallothionein induction following dietary cadmium 
exposure has also been observed (Chapter 3). These 
findings would imply a storage or sequestration role 
for metallothionein. However, it has been suggested 
that metallothionein is able to cross membranes and 
act in the role of transport and distribution of 
cadmium. An explanation for this apparent 
discrepancy may be that metallothionein is involved 
in the transport from liver to the kidney (and other 
organs) via the blood - a proportion returning to the 
liver. This metallothionein (and all the metals 
bound to this protein) may be involved in a "cycling" 
process with the aim of retaining essential metals 
(eg. copper and zinc) and amino acids (eg. cysteine). 
Meanwhile cadmium by binding to metallothionein also 
becomes involved in this process. This cycling 
hypothesis could explain the increased time dependent 
renal cadmium concentration as well as dose dependent 
increase in hepatic cadmium content observed in the
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dietary rat feeding study (Chapter 3). However, no 
blood determinations were made in this study to 
provide evidence for this hypothesis. In the human 
volunteer study (Chapter 6), however, consumption of 
the cadmium containing crabmeat revealed fluctuating 
plasma cadmium concentrations also suggestive of a 
possible 'cycling ' process described earlier.
However, as mentioned in Chapter 6, the 'cycling' may 
also be explained by a movement of cadmium from the 
gastro-intestinal tract to the liver, if non- 
metal lothionein bound, and to the liver and kidney if 
metallothionein bound. The 'cycling' hypothesis, 
where cadmium bound to metallothionein is in a state 
of flux, may also explain why cadmium has the long 
biological half life calculated in the human 
volunteers from the study in Chapter 6 as well as 
that described by other workers.
As suggested earlier, cadmium by binding to 
metallothionein appears to be involved in inter organ 
transport or 'cycling' process for metal 1othionein 
and essential metals. It is interesting to note that 
although the urinary cadmium levels observed in rats 
fed high doses (up to 150 ppm) of dietary cadmium 
(see Chapter 3) were raised, there was no increase in 
urinary metallothionein levels. This may be 
explained by a displacement of zinc and cadmium 
aboard metallothionein by copper - a process which 
appears to occur in the blood (described by Suzuki et_ 
al. 1981). The results presented in Chapter 3 and by
other workers (Suzuki et al. 1981) reveal that the
metal bound to metallothionein in the urine is 
copper, supporting this hypothesis. Urinary cadmium 
may be derived from low molecular peptides such as 
glutathione (Katoh et a1. 1984). This suggests that
prior to renal dysfunction, metallothionein has a 
minimal role in the urinary excretion of cadmium.
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However, from the results of Chapter 5 (section
5.3.1), it may be seen that both cadmium and 
metallothionein ^ are located in the renal cortex 10 
minutes after the intravenous injection of the 
protein, with a similar 1°3Cd (cadmium):3H 
(metallothionein) radioisotope ratio as found in the 
solution of metallothionein prior to injection. This 
does not support the hypothesis of metal replacement 
aboard metallothionein in the blood. To explain the 
presence of cadmium and metallothionein in the urine 
prior to renal dysfunction, a certain percentage of 
cadmium may be released from the renal cortex 
following the turnover of this protein in the kidney.
In humans, following dietary feeding of cadmium- 
containing brown crabmeat (Chapter 6), it appears 
that in general urinary cadmium concentrations 
parallel blood cadmium concentrations and an average 
of 38% of cadmium calculated to be orally absorbed is 
excreted in the urine. As the majority of cadmium in 
brown crabmeat is probably metallothionein-bound (see 
Chapter 1, section 1.6), and from animal studies 
renal uptake of Cd,Zn metallothionein is rapid and 
the renal uptake mechanism would probably not be 
saturated. Thus it is interesting to speculate 
whether cadmium bound to metallothionein is displaced 
by copper in the blood, or cadmium is released from 
the renal cortex following the turnover of this 
protein and the cadmium is excreted in urine as 
suggested from the animal studies. To date no time- 
dependent measurements of urinary metallothionein 
concentrations have been made in human cadmium 
feeding studies (Newton et a1. 1983; Sharma et a1,
1983) making any claims on metallothionein 
involvement in the excretion of cadmium difficult.
The other major route of cadmium excretion is via the 
alimentary canal and this results from the low
j-j
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absorption of the metal (between 1-7% of an oral 
dose). Cadmium may also reach the alimentary canal 
by means of bile. Certainly the results in Chapter 4 
suggest cadmium excretion by this route is minimal 
following acute exposure to naive or Cd-pretreated 
rats. This is in agreement with some workers. 
(Cherian, 1977; Cirkt and Hardeva, 1979), who suggest 
that cadmium may be excreted in the bile as a low 
molecular weight substance. Other workers suggest 
cadmium is excreted as a glutathione - cadmium 
complex (Cherian and Vostal, 1977), or as degradation 
products of metallothionein (Sato and Bremner, 1984). 
Although no immunoreactive metallothionein was 
detected in the bile, radiolabelling the protein 
revealed the existence of very low radioactivity in 
the bile (Chapter 4). This radioactivity may suggest 
the presence of low levels of metallothionein which 
were undetectable by RIA. Sato and Bremner (1984) 
reported the presence of aggregated metallothionein, 
which may not be detectable using the RIA described 
in this thesis. This suggestion was also supported 
by the indications that cadmium and metallothionein 
were not associated in the bile, concluding that a 
minimal role is played by metallothionein in the 
excretion of cadmium in bile.
7.3 Significance of metal lothionein In the toxicity 
of cadmium
Following acute parenteral exposure to cadmium, the 
toxic response is rapid and the pathological changes 
are many (see Chapter 1, section 1.11; and 
Samarwicki, 1979), implying that the toxic 
interactions involve many sites and occur either 
immediately or a short times after dosing. The liver 
(Dudley et al 1985) and the scrotal testes (see
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Samarwicki, 1979, for a review) are believed to be 
the main targets of toxicity. However, it is well 
established that endogenous and exogenous hepatic and 
renal, (Cd,Zn)- and CCd,Cu)-metallothioneins are 
effective nephrotoxins (this present study; Webb and 
Etienne, 1977; Suzuki and Tanabe 1978; Cherian, 1981; 
Squibb et al. 1984). In the present study (Chapter
5, section 5.3.1) an intravenous injection of 0.15 mg 
Cd/kg body weight administered to rats as 
metallothionein may have caused slight renal injury 
perhaps helping to explain the low content of 
exogenous cadmium and metallothionein in the kidney. 
The renal injury caused by the intravenous 
administration of cadmium-metallothionein may occur 
as the cadmium (as measured by lo-*Cd) was liberated 
from the protein very early in the uptake process (30 
mins), and endogenous renal metallothionein is 
reported not to be induced until 1 hr post injection 
(Shaikh and Smith, 1975; Holt and Webb, 1983). 
Certainly other workers report renal injury after the 
intravenous administration of cadmium as equine 
metallothionein at a dose of 0.2 mg/kg body weight 
(Holt et a1. 1985) or after the intraperitoneal
administration of cadmium (as rat metallothionein) at 
a dose of 0.4 mg/kg body weight (Squibb et al 1984).
Interestingly cadmium-metallothionein appears to be 
taken up by the liver (using the isolated perfused 
rat liver system, see Chapter 4) and, at a dose of 
120 pg cadmium, no treatment-related signs of 
toxicity were observed (as measured by the enzyme 
activities the perfusate medium). However, most of 
the cadmium (measured as 1c>s,Cd) was found mainly 
associated with endogenous metallothionein 3 hr after 
administration of the protein. Cadmium 
concentrations in the isolated perfused liver may be 
insufficient to induce hepatic metallothionein and 
cadmium is merely displacing zinc from this
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endogenous protein. However, using the isolated 
perfused liver system, Frazier and Puglese C1978) did 
report hepatic induction of metallothionein at a dose 
of 20 pg after a delay of 1 hr following 
administration of cadmium.
In both the liver and kidney, there appears to be a 
delay or lag period between the acute administration 
of cadmium and the induction of metallothionein. 
Therefore during the lag period (up to 3 hr) cadmium 
may insult these target organs possibly creating 
irreversible damage. It also seems unlikely that a 
protective agent against cadmium toxicity should 
demonstrate similar properties as metallothionein in 
that this protein should be able to 'cross' cell 
membranes and be 'targetted' for the kidney possibly 
causing injury to that organ. Thus it seems highly 
unlikely that metallothionein would play a protective 
role in the acute toxicity of cadmium. This 
contention is further supported by the apparent 
inability of certain target tissues to induce 
metallothionein, for example, the testes. Likewise, 
following chronic exposure to cadmium when the 
critical concentration of this metal is reached in 
the target organs, the target organs show signs of 
tissue injury and a dramatic increase in release of 
cadmium metallothionein into the body fluids occurs. 
Thus a protective role for metallothionein against 
cadmium toxicity following chronic exposure also 
seems doubtful.
7. 4 Metallothionein as a biological monitor of 
cadmium exposure
Biological monitoring has been defined as systematic 
continuous or repetitive measurement and assessement 
of agents or their metabolites either in tissues, 
secreta, excreta, expired air or any combination of
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these to evaluate the uptake of a chemical and the 
health risk Involved, for the purpose of prevention 
of health effects by corrective actions as needed 
(Berlin et al. 1984). Traditionally the diagnosis of
heavy metal induced adverse health effects have used 
analysis of blood and urine concentrations of the 
metal. However, there has been considerable debate 
regarding the value of Such determinations for 
cadmium, since it is believed, on the basis of both 
human epidemiological investigations (Lauwerys et a 1 
1976, 1979) and experimental studies (Bernard e t a1.
1980), that urinary cadmium concentrations reflect 
the accumulation of the metal in the body when 
exposure is low, but recent exposure to the metal 
when exposure is high. In contrast, the 
concentration of cadmium in blood appears to reflect 
current exposure regardless of dose. Such a 
situation makes meaningful interpretation of 
analytical data difficult if not impossible.
With the development of a radioimmunoassay for 
metallothionein, the measurement of urinary 
metallothionein in experimental animals (Toyhama et_ 
al. 1986) and cadmium exposed workers (Chang et al.
1980; Nordberg et al. 1982) and unexposed individuals
(Garvey, 1984) has been made possible. When 
analyzing metallothionein as a potential index of 
renal dysfunction and tissue burden of cadmium in 
experimental animals (after high dose exposure), a 
significant correlation between metallothionein in 
urine and cadmium in urine or cadmium in the liver or 
kidney was found (Toyhama et a1. 1981). In the
present study using lower dose regimes (Chapter 3, 
section 3.3.3), urinary metallothionein 
concentrations correlated well with liver and kidney 
cadmium concentrations in all dose groups but only 
correlated with urinary cadmium concentrations in the 
highest dose group (300 ppm in the diet). Urinary
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cadmium concentrations thus only correlated with 
liver and kidney cadmium.burden at the 300 ppm dose. 
This would indicate that at chronic, low dietary 
levels, cadmium in the urine reflects recent/current 
exposure. Urinary metallothionein concentrations 
however, reflect both recent exposure to cadmium, (as 
indicated by an increase in urinary concentrations of 
this protein after only 3 days) and tissure burden of 
cadmium. The 'cycling* of cadmium concentrations in 
the urine of volunteers in the crabmeat feeding study 
(Chapter 6) makes the use of urinary cadmium 
concentrations as an index of recent exposure or 
cadmium body burden difficult to interpret. However, 
as the urinary cadmium generally parallel blood 
cadmium concentrations - the latter of which is 
reported to be an index of recent exposure (Lauwerys 
et al. 1976), and hepatic cadmium burden in man
(Elinder et al. 1978), increased urinary cadmium
concentrations at weeks 2 and 6 of the study may also 
reflect recent exposure and be related to the liver 
cadmium burden. Also, elevations in blood and 
urinary cadmium at weeks 2 and 6 may be cadmium bound 
to metallothionein. The protein being widely taken 
up by the renal cortex and a percentage of cadmium 
released fom the renal cortex into the plasma. This 
would indicate that urinary cadmium concentrations 
may be an indicator of renal cadmium burden.
To possibly resolve this dilemma, the measurement of 
metallothionein concentrations could be made and 
suggest a more meaningful interpretation of urinary 
cadmium values. This protein would also be useful as 
an index for the biological monitoring of cadmium 
exposure and body burden as seen in the experimental 
animal study in this thesis (Chapter 3) and also in 
man (Cheng et a_l, 1980; Nordberg et. al, 1982; Garvey,
1984). To proceed with this suggestion further work 
to develop a radioimmunoassay for metallothionein
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would be required to detect metallothionein in human 
blood and urine. Also to confirm the use of urinary 
cadmium and metallothionein values as biological 
indicators of recent exposure and body burden of 
cadmium, a further volunteer study could be performed 
sampling urine and blood more frequently to confirm 
the profiles obtained in the present study and should 
be conducted for a longer period with the specific 
aim of examining the 'cycling' profile of urinary 
cadmium. Since the per capita consumption of 
crabmeat is extremely small, the cadmium intake from 
this source is unlikely to represent any significant 
hazard to the population as a whole. In my opinion 
it would be much more appropriate to investigate the 
intake of cadmium from vegetables and cereals, since 
these are consumed on a very large scale by virtually 
everyone in Britain.
REFERENCES
401
Adams, R.G., Harrison, J;F. and Scott, P. (1969) Q.J. 
Med. 38, 425-443.
Amacher, D.E. and Ewing, K.L. (1975) Arch. Environ. 
Health 30, 510-513.
Andersen, R.D. and Weser, U. (1978) Biochem J. 175. 
841-852.
Ando, M. , Sayato, Y. , Tonomura, M. and Osawa, T.
(1977) Toxicol. Appl. Pharmacol. 39, 321-327.
Ando, M., Sayato, Y., Tonomura, M. and Osawa, T.
(1978) Toxicol. Appl. Pharmacol. 46., 625-632.
Anwar, R. , Langham, R. , Hoppert, C.A., Alfredson,
B.V. , Byerrum, R. U. (1961) Arch. Environ. Health, 3., 
456-460.
Ashby, S.L., King, L.J. and Parke, D.V. (1980)
Environ. Res. 2_L» 177-185.
Axelsson, N. , Kroll, J. and Weeke, B. (1973) In "A
Manual of Quantitative Immunoe1ectophoresis",
Universitetsforlaget, Oslo.
Axelsson, B, and Piscator, M. (1960) Arch. Environ. 
Health. V2, 360-373.
Bakka, A. and Webb M. (1981) Biochem. Pharmacol. 30, 
(721-725).
Bakka, A., Johnson, A.S., Endresen, L. and Rugstad, 
H.E. (1982) Experienta 38. 381-383.
Banerjee, D., Onosaka, S. and Cherian, M.G. (1982) 
Toxicol. 24, 95-105.
402
Barr, M. (1973) Teratol. 7, 237-242.
Bartels, H. and Bohmer, J. (1970) Clin. Chim. Acta
32. 81-85.
Beltramini, M. and Lerch, K. (1983) Biochem. 22. 
2043-2048
Bergmeyer, H.U. (1974) Methods of Enzymatic Analysis, 
2nd edn., Vol. 2, Academic Press, New York.
Bergmeyer, H.U. and Bernt, E. (1974) Method Enzym. 
Anal., 1_ pp. 769-775, Bergmeyer (ed) , Verlag chem
(publ.)
Berlin, M. and Friberg, L. (1960) Arch. Environ.
Health 1, 478-486.
Berlin, M., Fredricsson, B. and Linge, G. (1961)
Arch. Environ. Health 3, 58-66.
Bernard, A. and Lauwreys, R. (1984) Experientia, 40. 
143-152.
Bernard, A. , Goret, A. , Buchet, J.P. , Roels, H. and
Lauwerys, R. (1980) J. Toxicol. Environ. Health, 6,
175-184.
Berson, G. (1983) Anal. Biochem., 134, 230-234.
Blouin, A., Bolender, R.P. and Weibel, E.R. (1977) J.
Cell Biol. 72, 441-445.
Bolton, A.E. and Hunter, W.M. (1973) Biochem J. 133.
529-539.
Boulanger, Y., Goodman, C.M., Forte, C.P., Fesik,
S. W. and Armitage, I. M. (1983) Proc. Natl. Amer. Sci. 
(USA) 80, 1501-1505.
403
Boumendi1-Podevin, E.F. and Podevin, R.A. (1983) 
Biochem. Biophys. Acta, 735. 86-94.
Bozelka, B.E. and Burkholder, P.M. Environ. Res. 17. 
390-402.
Brady, F.O. (1981) Life Sci., 28, 1647-1654.
Brady, F.O. (1982) Trends Biochem. Sci. 7, 143-145.
Brady, F.O.and Helvig, B. (1984) Amer. J. Physiol. 
247. E319-E322.
Brady, F.O. and Kafka, R.L. (1979) Anal. Biochem. 98. 
89-94.
Brady, F.O. and Webb, M. (1981) J. Biol. Chem. 256. 
3931-3935.
Brady, F.O., Panemangalore, M., Day, F.A., Fiskin,
A.M. and Peterson, G. (1979) Experienta Suppl. 34. 
261-271.
Bremner, I. (1979) Experienta Suppl. 34., 273-280.
Bremner, I. (1979) in "The Chemistry, Biochemistry 
and Biology of Cadmium" (Webb, M. ed. ) pp. 175-193 
Elsevier, Amsterdam, North Holland.
Bremner, I. (1980) In "Biological Roles of Copper" 
Elsevier, North Holland, New York, pp. 23-49.
Bremner, I., and Davies N.T. (1973). Biochem. Soc. 
Trans. JL, 982-985.
Bremner, I., Davies, N.T. (1975) Biochem. J. 149, 
733-738.
404
Bremner, I. and Marshall, R.B. (1974a) Br. J. Nutr. 
32, 283-291.
Bremner, I. and Marshall R.B. (1974b) Br. J. Nutr. 
32. 293-300).
Bremner, I. and Mehra, R. K. (1983) Chem. Scr.' 21.
199-123.
Bremner, I. and Young, B.W. (1976a) Biochem. J. 155.
631-635.
Bremner, I. and Young, B.W. (1976b) Biochem. J. 157.
517.
Bremner, I., Hoekstra, W. G. , Davies, N.T. and Young,
B.W. (1978) Biochem. J. 174, 883-892.
Brewster, D., Jones, R.S. and Parke, D.V. (1977) 
Xenobiotica 1_ 601-609.
Briggs, R.W. and Armitage, I.M. (1982) J. Biol. Chem.
257.(3), 1259-1262.
Bryan, S.E. and Hayes, E.F. (1972) FEBS Lett. 2.4, 21-
24.
BUhler, R.H.0. and Kagi, J.H.R. (1974) FEBS Lett. 39.
229-234.
BUhler, R.H.0. and Kagi, J.H.R. (1979) In
"Metallothionein" (Kagi, J.H.R. and Nordberg, M.
eds.) Birkhauser Verlag, Basel, pp. 211-220.
Bus, J.C. Vinegar, A. and Brookes, S.M. (1978) Am. 
Rev. Respir. Dis. 118. 573-580.
405
Byrd, J. and Winge, D.R. (1986) Arch. Biochem. 
Biophys. 250. 233-237.
Cain, K. and Griffiths, B. (1980) Biochem. Pharmacol.
29, 1852-1854.
Cain, K. and Griffiths, B. (1984) Biochem. J. 217.
85-92.
Cain, K. and Holt, D.E. (1979) Chem. Biol. Interact.
28, 91-106.
Cain, K, and Holt, D.E. (1983) Chem. Biol. Interact.
43. 223-237.
Cain, K. and Skilleter, D.N. (1983) Biochem. J. 210. 
769-773.
Camarkaris, J., Daniks, D.M. , Brown, R. , Phillips, M. 
and Stevenson, T. (1983) J-Inhert. Metab. Dis.
6 (Suppl. 1). 44-50.
Caperna, T.J. and Failla, M.L. (1984) Biochem. J. 221 
631-636.
C.E.G. (Commission of the European Communities),
(1978) Criteria (Dose/effect Relationships) for 
cadmium, Pergamon Press, Oxford.
Cempel, M. and Webb, M. (1976) Biochem. Pharmacol.
25. 2067-2071.
Chang, C.C., Vander Mai lie, R.J. and Garvey, J.S.
(1980) Tox and App. Pharmacol. 55., (94-102).
Chang, C.G. , Lauwerys, R. , Bernard, A. , Roels, H. 
Buchet, J.P., and Garvey, J.S. (1980a) Environ. Res. 
23, 422-428.
406
Charvenka, C.H. and Elrod, L. H. (1972) Manual of 
methods for large scale zonal centrifugation 
(Beckman-Spinco, Palo Alio, California.
Chen, R,W. and Whanger, P.D. (1980) Biochem. Med. 24. 
71-81.
Chen, R.W., Whanger, P.D., and Weswig, P.H. (1975) 
Biochem. Med. 12_, 95-105.
Cherian, M.G. (1974) Biochem. Biophys. Res. Commun.
61. 920-926.
Cherian, M.G. (1978) Biochem. Pharmacol. 27 1163- 
1166.
Cherian, M.G. (1982) In "Biological Roles of
Metallothionein" (Foulkes, E.C., ed,) Elsevier, North
Holland, Amsterdam, pp. 192-202.
Cherian, M.G. (1983) Bull. Env. Contam. and Tox.
30(1) 1983, pp. 33.
Cherian, M.G. and Shaikh, Z.A. (1975) B.B. Res. Comm. 
65(3). pp. 863-869.
Cherian, M.G. and Vostal, J.J. (1977) J. Toxicol. 
Environ. Health 2, 945-954.
Cherian, M. G. , Groyer, R.A. and Delaquerriere- 
Richardson, L. (1976) Toxicol. Appl. Pharmacol. 38. 
399-408.
Cherian, M. G. , Groyer, R.A. and Valberg, L.S. (1978)
J. Toxicol. Environ. Health 4, 861-866
Cherian, M.G., Yu, S. and Redman, C.M. (1981) Canad.
J. Biochem. 59., 301-306.
407
Cikrt, M. and Havrodova, J. (1979) Experlentia 35. 
1640.
Clarkson, J.P., Elmes, M.E., Jasani, B., Webb, M.
(1985) Histodhem, J. 17., 343.
Cline, G.B. and Ryel, R.B. (1971). Methods in 
Enzynology, 168-204
Cohen, D.I., Illowsky, B. and Linder, M.C, (1979) Am. 
J. Physiol. 236. E309-E315.
Coleman, J.E. and Vallee, B.L. (1960) J. Biol. Chem.
235. 390.
Colucci, A.V., Winge, D. and Krasno, J. (1975) Arch. 
Environ. Health 30, 153-157.
Corrigan, A.J. and Huang, P.C. (1981) Biol. Tr. El. 
Res. 3, 197-216.
Cousins, R.J. (1985) Physiol. Rev. 65., 238-309.
Cox, R.P. (1969) Science 165. 196-199.
Davies, M. (1975) In "Lysosomes in Biology and 
Pathology" (Dingle, J.R. and Dean, R.T. eds.) Vol. 4, 
pp. 305-348 Amsterdam, North Holland.
Delves, H.T., Shepherd, G. and Vinter, P. (1971) 
Analyst 96, 260-273.
Din, W.S. and Frazier, J . M. (1985) Biochem. J. 230. 
(395-402).
DiSilvestro, R.A. and Cousins, R.J. (1984) Life Sci. 
35, 2113-2118.
408
Dobrota, m , (1983) PhD Thesis - "Lysosomes of the 
rate liver and kidney". University of Surrey, U.K.
Dobrota, M. , Bonner, F.W. and Carter, B.A. (1982) In 
"Nephrotoxicity, Assessment and Pathogenesis" (Bach,
P.H. , Bonner, F. W. , Bridges, J .W. and Lock, E .A . , 
eds.) pp. 320-324, Wiley Chichester.
Dobrota, M. and Hinton, R.H. (1980) Anal Biochem.
102. 97-102
Dohi, Y. , Kosaka, K. , Ohba, K. and Yoneyama, Y.
(1986) Environ. Health Perspec. 65. 49-56.
Doyle, J.J., Pfander, W. H. , Grebing, S.E. and Pierce, 
J.O. (1974) J. Nutr. 104. 106-166.
Dudley, R.E. and Klaasen, C.D. (1984) Toxicol and 
App. Pharmacol 72.(3), p. 530.
Durnam, D.M,, and Palmiter, R. (1981) J. Biol. Chem. 
256. 6712-6716.
Elinder, C.G., Friberg, L., Lind, B. and Jawaid, M.
(1981) Env. Res. 30(1), p. 233.
Ellis, K.J., Vartsky, D., Zanzi, I. and Cohn, S.H.
(1979) Science, 205. 323-325.
Ellis, K.J., Morgan, W.D., Zanzi, I., Yasamurga, S., 
Vartsky, D. and Cohn, S.H. (1981) J. Tox. Env. Hlth. 
Z, 691-704.
Ellis, K.J., Yasumara, S. Vartsky, D. and Cohn, S.H.
(1983) Fund. Appl. Toxicol., 3 169-174.
Ellis, K.J., Yuen, K., Yasumura, S. and Cohn, S.H.
(1984) Env. Res. 33(1), 216-226.
409
Engstrbm, B. and Nordberg, G.F. (1979) Toxicol., 13., 
215-222.
Etzel, K.R., Shapiro, S.G. and Cousins, R.J. (1979) 
Biochem. Biophys. Res. Commun. , 89., 1120-1126.
Etzel, K.R. and Cousins, R.J. (1981) Proc. Soc. Exp., 
Biol. Med. 167. 233-236.
Evans, G. W. (1979) In “Metallothionein" (Kagi, J.H.R. 
and Nordberg, M. , eds. ) pp. 321-329, BirkhaUser, 
Verlag, Basel.
Evans, G. W. , Majors, P.F. and Cornatzer, W.E. (1970) 
Biochem. Biophys. Res. Commun. 40., 1142-1148.
Ewers, U., Brockhaus, A., Dolgner, R., Greer, I., 
Jerman, E. , Bernard, A., Sti11-Winkler, R. , Hahn, R. , 
Manojlovic, M. (1985) Int. Arch. Occup. Env. Hlth. 
55(3), p. 217.
Faeder, E.J., Chaney, S.Q., King, L.C., Hinners,
T.A., Bruce, R. and Fowler, B.A. (1977) Toxicol.
Appl. Pharmacol. 39., 473-487.
Failla, M.L. and Cousins, R.J. (1978) Biochem. 
Biophys. Acta 543. 293-304.
Fasman, G.D. (1980) Ann. N.Y. Acad. Sci. 348. 147-
159.
FAO/WHO (1981) Food and Animal Feed Contamination 
Monitoring Programme Summary of Data Received from 
Collaborating Centres 1977-1980, part B., World 
Health Organisation, Geneva.
Fehrnstrom, H. and Moberg, U. (1977) LKB Application 
Note 306, LKB Produkter, Bromma, Sweden.
410
Feldman, S.L. and Cousins, R.J. (1973) Nutr. Rep.
Int. 8, 251-260.
Feldman, S.L. and Cousins, R.J. (1976) Biochem. J.
160. 583-588.
Feldman, S.L. and Cousins, R.J. (1978) Biochem. J.
160. 583-588.
Feldman, S.L., Squibb, K.S. and Cousins, R.J. (1978a)
J.-Tox. Environ. Health, 4, 805-813.
Feldman, S.L., Failla, M.L. and Cousins, R.J. (1978b)
Biochem. Biophys, Acta 544. 638-646,
Ferm, V.H. and Carpenter, S.J. (1976) Nature 
(London), 216. 1123.
Ferm, V. H. (1971) Biol. Neonate, 19., 101-107.
Ferm, V.H. and Carpenter S.J. (1968) Lab. Invest. 18. 
429-432.
Fischer, G.M. and Thind, G.S. (1971) Arch. Environ. 
Health, 23, 107-110.
Fischer, P.W.F. ,. Giroux, A. and L'Abbe, M. R. (1983)
J. Nutr. 113. 462-469.
Fiskin, A.M., Petersen, G. and Brady, F.O. (1977) 
Ultramicroscopy, 2., 389-395.
Flanagan, P.R., McLellan, J.S., Haise, J. Cherian, 
M.G., Chamberlain, M.J. and Valberg, L.S. (1978) 
Gastroenterol. 74., 841-846.
Flanagan, P.R., Haist, J. and Valberg, L.S. (1980) J. 
Nutr. 110. 1754-1763.
411
Fleischer, M., Sarofirm, A.F., Fassett, D.W.,
Hammond, P., Shaklette, H.T. , Nisbet, I.C.T. and 
Epstein, S. <1974) Environ. Health Perspec., 7, 253-
323.
Flohe, L. and GrUnzler, W.A. <1976) Glutathione: 
Metabolism and Function <Arias, I. M. and Jakob-, W.B. 
eds.) Vol. 6, pp. 17-34, Rowen Press, New York.
Fogel, S. and Welch, J.W. <1982) Proc. Natl. Acad. 
Sci. USA Z9, 5342-5346.
Foulkes, E.C. <1982) Ed. "Biological Roles of 
Metallothionein" Vol. 9, Elsevier, Amsterdam.
Foulkes, E.C. and McMullen, D.M. <1986), Toxicology 
38. 285-291.
Fox, M.R.S., Fry <Jr.), B.E., Harland, B.F.,
Schertel, M. E. and Weeks, C.E. J. Nutr, 101. 1295-
1305.
Frazier, J.M. <1980), J. Toxicol. Env. Hlth. 6, 503-
518.
Frazier, J.M. <1982) Role of metallothionein in the 
systemic distribution of cadmium.
Frazier, J.M. <1986) Environ. Health Perspec. 65., 39-
44.
Frazier, J.M. and Kingsley, B.S. <1976) Toxicol, and 
App. Pharmacol. 38., <583-593).
Frey, M.H., Wagner, G. , VasaK, M. , Sorenson, 0. W. , 
Neuhaus, D. , Wttrgdtler, E. , KMgi, J.H.R., Ernst, R. R. 
and WUthrich, K. <1985) J. Am. Chem. Soc. 107. 6847-
6851.
412
Friberg, L. (1978) In Cadmium 77: Edited Proceedings, 
First International cadmium conference, pp. 167-173, 
Metal Bulletin Ltd., London.
Friberg, L. , Piscator, M. , Nordberg, G.F. and 
Kjellstrdmn, T. (1974) Cadmium in the Environment,
2nd edn., C.R.C. Press Inc., Cleveland, Ohio.
Friberg, L., Elinder, C.G., Kjellstrdmn, T. and 
Nordberg, G.F. (eds.) (1985) Cadmium and Health: A
Toxicological and Epidemiological Appraisal, volume I 
and II, C.R.C. Press Inc., Florida.
Friedman, R.L. and Stark, G.R. (1985) Nature, 314 
637-639.
Friedman, R.L., Manly, S.P., McMahon, M. , Kerr, I. M. 
and Stark G.R. (1984) Cell 38, 745-755.
Fry, J.R., Jones, C.A., Wiebkin, P., Bellman, P. and 
Bridges, J.W. (1976) Anal. Biochem. 7_L, 341-350.
Furey, W.F. , Robbins, A.H. , Clancy, L.L., Winge,
D.R., Wang, B.C. and Stout, C.D. (1986) Science 231. 
704-710.
Furuta, H. (1978) Experienta, 34, 41-44.
Fuzimaki, H. , Murakami, M. and Kobota K, (1982) 
Toxicol. Appl. Pharmacol. 62., 288-293.
Gabbiani, G. (1966) Experientia 22. 261-262.
Gabbiani, G., Gregory, A. and Baic, D. (1967) J. 
Neuropath. Exp. Neurol. 26, 498-506.
413
Gale, T.F. and Layton, W. M. <1980) Teratol, 21, 181-
186.
Garty, M. , Wong, K.L. and Klaasen, C.D. (1981) 
Toxicol. Appl. Pharmacol. 59., 548-554.
Garvey, J.S. <1984) Environ. Health Perspec. 54, 117-
128.
Garvey, J.S. and Chang, C.C. <1981) Science, 214. 
805-806.
Garvey, J.S., Vander Mai lie, R.J. and Chang, C.G. 
<1982) Methods Enzymol. 84. 121-138.
Gawarski, C.L. and Sharma, R.P. <1978) Toxicol. Appl. 
Pharmacol. 46., 305-313.
Gerson, R.J. and Shaikh, Z.A. <1984) Biochem. 
Pharmacol. 33<2), p.199.
Ghafghaxi, T. and Mennear, J.H. <1973) Toxicol. Appl. 
Pharmacol. 26., 231-240.
Gieske, T.H. and Foulkes, E.C. <1974) Toxicol. Appl. 
Pharmacol. 27., 292-299.
Gill, P.F. <1978) In "Cadmium 77": Edited 
Proceedings, First International Cadmium Conference, 
pp. 207-211, Metal Bulletin Ltd., London.
Gamulin, S., Car, N. and Narenesik, P. <1977) 
Experientia, 33., 1144-1145.
Gruden, N. <1977) Arch. Toxicol. 37., 149-154.
Gunn, S. A., Gould, T.C, and Anderson, W.A.D. <1968) 
Proc. Soc. Exp. Biol. Med. 128., 591-595.
414
Hadley, W. M. , Miya, T.S. and Bousquet, W.F. (1974) 
Toxicol. Appl. Pharmacol; 28., 284-291,
Haffner, F. and Rugstad, H.E. (1976) Acta Pharmacol. 
Toxicol 38., 525-528.
Hall, A.C., Young, B.W. and Bremner, I. (1979) J. 
Inorg. Biochem. JLL, 57-66.
Hamilton, D.L. and Valberg, L.S. (1974) Am. J. 
Physiol. 227, 1033-1037.
Hamilton, D.L. and Smith, M.W. (1978) Environ. Res. 
15, 175-184.
Hartman, H.J. and Weser, U. (1977) Biochem. Biophys, 
Acta, 491. 211-222.
Hastings, L., Chendbury, H., Petering, H.G. and 
Copper, G.P. (1978) Bull. Environ. Contam. Toxicol. 
20. 96-101.
Hayes, J.A., Snider, G.L. and Palmer, K.C. (1976) Am. 
Rev. Respir. Dis. 113. 121-130.
Heath, J.C., Dancel, M.R., Dingle, J.T. and Webb, M. 
(1962) Nature, 193. 592-593.
Hidalgo, H.A., Koppa, V, and Bryan, S.E. (1976) FEBS 
Lett. 64, 159-162.
Higham, D.P., Nicholson, J.K., Overnall, J. and 
Sadler, P.J. (1986) Environ. Health Perspec. 6J5, 157-
166.
Hildebrand, C.E., Enger, M.D. and Tobey, R.A. (1980) 
Biol. Trace Element Res, 2, (235-246),
415
Hildebrand, C.E., Griffith, J.K., Tobey, R. A. , 
Walters, R.A. and Enger, M.D. (1982) Devel. Toxicol. 
Environ. Sci. 9, 279-303.
Hinton, R.H. and Dobrota, M. (1969) Anal. Biochem.
30. 99-110.
Hinton, R.H. and Dobrota, M. (1976) In "Laboratory
Techniques in Biochemistry and Molecular Biology" 
(Work, T. S. and Work, E. , eds. ) Vol. 6, pp. 1-290, 
North Holland.
Hinton, R. H. and Norris, K.A. (1972) Anal. Biochem.
48. 247-258.
HMSO (1983) A Survey of Cadmium in food, 1st 
Supplement Report. Steering Group on food 
Surveillance, Paper No 12.
Hod, Y. , Short, J., and Hansew, J.W, (1984) Fed. 
Proc. 43., 2218.
Holt, D. and Webb, M. (1983) Arch. Toxicol. 52(4), 
291.
Huang, I.Y. Yoshida, A., Tsunoo, H. and Nakajima, H.
(1977) J. Biol. Chem. 252. 8217-8221.
Huang, I.Y. , Tsunoo, H. , Kimura, M. , Nakashima, H.
and Yoshida A. (1979) In "Metallothionein" (Kagi, 
J.H.R. and Nordberg, M. , eds.) Birkhatlser, Verlag,
Boshen, pp. 169-172.
Huang, I.Y. , Kimura, M. , Hatta, A., Tsunoo, H. , and
Yoshida, A. (1981) J. Biochem. 89, 1839-1845.
Huang, P.C., Smith, B., Bohdan, P. and Corrigan, A.
(1980) Biol. Tr. Elem. Res. 2, 211.
416
Hunziker, P.E. and Kagi, J.H.R. (1985) Biochem J.
231. 375-382.
Hultberg, B. and Ockerman, P.A. (1972) Clin. Chim. 
Acta 39, 49-58.
Ithakissios, D.S., Kessler, W.V., Arvesen, J.N. and 
Born, G.S. (1974) J. Pharm. Sci. 63, 146-149.
Itokawa, Y. and Tanaka, S. (1973) Arch. Environ. 
Health, 26, 241-244.
Itokawa, Y., Abe, T., Tabei, R. and Tanaka, S. (1974) 
Arch. Environ. Health, 28., 149-154.
Itokawa, Y. , Nishino, K. Takashima, M. , Nakata, T. , 
Kaito, H. , Okamoto, E. , Daijo, K. and Kawamura, J. 
(1978) Environ. Res. 15., 206-217.
Jacobs, R. M. , Spivey-Fox, M.R. and Aldridge, M.H. 
(1969) J. Nutr. 108. 22-32.
Jacobson, K.B., Opreski, L. , Owenby, R. K. and 
Christie, N.T. (1981) Toxicol Appl. Pharmacol 60., 
268-278.
Jenny, H.J., Copuis Peeboom-Stegeman, Melet, J., 
Copius Peerboom, J.W. and Hooghwinkel, G.J.M. (1979) 
Toxicol. 14, 67-80.
Johnson, A.D. and Walker, G.P. (1970) J. Reprod. 
Fertil. 23, 463-468.
Johnson, W.T. and Evans, G. W. (1980) Biochem.
Biophys. Res. Comm.
Johnston, R.E., Miya, T.S. and Schnell, R.C. (1975) 
Biochem. Pharmacol. 24, 877-881.
417
Junko, S. and Etsuko, F. (1984) Eisei Kagasku, 30., 
309-312. Cited in "Environmental Pollution ot 
Cadmium Biological, Physiological and Health 
Effects", Nath, R. (ed), Interprint, New Delhi.
Kagi, J.H.R. (1970) Proc. 5th Int. Congr. Biochem. 
(130-131).
Kagi, J.H.R. and Nordberg, M., (19/9) (Eds.)
"Metallothionein", BirkhMuser Verlag, Boston.
Kagi, J.H.R. and Vallee, B.L. (1960) J. Biol. Chem.
235. 3460-3465.
Kagi, J.H.R. and Vallee, B.L., (1961) J. Biol. Chem.
236. 2435-2442.
Kagi, J.H.R., Himmelhoch, S.R., Whanger, P.D.,
Behtune, J.L. and Vallee, B.L. (1974a) J. Biol. Chem. 
249. 3537-3542.
Kagi, J.H.R,, V6s6k, M. , Lerch, K. , Gilg, D.E.O.,
Hunziker, P., Bernard, W,R. and Good, M. (1984)
Environ. Health Perspec. 54, 93-103.
Karin, M. (1985), Cell, 41_, 9-10.
Karin, M. and Richards, R.I. (1982) Nature, 299. 797-
802.
Karin, M. and Herschman, H.R. (1979) Science, 204.
176-177.
Karin, M. and Herschmann, H.R. (1981) Eur. J.
Biochem. 113. 267-272.
Karin, M. , Hershmann, H. R. and Weinstein, D. (1980) 
Biochem. Biophys. Res. Commun. 92. 1052-1059.
418
Karin, J.H.R., Haslinger, A., Holtgreve, H., Cathala,
G. , Slater, E. and Baxter, J.D. (1984a) Cell, 36. 
371-379.
Karin, M., Najarian, R., Haslinger, A., Valenzuela, 
P., Welch, J., and Fogel, S. (1984b) Proc. Natl. 
Acad., Sci., U.S.A. 81_, 3332-3336.
Karin, M., Imbra, R.J., Heguy, A. and Wong, G. (1985) 
Mol. Cell Biol. 5, 2866-2869.
Katoh M. , Mizutani N. , Keino, H. and Kashuwamata, S.
(1984) Toxicol, and App. Pharmacol. Z3_d.>» p. 97.
Kaur, J. (1982) cited in "Environmental Pollution of 
Cadmium - Biological Physiological and Health 
Effects" R. Nath (ed.), Interprint, New Delhi.
Kawai, K., Fukuda, K. and Kimura, M. (1976) In: 
"Effects and dose-response relationships of toxic 
metals" (Nordberg G.F., ed.) pp. 343-370, Amsterdam, 
Elsevier.
Kawamura, J., Yoshida, 0., Nishino, K. and Itokawa,
Y. (1978) Nephron 20, 101-110.
Kazantis, G. (1979), Environ, Health Perspec. 28. 
155-158.
Kazantis, G. (1978) In "Cadmium 77": Edited 
Proceedings, First International Cadmium conference, 
pp. 194-198 Metal Boulletin Ltd., London.
Kazantis, G. and Armstrong, B.G. (1984), Environ. 
Health Perspec. 54. 193-196.
Kazantis, G., Flynn, F.V., Spowage, J.S. and Trott,
D.G. (1963) Q.J. Med. 32., 165-192.
419
Kello, D., Sugawara, N, Voner, C, Foulkes, E.C.
<1979) Toxicol. 1_4, 199-208.
Kimura, M., Otak, N. Yoshiki, S., Suzuki, M.,
Honuchl, N., and Suda, T. (1974) Arch. Biochem. 
Biophys. 165 (340-348).
Kimura, M., Otakl, N., and Imario, M. (1979a) In 
"Metallothionein" (Kagi, J.H.R. and Nordberg, N. 
eds.) Birkauser Verlag, Boston, pp. 163-168.
Kimura, M, Otakl, N. and Kakefuda, T. (1979b) In 
"Metallothionein" (Kagi J.H.R. and Nordberg, M., 
eds.) Birkhauser Verlag, Basel, pp. 187-196.
Kinglsey, B.S., and Frazier, J.M. (1979), Am. J. 
Physiol. 236. 139-143.
Kissling, M.M. and Kagi, J.H.R. (1977), FEBS Lett.
82. 247-250.
Kissling, M.M. and Kagi, J.H.R. (1979) In 
"Metallothionein" (Kagi J.H.R. and Nordberg, M., 
eds.) Birkhauser Verlag, Boston pp. 145-151.
Kito, H., Ose, Y. and Sato, T. (1986) Environ. Health 
Perspec. 65., 117-124.
Kiupers, P.J. and Cousins R.J. (1984) Fed. Proc., 43,
1403.
Kjellstrom, T. (1979) Environ. Health Perspec. 28, 
169-197.
Kjellstrom, T. (1985) In "Cadmium and Health: A
Toxicological and Epidemiological Appraisal",
Friberg, L. Elinder, C.G., Kjellstrbm, T. and
420
Nordberg, G.F. (eds.) (1985) Volume II pp. 21-109
C.R.C. Press Inc. Florida.
Kjellstrdm, T. and Nordberg, G. (1978) Environ. Res. 
16. 248-269.
Kjellstrdm, T. , Lind, B., Linnman, L., Elinder, C.G.
(1975) Arch. Environ. Health 30, 321-328.
Kjellstrdm, T., Evrin, P.E. and Rahnster, B. (1977) 
Environ. Res. 13., 318-344.
Klaassen, C.D. (1985) Fundam. Appl. Toxicol. 5., 806-
815.
Klaassen, C.D. and Luang, K.L. (1982) Can. J.
Physiol. Pharmacol. 60., 1027.
Klauser, S., Kagi, J.H.R. and Wilson, K.J. (1983) 
Biochem. J. 209. (71-80).
Kletzien, R.F., Webber, C.A. and Stumpo, D.J. (1981) 
J. Cell. Physiol. 109. 83-90.
Kojima, Y. , Berger, C. , Vallee, B.L. and Kagi, J.H.R.
(1976) Proc. Natl. Acad, Sci. 73, 3413-3417.
Kojima, Y., Berger, C. and Kagi, J.H.R. (1979) 
Experientia Suppl. 34, 153-161.
Koller, L.D. (1979) Drug and Chem. Toxicol. 2_, 99-
110.
Koller, L.D., Exon, J.H. and Roan, J.G. (1975) Arch. 
Environ. Health 30., 598-601.
Koller, L.D., Exon, J.H. and Roan J.G. (1976) Proc. 
Soc. Exp. Biol. Med. 151. 339-342.
421
Koller, L.D., Exon, J.H. and Roan, J.G. (1976) Proc.
Soc. Exp. Biol. Med. 151'. 339-342.
Koller, L.D., Roan, J.G. and Kirkvliet, N.I. (1979)
Environ. Health 19., 177-178.
Koo, S.I., Fullmer, C.S. and Wassoman, R.H. (1978) J.
Nurtr. 108 1812-1822.
Kotsonis, F.N. and Klaasen, C.D. (1979) Toxicol.
Appl. Pharmacol. 4J_, 667-680.
Kotsonis, F.N. and Klaassen, C.D. (1978) Toxicol. 
Appl. Pharmacol 4^ ., (39-54).
Kotosonis, F.N. and Klaasen, C.D. (1979) Toxicol. 
Appl. Pharmacol. 5_1_, 19-28.
Krasrig, H.C. and Holbrook, D.J. (1977) Mol.
Pharmacol. 1J3, 759-765.
Kuliszewski, M.J. and Nicholls, D.M. (1982) Intern. J. 
Biochem. 14., 33-40.
Laemli, (1970) Nature 227. 680-684.
Larsson, S.E. and Piscator, M. (1971) Isr. J. Med.
Sci. 7, 495-498.
Lastowski-Perry, D., Otto, E., and Maroni, G. (1985) 
J. Biol. Chem. 260. (1527-1530).
Lauwerys, R., Butchet, J.P, and Roels, H. (1976) Int.
Arch. Occup. Environ. Health, 36. 275-285.
Lauwerys, R., Stanecsu, D., Roels, H. and Buchet,
J.P. (1978) In "Cadmium 77": Edited Proceedings.
422
First International Cadmium conference pp. 201-204, 
Metal Bulletin Ltd., London.
Lauwerys, R., Roels, H., Regniers, M. Buchet, J.P. 
Bernard,- A. and Goret, A. (1979) Environ. Res. 20., 
375-391.
Law, A.Y.C. and Stillman, M.J. (1980) B.B.R.C. 94,
138-143.
Lawson, K.J., Danepure C.J. and Fyfe, D.A. (1977) 
Biochem. Pharmacol. 26., 2417.
Lee, I.P. and Dixon, R.L. (1973) J. Pharmacol. Exp. 
Ther. 187. 641-652.
Leone, A., Paulakis, G.N. and Hamer, D.H. (1985) 
Cell, 40, 301-309.
Lerch, K. (1979) In "Metallothionein" (Kagi, J.H.R. 
and Nordberg M., eds.) BirkhMuser Verlag, Basel pp. 
173-179.
Lerch, K., Amner, D. and Olafson, R.W. (1982) J. 
Biol. Chem. 257. 2420-2426.
Ley H.L. (Ill), Faula M.L. and Cherry D.S. (1983) 
Comp/ Biochem. Physiol. 74b. 507-513.
Lorentzon, R. and Larsson, S.E. (19/7) Clin. Sci. 
Mol. Med. 53, 439-446.
Lowry, 0.H. , Rosebrough, N.J., Farr, A.L. and 
Randall, R.J. (1951) J. Biol. Chem. 193. (265-275).
Lucas, P.A., Jariwalla, A.G., Jones J.H., Grough, J.
and Vale P.T. (1980) The Lancet, 8186, 26 July.
423
Maekawa, K. , Tsunenari, Y. , Nokubi, K. and Waki M. 
(1965) Acta, Anct. Nippon 4X)., 200-208.
Maitani, T., Watahiki, A. and Suzuki, K.T. (1986) 
Arch. Toxicol. 58, 136-140.
Maiti, I., Mbikay, M., Marengo, C. and Thirian, J.
(1982) J, Cell Physiol. 112. 35-41.
Mandapal1imatim, G. and Riordan, J.R, (1977) Biochem. 
Biophys. Res. Commun. 7_7» 1286-1293.
Marceau, N. and Aspin, N. (1973) Biochim. Biophys. 
Acta, 293. 338-350.
Margoshes, M. and Vallee, B.L. (1957) J. Amer. Chem. 
SoC. 79., 4813-4814.
Maroni, G., Lastowski-Perry, E.O. and Watson D.
(1986) Environ. Health Perspec. 65. 107-116.
Mason R., Brady, F.0. and Webb, M. (1981) Br. J.
Nutr. 45. (391-399).
Matsubara, J. , Ishioka, K. , Egawa, J. Inada, T. and 
Machida, K. (1982) Proc. 3rd Internat. Sump. Soc. 
Radiological Protection, Inverness, U.K. pp. 358-363.
Meister, A. (1975) In "Metabolism of Sulphur 
Compounds" (Greenberg, D.M. , ed. ) pp. 101-188, Acad. 
Press, New York.
Mehra, R.K. and Bremner, I. (1983) Biochem. J. 213 (2) 
459-465 .
Mehra, R.K. and Bremner, I. (1985) Biochem. J. 227. 
903-908.
424
Melis, K.A., Carter, D.C., Stout, D. and Winge, D.R. 
<1983)- J. Biol. Chem. 258(10) p. 6255.
Menzel, H., Abel, J, and Merfort, F. (1982) Schm.
Arch. Pharmacol. Suppl. 319. R26.
Meulenaar H. , Van Den Hamer, C. J.A. , Van Den Ingh, 
V.S.G.A.M. and Stoik, T.M.W. (1985) Biol. Trac. Elem. 
Res. 7(1) p. 49.
Milner, B.A. (1983) A Technical Report, Philips, 
Cambridge.
Minkel, D.T. , Poulsen, K. , Wielgus, S. , Shaw, C.F. 
and Petering, D.H. (1980) Biochem J. 191. 475-485.
Mitane, Y., Tohyama, C. and Saito, H. (1986) Fund.
Appl. Toxicol. 6.285-291.
Moglinicka, E.M. and Piotrowski, J.K. (1979) Biochem 
Pharmacol 28., 2625-2631.
Mogilnicka, E.M. and Webb (1982) Chem. Biol.
Interact. 4X). (247-256).
Muller, L., Abel, J., Ohnersorge, F.K. (1986)
Toxicol. 39 187-195.
Muller, S., Gillert, K.E., Krause, C.H., Jantzke, G.,
Gross, V. and Diamanstein, T. (1979) Experienta 35., 
909-910.
MUnger, K. , Germann, U.A. and Lerch, K. (1985). EMBO J. 4,
2665-2668.
McCormick, C.C., Menard, P.M. and Cousins, R.J.
(1981) Am. J. Physiol. 240. E414-E421.
425
Nagamura, A., Satoh, M., Koyama, Y. and Imura, N.
(1985) Toxicol. Lett. 24, 203-207.
Nandi, M. , Slone, D. , Jick, H. , Shapiro, S. and 
Lewis, G.P. (1969) Lancet, 2_, 1329-1330.
Nett1esheim, D.G., Engeseth, H.R. and Otuos, J.D.
(1985) Biochem. 24^  6744-6751.
Newton, D., Johnson, P., Lally, A.E., Penreath, R.J. 
and Swift, D.J. (1984) Human Toxicol., 3, 23-28.
Nielson, K.B. and Winge, D.R. (1983) J.Biol Chem. 259 
13063-13069.
Nielson, K.B. and Winge, D.R. (1984) J.Biol Chem. 259 
4941-4946.
Nishizumi, M. (1972) Arch. Environ. Health 24., 215- 
225.
NoSl-Lambot, F. (1976) Experienta 32., 324-325. 
No&l-Lambot, F., Gerday, C. and Disteche, A. (1978) 
Comp. Biochem. Physiol 61C. 177-187.
Nogawa, K., Ishizaki, A., Fukushima, M. Shibata, I. 
and Hagino, N. (1975) Environ. Res. 10., 280-287.
Nogawa, K., Ishizaki, A. and Kawano, S. (1978) 
Environ, Res. 15., 185-198.
Nomiyama, K. and Nomiyama, H. (1982) Dev. Toxicol. 
Environ, Sci. 9, 47-67.
Nomiyama, K., Sugata, Y., Murata, I. and Nakagawa, S
(1973) Environ. Res. 6, 373-381.
426
Nomiyama, K., Sugata. Y., Yamamoto, A. and Nomiyama,
H. (1975) Toxicol. Appl Pharmacol. 31_, 4-12.
Nomiyama, K., Nomiyama, H., Yotoriyama, M and 
Taguchi, T. (1978) In Cadmium 77: Edited Proceedings, 
First International Cadmium conference pp. 186-194, 
Metal Bulletin Ltd., London.
Nordberg, G.F. (1972) Environ. Physiol. Biochem. 2. 
(7-36).
Nordberg, G.F. (1976) Effects and Dose - Response
Relationships of Toxic Metals, Elsevier, Amsterdam.
Nordberg, G.F. (1978) Environ. Health Perspec. 25
(3-41).
Nordberg, G.F. and Kjellstrom, T. (1979) Environ.
Health Perspec. 28., 211-217.
Nordberg, G.F., Piscator, M. and Lind, B. (1971a)
Acta Pharmaco. Toxicol. 29 (456-470).
Nordberg, G.F., Piscator, M. and Nordberg, M. (1971b)
Acta Pharmacol. Toxicol. 30. (289-295).
Nordberg, G.F., Nordberg, M., Piscator, M. and
Vesterberg, 0. (1972) Biochem. J., 126. (491-498).
Nordberg, M., Trojanoska, B. and Nordberg, G.F.
(1974) Env. Physiol. Biochem. 4_ 149-158.
Nordberg, G.F., Goyer, R.A. and Nordberg, M. (1975) 
Arch. Pathol. 99 192-197.
Nordberg, M., Nuottaniemi, I., Cherian, M.G., 
Nordberg, G.F. Kjellstrom, T. Garvey, J.S. (1986)
Environ. Health Perspec. 65., 57-62.
427
Oh, S., Dogan, J.T. , Whanger, P.D., and Woswig, P.H. 
<1978) Amer. J. Physiol'. 234. E282-E285.
Ohanian, E.V. and Dahl, L.K. (1976) Fed. Proc. 35,
555.
Ohanian, E.V., Iwai, J., Leitt, G. and Tuthill, R.
(1978) Am. J. Physiol. 235. H285.
Ohi, S., Cardenosa, G., Pine R. and Huang, P.C.
(1981) J. Biol. Chem., 256. 2180-2184.
Ohtake, H. and Koga, M. (1979) Biochem. J. 183. 683- 
690.
Olafson, R.W. (1981) J. Biol. Chem. 256. 1263-1268.
Olafson, R.W. (1983) J. Nutrition, 113(2) . 276.
Olafson, R.W. and Sim, R.G. (1979) Anal. Biochem.
100. 343-351.
Olafson, R.W., Sim, R.G. and Boto, K.G. (1979) Comp. 
Biochem. Physiol. 62., 407-416.
Onosaka, S. and Cherian, M.G. (1981) Toxicol 22 
91-101.
Onosaka, S. and Cherian, M.G. (1982a) Toxicol. 23. 
11- 2 0 .
Onosaka, S. and Cherian, M.G. (1982b) Toxicol. Appl. 
Pharmacol. 63., 270-274.
Otvos, J.D. and Armitage, I.M. (1980) Proc. Natl. 
Acad. Sci. U.S. 77, 7094.
428
Overnall, J. and Coombs, T.F. (1979) Biochem. J. 183. 
277-283.
Overnall, J., Berger, C. and Wilson, K.J. (1981) 
Biochem. Soc. Trans. 9, 217-218.
Overnall, J. and Trewhella, E. (1979) Comp. Biochem. 
Physiol. 64c, 69-76.
Page, A.L. (1981) In 'The Proceeding of the Heavy 
Metals in the Envioronment Conference' pp. 206-213, 
CEP Consultants Ltd., Amsterdam.
Palmer, K.C., Snider, G.L. and Hayes, J.A. (1975) Am. 
Rev. Respir. Dis. 112. 173-179.
Panemangalore, M. and Brady, F.O. (1979) J. Nutr., 
109. 1825-1835.
Parizek, J. (1957) J. Endocrinol. 15., 56-63.
Patierno, S.R., Fellis, N.R., Evans, R.M., Costa, M. 
(1983) Life Sci, 32(14), p. 1629.
Pattison, S.E. and Cousins, R.J. (1984) Fed. Proc.
43. 3712 (abstr.).
Pence, D.H., Miya, T. S. and Schnell, R.C. (1977) 
Toxicol. Appl. Pharmacol. 39., 89-96.
Perry, H.M. and Erlanger, M, W. (1973) J. Lab. Clin. 
Med. 82., 399-405.
Perry, H.M. and Yunice, A. (1965) Proc. Soc. Exp. 
Biol. Med. 120. 805-808.
Perry, H.M. and Erlanger, M. W. (1974) J. Lab. Clin. 
Med. 83, 541-547.
429
Perry H.M. , Erlandger, M. W. , Yunice, A., Schoepele, 
E,, and Perry, E.F. (1970) Am. J. Physiol. 219. 755- 
761.
Piotrowski, J.R., Bolanowska, W. and Sapota, A.
(1973) Apta Biochem. Pol. 20, 207-215,
Piotrowski, J.K., Trojanowska, B. Arch. Toxicol. 32., 
351-360.
Piotrowski, J.K. (1979).
Piscator, M. (1964) Nord. Hyg. Tidski 48, 76-82.
Piscator, M. and Axelsson, B. (1970) Arch. Environ. 
Health, 24, 426-431.
Prasad, P.V.V. , Sridhar, M. K.C. and Desalu, A.B.0.
(1983) Arch. Env. Cont. Toxicol. 1_2, 293-297.
Prigge, E. (1978) Arch. Toxicol. 40, 231-247.
Prigge, E. Baumert, H. P. and Muchle, H. (1977) Bull. 
Environ. Contam. Toxicol. V7_, 585-590.
Probst, G.S., Bousquet, W.F. and Miya, T.S, (1977a) 
Toxicol. Appl. Pharmacol. 39., 51-60.
Probst, G.S., Bousquet, W.F. and Miya, T.S. (1977b) 
Toxicol. Appl. Pharmacol., 39., 61-69.
Pullido, P, Kagi, J.H.P. and Vallee B.L. (1966) 
Biochem. 5 (1768-1777).
Rauser, W.E. and Curvetto, N.R. (1980) Nature, 287. 
563-564.
Revis, N. (1978) Life Sci. 23, 409-418.
430
Richards, M.P. and Cousins, R.J. (1975) Biochem.
Biophys. Res. Commun. 64, 1215-1223.
Richards, M.P. and Cousins, R.J. (1976) J. Nutr. 106.
1591-1599.
Richards, M.P. and Cousins, R.J, (1977) Biochem.
Biophys. Res. Comm. 75., (286-294).
Richardson, M.E. , Spivey-Fox, M.R. and Fry, B.E.
(1974) J. Nutr. 104. 323-328.
Riordan, J.R. and Richards V. (1980) J. Biol. Chem. ,
255. 5380-5383.
Roe, J,F,C. , .Duken, C.F. , Cameron, K. M. Pugh, R.C.B,
and Mitchley, B.C.V. (1964) Br. J. Cancer 18 674-681.
Rodbard, D. and Lewald, J.E. (1970) Acta Endocrinol 
(Copenhagen) Suppl. 147. 79-98.
Roels, H.A., Lauwerys, R.R. , Buchet, J.P., Bernard,
A., Chetle, D.R., Harvey, T.C. and Al-Haddad, I.K.
(1981) Environ. Res. 26., 217-240.
Roels, H., Lauwerys R. and Dardenne, A.N. (1983) Tox. 
Letts 15(4), (357-360).
Rugstad, H.E. and Norseth, T. (1975) Nature, 257.
136-137.
Rupp, H. and Weser, U. (1978) Biochem. Biophys. Acta 
533. 206-226.
Ryd6n, L. and Deutsch, H.F. (1978) J Biol. Chem. 252.
519-524.
431
Sabbioni, E. and Marafante, E. (1975) Environ. 
Physiol. Biochem. 5, 465-473.
Sabbioni, E., Marfante, R., Pietra, L., Amantini and 
Ubertalli, L. (1978) Proc. Cadmium Symposium, Jena, 
DOR 1-3 August 1977.
Samarawickramama, G.P. (1979) In: The Chemistry, 
Biochemistry and Biology of Cadmium (Webb, M. , ed. ) 
pp. 341-421, Elsevier/North Holland Biochemical 
Press.
Saylor, W.W., Morrow, F.D. and Leach, R.M, (1980) J. 
Nutr. 110. 460-468.
Sato, M. and Bremner, I. (1984) Biochem. J. 223 (2) p. 
475-479.
Sato, M. and Takizawa, Y. (1982) Tox. Letts., 11.
269-275.
Scheuhammer, A.M., Onasaka, Rodgers, K. and Cherian, 
M.G. (1985) Toxicology 36. (2-3) p. 101-108.
Scheuhammer, A.M. and Cherian, G.M.G. (1986) Toxicol. 
Appl. Pharmacol. 82., 417-425.
Schnell, R.C., Pence, D.H., Prosser, T.D. and Miya, 
T.S. 9176) Toxicol 6, 277-279.
Schroeder, H.A. and Vinton, W.H. 91962) Am. J. 
Physiol. 202, 515-518.
Searle, P., Davison, B.L., Stuart, G.W. , Wilke, T.M. , 
Nordstedt, G. and Palmiter, R.D. (1984) Mol. Cell. 
Biol. 4, 1221-1230.
432
Selenke, W. and Foulkes, E.C. (1981) Proc. Soc. Exp.
Biol. Med., 167. 40-44.
Shaikh, Z.A. and Lucis, O.J. (1970) Fed. Proc. Fed.
Am. Soc. Exp. Biol. 29., 298.
Shaikh, Z.A. and Smith, J.C, (1975a) Abstr. Internat.
Conf. Heavy Metals in the Environment, Toronto, 27-31
October, B-108.
Shaikh, Z.A. and Smith, J.C. (1976) Chem. Biol.
Interact. 1.5, 327-336.
Shaikh, Z.A. and Smith, J.C. (1977) Chem. Bio.
Interact., T9, 161-171.
Shaikh, Z.A. and Smith, J.C. (1980) Mechanisms of
toxicity and hazard evaluations, Holmstedt, B. 
Lauwerys, R., Mercer, B. and Rooke, M., Elsevier, 
Amsterdam, pp. 569.
Shapiro, S.G., Squibb, K.S. Markowitz, L.A, and 
Cousins, R.J. (1978) Biochem J. 175. 833-840.
Sharma, R.P. and McQueen E.G. (1982) Biochem.
Pharmacol. 3l_ (12), (2153-2159).
Sharma, R.P., Kjellstromn, T. and McKenzie, J .M.
(1983) Toxicol. 29. 163-171.
Sherlock, J.C. (1984) Experientia 40., (1) 152-156.
Shiraishi, Y. and Yoshida, T.H. (1972) Proc. Jap.
Acad. 4J3, 248.
Shiraishki, Y. , Kurahashi, H. and Yosida, T.H. (1972) 
Proc. Jap. Acad. 4^., 133.
433
Singhai, K. , Kjellstrdm, T. , Kubota, K. , Evrin, P.E., 
Anayama, M., Vesterburg, 0., Shimada, T., Piacator,
M., Iwata, T. and Nishino, H. (1977) Environ. Res.
13. 407-424.
Skilleter, D.N. and Cain, K. (1981) Chem. Biol. 
Interact. 37., 289-298.
Smith, K.T. and Cousins, R.J. (1980) J. Nutr. 110. 
316-323.
Snider, G.L., Hayes, J.A., Korthy, A.L. and Lewis,
G.P. (1973) Am. Rev. Respir. Dis. 108. 40-48.
Sobocinski, P..Z. and Canterbury, W.J. (1982) Ann. NY 
Acad. Sci. 210. 354-367.
Sobocinski, P.Z., Canterbury Jr., W.J., Mapen, C.A. 
and Dinterman, R.E. (1978) Am. J. Physiol., 234. 
E399-E406.
Sommers, L.E. (1977) J Environ. Qual. 6, 225-231.
Squibb, K.S. and Cousins, R.J. (1974) Environ. 
Physiol, Biochem. 4, 24-30.
Squibb, K.S. and Fowler, B.A. (1984) Environ. Health 
Perspec. 54^ , 31-35.
Squibb, K., Cousins, R., Silson, B. and Lewis, S.
(1976) Exp. Mol. Pathol. 25., (163-171).
Squibb, K.S., Cousins, R.J. and Feldman, S.L. (1977) 
Biochem J. 164. 223-228.
Squibb, K.S., Ridlington, J .W., Charmichael, N.G. and 
Fowler, B.A. (1979) Environ. Health Perspec. 28. 287- 
296.
434
Squibb, K.S., Pritchard, J.B. and Fowler, B.A. (1982) 
In "Biological roles of' Metallothionein (Foulkes, 
E.C., ed.) pp. 181-192 Elsevier/North Holland, New 
York.
Squibb, K.S., Pritchard, J.B. and Fowler, B.A. (1984; 
J. Pharmacol. Expt. Therapeutics, 229. 311-321.
Stacey, N.H. and Klaassen, C.D. (1980) Toxicol. App. 
Pharm. 55, 448-455.
Stacey, N.H. and Klaassen, C.D. (1981). Biochem. 
Biophys. Acta. 640. 693-69/.
Stacey, N.H., Cantilena, L.R. Jr. and Klaassen, C.D.
(1980) Toxicol. Appl. Pharmacol. 53., 460-480.
Starcher, B.C., Glauber, J.G. and Madares, J .G.
(1980) J. Nutr. 110. 1391-1397.
Steele, W.J. and Busch, H. (1967) In "Methods in 
Cancer Research" (Busch, H., ed.) Vol. 3, pp. 61-152.
Stoeppler, M. , Brandt, K, and Fresenus, 2. (1980)
Anal. Chem. 300. 372-380.
Stoll, R.E., White, J.F., Miya, T.S. and Bousquet, 
W.F. (1976) Toxicol. Appl. Pharmacol. 37., 61-74.
Stonard, M. D. and Webb, M. (1976) Chem, Biol.
Interact. 15., (349-363).
Stone, H.C., Wilson, S.B. and Overnal1, J. (1986) 
Environ. Health. Perspec. 65., 189-192.
Stowe, H.D., Wilson, M. and Geyer, R.A. (1972) Arch. 
Pathol. 9j4, 389-405.
435
Suda, T. , Horiuchi, N. , Ogata, E., Ezawa, I. and 
Kimura, M. (1974) FEBS Lett. 42., 23-26.
Sugawara, N. 91977) Arch. Environ. Contam. Toxicol. 
6, 121-128.
Sugawara, N. and Sugawara, C. (1974) Arch. Toxicol. 
32. 297-306.
Sugawara, C. and Suguwara, N. (1977) Arch, environ, 
Contam. Toxicol. 6, 121-128.
Sugawara, N., Sadamoto, T. and Sugawara, C. (1983) 
Bull. Environ. Contam. Toxicol. 3_Z, 386-390.
Suzuki, K.T., Takenaka S. and Kubota, K. (1979) Arch 
Environ. Contam. Toxicol. 8, 85-95.
Suzuki, K.T., Matomura, T., Tsuchiya, K. and 
Yamamura, M. (1980) Anal. Biochem. 107. 75.
Suzuki, K.T. , Sunaga, H. , Aoki, Y. and Yamamura, M. 
(1983a) J. Chromatog. 281. 159-166.
Suzuki, K.T. , Ohnuki, R. , Vaguchi, K. , Yamada, Y.K. 
(1983a) J. of Tox. and Env. Health, i!_ (4-6) 727.
Suzuki, Y. (1980) Industrial Health, 18., 19-29.
Suzuki, Y. (1981) J. of Toxicol, and Environ. Health 
Z, 251-262.
Suzuki, Y. and Yoshikawa, H. (1981) J. of Toxicol, 
and Environ. Health 8, 497-487.
Swerdel, M. R. and Cousins, R.J. (1984) .Proc. Soc. 
Exp. Biol. Med. 175. 522-529.
436
Szasc, G. (1971) Clin. Chem. 17 641-645.
Taguchi, T. and Nakamura, K. (1982) J. Toxicol. 
Environ. Health 9, 401-409.
Takashima, M., Nishino, K. and Itokwawa, Y. (1978) 
Toxicol. Appl. Pharmacol. 41., 57-65.
Takenaka, S., Oldigien, H., Konig, H.,Hochrainer, D. 
and Oberdorster, G. (1983) J.N.C.L. ZQ., 367-373.
Talbot, B.G., Bilodeau, G. and Thirion, J.P. (1986) 
Molec. Immunol. 23., 1133-1136.
Tanaka, K. , Min, K.S. , Onosaka, S. , Fukuhara, C. and
Ueda, M. (1985) Toxicol. App. Pharmacol. 78., 63-68.
Tanaka, K., Nomura, H., Onosaka, S. and Kyong-son, M.
(1981) Toxicol. Appl. Pharmacol 59, 535-539.
Tanaka, K. , Min, K.S. , Ohyanagi, N. , Onosaka, S. and
Fukuhara, C. (1986) Toxicol, and App. Pharmacol. 83 
(197-202).
Teare, F.W. , Jasansky. P., Renaud, L. and Read, P.R.
(1977) Toxicol. Appl. Pharmacol 4JL, 57-65.
Terao, T. and Owen, C.A. (1973) Amer. J. Physiol.
224. 682-686.
Thind, G. S. (1972) J. Air Pollut. Control Assoc. 22., 
267-270.
Thomas, D.G., Cryer, A., Solbe, J.F. de L.G. and Kay, 
■J. (1983) Comp. Biochem. and Physiol. 76., 241-246.
437
Thomas, D.G., London, H.J. and Garvey, J.J. (1986) J. 
Immunol. Meth. 89., 239-247.
Thornally, P.J. and Vasak, M. (1985) Biochim.
Biophys. Acta, 827. 36-44.
Tohyama, C. and Shaikh, Z.A. (1978) B.B.R.C. 84, 907-
913.
Tohyama, C. and Shaikh, Z.A. (1981) Fund. Appl.
Toxicol. 1_, 1-7.
Tohyama C., Shaikh, Z.A., Ellis, K.J. and Cohn, S.H.
(1981) Toxicol. 22. 181-191.
Tohyama, C., Shaikh, Z.A., Nogawa, K., Kibayashi, E. 
and Honda, R. (1982) Arch, Toxicol. 50. 159-166.
Townsend, R. H. (1982) Brit. J. Ind. Med. 39., 411-412.
Unger, M. and Clausen, J. (1973) Environ. Physiol. 
Biochem. 3, 236-242.
Valberg, L.S., Sorbie, J. and Hamilton, D.L. (1976)
Amer. J. Physiol. 231, 462-467.
Valberg, L.S., Haist, J., Cherian, M.G.,
Delaquerriere-Richardson, L. and Groyer, R.A. (1977) 
Toxicol. Environ. Health 2., 963-975.
Vallee, B.L. and Ullmer, D.D. (1972) Ann. Rev.
Biochem. 41 91-128.
Vander Mallie, R.J. and Garvey, J.S. (1978)
Immunochemistry 15., (857-868) .
Vander Mallie, R.J. and Garvey, J.S. (1979) J. Biol.
Chem. 254. (17) (8416-8421).
438
VaS&k, M., Kdgi, J.H.R. and Hill, H.A.O. (1981) 
Biochem. U.S.A. 20., 2852-2856.
VaSdk, M., Berger, C. and Kdgi, J.H.R. (1984) FEBS 
Lett. 168. 174.
VaSdk, M. McClelland C.E., Hill, H.A.O. and Kagi, 
J.H.R. (1985) Experimentia 41_, 30- .
Waalkes, M.P., Chernoff, S.B. and Klaassen, C.D.
(1984) Biochem. J. 220. (811-818).
Walkes, M.P., Garvey, J.S. and Klaassen, C.D. 91985) 
Toxicol, and App. Pharmacol. 79.(3), p. 524.
Wake, S.A. and Mercer, J.F.B. (1985) Biochem. J. 219.
539-546.
Washko, P.W. and Cousins, R.J., (1977) J. Nutr. 107.
920-928.
Webb, M. (1972) Biochem. Pharmacol. 21_, 2751-2765.
Webb, M, (1972b). J. Reprod. Fertil. 30., 83-98.
Webb, M, (1972c) Biochem. Pharmacol. 2_1_, 2767-2771.
Webb, M. (1975) Biochem. Soc, Trans. 3. 632-634.
Webb, M. (1977) In "Clinical Chemistry and Chemical 
Toxicology of Metals" (Brown, S, ed. ) Elsevier, North 
Holland Biomed. Press, Amsterdam pp. 51-64.
Webb, M. (1979) Ed. , "The Chemistry, Biochemistry and 
Biology of Cadmium", Elsevier, Amsterdam.
Webb, M. and Cain, K. (1982) Biochem. Pharmacol. 31.
137-142.
439
Webb, M. and Daniel, M. (1975) Chem. Biol. Interact., 
10. 269-276.
Webb, M, and Etienne, A.T. C1977) Biochem Pharmacol. 
26. 25-30.
Webb, M, and Verschoyle, R.D. (1976) Biochem. 
Pharmacol. 25, 673-679.
Wehland, J., Willingham, M.C., Gallo, M.G. and 
Pastan, I. (1982) Cell, 28, 831-841.
Weigel, H.J., Edmadfa, I., Jager, H.J. (1984a) Arch. 
Env. Contam. and Toxicol. JJ3(3) , p. 289-296.
Weigel, H.J., Jager, H.J., Edmadfa, I. (1984b) Arch. 
Env. Contam. and Toxicol. 13.(3), (279-287).
Weser, U., Hubner, L. and Jung, H. (1970) FEBS Lett. 
Z, 356-358.
Weser, U. and Rupp. H. (1979) In 'The Chemistry, 
Biochemistry and Biology of Cadmium' (Webb, M., ed.) 
Elsevier, Amsterdam, pp. 267-283.
Weser, U. , Rupp, H. , Donay, F. , Linnemann, F. , 
Voelter, W, , Voetsch, W. and Jung, G. (1973a) Eur. J. 
Biochem. 39. (127-140).
Weser, U., Donay, F. and Rupp, H. (1973b) FEBS Lett. 
32. 171-174.
Whanger, P.D. and Oh, H. (1979) Experienta Suppl. 34. 
281-291.
440
Widnell and Little (1977) Methodol. Surv. Biochem. 6, 
149-162.
Winge, D.R. and Garvey, J.S. (1983) P.N.A.S. (U.S.A.) 
80(9), 2472-2476 Proc. Natl. Acad. Sci.
Winge, D.R. and Miklossy, K.A. (19820 J. Biol. chem. 
275(7), 3471-3476.
Winge, D.R. and Rajagopala, K.V. (1972) Arch.
Biochem. Biophys. 153. 755-762.
Winge, D.R., Premakumar, R. Wiley, R.D. and
Rajagaopalan, K.V. (1975) Arch. Biochem. Biophys.,
170. 253-266.
Winge, D.R., Geller, B.L. and Garvey, J.I. (1981) 
Arch. Biochem. Biophys., 208. (160-166).
Winge, D.R., Neilson, K.B., Zeikus, R.D. and Gray, 
W.R. 91984) J. Biol. Chem. 259(18), p. 11419.
Wisniewska-Knypl, J.M. (1975) Abstr. XVIII Internat. 
Congress Occupational Health, Brighton, England 14-19 
Sept. p. 291.
Wisse and Knook (1977) Eds. "Kupffer cells and other 
liver sinusoidal cells", Elsevier, North Holland.
World Health Organisation (WHO) (1972) Tech. Rep.
Ser. WHO No. 505
World Health Organisation (WHO) (1980) Report of a 
study group.
Yau, E.T. and Mennear, J.H. (1977) Toxicol. Appl. 
Pharmacol. 39. 515-520.
441
Yoshikawa, H. and Suzuki, Y. (1976) Ind. Health 14. 
103-108.
Yoshiki, S. Yanagisawa, T. , Kimura, M. , Otaki, N., 
Suzuki, M. and Suda, T. (1975) Arch. Environ. Health 
30. 559-562.
Yuhas, E.M. , Miya, T. S. and Schnell, R.C. (1978) 
Toxicol. Appl. Pharmacol. 43., 23-31.
Yokata and Fahimi, (1981) Proc. Nat. Acad. Sci. USA 
78 4970-4974.
Zelazowski, A.J., Szymanska, J.A. and Cierniewska, 
C.S. (1980a) Chem. Biol. Interact, 33, 115-125.
Zelazowski, A.J., Szymanska, J.A. and Witas, H.W. 
(1980a) Prep. Biochem. 10. 495.
Zelazowski, A.J., Garvey, J.S. and Hoeschelle, J.D. 
(1984) Arch. Biochem. Biophys. 229(1) 246-252.
442
APPENDIX I
Occurrence of "metallothlonein-1 ike” cadmium binding 
proteins
1. Mamina 1 s
Cadmium binding proteins from the testes of untreated 
rats can be separated by gel filtration into three 
major metal binding protein peaks, with apparent 
molecular weights of 30,000, 15,000 and 8,000 dal tons
(Brady and Webb, 1981). Several reports have 
indicated the presence of a metallothionein-1ike 
protein in rodent testes (Chen et a 1. 1974; Singh et_
al. 1974) after cadmium treatment. Further
characterisation of the low molecular weight (8,000 
daltons) cadmium binding protein by Waalkes et a1.
(1984), provided evidence that although the proteins 
behave similarly to metallothionein on gel filtration 
chromatography and ion-exchange chromatography (Brady 
and Webb, 1981); they differ in their amino acid 
content, U.V. absorbtion spectrum and properties 
with denaturing polyacrylamide electophoresis. The 
most distinctive difference between mammalian 
metallothioneins and the testicular protein is that 
the latter contains only 3-4 cysteine
residues/molecule unlike the 17-20 residues observed 
with the purified metallothionein. The testicular 
metalloproteins also contain approximately half the 
number of serine and lysine residues found in the two 
forms of metallothionein (Waalkes et al. 1984;
Waalkes and Perantoni 1986). The presence of 
aromatic amino acid in the testicular metalloprotein 
may also account for the ultra-violet spectral 
differences between it and metallothionein - an
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observation also noted in other studies (Chen et a1. 
1972; Singh et al. 1974).
Various assays for metallothionein, including the Cd- 
binding assay of Onosaka et al, (1978) and Hg-binding 
method of Piotrowski et a 1. (1973) will detect
relatively high levels of metallothionein in' 
untreated rat testes (Wong and Klaassen, 1980;
Onosaka and Cherian, 1981, 1982). However, these
assays measure either acid-stable Hg-binding moieties 
or heat stable Cd-binding ligends and as such are not 
specific for metallothioneins. Metallothionein has 
also been detected in the rat testes with a 
radioimmunoassay using an anti-rat metallothionein I 
antiserum. This does suggest that either the
antibody used in this assay is not solely specific
for metallothionein or, more likely, that the rat 
testicular cadmium binding proteins possess similar 
antigenic determinants(s) to the hepatic 
metallothionein used to evoke this antibody.
The presence of metallothionein-1ike protein in rat 
placenta, (Lucis et al. 1972) and human placenta (Ose
et a1. 1977) has been identified. Its molecular
weight was estimated to be about 10,000 daltons. 
Arizono et al. (1981) isolated two rat placenta
metallo-proteins of 6,000 and 11,000 daltons.
Further characterisation of these proteins by amino 
acid analysis showed them to have low cysteine 
content (4-6%) and the existence of aromatic amino 
acid residues. However, the cysteine content does 
not appear to be proportional to the cadmium-protein 
molar binding ratio.
After injection of CdCl::s, the mammary gland of 
pregnant and lactating rats accumulates cadmium bound 
to a component of greater than 50,000 daltons (Lucis 
et al. 1972). Maytin and Young, (1983) reported that
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cadmium in thymic lymphocytes induced two proteins, 
metallothionein and a 27,000 dalton protein, but 
provided no indication whether the latter binds 
cadmi urn.
2. Fish
Thomas et a1. (1983), by exposing rainbow trout
(Salmo Qairdneri Richardson) to a low cadmium 
concentration in the water (9pg/l) for up to 36 
weeks, identified two hepatic low molecular weight 
proteins (13.5 and 14.0 kilodaltons) distinct from 
metallothioneins. These proteins were low in 
cysteine content (<5%) and appeared to be responsible 
for binding most of the cadmium that accumulated in 
the liver. They co-elute on G75 gel filtration 
chromatrography with zinc-thionein from the liver of 
the animals. However, these proteins were separated 
by ion-exchange chromatography. Their immunological 
properties also appeared to be different when 
assessed for immunoreactivity in a radioimmunoasay 
for mammalian metallothionein (Kay et a1. 1986)
3. Invertebrates
Two electrophoretically pure binding proteins with 
molecular weights of 3000 daltons and 13,000 daltons 
and classed as FIIA and FI IB, have been isolated from 
the whelk Buccinium tenassium hepatopancreas (Dohi et 
a1. 1983, 1986). FIIB appears to be a dimer of FIIA
as the former dissociates to an 8000 dalton component 
in the presence of 2-mercaptoethanol. These two 
components also appear to be glycoproteins; FIIA 
consisting of 79.7% protein and 20.3% carbohydrate, 
whereas FIIB consists of 91.3% protein and 8.7% 
carbohydrate. The carbohydrate fraction consists of 
galactose, fucose and mannose.
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The whelk cadmium binding protein (CdBP) showed 
metal-binding characteristics markedly different from 
those of mammalian metallothionein, in which metals 
ligate to the 20 metal co-ordinating cysteine 
residues to form a cadmium cluster COtvos and 
Armitage et a1. 1980). Whelk CdBP has a high
affinity for cadmium and copper but not zinc. As 
cadmium binding to the glycoprotein, took place in 
the presence of Hg^ -*", there are indications that the 
sulphydryl groups of the glycoprotein are necessary 
not for metal co-ordination, but for retaining the 
conformation of the protein. Dohi et a 1. (1986)
suggest that this glycoprotein is a normal cellular 
constituent, to which cadmium binds following 
exposure to the metal.
Working with the New Zealand oyster (Ostrea lutaria). 
Sharma et al. (1983) found that about 60% of the
total cadmium was bound to high molecular weight 
proteins. Other workers (Casterline and Yip, 1975; 
Ridlington and Fowler, 1979) have found that about 
40% of the total cadmium content of American oysters 
was associated with an organic ligand (possibly 
taurine), while the remaining cadmium that associated 
with peptides or organic complexes. This difference 
in cadmium distribution in the soluble fraction of 
homogenates from oysters of different gena was also 
observed by Nordberg et al. (1986). These workers
observed that cadmium was mainly bound to a heat 
stable protein of about 10,000 daltons in the dredge 
oyster (Ostrea lutaria) ; whereas in the rock oyster 
(Crassostrea glomerata). no such cadmium binding 
protein was found, and most of the cadmium was 
associated with low molecular weight components 
(<1000 daltons).
The low molecular weight cadmium peptides located in 
American oyster by Ridlington and Fowler (1979) were
446
further studied by Fowler et a 1. (1986), using DEAE
ion-exchange chromatography, where a single component 
was isolated. This component had a molecular weight 
of 10,000 daltons, contained a lower cysteine content 
that mammalian metallothionein and contained aromatic 
amino-acids. The protein was found to bind mainly 
cadmium, with moderate amounts of copper and a little 
zinc. The ultra-violet absorbtion spectrum of the 
purified protein varied with the isolation and 
handling technique.
4. P1 ants
Cadmium binding proteins have been isolated from the 
vascular plants, maize (Rausser et a1. 1984a), tall
bent grass, cabbage (Rausser et al. 1984b,c) and
tomato (Rausser, 1985). These plant proteins are 
highly acidic (containing 38.58% glutamic and 
aspartic acids), which contributes to the large 
differences in shape of the complex at high and low 
ionic strengths. Cysteine (about 25%) and glycine 
(about 13%) are the other major amino acids.
The tomato, maize and bent grass proteins have 
apparent molecular weights between 3000 and 3700 
daltons under reducing conditions. However, the 
proteins tend to aggregate and migrate as molecules 
about 7 times larger upon isolation using gel 
f i1trat ion.
These polypeptides are composed exclusively of 
glutamate, cysteine and glycine (molar ratio of 
8:7:10) and may exist as aggregated 1.5-2.0 
kilodalton units. The Cd:cysteine ratio of these 
polypeptides has been estimated to be about 1:3. The 
chemical form of cadmium in the rice and wheat plants 
appears to be in 3 main protein fractions following 
gel filtration with Sephadex G75 - large molecular
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weight protein(s) (440,000 daltons), 31000 dalton 
protein(s) and 7000 dalton protein(s). (Kaneta et_ 
al. 1986).
Meisch and Schmitt, (1986) reported the existance of 
four glycoproteins which contain sulphur and bind 
cadmium and copper in the mushroom (Agaricus • 
macrosporus). These glyco proteins are of low 
molecular weight and contain about 3.8% cysteine with 
glutamic and aspartic acids and glycine as the major 
amino-acids.
As these plant cadmium binding proteins are smaller 
and more acidic than mammalian metallothioneins they 
have been classed as phytometallothioneins by Rausser 
et al. 1984. Grill et a 1. (1985) detected a metal
binding peptide in plant suspension cultures 
following Cd,Zn,Cu,Hg, and Pb induction. They 
classed these as phytochelatins. These peptides had 
a molecular weight of about 3500 daltons, similar 
U.V, and C.D. absorption spectra to mammalian 
metallothionein, and consist of between 7 and 9 amino 
acids (glutamic acid, cysteine and glycine only).
The phytochelatins are not believed to be directly 
coded by genes, but are synthesised enzymatically as 
demonstrated by their amino acid sequence containing 
Y-glutamyl bonds.
5. Bacteria
Higham et al. (1984) showed that Pseudomonas putida
actively accumulates cadmium from the growth medium 
and their resistance mechanism appears to involve 
initial immobilization of cadmium in polyphosphate 
granules until a series of low molecular weight 
cadmium binding proteins; 'Pseudothioneins' are 
induced. Three cysteine-rich proteins (molecular 
weight 4-7 kilodaltons) with 4-7 gram atoms of
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cadmium, zinc or copper/mole are induced during 
different phases of growth, following exposure to 
cadmium [classed as CdBPI <6,700 daltons), CdBPII 
<6900 daltons) and CdBP3 <360 daltons)]. The CdBP3 
binds the highest proportion of cadmium in these 
bacteria. The amino acid composition of these three 
components consists of between 6-8 cysteine residues 
and low aromatic amino acid content <0-1.6%). This 
indicates that these pseudothioneins have a lower 
cysteine content than that of mammalian 
metal 1othioneins < 33%), thus the metal:cysteine 
stoichiometry cannot be 1:4 as that found in the 'A* 
cluster of the mammalian metallothioneins. They have 
lower serine and lysine contents but higher 
glutamate, alanine, valine and leucine contents - 
rarely found in mammalian metallothioneins. Despite 
the similarities in amino acid content between these 
pseudothioneins, the composition of amino acids is 
different enough for Higham et a1« <1986) to suggest
that these CdBPs are distinct proteins/peptides.
A cadmium binding protein was identified in Cyano­
bacteria Svnechococcus strain TX20 <01afson, 1986). 
The prokaryotic molecule was found to be induced in 
the presence of cadmium or zinc salts with regulation 
occuring at the level of transcription. Copper did 
not appear to induce the synthesis of this protein. 
This cadmium binding protein of about 10,000 daltons, 
contained the characterisitc cysteine-residue- 
cysteine sequence, apparent with mammalian 
metallothionein. However, the cyanobacterial protein 
differed from mammalian metallothionein by its many 
aromatic and aliphatic residues and the lack of 
associated hydroxylated and basic amino acid residues 
with cysteine. This lead these workers to conclude 
the cyanobacterial protein is not a metal 1othionein.
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APPENDIX II
The preparation of samples for the measurement of 
metals by atomic absorbtion spectromtry
1. T 1ssues
To 0,5g quantities of sample in 50 ml concial flasks,
5.0 ml of HN03 (sp.gr. 1.42) and 1.0 ml of HCIO^ , 
(sp.gr. 1.54) were added, and allowed to stand for 30 
min. The flasks were then heated gently to 150° on a 
hotplate, avoiding a vigorous reaction. After the 
initial reaction had subsided and a yellow-brown 
solution formed, the samples were evaporated to 
dryness at 200-300°C. When cool, the residues were 
made up with 5.0 ml of reverse osmosis/deionized 
(RO/DI) water and prepared for metal determinations 
as foilows:
Cadmi urn
Stock Standard Solution: CdCl3 1.0 mg/ml.
Working Standard Solution: 1.0 jjig/ml.
A range of standards from 0-0.2 pg/ml were prepared 
in 4.5 M HN03 , and samples diluted with RO/DI water 
as necessary.
Zinc and Copper
Stock Standard Solutions: (CH3C00)3Zn,2H30) 10 mM
C uC13 .2H30 )
Working Standard Solutions: 100 jiM
453
A range of standards from 0-10 pM was prepared in 4.5 
M HNO3, and samples diluted with RO/DI water as 
necessary,
2. Ur ine
To 1.0 ml samples of urine in 5 ml conical flasks,
1.0 ml of HNO3 (sp.gr. 142) was added. The flasks 
were then heated gently to 150°C on a hot plate, 
avoiding a vigourous reaction. After the initial 
reaction had subsided, the samples were evaporated'to 
dryness at 200-300°C. When cool, the residues were* 
made up with 1.0 ml of RO/DI water and prepared for 
metal determinations as follows:
Cadmi urn
Stock standard soluction: CdCl3 1.0 mg/ml 
Working Standard Solution: 1.0 pg/ml
A range of standards from 0-0.2 pg/ml was prepared in 
4.5 M HN03 and samples diluted with RO/DI water as 
necessary.
Zinc
Interference of the urine matrix was avoided by using 
the method of standard additions, the urine samples 
being used to prepare a standard curve. Thus any 
matrix effect was identical for standards and 
samples.
Stock Standard Solution: (CH3 . COO)2Zn. 2H;n;0 10 mM
Working Standard Solution: 2.5 jjiM 
A range of standards from 0-50 pM was prepared.
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Copper
Stock Standard Solution: CuCl;n;. 2HS0 10 mM 
Working Standard Solution: 0.1 mM
A range of standards from 0-6 pM was prepared in 
urine.
APPENDIX III
Composition of Laboratory Animal Diet
Chemical Composition %
Moisture 8/8
Ether extract 3. 5
Crude protein 21.5
Crude fibre 2 ; 7
Total digestible nutrients 78.0
Vitamin and Mineral Composition
Lysine % 1. 1
Methionine % 0. 39
Calcium % 0. 9
Phospate % 0.8
Vitamin A i.u./kg 11,000
Vitamin D3 i.u./kg 1, 200
a-tocopherol i.u./kg 24
Vitamin K3 mg/kg 10
Riboflavin mg/kg 7
Pyridoxine mg/kg 1
Pantothenic acid mg/kg 17
Folic acid mg/kg 80
Nicotinic acid mg/kg 0 . 2
Choline chloride mg/kg 450
Cyanocobalamin mg/kg 15
Manganese mg/kg 65
Iron mg/kg 100
Iodine mg/kg 0. 5
Copper mg/kg 20
Zinc mg/kg 40
Cobalt mg/kg 1
Data supplied by manufacturer
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APPENDIX IV
The plasma and urinary parameters measured in 12 
subjects before, during amd after the 12 weeks of 
dietary exposure to brown crabmeat containing cadmium 
(see Chapter 6 for further details).
Results are given as mean ± SEM of duplicate 
observations.
The two samples taken at week 0 are two control 
samples collected before the beginning of the feeding 
trial.
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